3 The Library - UC Berk
.;_ . ' 2 Received on: O8- —24— 94eley

"RG ' Current bibliographies in
461 medicine
A12 '

. 06 m No.94—2
1991s. ‘- ‘

-~PUBL '2

 

1., e @RRENT
llRLߨGRAPHEES
IN MEDEGENE

 

   

i C Ovarian
Cancer

 

 

 

 

 

January 1990
through
January 1994

National Library
of Medicine

    
 
 
 

  

1908 Citations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NATIONAL INSTITUTES OF HEALTH . National Library of Medicine DEFCS‘CTGRY
U 15%.
at“:

 

 

CBM 94-2

OVARIAN CANCER

January 1990 through January 1994, plus selected earlier references

1908 Citations

Prepared by

Mary E. Conway, M.L.S., National Library of Medicine
Edward L. Trimble, M.D., M.P.H., National Cancer Institute

US. DEPARTMENT OF HEALTH
AND HUMAN SERVICES

Public Health Service

National Institutes of Health

National Library of Medicine
Reference Section

8600 Rockville Pike
Bethesda, Maryland 20894

1994

National Library of Medicine Cataloging in Publication

Conway, Mary E. (Mary Elizabeth)

Ovarian cancer : January 1990 through January 1994, plus
selected earlier references 2 1908 citations / prepared by
Mary E. Conway, Edward L. Trimble. -— Bethesda, Md. (8600
Rockville Pike, Bethesda 20894) : U.S. Dept. of Health and
Human Services, Public Health Service, National Institutes
of Health, National Library of Medicine, Reference Section
; Pittsburgh, PA : Sold by the Supt. of Docs., U.S.
G.P.0., 1994.

-— (Current bibliographies in medicine ; 94-2)

Available from NLM at no cost through Internet FTP.

1. Ovarian Neoplasms — prevention & control -
bibliography 2. Ovarian Neoplasms - therapy -
bibliography 3. Mass Screening - bibliography I.
Trimble, Edward L. II. National Library of Medicine
(U.S.). Reference Section III. Title IV. Series

OZNLM: ZW l N272 no.94-2

SERIES NOTE

Current Bibliographies in Medicine (CBM) is a continuation in part of the National Library of Medicine’s
Literature Search Series, which ceased in 1987 with No. 87-15. In 1989 it also subsumed the Specialized
Bibliography Series. Each bibliography in the new series covers a distinct subject area of biomedicine and
is intended to fulfill a current awareness function. Citations are usually derived from searching a variety
of online databases. NLM databases utilized include MEDLINE', AVLINE', BIOETI-IICSLINE',
CANCERLIT', CATLINE', HEALTH, POPLINE" and TOXLINE'. The only criterion for the inclusion
of a particular published work is its relevance to the topic being presented; the format, ownership, or
location of the material is not considered.

Cements and suggestions on this series may be addressed to:

Karen Patrias, Editor

Current Bibliographies in Medicine
Reference Section

National Library of Medicine
Bethesda, MD 20894

Phone: 301-496-6097

Fax: 301-402-1384

Internet: patrias@nlm.nih.gov

Ordering Information:

Current Bibliographies in Medicine is sold by the Superintendent of Documents, U.S. Government Printing
Office, PD. 371954, Pittsburgh, PA 15250-7954. To order the entire CBM series for calendar year 1994
(approximately 10 bibliographies), send $60.00 ($75.00 foreign) to the Superintendent of Documents citing
GPO List ID: CBM94. For your convenience an order blank is given inside the back cover. Orders for
individual bibliographies in the series ($8.50, $10.63 foreign) should be sent to the Superintendent of
Documents citing the title. CBM number, and the GPO List ID given above.

Internet Access:
The Current Bibliographies in Medicine series is also available at no cost to anyone with Internet access

through FTP (File Transfer Protocol). FTP to nlmpubs.nlm.nih. gov and login: as nlmpubs. The index
file in the "bibs" directory provides information on the bibliographies available.

Use of funds for printing this periodical has been approved by the Director
of the Ofi‘ice of Management and Budget through September 30, 1994.

iii

OVARIAN CANCER

Ovarian cancer is the leading cause of death from gynecologic malignancies in the United States. In 1994,
approximately 24,000 new cases of ovarian cancer will be diagnosed, and 13,600 women will die of
ovarian cancer. Over the past several years much attention has been paid to the epidemiology, biology,
screening, treatment, and follow-up of ovarian cancer.

This bibliography was prepared in support of the National Institutes of Health Consensus Development
Conference titled "Ovarian Cancer: Screening, Treatment and Follow-up" convened in Bethesda, Maryland
on April 5-7, 1994. The purpose of the conference was to examine the relevant data concerning the
following questions:

What is the current status of screening for ovarian cancer?

What is the appropriate management of early ovarian cancer?

What is the appropriate management of advanced epithelial ovarian cancer?
What is appropriate follow-up after primary therapy for ovarian cancer?
What are directions for future research?

3"?pr

The organization of the bibliography reflects the focus of these five questions. The main subject categories
are General Articles; Screening and Prevention; Management of Early Stage Ovarian Cancer; Management
of Advanced Epithelial Ovarian Cancer; Follow-Up after Primary Therapy; and New Directions for
Research. Separate sections for monographs and audiovisuals appear at the end. The 1908 citations include
English language journal articles, monographs, book chapters, dissertations, conference proceedings, and
audiovisuals covering the period January 1990 through January 1994 with some selected earlier references.
Citations under the subject "New Directions for Research" cover the period January 1992 through January
1994. In general, letters, case reports, and editorials have been omitted. Audiovisuals are arranged
alphabetically by title; all other sections are arranged alphabetically by author. A citation may appear in
more than one category.

SEARCH STRATEGY

A variety of online databases are usually searched in preparing bibliographies in the CBM series. To assist
you in updating or otherwise manipulating the material in this search, the strategy used for the NLM’S
MEDLINE database is given below. Please note that the search strategies presented here differ from
individual demand searches in that they are generally broadly formulated and irrelevant citations edited out
prior to printing.

SS 1 = EXP OVARIAN NEOPLASMS
SS 2 = EXP OVARIAN DISEASES AND NEOPLASMS (PX)
SS 3 = EXP ENDOCRINE GLAND NEOPLASMS OR EXP GENITAL NEOPLASMS, FEMALE
SS 4 = (TW) OVARY OR OVARIES OR OVARIAN OR ALL OOPHORECTOM: OR ADNEXAL
SS 5 = EXP ADNEXAL DISEASES OR ADNEXA UTERI OR OVARIECTOMY
SS 6 = 3AND4OR3ANDS
SS 7 = EXP CYSTADENOMA OR EXP NEOPLASMS, GERM CELL A#D EMBRYONAL
SS 8 = 7AND4OR7AND5
SS 9 = 2 OR 6 OR 8
SS 10 = ALL TAXOL OR ALL TAXANE# (TW) OR ALL TAXOID# (TW)
SS11=1AND100R9AND10
SS 12 = 9 AND TH& (PX) OR 9 AND DI& (PX) OR 9 AND SN& (PX)
SS 13 = 9 AND EXP ULTRASONOGRAPHY OR 9 AND EXP ULTRASONICS
SS 14 = ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE OR
EXP TUMOR MARKERS, BIOLOGICAL OR GENETIC MARKERS
SS 15 QUALITY OF LIFE OR EXP ADAPTATION, PSYCHOLOGICAL

SS 16 = 9 AND 14 OR 9 AND 15 OR 9 AND PX (SH)

= EXP SURGERY, LAPAROSCOPIC OR EXP LAPAROSCOPY OR EXP LAPAROTOMY
SS 18 = 9 AND 17
SSl9= lORllOR120R13OR16OR18

GRATEFUL MED.

To make online searching easier and more efficient, the Library offers GRATEFUL MED, microcomputer-
based software that provides a user-friendly interface to most NLM databases. This software was
specifically developed for health professionals and features multiple choice menus and "fill in the blank"
screens for easy search preparation. GRATEFUL MED runs on an IBM PC (or IBM-compatible) with
DOS 2.0 or a Macintosh, and requires a Hayes (or Hayes-compatible) modem. It may be purchased from
the National Technical Information Service in Springfield, Virginia, for $29.95 (plus $3.00 per order for
Shipping). For your convenience, an order blank has been enclosed at the back of this bibliography.

vi

SANIPLE CITATIONS

Citations in this bibliographic series are formatted according to the rules established for Index Medicus'*.
Sample journal, monograph, and audiovisual citations appear below. Note also that a colon (2) may appear
within an author’s name or article title. The NLM computer system automatically inserts this symbol in
the place of a diacritical mark.

Journal Article:

Authors Article Title
/ ‘\ /
Deppe G, Malviya VK. Ovarian cancer. Advances in management.
Surg Clin North Am 1991 Oct;71(5):1023-39.

/ / _/ \ \
Abbreviated Journal Date Volume Issue Pages
Title
Monograph:
Authors/Editors Title
/ \ /

Markman, Maurie; Hoskins, William J ., eds. Cancer of the ovary.
New York: Raven Press; 1993. 442 p.

/ l \ \
Place of Publisher Date Total No.
Publication of Pages
Audiovisual:

Title Media Type Place of Publication Publisher Date
‘ ‘\ l / \
Cancers that threaten women [videorecording]. Princeton (NJ): Films for the Humanities; c1992.
1 videocassette: 19 min., sound, color, 1/2 in. Credits: Herbert Hyman.
\ / \
Physical Description Note

 

*For details of the formats used for references, see the following publication:

Patrias, Karen. National Library of Medicine recommended formats for bibliographic citation.
Bethesda (MD): The Library; 1991 Apr. Available from: NTIS, Springfield, VA; PB91-182030.

vii

TABLE OF CONTENTS

page
GENERAL ARTICLES 1
SCREENING AND PREVENTION
Epidemiology 3
Screening 9
Prevention 21
MANAGEMENT OF EARLY STAGE OVARIAN CANCER
Management of the Adnexal Mass 22
Early Stage Epithelial Ovarian Cancer 24
Ovarian Tumors of Low Malignant Potential
(Borderline Tumors) 26
Management of Germ Cell and Sex-Cord Stromal Tumors 28
Radiotherapy 32
MANAGEMENT OF ADVANCED EPITHELIAL OVARIAN CANCER
Preoperative Evaluation and Preparation 35
Principles of Primary Surgery 37
Primary Adjuvant Chemotherapy 40
Taxanos 49
Second-Look Surgery 52
FOLLOW-UP AFI‘ER PRIMARY THERAPY
Follow-Up of the Asymptomatic Patient 55
Surgery for the Symptomatic Patient 58
Salvage Chemotherapy 59
Quality of Life Considerations 66
NEW DIRECTIONS FOR RESEARCH 67
MONOGRAPHS 87

AUDIOVISUALS 90

ix

GENERAL ARTICLES

Alberts DS. Best papers on ovarian cancer. Cancer
Invest l992;10(6):603-4.

Andersen BL, Anderson B. Psychosomatic aspects of
gynecologic oncology: Present status and future
directions. Special Issue: Gynecologic oncology.
J Psychosom Obstet Gynaecol 1986 Dec;5(4):
233-244.

Averette HE, Donato DM. Ovarian carcinoma.
Advances in diagnosis, staging, and treatment.
Cancer 1990 Feb 1;65(3 Suppl):703-8.

Balvert-Locht HR, Coebergh JW, Hop WC, Brolmann
HA, Crommelin M, van Wijck DJ, Verhagen—
Teulings MT. Improved prognosis of ovarian cancer
in The Netherlands during the period 1975-1985: a
registry—based study. Gynecol Oncol 1991 Jul;
42(1):3-8.

Barakat RR, Benjamin 1. Surgery for malignant
gynecologic disease. Curr Opin Obstet Gynecol
1993 Jun;5(3):3ll-7.

Barber HR. New frontiers in ovarian cancer diagnosis
and management. Yale J Biol Med 1991 Mar-Apr;
64(2):127-41.

Barker GH. Recent advances in the treatment of
carcinoma of the ovary. Br J Obstet Gynaecol 1993
Sep;100(9):803-5.

Brown MF, Hebra A, McGeehin K, Ross A] 3d.
Ovarian masses in children: a review of 91 cases of
malignant and benign masses. J Pediatr Surg 1993
Jul;28(7):930-3.

Cancer of the ovary. ACOG technical bulletin number
141--May 1990 (replaces #73, October 1983). Int J
Gynaecol Obstet 1991 Aug;35(4):359-66.

Cannistra SA. Cancer of the ovary. N Engl J Med 1993
Nov 18;329(21):1550-9.

de Souza PL, Friedlander ML. Prognostic factors in
ovarian cancer. Hematol Oncol Clin North Am
1992 Aug;6(4):761-82.

Deppe G, Malviya VK. Ovarian cancer. Advances in
management. Surg Clin North Am 1991 Oct;
71(5):1023-39.

Eriksson JH, Walczak JR. Ovarian cancer. Semin
Oncol Nurs 1990 Aug;6(3):214—27.

Ferrier A. Ovarian carcinoma: a continuing challenge.
Med J Aust 1993 May 3;158(9):584-6.

Friedlander ML, Dembo AJ. Prognostic factors in
ovarian cancer. Semin Oncol 1991 Jun;18(3):
205-12.

1

Gargano G, Catino A, Correale M, Lorusso V, Abbate
I, Izzi G, Cramarossa A, Picciariello M, Paradiso
A, De Leonardis A, et al. Prognostic factors in
epithelial ovarian cancer. Eur J Gynaecol Oncol
1992;13(l Suppl):45-55.

Gitsch E, Salzer H. The management in ovarian cancer
at the First Dept. of Obstetrics and Gynecology,
University of Vienna. Eur J Gynaecol Oncol 1992;
13(1):61-4.

Gitsch E, Salzer H, Sevelda P. Ovarian cancer:
introduction and development in the treatment.
Eur J Obstet Gynecol Reprod Biol 1991 Aug 20;
41(1):43-6.

Hamilton TC. Ovarian cancer, Part I: Biology. Curr
Probl Cancer 1992 Jan-Feb;16(1):1-57.

Hanai A. Trends and differentials in ovarian cancer:
incidence, mortality and survival experience.
APMIS Suppl 1990;12:1-20.

Hole DJ, Gillis CR. Use of cancer registry data to
evaluate the treatment of ovarian cancer on a
hospital basis. Health Rep 1993;5(1):117-9.

Kennedy AW, Biscotti CV, Hart WR, Tuason Ll.
Histologic correlates of progression-free interval
and survival in ovarian clear cell adenocarcinoma.
Gynecol Oncol 1993 Sep;50(3):334-8.

Khoo SK, Battistutta D, Hurst T, Sanderson B, Ward
BG, Free K. The prognostic value of clinical,
pathologic, and biologic parameters in ovarian
cancer. Cancer 1993 Jul 15;72(2):531-7.

Kjaer SK, Storm HI-I. Survival of Danish cancer
patients 1943-1987. Female genital organs. APM'IS
Suppl 1993;33:107-21.

Kline RC, Wharton JT, Atkinson EN, Burke TW,
Gershenson DM, Edwards CL. Endometrioid
carcinoma of the ovary: retrospective review of 145
cases. Gynecol Oncol 1990 Dec;39(3):337-46.

Knobf MT, Morra ME. Women and cancer.
NAACOGS Clin Issu Perinat Womens Health Nurs
1993;4(2):287-301.

Lack BE, Young RH, Scully RE. Pathology of ovarian
neoplasms in childhood and adolescence. Pathol
Annu 1992;27(Pt 2):281-356.

Leung Y, DePetrillo AD. Etiology, epidemiology, risk
and prognostic factors, screening, and imaging of
gynecologic cancers. Curr Opin Oncol 1993 Sep;
5(5):869-76.

Lowry S. Molecular basis for hormonerelated cancer.
Lancet 1993 Jun 26;341(8861):1630.

Lowry WS, Atkinson RJ. Tumour suppressor genes and

risk of metastasis in ovarian cancer. BMJ 1993
Aug 28;307(6903):542.

2

Lund B, Thomsen HK, Olsen J. Reproducibility of
histopathological evaluation in epithelial ovarian
carcinoma. Clinical implications. APMIS 1991 Apr;
99(4):353-8.

Lund B, Williamson P, van Houwelingen HC, Neijt JP.
Comparison of the predictive power of different
prognostic indices for overall survival in patients
with advanced ovarian carcinoma. Cancer Res 1990
Aug 1;50(15):4626-9.

Markman M, Lewis JL Jr, Saigo P, Hakes T, Rubin S,
Jones W, Reichman B, Curtin J, Barakat R,
Almadrones L, et al. Impact of age on survival of
patients with ovarian cancer. Gynecol Oncol 1993
May;49(2):236—9.

Marsoni S, Torri V, Valsecchi MG, Belloni C, Bianchi
U, Bolis G, Bonazzi C, Colombo N, Epis A,
Favalli G, et al. Prognostic factors in advanced
epithelial ovarian cancer. (Gruppo Interregionale
Cooperativo di Oncologia Ginecologica (GICOG)).
Br J Cancer 1990 Sep;62(3):444-50.

Marsoni S, Torri W, Taiana A, Gambino A, Grilli R,
Liati P, Franzosi MG, Pistotti V, Parazzini F,
Focarile F, et al. Critical review of the quality and
development of randomized clinical trials (RCTs)
and their influence on the treatment of advanced
epithelial ovarian cancer. Ann Oncol 1990 Sep;
1(5):343=50.

McGowan L. Pathology of the ovary. Curr Opin Obstet
Gynecol 1991 Aug;3(4):580-6.

Merino MJ, Jaffe G. Age contrast in ovarian pathology.
Cancer 1993 Jan 15;71(2 Suppl):537-44.

Montella M, De Marco MR, Romeo F, Ventura R.
Survival in ovarian cancers treated at National
Cancer Institute in Naples Italy 1985—1990. Eur J
Gynaecol Oncol 1993;14(3):249-54.

Nakashima N, Nagasaka T, Fukata S, Oiwa N, Nara Y,
Fukatsu T, Takeuchi J. Study of ovarian tumors
treated at Nagoya University Hospital, 1965-1988.
Gynecol Oncol 1990 Apr;37(l):103-11.

Nash JD, Young RC. Gynecological malignancies.
Cancer Chemother Biol Response Modif 1990;
1 1 2484-509.

Niloff J M. Ovarian malignancy. Curr Opin Obstet
Gynecol 1991 Feb;3(1):66-72.

Onwude JL, Holohan MB, Codd MB, Coughlan BM.
Prognosis of ovarian cancer. Ir Med J 1990 Mar;
83(1):14—6.

Ozols RF, Hamilton TC, Hoskins WJ, Bast RC Jr,
Young RC. Summary of symposium: Biology and
therapy of ovarian cancer. Semin Oncol 1991 Jun;
18(3):297-306.

Perez RP, Godwin AK, Hamilton TC, Ozols RF.
Ovarian cancer biology. Semin Oncol 1991
Jun;18(3):186—204.

Perspectives on Ovarian Cancer in Older-Aged Women.
Current Knowledge and Recommendations for
Research. Working conference. Bethesda,
Maryland, November 20-21, 1991. Cancer 1993
Jan 15;71(2 Suppl):513-659.

Plaxe SC, Braly PS, Freddo JL, McClay E, Kirmani S,
Howell SB. Profiles of women age 30-39 and age
less than 30 with epithelial ovarian cancer. Obstet
Gynecol 1993 May;81(5 Pt 1):651-4.

Protopapa E, Miaoulis G, Ferreiro M, Panayiotides J,
Katsikas SK, Delides G. A new expert system for
histopathological diagnosis of human ovarian
epithelial cancer. In Vivo 1993 Jul-Aug; 7(4):
369-72.

Saeed M, Khawaja K, Rizwana I, Malik I, Rizvi J,
Khan A. A clinicopathological analysis of ovarian
tumours. JPMA J Pak Med Assoc 1991 Jul; 41(7):
161-4.

Silva EG, Jenkins R. Serous carcinoma in endometrial
polyps. Mod Pathol 1990 Mar;3(2):120—8.

Silva EG, Tomos C, Bailey MA, Morris M.
Undifferentiated carcinoma of the ovary. Arch
Pathol Lab Med 1991 Apr;115(4):377-8l.

Singh P, Arunachalam I, Singh P, Tan BY, Tock EP,
Ratnam SS. Ovarian cancer in Oriental women from
Singapore: disease pattern and survival. Int Surg
1990 Apr-Jun;75(2): 115-22.

Swenerton KD. Prognostic indices in ovarian cancer.
Their significance in treatment planning. Acta
Obstet Gynecol Scand Suppl 1992;155:67-74.

Talerrnan A. Ovarian pathology. Curr Opin Obstet
Gynecol 1992 Aug;4(4):608-15.

Thigpen T, Brady MF, Omura GA, Creasman WT,
McGuire WP, Hoskins WJ, Williams S. Age as a
prognostic factor in ovarian carcinoma. The

Gynecologic Oncology Group experience. Cancer
1993 Jan 15;71(2 Suppl):606—14.

Tintara H, Mita.mun W. Ovarian neoplasms in
childhood and adolescents in Songklanagarind
Hospital, February l983—March 1989. J Med Assoc
Thai 1990 Jul;73(7):375-80.

Trope C, Makar A. Unsettled questions regarding
ovarian cancer. Acta Obstet Gynecol Scand Suppl
1992;155:7-18.

Tyler CW Jr, Lee NC, Robboy SJ, Kurman RJ, Paris
AL, Wingo PA, Williamson GD. The diagnosis of
ovarian cancer by pathologists: how ofien do
diagnoses by contributing pathologists agree with a

panel of gynecologic pathologists? Am J Obstet
Gynecol 1991 Jan;164(1 Pt 1):65-70.

Vani R, Kuntal R, Rao PL. Ovarian tumors in the
second decade of life. Asia Oceania J Obstet
Gynaecol 1991 Sep;17(3):231-5.

Watkin W, Silva EG, Gershenson DM. Mucinous
carcinoma of the ovary. Pathologic prognostic
factors. Cancer 1992 Jan 1;69(1):208-12.

Williams C. Ovarian and cervical cancer. BMJ 1992
Jun 6;304(6840):1501-4.

Yancik R. Ovarian cancer. Age contrasts in incidence,

histology, disease stage at diagnosis, and mortality.

Cancer 1993 Jan 15;71(2 Suppl):517-23.

Yancik R, Moore TD, Martin G, Obrams GI, Reed E.
Older women as the focus for research and
treatment of ovarian cancer. An overview for the
National Institute on Aging, National Cancer
Institute, and American Cancer Society
Multidisciplinary Working Conference. Cancer
1993 Jan 15;71(2 Suppl):514-6.

SCREENING AND PREVENTION
Epidemiology

Adami HO, Bergstrom R, Persson I, Sparen P. The
incidence of ovarian cancer in Sweden, 1960-1984.
Am J Epidemiol 1990 Sep;132(3):446-52.

Amos CI, Shaw GL, Tucker MA, Hartge P. Age at
onset for familial epithelial ovarian cancer. J AMA
1992 Oct 14;268(14):1896-9.

Amos CI, Struewing JP. Genetic epidemiology of
epithelial ovarian cancer. Cancer 1993 Jan 15;
71(2 Suppl):566-72.

Anderson DE, Badzioch MD. Familial breast cancer
risks. Effects of prostate and other cancers. Cancer
1993 Jul 1;72(1):114w9.

Augustin J, Wotke R. Ovarian malignancies in the
Czech Cancer Registry. Neoplasma 1990;37(2):
213-7.

Ayhan A, Yalcin OT, Tuncer ZS, Gurgan T, Kucukali
T. Synchronous primary malignancies of the female
genital tract. Eur J Obstet Gynecol Reprod Biol
1992 Jun 16;45(1):63-6.

Badawy YA, Bayoumi DM. An epidemiologic study of
ovarian cancer. Part 1: Reproductive and social
factors. J Egypt Public Health Assoc 1992;
67(3-4):465-77.

Badawy YA, Bayoumi DM. An epidemiologic study of
ovarian cancer. Part 2: Oral contraceptive use and
menstrual events. J Egypt Public Health Assoc
1992;67(5—6):579-91.

Balasch J, Barri PN. Follicular stimulation and ovarian
cancer? Hum Reprod 1993 Jul;8(7):990—6.

Barrett-Connor E. Hormone replacement and cancer.
Br Med Bull 1992 Apr;48(2):345-55.

Bernstein J L, Thompson WD, Risch N, Holford TR.
The genetic epidemiology of second primary breast
cancer. Am J Epidemiol 1992 Oct 15;136(8):
937-48.

Bernstein L, Ross RK, Henderson BE. Relationship of
hormone use to cancer risk. Monogr Natl Cancer
Inst 1992;(12):137-47.

Bewtra C, Watson P, Conway T, Read-Hippee C,
Lynch HT. Hereditary ovarian cancer: a
clinicopathological study. Int J Gynecol Pathol 1992
Jul;11(3):180-7.

Black DM, Solomon E. The search for the familial
breast/ovarian cancer gene. Trends Genet 1993
Jan;9(1):22-6.

4

Bokhman J B, Maximov SJ. Relative risk of
development and active detection of primary
multiple endometrial, breast and ovarian cancer.
Eur J Gynaecol Oncol 1993;14(2):114-8.

Boring CC, Squires TS, Tong T, Montgomery S.
Cancer statistics, 1994. CA Cancer J Clin 1994;
44(1):7-26.

Brenner H, Siegle S, Stegmaier C, Ziegler H. Second
primary malignancies following gynecological
tumours in Saarland, Germany, 1968-1987.

J Cancer Res Clin Oncol 1993;119(3):179-83.

Brenner H, Siegle S, Stegmaier C, Ziegler H. Second
primary neoplasms following breast cancer in
Saarland, Germany, 1968-1987. Eur J Cancer 1993;
29A(10):1410—4.

Chen Y, Wu PC, Lang JH, Ge WJ, Hartge P, Brinton
LA. Risk factors for epithelial ovarian cancer in
Beijing, China. Int J Epidemiol 1992 Feb;21(l):
23-9.

Chi I. The safety and efficacy issues of progestin-only
oral contraceptives--an epidemiologic perspective.
Contraception 1993 Jan;47(1):1—21.

Cohen J, Forman R, Harlap S, Johannisson E,
Lunenfeld B, de Mouzon J, Pepperell R, Tarlatzis
B, Templeton A. IFFS expert group report on the
Whittemore study related to the risk of ovarian
cancer associated with the use of infertility agents.
Hum Reprod 1993 Jul;8(7):996—9.

Cramer DW. Epidemiologic aspects of early menopause
and ovarian cancer. Ann N Y Acad Sci 1990;592:
363-75; discussion 390-4.

Daly MB. The epidemiology of ovarian cancer.
Hematol Oncol Clin North Am 1992 Aug;
6(4):729-38.

Depot-medroxyprogesterone acetate (DMPA) and risk
of epithelial ovarian cancer. The WHO
Collaborative Study of Neoplasia and Steroid
Contraceptives. Int J Cancer 1991 Sep 9;
49(2):191-5.

DePriest PD, Banks ER, Powell DE, van Nagell JR Jr,
Gallion HH, Puls LE, Hunter JE, Kryscio RJ,
Royalty MB. Endometrioid carcinoma of the ovary
and endometriosis: the association in
postmenopausal women. Gynecol Oncol 1992
Oct;47(1):71-5.

Diet] J, Marzusch K. Ovarian surface epithelium and
human ovarian cancer. Gynecol Obstet Invest
1993;35(3):129-35.

Edgren RA. Oral contraceptives and cancer. Int J Fertil
1991;36 Suppl 3:37-50.

Engle A, Muscat JE, Harris RE. Nutritional risk factors
and ovarian cancer. Nutr Cancer 1991;15(3-4):
239-47.

Fertility drugs and ovarian cancer. International
Federation of Fertility Societies (IFFS). Fertil Steril
1993 Sep;60(3):406—8.

Franceschi S. Female hormones: for which cancers do
they matter? Dev Oncol 1991;63:89-106.

Franceschi S, La Vecchia C, Booth M, Tzonou A,
Negri E, Parazzini F, Trichopoulos D, Beral V.
Pooled analysis of 3 European case-control studies
of ovarian cancer: H. Age at menarche and at
menopause. Int J Cancer 1991 Aug 19;49(1):57-60.
Comment in: Int J Cancer 1992 May 8;51(2):333-4.

Franceschi S, Parazzini F, Negri E, Booth M, La
Vecchia C, Beral V, Tzonou A, Trichopoulos D.
Pooled analysis of 3 European case-control studies
of epithelial ovarian cancer: HI. Oral contraceptive
use. Int J Cancer 1991 Aug 19;49(1):61-5.

Freddo JL. Genetic predisposition to ovarian cancer.
West J Med 1992 Jun;156(6):652.

Gast K, Snyder T. Combination oral contraceptives and
cancer risk. Kans Med 1990 Jul;91(7):201-8.

Gatphoh ED, Damal I-IK. Pattern of ovarian neoplasm
in Manipur. J Indian Med Assoc 1990 Dec;88(12):
338—9.

Greggi S, Genuardi M, Benedetti-Panici P, Cento R,
Scambia G, Neri G, Mancuso S. Analysis of 138
consecutive ovarian cancer patients: incidence and
characteristics of familial cases. Gynecol Oncol
1990 Dec;39(3):300—4.

Grimes DA. Neoplastic effects of oral contraceptives.
Int J Fertil 1991;36 Suppl 1:19-24.

Gross TP, Schlesselman JJ, Stadel BV, Yu W, Lee NC.
The risk of epithelial ovarian cancer in short-term
users of oral contraceptives. Am J Epidemiol 1992
Jul 1;136(1):46-53.

Grover S, Quinn MA, Weideman P. Patterns of
inheritance of ovarian cancer. An analysis from an

ovarian cancer screening program. Cancer 1993
Jul 15;72(2):526-30.

Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin
GL. Pregnancy, breast feeding, and oral
contraceptives and the risk of epithelial ovarian
cancer. J Clin Epidemiol 1990;43(6):559—68.

Hankinson SE, Colditz GA, Hunter DJ, Spencer TL,
Rosner B, Stampfer MJ . A quantitative assessment

of oral contraceptive use and risk of ovarian cancer.
Obstet Gynecol 1992 Oct;80(4):708- 14.

Harlow BL, Cramer DW, Bell DA, Welch WR.
Perineal exposure to talc and ovarian cancer risk.
Obstet Gynecol 1992 Jul;80(l):l9-26.

Harlow BL, Cramer DW, Geller J, Willett WC, Bell
DA, Welch WR. The influence of lactose
consumption on the association of oral contraceptive
use and ovarian cancer risk. Am J Epidemiol 1991
Sep l;134(5):445-53. Comment in: Am J Epidemiol
1991 Sep l;134(5):454-6 and Am J Epidemiol 1991
Sep l;134(5):457-9; discussion 460-1.

Harris R, Whittemore AS, Itnyre J. Characteristics
relating to ovarian cancer risk: collaborative
analysis of 12 US case-control studies. [EL
Epithelial tumors of low malignant potential in
white women. Collaborative Ovarian Cancer Group.
Am J Epidemiol 1992 Nov 15;l36(10):1204-11.

Henderson BE, Ross RK, Pike MC. Hormonal
chemoprevention of cancer in women. Science 1993
Jan 29;259(5095):633-8.

Henderson J, Seagroatt V, Goldacre M. Ovarian cancer
and ABO blood groups. J Epidemiol Community
Health 1993 Aug;47(4):287—9.

Horn-Ross PL, Whittemore AS, Harris R, Itnyre J.
Characteristics relating to ovarian cancer risk:
collaborative analysis of 12 U.S. case-control
studies. VI. Nonepithelial cancers among adults.

Collaborative Ovarian Cancer Group. Epidemiology
1992 Nov;3(6):490-5.

Houlston RS, Boume TH, Collins WP, Whitehead MI,
Campbell S, Slack J. Risk of ovarian cancer and
genetic relationship to other cancers in families.
Hum Hered 1993 Mar-Apr;43(2):111-5.

Irwin KL, Weiss NS, Lee NC, Peterson HB. Tubal
sterilization, hysterectomy, and the subsequent
occurrence of epithelial ovarian cancer. Am J
Epidemiol 1991 Aug 15;134(4):362-9.

Jacobs IJ, Kohler MF, Wiseman RW, Marks JR,
Whitaker R, Kems BA, Humphrey P, Berchuck A,
Ponder BA, Bast RC Jr. Clonal origin of epithelial
ovarian carcinoma: analysis by loss of
heterozygosity, p53 mutation, and X-chromosome
inactivation. J Natl Cancer Inst 1992 Dec 2;
84(23): 1793-8.

Jacobsen BK, Vollset SE, Kvale G. Reproductive
factors and survival from ovarian cancer. Int J
Cancer 1993 Jul 30;54(6):904—6.

Jin F, Shu X0, Devesa SS, Zheng W, Blot WJ, Gao
YT. Incidence trends for cancers of the breast,
ovary, and corpus uteri in urban Shanghai,
1972-89. Cancer Causes Control 1993 Jul;
4(4):355-60.

John EM, Whittemore AS, Harris R, Itnyre J.
Characteristics relating to ovarian cancer risk:
collaborative analysis of seven U.S. case-control

studies. Epithelial ovarian cancer in black women.
Collaborative Ovarian Cancer Group. J Natl Cancer
Inst 1993 Jan 20;85(2):142-7.

Katchy KC, Briggs ND. Clinical and pathological
features of ovarian tumours in Rivers state of
Nigeria. East Afr Med J 1992 Aug;69(8):456-9.

Kaunitz AM. Oral contraceptives and gynecologic
cancer: an update for the 1990s. Am J Obstet
Gynecol 1992 Oct;167(4 Pt 2):117l-6.

Koch M, Hanson J, Raphael M. Follow-up of controls
participating in case-control studies for cancer risk
factors. Int J Epidemiol 1990 Dec;l9(4):877-80.
Comment in: Int J Epidemiol 1991 Sep;20(3):820.

Kodama M, Kodama T, Totani R, Suzuoki Y, Kodama
M. Relation between the hormonal and
epidemiological aspects of ovarian cancer patients in
Japan. Anticancer Res 1992 Sep-Oct;12(5):
1593-602.

Koonings PP, Grimes DA, Campbell K, Sommerville
M. Bilateral ovarian neoplasms and the risk of
malignancy. Am J Obstet Gynecol 1990 Jan;
162(1):167-9.

Kuznesov VV. Selective screening on
hormonedependent tumours of women’s
reproductive system organs. Eur J Gynaecol Oncol
1992;13(1 Suppl):65-8.

Kvale G, Heuch I, Nilssen S. Reproductive factors and
cancers of the breast and genital organs--are the
different cancer sites similarly affected? Cancer
Detect Prev 1991;15(5):369-77.

La Vecchia C, Levi F, Lucchini F, Negri E, Franceschi
S. Descriptive epidemiology of ovarian cancer in
Europe. Gynecol Oncol 1992 Aug;46(2):208-15.

La Vecchia C, Negri E, Franceschi S, Parazzini F,
Gentile A, Fasoli M. Alcohol and epithelial ovarian
cancer. J Clin Epidemiol 1992 Sep;45(9):1025-30.

Land JA. Ovulation, ovulation induction and ovarian
carcinoma. Baillieres Clin Obstet Gynaecol 1993
Jun;7(2):455-72.

Lanza E, Shankar S, Trock B. Dietary fiber. In:
Micozzi MS, Moon TE, eds. Macronutrients:
investigating their role in cancer. New York:
Marcel Dekker; 1992. p. 293-319.

Lauchlan SC. Non-invasive ovarian carcinoma. Int J
Gynecol Pathol 1990;9(2):158-69.

Levi F, Franceschi S, La Vecchia C, Ruzicka J, Gloor
E, Randimbison L. Epidemiologic pathology of
ovarian cancer from the Vaud Cancer Registry,
Switzerland. Ann Oncol 1993 Apr;4(4):289-94.

6

Leviton A. Methylxanthine consumption and the risk of
ovarian malignancy. Cancer Lett 1990 May 30;
51(2):91-101.

Lund E. Mortality from ovarian cancer among women
with many children. Int J Epidemiol 1992 Oct;
21(5):872-6.

Lund E. Number of children and death from hormone-
dependent cancers. Int J Cancer 1990 Dec 15;
46(6):998-1000.

Lynch HT, Conway T, Lynch J. Hereditary ovarian
cancer. Pedigree studies, Part II. Cancer Genet
Cytogenet 1991 Jun;53(2):161-83.

Lynch HT, Fitzsimmons ML, Conway TA, Bewtra C,
Lynch J. Hereditary carcinoma of the ovary and
associated cancers: a study of two families. Gynecol
Oncol 1990 Jan;36(1):48-55.

Lynch HT, Lynch JF. Hereditary ovarian carcinoma.
Hematol Oncol Clin North Am 1992 Aug;6(4):
783-811.

Lynch HT, Watson P, Bewtra C, Conway TA, Hippee
CR, Kaur P, Lynch JF, Ponder BA. Hereditary
ovarian cancer. Heterogeneity in age at diagnosis.
Cancer 1991 Mar 1;67(5):1460—6.

Lynch HT, Watson P, Conway TA, Lynch J F,
Slominski-Caster SM, Narod SA, Feunteun J,
Lenoir G. DNA screening for breast/ovarian cancer
susceptibility based on linked markers. A family
study. Arch Intern Med 1993 Sep 13;153(17):
1979-87.

Lynch HT, Watson P, Lynch JF, Conway TA, Fili M.
Hereditary ovarian cancer. Heterogeneity in age at
onset. Cancer 1993 Jan 15;71(2 Suppl):573-81.

Mahoney MC, Youngblood LG, Weinstein AL, Burnett
WS. Evidence for a spatiotemporal cluster of
ovarian cancer cases. Gynecol Oncol 1991 Jun;
41(3):234-8.

Makar AP, Trope CG. Endometrial and ovarian
malignancies: epidemiology, etiology and
prognostic factors. Acta Obstet Gynecol Scand 1992
Jul;7l(5):331-6.

Maximov SJ, Bokhman JB. Syndrome of primary
multiple endometrial, breast, ovarian and colon
adenocarcinoma. Eur J Gynaecol Oncol 1993;
14(2):109-13.

Menczer J, Ben-Baruch G. Familial ovarian cancer in
Israeli Jewish women. Obstet Gynecol 1991 Feb;
77(2):276-7.

Mettlin CJ. Invited commentary: progress in the
nutritional epidemiology of ovary cancer. Am J
Epidemiol 1991 Sep l;134(5):457-9; discussion
460-1. Comment on: Am J Epidemiol 1991 Sep 1;

134(5):445-53 ; Comment on: Am J Epidemiol
1991 Sep 1;134(5):454-6.

Mettlin CJ, Piver MS. A case-control study of milk-
drinking and ovarian cancer risk. Am J Epidemiol
1990 Nov;132(5):87l-'6. Comment in: Am J
Epidemiol 1991 Sep 1;134(5):454-6.

Miller WR, Fraser I-IM. Is cancer in women
preventable by hormone manipulation? J Endocrinol
1991 Aug;l30(2):165-8.

Mukherjee AK, Leck 1, Langley FA, Ashcroft C. The
completeness and accuracy of health authority and
cancer registry records according to a study of
ovarian neoplasms. Public Health 1991 Jan;
105(1):69—78.

Negri E, Franceschi S, La Vecchia C, Parazzini F.
Incomplete pregnancies and ovarian cancer risk.
Gynecol Oncol 1992 Nov;47(2):234—8.

Negri E, Franceschi S, Tzonou A, Booth M, La
Vecchia C, Parazzini F, Beral V, Boyle P,
Trichopoulos D. Pooled analysis of 3 European
case-control studies: I. Reproductive factors and
risk of epithelial ovarian cancer. Int J Cancer 1991
Aug 19;49(1):50—6.

Olsson H, Andersson H, Johansson 0, Moller TR,
Kristoffersson U, Wenngren E. Population-based
cohort investigations of the risk for malignant
tumors in first-degree relatives and wives of men
with breast cancer. Cancer 1993 Feb 15;71(4):
1273-8.

Parazzini F, Franceschi S, La Vecchia C, Fasoli M.
The epidemiology of ovarian cancer. Gynecol Oncol
1991 0ct;43(1):9-23.

Parazzini F, La Vecchia C, Negri E, Bocciolone L,
Fedele L, Franceschi S. Oral contraceptive use and
the risk of ovarian cancer: an Italian case-control
study. Eur J Cancer 1991;27(5):594-8.

Parazzini F, La Vecchia C, Negri E, Franceschi S,
Tozzi L. Family history of breast, ovarian and
endometrial cancer and risk of breast cancer. Int J
Epidemiol 1993 Aug;22(4):614-8.

Parazzini F, Negri E, La Vecchia C, Restelli C,
Franceschi S. Family history of reproductive
cancers and ovarian cancer risk: an Italian case-
control study. Am J Epidemiol 1992 Jan 1;l35(1):
35-40.

Patel AR, Obrams GI. Epidemiology of ovarian cancer.
Cancer Epidemiol Biomarkers Prev 1993 Jan-Feb;
2(1):79-83.

Pearl ML, Johnston CM, Frank TS, Roberts JA.
Synchronous dual primary ovarian and endometrial
carcinomas. Int J Gynecol Obstet 1993;43(3):
305-12.

Pejovic T, Heim S, Mandahl N, Elmfors B, Furgyik S,
Floderus UM, Helm G, Willen H, Mitelman F.
Bilateral ovarian carcinoma: cytogenetic evidence of
unicentric origin. Int J Cancer 1991 Feb 1;47(3):
358-61.

Petitti DB, Porterfield D. Worldwide variations in the
lifetime probability of reproductive cancer in
women: implications of best—case, worst-case, and
likely—case assumptions about the effect of oral
contraceptive use. Contraception 1992 Feb;45(2):
93-104.

Pike M. We are on the threshold of an era when breast
cancer can be prevented [interview]. Oncology
(Huntingt) 1991 May;5(5):14, 16, 21-2.

Pike MC. Reducing cancer risk in women through
lifestyle-mediated changes in hormone levels.
Cancer Detect Prev 1990;14(6):595-607.

Piver MS, Baker TR, J ishi MF, Sandecki AM, Tsukada
Y, Natarajan N, Mettlin CJ, Blake CA. Familial
ovarian cancer. A report of 658 families from the
Gilda Radner Familial Ovarian Cancer Registry
1981-1991. Cancer 1993 Jan 15;71(2 Suppl):582-8.

Piver MS, Baker TR, Piedmonte M, Sandecki AM.
Epidemiology and etiology of ovarian cancer.
Semin Oncol 1991 Jun;18(3):177-85.

Polychronopoulou A, Tzonou A, Hsieh CC, Kaprims
G, Rebelakos A, Toupadaki N, Tnchopoulos D.
Reproductive variables, tobacco, ethanol, coffee and
somatometry as risk factors for ovarian cancer. Int J
Cancer 1993 Sep 30;55(3):402-7.

Ponder MA. Can cancers be inherited? Prof Nurse 1991
Jul;6(10):593-7.

Prat J, Matias-Guiu X, Barreto J. Simultaneous
carcinoma involving the endometrium and the
ovary. A clinicopathologic, immunohistochemical,
and DNA flow cytometric study of 18 cases.
Cancer 1991 Dec 1;68(11):2455-9.

Prentice RL, Sheppard L. Dietary fat and cancer:
consistency of the epidemiologic data, and disease
prevention that may follow from a practical
reduction in fat consumption. Cancer Causes
Control 1990 Jul;1(1):81-97; discussion 99-109.
Published erratum appears in Cancer Causes
Control 1990 Nov;1(3):253.

Preston-Martin S, Pike MC, Ross RK, Henderson BE.
Epidemiologic evidence for the increased cell

proliferation model of carcinogenesis. Prog Clin
Biol Res 1991;369:21—34.

Pukkala E, Poskiparta M, Apter D, Vihko V. Life-long
physical activity and cancer risk among Finnish
female teachers. Eur J Cancer Prev 1993 Sep;
2(5):369-76.

7

Puls LE, Powell DE, DePriest PD, Gallion HH, Hunter
JE, Kryscio RJ, van Nagell JR Jr. Transition from
benign to malignant epithelium in mucinous and
serous ovarian cystadenocarcinoma. Gynecol Oncol
1992 Oct;47(1):53-7.

Rao BR, Slotman BJ. Endocrine factors in common
epithelial ovarian cancer. Endocr Rev 1991 Feb;
12(1):]4-26.

Resta L, Russo S, Colucci GA, Prat J. Morphologic
precursors of ovarian epithelial tumors. Obstet
Gynecol 1993 Aug;82(2):181-6.

Ries LA. Ovarian cancer. Survival and treatment
differences by age. Cancer 1993 Jan 15;71
(2 Suppl):524-9.

Rosenblatt KA, Szklo M, Rosenshein NB. Mineral fiber
exposure and the development of ovarian cancer.
Gynecol Oncol 1992 Apr;45(1):20-5.

Rosenblatt KA, Thomas DB. Lactation and the risk of
epithelial ovarian cancer. The WHO Collaborative
Study of Neoplasia and Steroid Contraceptives. Int J
Epidemiol 1993 Apr;22(2):192-7.

Rosenblatt KA, Thomas DB, Noonan EA. High-dose
and low-dose combined oral contraceptives:
protection against epithelial ovarian cancer and the
length of the protective effect. The WHO
Collaborative Study of Neoplasia and Steroid
Contraceptives. Eur J Cancer 1992;28A(11):1872-6.

Sellers TA, Gapstur SM, Potter JD, Kushi LH, Bostick
RM, Folsom AR. Association of body fat
distribution and family histories of breast and
ovarian cancer with risk of postmenopausal breast
cancer. Am J Epidemiol 1993 Nov 15;138(10):
799-803.

Shah S, Evans DG, Blair V, Bumell LD, Birch JM.
Assessment of relative risk of second primary
tumors after ovarian cancer and of the usefulness of
double primary cases as a source of material for
genetic studies with a cancer registry. Cancer 1993
Aug l;72(3):819—27.

Smith PE. Familial breast and ovarian cancers. Semin
Oncol Nurs 1992 Nov;8(4):258-64.

Tavani A, Negri E, Franceschi S, Parazzini F, La
Vecchia C. Risk factors for epithelial ovarian
cancer in women under age 45. Eur J Cancer
1993;29A(9):1297-301.

Thanikasalam K, Ho CM, Adeed N, Shahidan MN,
Azizah WK. Pattern of ovarian tumours among
Malaysian women at General Hospital, Kuala
Lumpur. Med J Malaysia 1992 Jun;47(2):l39-46.

Thomas DB. The WHO Collaborative Study of
Neoplasia and Steroid Contraceptives: the influence
of combined oral contraceptives on risk of

neoplasms in developing and developed countries.
Contraception 1991 Jun;43(6):695-710.

Tomao S, Taggi F, Sbema RC, Villani C. Ovarian
cancer and dietary habits. Eur J Gynaecol Oncol
1992;13(1):91—5.

Trichopoulou A, Mossialos E, Skalkides J.
Mediterranean diet and cancer. Dev Oncol
1991;63:17-25.

Trope CG, Makar AP. Epidemiology, etiology,
screening, prevention, and diagnosis in female
genital cancer. Curr Opin Oncol 1991 Oct;
3(5):908-19.

Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H.
Risk of prostate, ovarian, and endometrial cancer
among relatives of women with breast cancer.

BMJ 1992 Oct 10;305(6858):855-7.

Tzonou A, Hsieh CC, Polychronopoulou A, Kaprinis
G, Toupadaki N, Trichopoulou A, Karakatsani A,
Trichopoulos D. Diet and ovarian cancer: a case-
control study in Greece. Int J Cancer 1993
Sep 30;55(3):411-4.

Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos
A, Karakatsani A, Trichopoulos D. Hair dyes,
analgesics, tranquilizers and perineal talc
application as risk factors for ovarian cancer. Int J
Cancer 1993 Sep 30;55(3):408-10.

Westhoff C, Murphy P, Heller D, Halim A. Is ovarian
cancer associated with an increased frequency of
germinal inclusion cysts? Am J Epidemiol 1993
Jul 15;l38(2):90—3.

Whelan SL. Cancer Incidence in Five Continents.
Coding practices. IARC Sci Publ 1992;(120):31-8.

Whittemore AS. Fertility drugs and risk of ovarian
cancer. Hum Reprod 1993 Jul;8(7):999-1000.

Whittemore AS. Personal characteristics relating to risk
of invasive epithelial ovarian cancer in older women
in the United States. Cancer 1993 Jan 15;7l
(2 Suppl):558—65.

Whittemore AS, Harris R, Itnyre J. Characteristics
relating to ovarian cancer risk: collaborative
analysis of 12 US case-control studies. IV. The
pathogenesis of epithelial ovarian cancer.
Collaborative Ovarian Cancer Group. Am J
Epidemiol 1992 Nov 15;136(10):1212-20.

Whittemore AS, Harris R, Itnyre J. Characteristics
relating to ovarian cancer risk: collaborative
analysis of 12 US case-control studies. II. Invasive
epithelial ovarian cancers in white women.
Collaborative Ovarian Cancer Group. Am J
Epidemiol 1992 Nov 15;136(10):1184-203.
Comment in: Am J Epidemiol 1993 Apr 15;
137(8):928-9.

Whittemore AS, Harris R, Itnyre J, Halpem J.
Characteristics relating to ovarian cancer risk:
collaborative analysis of 12 US case-control studies.
1. Methods. Collaborative Ovarian Cancer Group.
Am J Epidemiol 1992 Nov 15;136(10):ll75-83.

Williams JK. Oral contraceptives and reproductive
system cancer. Benefits and risks. J Reprod Med
1991 Mar;36(3 Suppl):247-52.

Yoder LH. The epidemiology of ovarian cancer: a
review. Oncol Nurs Forum 1990 May-Iun;l7(3):
411-5. Comment in: Oncol Nurs Forum 1990 Jul—
Aug;17(4):483-4.

Zheng W, Shu XO, McLaughlin JK, Chow WH, Gao
YT, Blot WJ. Occupational physical activity and the
incidence of cancer of the breast, corpus uteri, and
ovary in Shanghai. Cancer 1993 Jun l;71(11):
3620-4.

Screening

Acar B, Posaci C, Dicle O, Topuz A. Erten 0.
Diagnostic value of magnetic resonance imaging in
gynaecology. Aust N Z J Obstet Gynaecol 1992
Aug;32(3):252-5.

Adams CH, Smith NJ, Wilbur DC, Grady KB. The
relationship of obesity to the frequency of pelvic
examinations: do physician and patient attitudes
make a difference? Women Health 1993;20(2):
45-57.

Andolf E. Ultrasound screening in women at risk for
ovarian cancer. Clin Obstet Gynecol 1993 Jun;
36(2):423-32.

Andolf E, Jorgensen C. A prospective comparison of
transabdominal and transvaginal ultrasound with
surgical findings in gynecologic disease.

J Ultrasound Med 1990 Feb;9(2):71-5.

Andolf E, Jorgensen C, Astedt B. Ultrasound
examination for detection of ovarian carcinoma in
risk groups. Obstet Gynecol 1990 Jan;75(1):106-9.

Aubel S, Wozney P, Edwards RP. MRI of female
uterine and juxta-uterine masses: clinical application
in 25 patients. Magn Reson Imaging 1991;9(4):
485-91.

Averette HE, Steren A, Nguyen HN. Screening in
gynecologic cancers. Cancer 1993 Aug 1;72
(3 Suppl):1043-9.

Bax-zen G, Hierholzer J, Cordes M, Friedmann W,
Felix R. Primary diagnosis and follow—up of
ovarian cancer: radioimmunoscintigraphy with
iodine-131 labeled 0C 125 monoclonal antibodies
versus computed tomography and second look. Int J
Rad Appl Instrum [B] 1991;18(1):69—76.

Benacerraf BR, Finkler NJ, Wojciechowski C, Knapp
RC. Sonographic accuracy in the diagnosis of
ovarian masses. J Reprod Med 1990 May;35(5):
491-5.

Berchuck A, Olt GJ, Soisson AP, Kamel A, Soper JT,
Boyer CM, Clarke-Pearson DL, Leslie DS, Bast
RC Jr. Heterogeneity of antigen expression in
advanced epithelial ovarian cancer. Am J Obstet
Gynecol 1990 Apr;l62(4):883—8.

Berkowitz RS. CA125 measurement in epithelial
ovarian cancer: A 10-year anniversary of clinical
investigation. Gynecol Oncol 1993;49(1):1-2.

Biesecker BB, Boehnke M, Calzone K, Markel DS,
Garber J E, Collins FS, Weber BL. Genetic
counseling for families with inherited susceptibility
to breast and ovarian cancer. JAMA 1993 Apr 21;
269(15):1970—4. Published erratum appears in
JAMA 1993 Aug 18;270(7):832.

Bischof P. What do we know about the origin of CA
125? Eur J Obstet Gynecol Reprod Biol 1993 Apr;
49(1-2):93-8.

Bonilla-Musoles F, Ballester MJ, Simon C, Serra V,
Raga F. ls avoidance of surgery possible in patients
with perimenopausal ovarian tumors using
transvaginal ultrasound and duplex color Doppler
sonography? J Ultrasound Med 1993 Jan;12(1):
33-9.

Boume T, Reynolds K, Campbell S. Ovarian cancer
screening. Eur J Cancer 1991;27(5):655-9.

Boume TH, Campbell S, Reynolds KM, Whitehead MI,
Hampson J, Royston P, Crayford TJ, Collins WP.
Screening for early familial ovarian cancer with
transvaginal ultrasonography and colour blood flow
imaging. BMJ 1993 Apr 17;306(6884):1025~9.
Comment in: BMJ 1993 Apr 17;306(6884):1015—6
and BMJ 1993 Jun 19;306(6893):1685-6.

Boume TH, Hampson J, Reynolds K, Collins WP,
Campbell S. Screening for early ovarian cancer.
Br J Hosp Med 1992 Oct 21—Nov 3;48(8):454-9.

Boume TH, Reynolds K, Campbell S. Ovarian cancer
screening. Curr Opin Radiol 1991 Apr;3(2):216-24.

Boume TH, Whitehead MI, Campbell S, Royston P,
Bhan V, Collins WP. Ultrasound screening for
familial ovarian cancer. Gynecol Oncol 1991
Nov;43(2):92-7. Comment in: Gynecol Oncol 1991
Nov;43(2):89-91 and Gynecol Oncol 1992
Dec;47(3):404.

Bronshtein M, Yoffe N, Brandes J M, Blumenfeld Z.
Hair as a sonographic marker of ovarian teratomas:
improved identification using transvaginal
sonography and simulation model. J Clin
Ultrasound 1991 Jul-Aug;19(6):351-5.

Brucks JA. Ovarian cancer. The most lethal
gynecologic malignancy. Nurs Clin North Am 1992
Dec;27(4):835-45.

Buamah PK, Rake MO, Drake SR, Skillen AW. Serum
CA 12-5 concentrations and CA 12-5/CEA ratios in
patients with epithelial ovarian cancer. J Surg Oncol
1990 Jun;44(2):97-9.

Buy JN, Ghossain MA, Sciot C, Bazot M, Guinet C,
Prevot S, Hugol D, Laromiguiere M, True JB,
Poitout P, et al. Epithelial tumors of the ovary: CT
findings and correlation with US. Radiology 1991
Mar;178(3):811-8.

Campbell S, Bhan V, Royston P, Whitehead M],
Collins WP. Transabdominal ultrasound screening
for early ovarian cancer. BMJ 1989 Dec 2;
299(6712):1363-7. Comment in: BMJ 1990 Jan 20;
300(6718):193-5 and BMJ 1990 Feb 3;
300(6720):330.

10

Campbell S, Boume T, Bradley E. Screening for
ovarian cancer by transvaginal sonography and
colour Doppler. Eur J Obstet Gynecol Reprod Biol
1993 Apr;49(1-2):33-4.

Campbell S, Royston P, Bhan V, Whitehead MI,
Collins WP. Novel screening strategies for early
ovarian cancer by transabdominal ultrasonography.
Br J Obstet Gynaecol 1990 Apr;97(4):304-11.

Campion MJ, Reid R. Screening for gynecologic
cancer. Obstet Gynecol Clin North Am 1990
Dec; 17(4) : 695-727 .

Capstick V, Maclean GD, Suresh MR, Bodnar D,
Lloyd S, Shepcrt L, Longenecker BM, Krantz M.
Clinical evaluation of a new two-site assay for
CA125 antigen. Int J Biol Markers 1991 Apr-Jun;
6(2):129-35.

Chen DX, Schwartz PE, Li FQ. Saliva and serum CA
125 assays for detecting malignant ovarian tumors.
Obstet Gynecol 1990 Apr;75(4):701—4.

Chenevix-Trench G, Leary J, Kerr J, Michel J, Kefford
R, Hurst T, Parsons PG, Friedlander M, Khoo SK.
Frequent loss of heterozygosity on chromosome 18
in ovarian adenocarcinoma which does not always
include the DCC locus. Oncogene 1992 Jun;7(6):
1059-65._

Ciotti MC. Screening for gynecologic and colorectal
cancer: is it adequate? Womens Health Issues 1992
Summer;2(2):83-92; discussion 92-3.

Cliby W, Ritland S, Hartmann L, Dodson M, Halling
KC, Keeney G, Podratz KC, Jenkins RB. Human
epithelial ovarian cancer allelotype. Cancer Res
1993 May 15;53(10 Suppl):2393-8.

Cliby W, Sarkar G, Ritland SR, Hartmann L, Podratz
KC, Jenkins RB. Absence of prohibitin gene
mutations in human epithelial ovarian tumors.
Gynecol Oncol 1993 Jul;50(1):34-7.

Cole LA, Nam JH, Chambers JT, Schwartz PE.
Urinary gonadotropin fragment, a new tumor
marker. H. Differentiating a benign from a

malignant pelvic mass. Gynecol Oncol 1990
Mar;36(3):391—4.

Conte M, Guariglia L, Benedetti Panici PL, Scambia G,
Cento R, Laurelli G, Mancuso S. Ovarian
carcinoma: an ultrasound study. Eur J Gynaecol
Oncol 1990;11(1):33-6.

Creasman WT, DiSaia PJ. Screening in ovarian cancer.
Am J Obstet Gynecol 1991 Jul;165(l):7-10.
Comment in: Am J Obstet Gynecol 1992 May;
l66(5):1591-3.

de Bruijn HW, ten Hoor KA, Boonstra H, Marrink J,
Krans M, Aalders JG. Cancer-associated antigen
CA 195 in patients with mucinous ovarian tumours:
a comparative analysis with CEA, TATI and CA

125 in serum specimens and cyst fluids. Tumour
Biol 1993;14(2):105-15.

de los Frailes MT, Stark S, Jaeger W, Hoerauf A,
Wildt L. Purification and characterization of the CA
125 tumor—associated antigen from human ascites.
Tumour Biol 1993;14(1):18-29.

Demaerel P, Baert AL, Ide P, Obletter N, Marchal G,
Van Hecke P, Bonte J. Magnetic resonance imaging
of the pathological female pelvis: assessment of 24
patients with high-field magnetic resonance
imaging. In: Breit A, ed. Magnetic resonance in
oncology. New York: Springer-Verlag; 1990.
p. 117-24.

DePriest PD, Shenson D, Fried A, Hunter JE, Andrews
SJ, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell
JR Jr. A morphology index based on sonographic
findings in ovarian cancer. Gynecol Oncol 1993
Oct;51(1):7-ll. Comment in: Gynecol Oncol 1993
Oct;51(1):4-6.

DePriest PD, van Nagell JR Jr. Transvaginal ultrasound
screening for ovarian cancer. Clin Obstet Gynecol
1992 Mar;35(l):40—4.

DePriest PD, van Nagell JR Jr, Gallion HH, Shenson
D, Hunter JE, Andrews SJ, Powell DE, Pavlik EJ.
Ovarian cancer screening in asymptomatic
postmenopausal women. Gynecol Oncol 1993 Nov;
51(2):205-9.

Dgani R, Shani A, Elchalal U, Harpaz N, Bentwich Z,
Fink A. The leukocyte adherence inhibition test
(LAI) in preoperative diagnosis of epithelial ovarian
cancer. Gynecol Oncol 1993 Jun;49(3):349—53.

DiCioccio RA, Piver MS. The genetics of ovarian
cancer. Cancer Invest 1992;10(2):135-41.

DiSantis DJ, Scatarige JC, Kemp G, Given FT, Hsiu
JG, Cramer MS. A prospective evaluation of
transvaginal sonography for detection of ovarian
disease. AJR Am J Roentgenol 1993 Jul;161(1):
91-4. Comment in: AJR Am J Roentgenol 1993
Jul;161(1):95-6.

Dodson MK, Hartmann LC, Cliby WA, DeLacey KA,
Keeney GL, Ritland SR, Su JQ, Podratz KC,
Jenkins RB. Comparison of loss of heterozygosity
patterns in invasive low-grade and high—grade
epithelial ovarian carcinomas. Cancer Res 1993
Oct 1;53(19):4456-60.

Dudzinski MR. Tumor markers in ovarian carcinoma.
Curr Opin Obstet Gynecol 1990 Feb;2(1):52—6.

Easton DF, Bishop DT, Ford D, Crockford GP.
Genetic linkage analysis in familial breast and
ovarian cancer: results from 214 families. The
Breast Cancer Linkage Consortium. Am J Hum
Genet 1993 Apr;52(4):678-701.

Eccles DM, Cranston G, Steel CM, Nakamura Y,
Leonard RC. Allele losses on chromosome 17 in

human epithelial ovarian carcinoma. Oncogene 1990
Oct;5(10):1599—601.

Eccles DM, Gruber L, Stewart M, Steel CM, Leonard
RC. Allele loss on chromosome 11p is associated
with poor survival in ovarian cancer. Dis Markers
1992 Mar—Apr;10(2):95-9.

Eccles DM, Russell SE, Haites NE, Atkinson R, Bell
DW, Gruber L, Hickey 1, Kelly K, Kitchener H,
Leonard R, et al. Early loss of heterozygosity on
17q in ovarian cancer. The Abe Ovarian Cancer
Genetics Group. Oncogene 1992 Oct;7(10):2069-72.

Ehlen T, Dubeau L. Loss of heterozygosity on
chromosomal segments 3p, 6q and 11p in human
ovarian carcinomas. Oncogene 1990 Feb;5(2):
219-23.

Einhom N. Ovarian cancer. Early diagnosis and
screening. Hematol Oncol Clin North Am 1992
Aug;6(4):843-50.

Einhom N, Sjovall K, Knapp RC, Hall P, Scully RE,
Bast RC Jr, Zurawski VR Jr. Prospective evaluation
of serum CA 125 levels for early detection of
ovarian cancer. Obstet Gynecol 1992 Jul;80(1):
14-8.

Ferdeghini M, Gadducci A, dell’Hoste M, Prontera C,
Ceccarini T, Rispoli G, Bianchi R, Fioretti P.
CAM26, CAM29 and mucin-like carcinoma
associated antigen in epithelial ovarian cancer. Eur
J Gynaecol Oncol 1990;11(5):395—401.

Ferdcghini M, Gadducci A, Prontera C, Malagnino G,
Annicchiarico C, Prato B, Bianchi R, Fioretti P.
Combined evaluation of serum CA 125 and CAM
29 in patients with epithelial ovarian cancer.
Tumour Biol 1992;13(5-6):287~93.

Ferdeghini M, Gadducci A, Prontera C, Malagnino G,
Fanucchi A, Annicchiarico C, Facchini V, Bianchi
R. Serum soluble interleukin-2 receptor assay in
epithelial ovarian cancer. Tumour Biol 1993;
14(5):303-9.

Feunteun J, Narod SA, Lynch HT, Watson P, Conway
T, Lynch J, Parboosingh J, O’Connell P, White R,
Lenoir GM. A breast-ovarian cancer susceptibility

gene maps to chromosome 17q21. Am J Hum Genet
1993 Apr;52(4):736-42.

Finkler NJ. Clinical utility of CA 125 in preoperative
diagnosis of patients with pelvic masses. Eur J
Obstet Gynecol Reprod Biol 1993 Apr;49(1-2):
105-7.

Fleischer AC. New applications of pelvic sonography.
Urol Radiol 1991;13(1):9-15.

ll

Fleischer AC. Transabdominal and transvaginal
sonography of ovarian masses. Clin Obstet Gynecol
1991 Jun;34(2):433-42.

Fleischer AC, McKee MS, Gordon AN, Page DL,
Kepple DM, Worrell JA, Jones HW 3d, Burnett
LS, James AE Jr. Transvaginal sonography of
postmenopausal ovaries with pathologic correlation.
J Ultrasound Med 1990 Nov;9(11):637—44.

Fleischer AC, Rodgers WH, Kepple DM, Williams LL,
Jones HW 3d. Color Doppler sonography of
ovarian masses: a multiparameter analysis.

J Ultrasound Med 1993 Jan;12(1):41-8.

Fleischer AC, Rodgers WH, Kepple DM, Williams LL,
Jones HW 3d, Gross PR. Color Doppler
sonography of benign and malignant ovarian
masses. Radiographics 1992 Sep;12(5):879—85.

Fleischer AC, Rodgers WH, Rao BK, Kepple DM,
Worrell JA, Williams L, Jones HW 3d. Assessment
of ovarian tumor vascular-ity with transvaginal color
Doppler sonography. J Ultrasound Med 1991 Oct;
10(10):563-8. Comment in: J Ultrasound Med 1993
Jan;12(1):10, 16.

Foglia M, Verri PG, Calabrese A, Corongiu F, Tarani
A, Margiaria ML, De Pascale A, Tagliati D.
Echography and CA 125 in ovarian pathology.
Preliminary data of a new score. J Nucl Med Allied
Sci 1990 Oct—Dec;34(4 Suppl):67—70.

Foulkes WD, Black DM, Stamp GW, Solomon E,
Trowsdale J. Very frequent loss of heterozygosity
throughout chromosome 17 in sporadic ovarian
carcinoma. Int J Cancer 1993 May 8;54(2):220—5.

Foulkes WD, Campbell IG, Stamp GW, Trowsdale J.
Loss of heterozygosity and amplification on
chromosome 11q in human ovarian cancer. Br J
Cancer 1993 Feb;67(2):268-73.

Foulkes WD, Ragoussis J, Stamp GW, Allan G],
Trowsdale J. Frequent loss of heterozygosity on
chromosome 6 in human ovarian carcinoma. Br J
Cancer 1993 Mar;67(3):551-9.

Freimanis MG, Jones AF. Transvaginal
ultrasonography. Radiol Clin North Am 1992 Sep;
30(5):955—76.

Fuith LC, Marth C, Muller-Holzner E, Zechmann W,
Daxenbichler G. Enhancement of CA 125
expression by interferon-gamma in ovarian
carcinoma xenographs. J Tumor Marker Oncol
1991;6(2):85-9.

Gadducci A, Ciancia EM, Malagnino G, De Luca F,
Campani D, Ferdeghini M, Facchini V, Pingitore
R, Fioretti P. Comparison between serum CA 125
and CA 19—9 assays and tissular 0C 125 and
1116NS 19-9 reactivity in malignant and benign
ovarian tumors. Eur J Gynaecol Oncol 1992;
13(4):346—54.

12

Gadducci A, Ferdeghini M, Prontera C, Moretti L,
Mariani G, Bianchi R, Fioretti P. The concomitant
determination of different tumor markers in patients
with epithelial ovarian cancer and benign ovarian
masses: relevance for differential diagnosis.
Gynecol Oncol 1992 Feb;44(2):147-54.

Gadducci A, Ferdeghini M, Prontera C, Moretti L,
Pellagatta L, Bianchi R, Fioretti P. CA 195: a new
monoclonal antibody—defined Lea blood group-
related tumor marker in patients with epithelial
ovarian cancer. J Nucl Biol Med 1991 Jan-Mar;
35(1):33-7.

Gadducci A, Ferdeghini M, Rispoli G, Prontera C,
Bianchi R, Fioretti P. Comparison of tumor-
associated trypsin inhibitor (T ATI) with CA125 as a
marker for diagnosis and monitoring of epithelial

ovarian cancer. Scand J Clin Lab Invest Suppl
1991;207:19-24.

Gallion HH, Bast RC Jr. National Cancer Institute
Conference on Investigational Strategies for
Detection and Intervention in Early Ovarian Cancer.
Cancer Res 1993 Aug 15;53(16):3839-42.

Gallion HH, Powell DE, Morrow JK, Pieretti M, Case
E, Turker MS, DePriest PD, Hunter J E, van Nagell
JR Jr. Molecular genetic changes in human
epithelial ovarian malignancies. Gynecol Oncol
1992 Nov;47(2):137-42. Comment in: Gynecol
Oncol 1992 Nov;47(2)2135-6.

Gallion HH, Powell DE, Smith LW, Morrow JK,
Martin AW, van Nagell JR, Donaldson ES.
Chromosome abnormalities in human epithelial

ovarian malignancies. Gynecol Oncol 1990 Sep;
38(3):473-7.

Gargano G, Correale M, Abbate I, Falco G, De Frenza
N, Lorusso V, De Lena M, De Leonardis A. The
role of tumour markers in ovarian cancer. Clin Exp
Obstet Gynecol 1990;17(1):23-9.

Genetic risk and screening techniques for epithelial
ovarian cancer. ACOG Committee Opinion:
Committee on Gynecologic Practice. Number 117--
December 1992. Int J Gynaecol Obstet 1993 Jun;
41(3):321-3.

Ghazizadeh M, Sasaki Y, Oguro T, Aihara K, Tenjin
H, Araki T. Combined immunohistochemical study
of tissue polypeptide antigen and cancer antigen 125
in human ovarian tumours. Histopathology 1990
Aug;17(2):123-8.

Ghossain MA, Buy JN, Ligneres C, Bazot M, Hassen
K, Malbec L, Hugol D, Truc JB, Decroix Y,
Poitout P, et al. Epithelial tumors of the ovary:
comparison of MR and CT findings. Radiology
1991 Dec;181(3):863-70.

Granberg S. Ultrasound in the diagnosis and treatment
of ovarian tumors. Acta Obstet Gynecol Scand
1991;70(4-5):385-6.

Granberg S, Norstrom A, Wikland M. Comparison of
endovaginal ultrasound and cytological evaluation of

cystic ovarian tumors. J Ultrasound Med 1991 Jan;
10(1):9-14.

Granberg S, Wikland M. Ultrasound in the diagnosis
and treatment of ovarian cystic tumours.
Hum Reprod 1991 Feb;6(2):177-85.

Granberg S, Wikland M. Friberg LG. Tumor marker
CA 125 level and ovarian volume at different cycle
day periods and in postmenopause. Int J Gynaecol
Obstet 1990 Oct;33(2):149-52.

Granberg S, Wikland M, Jansson I. Macroscopic
characterization of ovarian tumors and the relation
to the histological diagnosis: criteria to be used for
ultrasound evaluation. Gynecol Oncol 1989 Nov;
35(2):139-44.

Green J, Murton F, Statham H. Psychosocial issues
raised by a familial ovarian cancer register. J Med
Genet 1993 Jul;30(7):575-9.

Grover S, Quinn MA, Weideman P, Koh H. Factors
influencing serum CA 125 levels in normal women.
Obstet Gynecol 1992 Apr;79(4):511-4.

Guinet C, Buy JN, Ghossain MA, Malbec L, Hugol D,
True JB, Poitout P, Vadrot D. Fat suppression
techniques in MR imaging of mature ovarian
teratomas: comparison with CT. Eur J Radiol 1993
Sep; 17(2): 1 17-21 .

Gynecologic sonography. Report of the ultrasonography
task force. Council on Scientific Affairs, American
Medical Association. JAMA 1991 Jun 5;265(21):
2851-5.

Hall JM, Friedman L, Guenther C, Lee MK, Weber
JL, Black DM, King MC. Closing in on a breast
cancer gene on chromosome 17q. Am J Hum Genet
1992 Jun;50(6):1235-42.

Hall KL, Dewar MA, Perchalski J. Screening for
gynecologic cancer. Vulvar, vaginal, endometrial,
and ovarian neoplasms. Prim Care 1992 Sep;
19(3):607-20.

Hamper UM, Sheth S, Abbas FM, Rosenshein NB,
Aronson D, Kurman RJ. Transvaginal color
Doppler sonography of adnexal masses: differences
in blood flow impedance in benign and malignant
lesions. AJR Am J Roentgenol 1993 Jun;160(6):
1225-8.

Harlozinska A, Bar JK, Gawlikowski W, Richter R,
Cislo M. CA 125 and carcinoembryonic antigen
levels in cyst fluid, ascites and serum of patients
with ovarian neoplasms. Ann Chir Gynaecol 1991;
80(4):368—75.

Hata K, Hata T, Manabe A, Sugimura K, Kitao M. A
critical evaluation of transvaginal Doppler studies,
transvaginal sonography, magnetic resonance

imaging, and CA 125 in detecting ovarian cancer.
Obstet Gynecol 1992 Dec;80(6):922-6.

Hata K, Makihara K, Hata T, Takahashi K, Kitao M.
Transvaginal color Doppler imaging for
hemodynamic assessment of reproductive tract
tumors. Int J Gynaecol Obstet 1991 Dec;
36(4):301-8.

Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacur
H, Comstock GW. Prospective study of serum
CA-125 levels as markers of ovarian cancer. JAMA
1993 Mar 3;269(9):1123-6. Comment in: JAMA
1993 Mar 3;269(9):1163 and JAMA 1993 Jun
23-30;269(24):3106-7.

Herrmann UJ. Sonographic patterns of ovarian tumors.
Clin Obstet Gynecol 1993 Jun;36(2):375-83.

Higgins RV, van Nagell JR Jr, Woods CH, Thompson
EA, Kryscio RJ. Interobserver variation in ovarian
measurements using transvaginal sonography.
Gynecol Oncol 1990 Oct;39(1):69-71.

Hirai T, Akamatsu N, Sekiba K, Tsubota N, Tsuru S.
Qualificated discrimination of ovarian malignancy

by diagnostic ultrasound. Asia Oceania J Obstet
Gynaecol 1993 Jun;19(2):181-9.

Hosono MN, Endo K, Sakahara H, Watanabe Y, Saga
T, Nakai T, Hosono M, Nakajima T, Onoyama Y,
Konishi J. Different antigenic nature in apparently
healthy women with high serum CA 125 levels
compared with typical patients with ovarian cancer.
Cancer 1992 Dec 15;70(12):2851-6.

Houlston R, Boume TH, Davies A, Whitehead MI,
Campbell S, Collins WP, Slack J. Use of family
history in a screening clinic for familial ovarian
cancer. Gynecol Oncol 1992 Nov;47(2):247-52.

Houlston RS, Collins A, Slack J, Campbell S, Collins
WP, Whitehead MI, Morton NE. Genetic
epidemiology of ovarian cancer: segregation
analysis. Ann Hum Genet 1991 Oct;55(Pt 4):291-9.

Houvenaeghel G, Delpero JR, Rosello R, Resbeut M,
Viens P, Jacquemier J, Noirclerc M, Guerinel G.
Results of a prospective study with comparison of
clinical, endosonographic, computed tomography,
magnetic resonance imaging and pathologic staging
of advanced gynecologic carcinoma and recurrence.
Surg Gynecol Obstet 1993 Sep;177(3):231-6.

Hricak H. Carcinoma of the female reproductive
organs. Value of cross-sectional imaging. Cancer
1991 Feb 15;67(4 Suppl):1209-18.

Huengsberg M, MacDonald LM, Bradbeer CS. The use
of pelvic ultrasound in female patients attending a
GUM clinic. Int J STD AIDS 1993 Jul-Aug;4(4):
190—3.

Hunter VJ, Weinberg JB, Haney AF, Soper JT, Lavin
P, Metsch L, Knapp RC, Bast RC Jr. CA 125 in

13

peritoneal fluid and serum from patients with
benign gynecologic conditions and ovarian cancer.
Gynecol Oncol 1990 Feb;36(2):161—5.

Inoue M, Fujita M, Nakazawa A, Ogawa H, Tanizawa
O. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125,
carcinoembryonic antigen, and tissue polypeptide
antigen in differentiating ovarian cancer from
benign tumors. Obstet Gynecol 1992 Mar;79(3):
434-40.

Iwanari O, Miyako J, Date Y, Nakayama S, Kijima S,
Moriyama M, Karino K, Endoh J, Kitao M.
Clinical evaluations of the tumor marker sialyl
SSEA-l antigen for clinical gynecological disease.
Gynecol Obstet Invest 1990;29(3):214-8.

Iwanari O, Miyako J, Date Y, Nakayama S, Kijima S,
Moriyama M, Takahashi K, Yoshino N, Karino K,
Endoh J, et al. Differential diagnosis of ovarian
cancer, benign ovarian tumor and endometriosis by
a combination assay of serum sialyl SSEA-l antigen
and CA125 levels. Gynecol Obstet Invest 1990;
29(1):71-4.

Jacobs I, Bast RC Jr. Immunodiagnosis of ovarian
tumors. Immunol Ser 1990;53:323-38.

Jacobs I, Davies AP, Bridges J, Stabile I, Fay T,
Lower A, Grudzinskas JG, Oram D. Prevalence
screening for ovarian cancer in postmenopausal
women by CA 125 measurement and
ultrasonography. BMJ 1993 Apr 17;306(6884):
1030—4. Comment in: BMJ 1993 Apr 17;306(6884):
1015-6 ; BMJ 1993 Jun 19;306(6893): 1684;
discussion 1685-6 ; BMJ 1993 Jun l9;306(6893):
1685 ; BMJ 1993 Jun 19;306(6893):1685-6.

Jacobs 1, Oram D, Fairbanks J, Turner J, Frost C,
Grudzinskas JG. A risk of malignancy index
incorporating CA 125, ultrasound and menopausal
status for the accurate preoperative diagnosis of
ovarian cancer. Br J Obstet Gynaecol 1990 Oct;
97(10):922-9.

Jacobs 11, Gram DH, Bast RC Jr. Strategies for
improving the specificity of screening for ovarian
cancer with tumor-associated antigens CA 125, CA
15-3, and TAG 72.3. Obstet Gynecol 1992 Sep;80
(3 Pt 1):396-9.

Jacobs IJ, Smith SA, Wiseman RW, Futreal PA,
Harrington T, Osborne RJ, Leech V, Molyneux A,
Berchuck A, Ponder BA, et al. A deletion unit on
chromosome 17q in epithelial ovarian tumors distal
to the familial breast/ovarian cancer locus. Cancer
Res 1993 Mar 15;53(6):1218-21.

Jain KA, Friedman DL, Pettinger TW, Alagappan R,
Jeffrey RB Jr, Sommer FG. Adnexal masses:
comparison of specificity of endovaginal US and
pelvic MR imaging. Radiology 1993 Mar;186(3):
697-704.

14

Jain KA, Jeffrey RB Jr. Pictorial essay: transabdominal
and endovaginal sonography of adnexal masses.
Clin Imaging 1991 Oct-Dec;15(4):245-52.

Jones MH, Nakamura Y. Deletion mapping of
chromosome 3p in female genital tract malignancies
using microsatellite polymorphisms. Oncogene 1992
Aug;7(8):1631-4.

Juhasz B, Kurjak A, Lampe L, Zalud I, Crvenkovic G,
Hemadi Z. Tissue characterization by transvaginal
colour Doppler for the evaluation of gynaecological
tumours. 2. Clinical experiences. Acta Med Hung
1990;47(3-4):149—56.

Karlan BY, Raffel Ll, Crvenkovic G, Smrt C, Chen
MD, Lopez E, Walla CA, Garber C, Cane P, Sarti
DA, et al. A multidisciplinary approach to the early
detection of ovarian carcinoma: rationale, protocol
design, and early results. Am J Obstet Gynecol
1993 Sep;169(3):494-501.

Kawai M, Kano T, Kikkawa F, Maeda O, Oguchi H,
Tomoda Y. Transvaginal Doppler ultrasound with
color flow imaging in the diagnosis of ovarian
cancer. Obstet Gynecol 1992 Feb;79(2):163—7.

Kenemans P, Bon GG, Kessler AC, Verstraeten AA,
van Kamp GJ. Multicenter technical and clinical
evaluation of a fully automated enzyme
immunoassay for CA 125. Clin Chem 1992 Aug;
38(8 Pt l):1466-71.

Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA.
Heterologous double-determinant
immunoradiometric assay CA 125 I]: reliable
second-generation immunoassay for determining CA
125 in serum. Clin Chem 1993 Dec;39(12):
2509-13.

Kenemans P, Yedema CA, Bon GG, von Mensdorff—
Pouilly S. CA 125 in gynecological pathology--a
review. Eurl Obstet Gynecol Reprod Biol 1993
Apr;49(1-2):115—24.

Kiechle-Schwarz M, Bauknecht T, Wienker T, Walz L,
Pfleiderer A. Loss of constitutional heterozygosity
on chromosome 11p in human ovarian cancer.

Positive correlation with grade of differentiation.
Cancer 1993 Oct 15;72(8):2423—32.

Kier R, Smith RC, McCarthy SM. Value of lipid- and
water-suppression MR images in distinguishing
between blood and lipid within ovarian masses.
AJR Am J Roentgenol 1992 Feb;158(2):321-5.

King MC, Rowell S, Love SM. Inherited breast and
ovarian cancer. What are the risks? What are the
choices? JAMA 1993 Apr 21;269(15):l975-80.

Kobayashi H, Tamura M, Satoh T, Terao T. Clinical
evaluation of new cancer-associated antigen CA125
II in epithelial ovarian cancers: comparison with
CA125. Clin Biochem 1993 Jun;26(3):213-9.

Kopf I, Strid KG, Islam MQ, Granberg S, Friberg LG,
Levan G, Carstensen J. Heterochromatin variants in
109 ovarian cancer patients and 192 healthy
subjects. Hereditas 1990;113(1):7-16.

Kramer BS, Gohagan J, Prorok PC, Smart C. A
National Cancer Institute sponsored screening trial
for prostatic, lung, colorectal, and ovarian cancers.
Cancer 1993 Jan 15;71(2 Suppl):589—93.

Kucsel AC, Kroft T, Prefontaine M, Smith IC.
Lipoprotein(a) and CA125 levels in the plasma of
patients with benign and malignant ovarian disease.
Int J Cancer 1992 Sep 30;52(3):341-6.

Kupfer MC, Schwimer SR, Lebovic J. Transvaginal
sonographic appearance of endometriomata:
spectrum of findings. J Ultrasound Med 1992 Apr;
11(4): 129-33.

Kurjak A, Predanic M. New scoring system for
prediction of ovarian malignancy based on
transvaginal color Doppler sonography.

J Ultrasound Med 1992 Dec;11(12):631-8.

Kurjak A, Predanic M, Kupesic-Urek S, Jukic S.
Transvaginal color and pulsed Doppler assessment
of adnexal tumor vascularity. Gynecol Oncol 1993
Jul;50(l):3-9.

Kurjak A, Salihagic A, Kupesic-Urek S, Predanic A.
Clinical value of the assessment of gynaecological
tumour angiogenesis by transvaginal colour
Doppler. Ann Med 1992 Apr;24(2):97—103.

Kurjak A, Schulman H, Sosic A, Zalud I, Shalan H.
Transvaginal ultrasound, color flow, and Doppler
waveform of the postmenopausal adnexal mass.
Obstet Gynecol 1992 Dec;80(6):917-21.

Kurjak A, Zalud I, Alfirevic Z. Evaluation of adnexal
masses with transvaginal color ultrasound.
J Ultrasound Med 1991 Jun;lO(6):295—7. Comment
in: J Ultrasound Med 1992 Mar;11(3):80.

Laing FC. Ultrasound of gynecologic pathologies. Curr
Opin Radiol 1992 Apr;4(2):78-84.

Lee JH, Kavanagh JJ, Wildrick DM, Wharton JT, Blick
M. Frequent loss of heterozygosity on
chromosomes 6q, 11, and 17 in human ovarian
carcinomas. Cancer Res 1990 May 1;50(9):2724-8.

Li FP, Garber J E. Gene for familial breast and ovarian
cancer. Lancet 1993 Apr 24;341(8852):1060—1.
Comment on: Lancet 1993 Apr 24;341(8852):
1101-2 ; Comment in: Lancet 1993 May 29;
341(8857):1422.

Lotzniker M, Pavesi F, Scarabelli M, Vadacca G,
Franchi M, Moratti R. Tumour associated antigens
CA 15.3 and CA 125 in ovarian cancer. Int J Biol
Markers 1991 Apr-Jun;6(2):115—21.

Luxman D, Bergman A, Sagi J, David MP. The
postmenopausal adnexal mass: correlation between
ultrasonic and pathologic findings. Obstet Gynecol
1991 May;77(5):726-8. Comment in: Obstet
Gynecol 1991 Oct;78(4):726.

Macri CI, DiSaia PJ. Ovarian cancer screening. West J
Med 1992 Jun;156(6):652-3.

Mahon SM, Casperson DS. Focus on oncology: ovarian
cancer screening and early detection. J Urol Nurs
1992 Apr-Jun;11(2):112-9.

Mazoyer S, Lalle P, Narod SA, Bignon YJ, Courjal F,
Jamot B, Dutrillaux B, Stoppa-Lyonnett D, Sobol
H. Linkage analysis of 19 French breast cancer
families, with five chromosome 17q markers. Am J
Hum Genet 1993 Apr;52(4):754-60.

Menczer J, Ben-Baruch G, Moran O, Lipitz S. Cyst
fluid CA 125 levels in ovarian epithelial neoplasms.
Obstet Gynecol 1993 Jan;81(1):25-8.

Mendelson EB, Bohm-Velez M. Transvaginal
ultrasonography of pelvic neoplasms. Radiol Clin
North Am 1992 Jul;30(4):703—34.

Milner BJ, Allan LA, Kelly KF, Cruickshank D, Hall
M, Johnston A, Kitchener H, Parkin D, Haites N.
Linkage studies with 17q and 18q markers in a
breast/ovarian cancer family. Am J Hum Genet
1993 Apr;52(4):761-6.

Miyao M, Takahashi M, Sumi M, Miyazaki K,
Okamura H. Correlation of CT patterns with
histologic findings in parauterine masses. Radiat
Med 1992 Nov-Dec;10(6):223-31.

Mogensen O, Mogensen B, Jakobsen A. Tumor-
associated trypsin inhibitor and cancer antigen 125
in pelvic masses. Gynecol Oncol 1990 Aug;
38(2):170—4.

Mogensen O, Mogensen B, Jakobsen A. Tumour-
associated trypsin inhibitor (TATI) and cancer

antigen 125 (CA 125) in mucinous ovarian tumours.

Br J Cancer 1990 Feb;61(2):327-9.

Molina R, Ojeda B, Filella X, Borras G, Jo J, Mas E,
Lopez JJ , Ballesta A. A prospective study of tumor
markers CA 125 and CA 19.9 in patients with
epithelial ovarian carcinomas. Tumour Biol 1992;
13(5-6):278-86.

Monoclonal antibodies in breast and ovarian cancer.
Proceedings of the British Association for Cancer
Research Workshop, Oxford, 17-19 March, 1991.
Dis Markers 1991 May-Aug;9(3-4):125-238.

Motoyama T, Watanabe H, Takeuchi S, Watanabe T,
Gotoh S, Okazaki E. Cancer antigen 125,
careinoembryonic antigen, and carbohydrate

determinant 19-9 in ovarian tumors. Cancer 1990
Dec 15;66(12):2628-35.

15

Muto MG, Cramer DW, Brown DL, Welch WR,
Harlow BL, Xu H, Brucks JP, Tsao SW, Berkowitz
RS. Screening for ovarian cancer: the preliminary
experience of a familial ovarian cancer center.
Gynecol Oncol 1993 Oct;51(1):12-20.

Nadji M. Tumor markers in gynecologic neoplasms.
Clin Lab Med 1990 Mar;10(l):105-17.

Narod SA, Feunteun J, Lynch HT, Watson P, Conway
T, Lynch J, Lenoir GM. Familial breast-ovarian
cancer locus on chromosome l7q12-q23. Lancet
1991 Jul 13;338(8759):82~3. Comment in: Lancet
1991 Aug 17;338(8764):444—5.

Neal CE, Baker MR, Hilgers RD, Fanning J, Burke
RC, Snodgrass J, Cull RD. In—lll CYT-103
immunoscintigraphy in the imaging of ovarian
carcinoma. Clin Nucl Med 1993 Jun;18(6):472-6.

Neal CE, Swenson LC, Fanning J, Texter JH.
Monoclonal antibodies in ovarian and prostate
cancer. Semin Nucl Med 1993 Apr;23(2):114-26.

Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M,
Okabe K, Sato H, Asano G. Serum and tissue
measurements of CA72-4 in ovarian cancer patients.
Gynecol Oncol 1993 Feb;48(2):148-54.

Nelson CL, Sellers TA, Rich SS, Potter JD, McGovern
PG, Kushi LH. Familial clustering of colon, breast,
uterine, and ovarian cancers as assessed by family
history. Genet Epidemiol 1993;10(4):235-44.

Normand T, Narod S, Labrie F, Simard J. Detection of
polymorphisms in the estradiol 17 beta-
hydroxysteroid dehydrogenase II gene at the
EDH17B2 locus on 17q11-q21. Hum Mol Genet
1993 Apr;2(4):479-83.

Nozawa S, Aoki D, Yajima M, Tsukazaki K,
Kobayashi T, Kimura E, Terashima Y, Inaba N,
Takamizawa H, Negishi Y, et a1. CA54/61 as a
marker for epithelial ovarian cancer. Cancer Res
1992 Mar 1;52(5):1205-9.

Nozawa S, Yajima M, Sakuma T, Udagawa Y, Kiguchi
K, Sakayori M, Narisawa S, Iizuka R, Uemura M.
Cancer-associated galactosyltransferase as a new
tumor marker for ovarian clear cell carcinoma.
Cancer Res 1990 Feb 1;50(3):754-9.

Nozawa S, Yajima M, Sasaki H, Tsukazaki K, Aoki D,
Sakayori M, Udagawa Y, Kobayashi T, Sato I,
Furusako S, et al. A new CA125-like antigen
(CA602) recognized by two monoclonal antibodies
against a newly established ovarian clear cell
carcinoma cell line (RMG-H). Jpn J Cancer Res
1991 Jul;82(7):854-61.

Occhipinti KA, Frankel SD, Hricak H. The ovary.
Computed tomography and magnetic resonance
imaging. Radiol Clin North Am 1993 Sep;31(5):
1 1 15-32.

16

Ohkawa K, Takada K, Hatano T, Takizawa N, Tsukada
Y, Yamada K, Terashima Y, Matsuda M, Machida
K. An evaluation of ovarian carcinoma-associated
antigen defined by murine monoclonal antibody
CF511 in sera from patients with ovarian
carcinoma. Br J Cancer 1991 Aug;64(2):259—62.

Ohuchi N, Gero E, Mori S, Akimoto M, Matoba N,
Nishihira T, Hirayama K, Colcher D, Schlom J .
Clinical evaluation of CA72-4 immunoradiometric
assay for serum TAG-72 antigen in patients with
carcinoma. J Tumor Marker Oncol 1990;5(1):1—10.

Okamoto A, Sameshima Y, Yokoyama S, Terashima Y,
Sugimura T, Terada M, Yokota J. Frequent allelic
losses and mutations of the p53 gene in human
ovarian cancer. Cancer Res 1991 Oct 1;51(19):
5171-6.

Onnis A, Marchetti M, Maggino T, De Toffoli J,
Blandamura S. Clinical experience in gynecological
cancer management. d). Ovarian tumors--1)
Epithelial: report from the Gynaecological Institutes
of Padua University (1963-1990). Eur J Gynaecol
Oncol 1992;13(1):17-33.

Oram DH, Jacobs 1], Brady J L, Prys—Davies A. Early
diagnosis of ovarian cancer. Br J Hosp Med 1990
Nov;44(5):320, 322, 324.

Patsner B. Preoperative serum CA-125 levels in early
stage ovarian cancer. Eur J Gynaecol Oncol
1990;11(5):319-21.

Pejovic T, Heim S, Mandahl N, Baldetorp B, Elmfors
B, Flodenis UM, Furgyik S, Helm G, Himmelmann
A, Willen H, et al. Chromosome aberrations in 35
primary ovarian carcinomas. Genes Chromosom
Cancer 1992 Jan;4(1):58-68.

Perkins AC, Powell MC, Wastie ML, Scott IV,
Hitchcock A, Worthington BS, Symonds EM. A
prospective evaluation of OC125 and magnetic
resonance imaging in patients with ovarian
carcinoma. Eur J Nucl Med 1990;16(4—6):311-6.

Persons DL, Hartmann LC, Herath JF, Borell TJ, Cliby
WA, Keeney GL, Jenkins RB. lnterphase molecular
cytogenetic analysis of epithelial ovarian
carcinomas. Am J Pathol 1993 Mar;142(3):733-41.

Phillips N, Ziegler M, Saha B, Xynos F. Allelic loss on
chromosome 17 in human ovarian cancer. Int J
Cancer 1993 Apr 22;54(1):85-91.

Piver MS, Hempling RE. Screening for gynecologic
malignancies in primary care: ovarian cancer.
Emerg Med 1993 Mar;25(4):141-2, 145-6, 148.

Plebani M, Faggian D, Masiero M, Giacomini A,
Burlina A. CA 19-9 and CA 125 determination by
immunoluminometric assay. J Clin Chem Clin
Biochem 1990 Dec;28(12):919—21.

Popp LW, Gaetje R, Stoyanov M. Accuracy of
bimanual palpation versus vaginosonography in
determination of the measurements of pelvic
tumors. Arch Gynecol Obstet 1993;252(4):197—202.

Porter DE, Cohen BB, Wallace MR, Carothers A, Steel
CM. Linkage mapping in familial breast cancer:
improved localisation of a susceptibility locus on
chromosome 17q12-21. Int J Cancer 1993 Jan 21;
53(2):188-98.

Powell MA. Screening for ovarian cancer. J Am Acad
Nurse Pract 1992 Jan-Mar;4(1):36—7.

Pyrgiotis E, Salamalekis E, Loghis C, Dima C, Zourlas
PA. CA 125 in preoperative evaluation of pelvic
masses. Eur J Gynaecol Oncol 1993;14(4):279-82.

Quillin SP, Siege] MJ. CT features of benign and
malignant teratomas in children. J Comput Assist
Tomogr 1992 Sep—Oct;16(5):722-6.

Reinsberg , Nocke W. Falsely low results in CA 125
deter-mi ation due to anti-idiotypic antibodies
induced by infusion of [1311]F(ab’)2 fragments of
the OC125 antibody. Eur J Clin Chem Clin
Biochem 1993 May;31(5):323-7.

Reinsberg J, Schultes B, Wagner U, Krebs D.
Monitoring cancer antigen 125 in serum of ovarian
cancer patients after administration of 13II-labeled
F(ab’)2 fragments of OC125 antibody. Clin Chem
1993 May;39(5):891-6.

Riccio TJ, Adams HG, Munzing DE, Mattrey RF.
Magnetic resonance imaging as an adjunct to

sonography in the evaluation of the female pelvis.
Magn Reson Imaging 1990;8(6):699-704.

Roberts CG, Tattersall MH. Cytogenetic study of solid
ovarian tumors. Cancer Genet Cytogenet 1990 Sep;
48(2):243-53.

Ronay G, lager W, Weiss K, Feistel H, Wolf F,
Tulusan AH, Lang N. Immunohistochemical
identification of CA 125 and the F(ab’)2 fragments
of the murine monoclonal antibody OC125 in
ovarian cancer tissue. Br J Cancer Suppl 1990 Jul;
10:67-9.

Runowicz CD. Advances in the screening and treatment
of ovarian cancer. CA Cancer J Clin 1992 Nov-
Dec;42(6):327-49. Published erratum appears in
CA Cancer J Clin 1993 May-Jun;43(3):191-2.

Runowicz CD, Goldberg GL, Smith HO. Cancer
screening for women older than 40 years of age.
Obstet Gynecol Clin North Am 1993 Jun;20(2):
391-408.

Russell SE, Hickey GI, Lowry WS, White P, Atkinson
R1. Allele loss from chromosome 17 in ovarian
cancer. Oncogene 1990 Oct;5(lO):1581-3.

Rustin GJ. Impact of tumour marker measurements
upon management of patients with carcinoma of the
ovary. Dis Markers 1991 May-Aug;9(3-4):153—8.

Saga T, Endo K, Nakashima T, Awaji T, Koizumi M,
Kawamura Y, Watanabe Y, Konishi J, Nonogaki H,
Nanbu Y, et al. Construction of an
immunoradiometric assay for ovarian cancer
associated antigen CA125 recognizing different
antigenic determinant. Acta Obstet Gynecol Scand
1990;69(2): 175-81.

Saito H, Inazawa J, Saito S, Kasumi F, Koi S, Sagae S,
Kudo R, Saito J, Noda K, Nakamura Y. Detailed
deletion mapping of chromosome l7q in ovarian
and breast cancers: 2—cM region on 17q21.3 often
and commonly deleted in tumors. Cancer Res 1993
Jul 15;53(14):3382-5.

Saito S, Saito H, Koi S, Sagae S, Kudo R, Saito J,
Noda K, Nakamura Y. Fine-scale deletion mapping
of the distal long arm of chromosome 6 in 70
human ovarian cancers. Cancer Res 1992 Oct 15;
52(20):5815-7.

Sarti DA. Transvaginal sonography: a call for tempered
enthusiasm. AJR Am J Roentgenol 1993 Jul;161(1):
95-6. Comment on: AJR Am J Roentgenol 1993
Jul;161(1):9l-4.

Sassone AM, Timor-Tritsch IE, Artner A, Westhoff C,
Warren WB. Transvaginal sonographic
characterization of ovarian disease: evaluation of a
new scoring system to predict ovarian malignancy.
Obstet Gynecol 1991 Jul;78(l):70-6. Comment in:
Obstet Gynecol 1991 Dec;78(6):1151-2.

Sato T, Saito H, Morita R, Koi S, Lee JH, Nakamura
Y. Allelotype of human ovarian cancer. Cancer Res
1991 Oct l;51(19):5118-22.

Satoskar P, Deshpande A. The value of ultrasonography
in the diagnosis of adnexal masses. J Postgrad Med
1991 Jan;37(1):35—9.

Schapira MM, Matchar DB, Young M]. The
effectiveness of ovarian cancer screening. A
decision analysis model. Ann Intern Med 1993
Jun 1;118(11):838-43. Comment in: Ann Intern
Med 1993 Jun 1;118(11):901-2.

Schoenfeld A, Levavi H, Hirsch M, Pardo J, Ovadia J.
Transvaginal sonography in postmenopausal
women. J Clin Ultrasound 1990;18(4):350—8.

Schoenfeld A, Levavi H, Ovadia J. Surgery in
postmenopausal women--the value of transvaginal
sonography. Surg Endosc 1990;4(2):108-13.

Schwartz MK. Screening for cancer: is it cost effective?
Clin Chem 1993 Nov;39(11 Pt 2):2397-403.

Schwartz PE. Ovarian masses: serologic markers. Clin
Obstet Gynecol 1991 Jun;34(2):423-32.

l7

Schwartz PE. The role of tumor markers in the
preoperative diagnosis of ovarian cysts. Clin Obstet
Gynecol 1993 Jun;36(2):384-94.

Schwartz PE, Chambers JT, Taylor KJ, Pellerito J,
Hammers L, Cole LA, Yang-Feng TL, Smith P,
Mayne ST, Makuch R. Early detection of ovarian
cancer: background, rationale, and structure of the
Yale Early Detection Program. Yale J Biol Med
1991 Nov-Dec;64(6):557-71.

Scott IV. The identification of high risk and practical
strategies for a population based randomized trial of
ovarian cancer screening. Dis Markers 1991 May-
Aug;9(3-4):133-52.

Scoutt LM, McCarthy SM. Applications of magnetic
resonance imaging to gynecology. Top Magn Reson
Imaging 1990 Jun;2(3):37-49.

Scoutt LM, McCarthy SM. Imaging of ovarian masses:
magnetic resonance imaging. Clin Obstet Gynecol
1991 Jun;34(2):443-51.

Semelka RC, Lawrence PH, Shoenut JP, Heywood M,
Kroeker MA, Lotocki R. Primary ovarian cancer:
prospective comparison of contrast-enhanced CT
and pre-and postcontrast, fat-suppressed MR
imaging, with histologic correlation. J Magn Reson
Imaging 1993 Jan-Feb;3(1):99-106.

Serreyn R, DeBoever J, Martens G, Vandekerckhove
D. Quantitive assessment of CA-125 in the normal
ovary and in benign and malignant ovarian tumors.
J Tumor Marker Oncol 1990;5(4):341-9.

Siege] MJ, Surratt JT. Pediatric gynecologic imaging.
Obstet Gynecol Clin North Am 1992 Mar;l9(1):
103-27.

Simard J, Feunteun J, Lenoir G, Tonin P, Normand T,
Luu The V, Vivier A, Lasko D, Morgan K,
Rouleau GA, et al. Genetic mapping of the breast-
ovarian cancer syndrome to a small interval on
chromosome 17q12-21: exclusion of candidate
genes EDH17B2 and RARA. Hum Mol Genet 1993
Aug;2(8):1193-9.

Skates SJ, Singer DE. Quantifying the potential benefit
of CA 125 screening for ovarian cancer. J Clin
Epidemic] 1991;44(4-5):365—80.

Smith SA, Easton DF, Evans DG, Ponder BA. Allele
losses in the region 17q12-21 in familial breast and
ovarian cancer involve the wild-type chromosome.
Nat Genet 1992 Oct;2(2):128-31.

Smith SA, Easton DF, Ford D, Pete I, Anderson K,
Averill D, Stratton M, Ponder M, Pye C, Ponder
BA. Genetic heterogeneity and localization of a
familial breast-ovarian cancer gene on chromosome
17q12-q21. Am J Hum Genet 1993 Apr;52(4):
767-76.

18

Soper JT, Hunter VJ, Daly L, Tanner M, Creasman
WT, Bast RC Jr. Preoperative serum tumor-
associated antigen levels in women with pelvic
masses. Obstet Gynecol 1990 Feb;75(2):249-54.

Sparks J M, Varner RE. Ovarian cancer screening.
Obstet Gynecol 1991 May;77(5):787-92.

Spreafico C, Frigerio L, Lanocita R, Spatti GB,
Marchiano A, Milella M, Garbagnati F, Bohm S,
Damascelli B. Color-Doppler ultrasound in ovarian
masses: anatomo-pathologic correlation. Tumori
1993 Aug 31;79(4):262-7.

Spurr NK, Kelsell DP, Black DM, Murday VA, Turner
G, Crockford GP, Solomon E, Cartwright RA,
Bishop DT. Linkage analysis of early—onset breast
and ovarian cancer families, with markers on the

long arm of chromosome 17. Am J Hum Genet
1993 Apr;52(4):777-85.

Stevens SK, Hricak H, Stern J L. Ovarian lesions:
detection and characterization with gadolinium-
enhanced MR imaging at 1.5 T. Radiology 1991
Nov;181(2):481—8.

Stigbrand T, Riklund K, Tholander B, Hirano K, Lalos
O, Stendahl U. Placental alkaline phosphatase
(PLAP)/PLAP-like alkaline phosphatase as tumour
marker in relation to CA 125 and TPA for ovarian
epithelial tumours. Eur J Gynaecol Oncol 1990;
11(5):351-60.

Surratt JT, Siegel MJ. Imaging of pediatric ovarian
masses. Radiographics 1991 Jul;11(4):533-48.

Sutton CL, McKinney CD, Jones JE, Gay SB. Ovarian
masses revisited: radiologic and pathologic
correlation. Radiographics 1992 Sep;12(5):853-77.

Suzuki M, Ohwada M, Aida I, Tamada T, Hanamura
T, Nagatomo M. Macrophage colony-stimulating
factor as a tumor marker for epithelial ovarian
cancer. Obstet Gynecol 1993 Dec;82(6):946—50.

Suzuki M, Sekiguchi I, Tamada T. Clinical evaluation
of tumor-associated mucin—type glycoprotein CA
54/61 in ovarian cancers: comparison with CA 125.
Obstet Gynecol 1990 Sep;76(3 Pt 1):422—7.

Taccone W, Mazzon W, Belli M. Evaluation of TATI
and other markers in solid tumors. Scand J Clin
Lab Invest Suppl 1991;207:25-32.

Tay SK, Tan YY. Risk factors and a risk scoring
system for the prediction of malignancy in ovarian

cysts. Aust N Z J Obstet Gynaecol 1992 Nov;32(4):

341-5.

Theillet C, Adelaide J, Louason G, Bonnet-Dorion F,
Jacquemier J, Adnane J, Longy M, Katsaros D,
Sismondi P, Gaudray P, et al. FGFRI and PLAT
genes and DNA amplification at 8p12 in breast and
ovarian‘ cancers. Genes Chromosom Cancer 1993
Aug;7(4):219-26.

Tholander B, Taube A, Lindgren A, Sjoberg O,
Stendahl U, Kiviranta A, Hallman K, Holm L,
Weiner E, Tamsen L. Pretreatment serum levels of
CA-125, carcinoembryonic antigen, tissue
polypeptide antigen, and placental alkaline
phosphatase, in patients with ovarian carcinoma,
borderline tumors, or benign adnexal masses:
relevance for differential diagnosis. Gynecol Oncol
1990 0ct;39(1):16-25.

Tholander B, Taube A, Lindgren A, Sjoberg O,
Stendahl U, Tamsen L. Pretreatment serum levels
of CA-125, carcinoembryonic antigen, tissue
polypeptide antigen, and placental alkaline
phosphatase in patients with ovarian carcinoma:
influence of histological type, grade of
differentiation, and clinical stage of disease.
Gynecol Oncol 1990 Oct;39(1):26-33.

Thorvinger B. Diagnostic and interventional radiology
in gynecologic neoplasms. Acta Radiol Suppl 1992;
378(Pt 3):93-108.

Thumher S, Hodler J, Baer S, Marincek B, von
Schulthess GK. Gadolinium-DOTA enhanced MR
imaging of adnexal tumors. J Comput Assist
Tomogr 1990 Nov-Dec;14(6):939-49.

Timor-Tritsch LE, Lerner JP, Monteagudo A, Santos
R. Transvaginal ultrasonographic characterization of
ovarian masses by means of color flow—directed
Doppler measurements and a morphologic scoring
system. Am J Obstet Gynecol 1993 Mar;168
(3 Pt 1):909-13.

Toftager—Larsen K, Hording U, Dreisler A, Daugaard
S, Lund B, Bock J, Lundvall F, Frederiksen K,
Norgaard-Pedersen B. CA-125, placental alkaline
phosphatase and tissue polypeptide antigen as
preoperative serum markers in ovarian carcinoma.
Gynecol Obstet Invest 1992;33(3):177-82.

Tomas C, Penttinen J, Risteli J, Risteli L, Kauppila A.
Simultaneous evaluation of epithelial cell function
by CA 125 and stromal cell activity by
aminoterminal propeptide of type III procollagen
(PIIINP) in ovarian carcinoma. Ann Med 1990 Apr;
22(2): 1 15-21.

Tsao SW, Mok CH, Knapp RC, Oike K, Muto MG,
Welch WR, Goodman HM, Sheets EE, Berkowitz
RS, Lau CC. Molecular genetic evidence of a
unifocal origin for human serous ovarian
carcinomas. Gynecol Oncol 1993 Jan;48(1):5-10.
Comment in: Gynecol Oncol 1993 Jan;48(1):1-3.

Tsao SW, Mok CH, Oike K, Muto M, Goodman HM,
Sheets EE, Berkowitz RS, Knapp RC, Lau CC.
Involvement of p53 gene in the allelic deletion of
chromosome 17p in human ovarian tumors.
Anticancer Res 1991 Nov-Dec;11(6):1975-82.

van der Burg ME, Lammes FB, Verweij J. CA 125 in
ovarian cancer. Neth J Med 1992 Feb;40(l-2):
36—5 1.

van der Zee AG, Duk JM, Aalders JG, Boontje AH,
ten Hoor KA, de Bruijn HW. The effect of
abdominal surgery on the serum concentration of
the tumour-associated antigen CA 125. Br J Obstet
Gynaecol 1990 Oct;97(10):934-8.

van Kamp GJ, Verstraeten AA, Kenemans P.
Discordant serum CA 125 values in commercial
immunoassays. Eur J Obstet Gynecol Reprod Biol
1993 Apr;49(1-2):99-103.

van Nagell JR Jr, DePriest PD, Gallion HH, Pavlik El.
Ovarian cancer screening. Cancer 1993 Feb 15;71
(4 Suppl):1523-8.

van Nagell JR Jr, Higgins RV, Donaldson ES, Gallion
HH, Powell DE, Pavlik EJ, Woods CH, Thompson
EA. Transvaginal sonography as a screening
method for ovarian cancer. A report of the first
1000 cases screened. Cancer 1990 Feb 1;65(3):
573-7.

Vandamme B, Lissens W, Amfo K, De Sutter P,
Bourgain C, Vamos E, De Greve J. Deletion of
chromosome 11p13-11p15.5 sequences in invasive
human ovarian cancer is a subclonal progression
factor. Cancer Res 1992 Dec 1;52(23):6646-52.

Varpula M. Magnetic resonance imaging of female
pelvic masses and local recurrent tumors at an ultra
low (0.02 T) magnetic field: correlation with
computed tomography. Magn Reson Imaging 1993;
11(1):35-46.

Vergote IB, Abeler VM, Bonner OP, Stigbrand T,
Trope C, Nustad K. CA125 and placental alkaline
phosphatase as serum tumor markers in epithelial
ovarian carcinoma. Tumour Biol 1992;13(3):
168-74.

Viel A, Giannini F, Tumiotto L, Sopracordevole F,
Visentin MC, Boiocchi M. Chromosomal
localisation of two putative 11p oncosuppressor
genes involved in human ovarian tumours. Br J
Cancer 1992 Dec;66(6):1030—6.

Vinokurov VL, Dudarev AL, Jurkova LE, Lapchenkov
VI, Barbanel El. Tumor marker CA 125 in
diagnosis, monitoring management and follow-up of
patients with ovarian tumors. Eur J Gynaecol Oncol
1992;13(2):205-8.

Wade RV. Gynecologic applications of real time
ultrasound. Appl Radiol 1993 Feb;22(2):15-9.

Wahl RL. Radiolabeled monoclonal antibodies for the
diagnosis and treatment of ovarian carcinoma. Front
Radiat Ther Oncol 1990;24:228-39.

Walsh JM. Cancer screening in older adults. West J
Med 1992 May;156(5):495-500. Comment in: West
J Med 1992 Oct;157(4):469-70.

Wardle FJ, Collins W, Pemet AL, Whitehead MI,
Bourne TH, Campbell S. Psychological impact of

19

screening for familial ovarian cancer. J Natl Cancer
Inst 1993 Apr 21;85(8):653-7.

Warner BW, Kuhn JC, Barr LL. Conservative
management of large ovarian cysts in children: the
value of serial pelvic ultrasonography. Surgery
1992 Oct; 1 12(4):749-55 .

Weiner Z, Beck D, Shteiner M, Borovik R, Ben-
Shachar M, Robinzon E, Brandes J M. Screening
for ovarian cancer in women with breast cancer
with transvaginal sonography and color flow
imaging. J Ultrasound Med 1993 Jul;12(7):387-93.

Weiner Z, Thaler I, Beck D, Rottem S, Deutsch M,
Brandes JM. Differentiating malignant from benign
ovarian tumors with transvaginal color flow
imaging. Obstet Gynecol 1992 Feb;79(2):159-62.
Comment in: Obstet Gynecol 1992 Jul;80(1):156—7.

Weinreb JC, Barkoff ND, Megibow A, Demopoulos R.
The value of MR imaging in distinguishing
leiomyomas from other solid pelvic masses when
sonography is indeterminate. AJR Am J Roentgenol
1990 Feb;154(2):295-9.

Welander CE. What do CA 125 and other antigens tell
us about ovarian cancer biology? Acta Obstet
Gynecol Scand Suppl 1992;155:85-93.

Westhoff C, Clark C]. Benign ovarian cysts in England
and Wales and in the United States. Br J Obstet
Gynaecol 1992 Apr;99(4):329-32.

Westhoff C, Levin B, Ladd G, O’Connor J. Sources of
variability in normal CA 125 levels. Cancer
Epidemiol Biomarkers Prev 1992 Jul-Aug;1(5):
357-9.

Westhoff C, Randall MC. Ovarian cancer screening:
potential effect on mortality. Am J Obstet Gynecol
1991 Sep;165(3):502-5.

Wikbom C, Pettersson F, Silfversward C, Moberg PJ.
Symptoms and diagnostic difficulties in ovarian
epithelial cancer. Int J Gynaecol Obstet 1993 Sep;
42(3):261-4.

Williams L. Ovarian cancer screening. The search for
cost-effective methods. Postgrad Med 1992 Dec;
92(8):63-6, 72.

Willson JR. Ultrasonography in the diagnosis of
gynecologic disorders. Am J Obstet Gynecol 1991
Apr;164(4):1064—7; discussion 1067-71. Comment
in: Am J Obstet Gynecol 1992 Apr;166(4):1310-1.

Wolf SI, Gosink BB, Feldesman MR, Lin MC,
Stuenkel CA, Braly PS, Pretorius DH. Prevalence
of simple adnexal cysts in postmenopausal women.
Radiology 1991 Jul;180(1):65-71.

Wong JG, Feussner JR. Screening for ovarian cancer:
not worthwhile for most patients. N C Med J 1993
Sep;54(9):438-40.

20

Wu JT, Carlisle P. Low frequency and low level of
elevation of serum CA 72-4 in human carcinomas in
comparison with established tumor markers. J Clin
Lab Anal 1992;6(1):59-64.

Yang-Fcng TL, Han H, Chen KC, Li SB, Claus EB.
Carcangiu ML, Chambers SK, Chambers JT,
Schwartz PE. Allelic loss in ovarian cancer. Int J
Cancer 1993 Jun 19;54(4):546—51.

Yang-Feng TL, Li S, Han H, Schwartz PE. Frequent
loss of heterozygosity on chromosomes Xp and 13q

in human ovarian cancer. Int J Cancer 1992 Oct 21;
52(4):575-80.

Yang-Feng TL, Li SB, Leung WY, Carcangiu ML,
Schwartz PE. Trisomy 12 and K-ras-Z amplification
in human ovarian tumors. Int J Cancer 1991 Jul 9;
48(5):678-81.

Yedema CA, Kenemans P, Wobbes T, Thomas CM,
Bon GG, Mulder C, Voorhorst FJ, Verstraeten AA,
van Kamp GJ, Hilgers J. Use of serum tumor
markers in the differential diagnosis between

ovarian and colorectal adenocarcinomas. Tumour
Biol 1992;13(1-2):18-26.

Yedema KA, Kenemans P, Wobbes T, van Kamp GJ ,
de Bruijn HW, Thomas CM, Massuger LF, Schijf
CP, Bon GG, Vermorken JB, et al. Carcinoma-
associated mucin serum markers CA M26 and CA
M29: efficacy in detecting and monitoring patients
with cancer of the breast, colon, ovary,

endometrium and cervix. Int J Cancer 1991 Jan 21;
47(2):170—9.

Yedema KA, Thomas CM, Segers MF, Doesburg WH,
Kenemans P. Comparison of five immunoassay
procedures for the ovarian carcinoma-associated
antigenic determinant CA 125 in serum. Eur J
Obstet Gynecol Reprod Biol 1992 Dec 28;47(3):
245-52.

Yoder LH. The epidemiology of ovarian cancer: a
review. Oncol Nurs Forum 1990 May-Jun;17(3):
411-5. Comment in: Oncol Nurs Forum 1990 Jul-
Aug;17(4):483-4.

Yoffe N, Bronshtein M, Brandes J, Blumenfeld Z.
Hemorrhagic ovarian cyst detection by transvaginal

sonography: the great imitator. Gynecol Endocrinol
1991 Jun;5(2)2123-9.

Yu YH, Schlossman DM, Harrison CL, Rhinehardt—
Clark A, Soper JT, Klug TL, Zurawski VR Jr, Bast
RC Jr. Coexpression of different antigenic markers
on moieties that bear CA 125 determinants. Cancer
Res 1991 Jan 15;51(2):468-75.

Zangwill BC, Balsara G, Dunton C, Varello M, Rebane
BA, Hernandez E, Atkinson BF. Ovarian carcinoma
heterogeneity as demonstrated by DNA ploidy.
Cancer 1993 Apr 1;71(7):2261-7.

Zawin M, McCarthy S, Scoutt LM, Comite F. High-
field MRI and US evaluation of the pelvis in
women with leiomyomas. Magn Reson Imaging
1990;8(4):371—6.

Zeimet AG, Muller—Holzner E, Marth C, Daxenbichler
G, Dapunt 0. Tumor marker CA-125 in tissues of
the female reproductive tract and in serum during
the normal menstrual cycle. Fertil Steril 1993 May;
59(5):1028-35.

Zimmermann W, Bender E, Rohde K, Reis A,
Wiseman R, Futreal A, Krause H, Prokoph H,
Werner S, Schemeck S. Linkage analysis in
German breast cancer families with early onset of
the disease, using highly polymorphic markers from
the chromosome 17q11-q24 region. Am J Hum
Genet 1993 Apr;52(4):789-91.

Zimny ME. Ovarian cancer: a nursing overview.
Oncology (Huntingt) 1991 Aug;5(8):147-53;
discussion 154.

Zurawski VR Jr, Sjovall K, Schoenfeld DA, Broderick
SF, Hall P, Bast RC Jr, Eklund G, Mattsson B,
Connor RJ, Prorok PC, et a1. Prospective
evaluation of serum CA 125 levels in a normal
population, phase I: the specificities of single and
serial determinations in testing for ovarian cancer.
Gynecol Oncol 1990 Mar;36(3):299-305.

Prevention

Barber HR. Prophylaxis in ovarian cancer. Cancer 1993
Feb 15;71(4 Suppl):1529-33.

Boike G, Averette H, Hoskins W, Chmiel J, Zuber K,
Kamell L, Winchester D. National survey of
ovarian carcinoma. IV. Women with prior

hysterectomy: a failure of prevention? [abstract].
Gynecol Oncol 1993 Apr;49(1):112—3.

Cruickshank DJ, Haites N, Anderson S, Matheson H,
Hall MH, Milner B, Ah—See A, Gunn I, Eremin 0,
Gilbert F, et al. The multidisciplinary management
of a family with epithelial ovarian cancer. Br J
Obstet Gynaecol 1992 Mar;99(3):226-31.

Dicker RC, Scally MJ, Greenspan JR, Layde PM, Ory
HW, Maze JM, Smith JC. Hysterectomy among
women of reproductive age. Trends in the United
States, 1970—1978. JAMA 1982 Jul 16;248(3):
323-7.

Estrogen use and postmenopausal women: a National
Institutes of Health Consensus Development
Conference. Ann Intern Med 1979 Dec;91(6):
921-2.

Fine BA, Yazigi R, Risser R. Prognosis of ovarian
cancer developing in the residual ovary. Gynecol
Oncol 1991 Nov;43(2):164-6.

Fogarty P. Prophylactic oophorectomy in Northern
Ireland. Ulster Med J 1991 Oct;60(2):172-5.

Houlston RS, Hampson J, Collins WP, Whitehead MI,
Campbell S, Slack J. Correlation in ages at death
from familial ovarian cancer among sisters. Gynecol
Oncol 1992 Nov;47(2):253-4.

Kerlikowske K, Brown J S, Grady DG. Should women
with familial ovarian cancer undergo prophylactic
oophorectomy? Obstet Gynecol 1992 Oct;80(4):
700-7. Comment in: Obstet Gynecol 1993 Feb;
81(2):315—6.

Klein B, Lurie H, Stein M, Kuten A, Steinherz R.
Hereditary ovarian cancer: a dilemma in prognosis.
Isr J Med Sci 1992 Jan;28(l):l6—9.

Madsen EM, Lidegaard O, Tabor A. Oophorectomy in
the prevention of ovarian cancer. Acta Obstet
Gynecol Scand 1993 Nov;72(8):599-600.

Meijer W], van Lindert AC. Prophylactic
oophorectomy. Eur J Obstet Gynecol Reprod Biol
1992 Oct 23;47(1):59-65.

Parazzini F, Negri E, La Vecchia C, Luchini L,
Mezzopane R. Hysterectomy, oophorectomy, and
subsequent ovarian cancer risk. Obstet Gynecol
1993 Mar;81(3):363-6.

21

Polq'as R, Hufnagel VG. Hysterectomy in the United
States, 1965-84. Am J Public Health 1988 Jul;
78(7):852-3.

Ponder BA, Easton DF, Peto J. Risk of ovarian cancer
associated with a family history: preliminary report
of the OPCS study. In: Sharp F, Mason WP, Leake
RE, eds. Ovarian cancer: biological and therapeutic
challenges. London: Chapman and Hall Medical;
1990. p. 3-6.

Schildkraut JM, Thompson WD. Familial ovarian
cancer: a population-based case-control study. Am J
Epidemiol 1988 Sep;128(3):456—66.

Schumaker D. Preventing gynecologic cancer: every
woman’s guide... a risk factor checklist. Can Nurs
1991 Oct;87(9):23-4.

Schwartz PB. The role of prophylactic oophorectomy in
the avoidance of ovarian cancer. Int J Gynaecol
Obstet 1992 Nov;39(3):175-84.

Sheth S, Malpani A. Routine prophylactic
oophorectomy at the time of vaginal hysterectomy
in postmenopausal women. Arch Gynecol Obstet
1992;251(2):87-91.

Sightler SE, Boike GM, Estape RE, Averette HE.
Ovarian cancer in women with prior hysterectomy:
a 14-year experience at the University of Miami.
Obstet Gynecol 1991 Oct;78(4):681-4. Comment in:
Obstet Gynecol 1992 Feb;79(2):3l7-9.

Speroff T, Dawson NV, Speroff L, Haber RJ. A risk-
benefit analysis of elective bilateral oophorectomy:
effect of changes in compliance with estrogen
therapy on outcome. Am J Obstet Gynecol 1991
Jan;164(1 Pt 1):165-74.

22

MANAGER'IENT OF EARLY STAGE
OVARIAN CANCER

Management of the Adnexal Mass

Alvarez RD, Kilgore LC, Partridge EE, Austin JM,
Shingleton HM. Staging ovarian cancer diagnosed
during laparoscopy: accuracy rather than
immediacy. South Med J 1993 Nov;86(11)21256-8.

Archie J T, Witt TR. Peritoneoscopy for biopsy,
staging, and therapy of intra-abdominal tumors. In:
Economou SG, Witt TR, Deziel DJ, et al., eds.
Adjuncts to cancer surgery. Philadelphia: Lea and
Febiger; 1991. p. 195-203.

Barber HRK, Creasman WT, Knapp RC. A rational
approach to ovarian masses. Patient Care 1993
Jan 15;27(l):50-4, 61-2, 65-8 passim.

Bouwman DL. The management of unexpected findings
at surgery. Surg Clin North Am 1993 Apr; 73(2):
203-12.

Bret PM, Atri M, Guibaud L, Gillett P, Seymour RJ,
Senterman MK. Ovarian cysts in postmenopausal
women: preliminary results with transvaginal
alcohol sclerosis. Work in progress. Radiology
1992 Sep;184(3):661-3. Comment in: Radiology
1992 Sep;184(3):605-6.

Bret PM, Guibaud L, Atri M, Gillett P, Seymour RJ,
Senterman MK. Transvaginal US-guided aspiration
of ovarian cysts and solid pelvic masses. Radiology
1992 Nov;185(2):377-80. Comment in: Radiology
1993 Jun;187(3):878.

Bruhat MA, Mage G, Pouly J L, Canis M, Wattiez A,
Chapron C. Advances in pelviscopic surgery. Ann
N Y Acad Sci 1991;626:367-71.

Caspi B, Zalel Y, Lurie S, Elchlal U, Katz Z.
Ultrasound-guided aspiration for relief of pain
generated by simple ovarian cysts. Gynecol Obstet
Invest 1993;35(2):121-2.

Conklin JT, Maguire RT. Monoclonal antibodies as an
aid in the imaging of cancer. In: Economou SG,
Witt TR, Deziel DJ, et al., eds. Adjuncts to cancer
surgery. Philadelphia: Lea and Febiger; 1991.

p. 219-28.

Cristalli B, Cayol A, Izard V, Levardon M. Benefit of
operative laparoscopy for ovarian tumors suspected
of benignity. J Laparoendosc Surg 1992 Apr;2(2):
69-73.

Curtin JP. Diagnosis and staging of epithelial ovarian
cancer. In: Markman M, Hoskins WJ, eds. Cancer
of the ovary. New York: Raven Press; 1993.
p. 153-62.

Davies AP, Jacobs I, Woolas R, Fish A, Oram D. The
adnexal mass: benign or malignant? Evaluation of a

risk of malignancy index. Br J Obstet Gynaecol
1993 Oct;100(10):927—31.

Dordoni D, Zaglio S, Zucca S, Favalli G. The role of
sonographically guided aspiration in the clinical
management of ovarian cysts. J Ultrasound Med
1993 Jan;12(1):27-31.

el-Yahia AR, Rahman J, Rahman MS, al-Suleiman SA.
Ovarian tumours in pregnancy. Aust N Z J Obstet
Gynaecol 1991 Nov;31(4):327-30.

Fleischer AC, Shah DM, Entman SS. Sonographic
evaluation of maternal disorders during pregnancy.
Radiol Clin North Am 1990 Jan;28(1):51-8.

Grimes DA. Frontiers of operative laparoscopy: a
review and critique of the evidence. Am J Obstet
Gynecol 1992 Apr;166(4):1062-71. Comment in:
Am J Obstet Gynecol 1993 Apr;168(4):l333—4.

Hasson HM. Laparoscopic management of ovarian
cysts. J Reprod Med 1990 Sep;35(9):863-7.

Heloury Y, Guiberteau V, Sagot P, Plattner V, Baron
M, Rogez J M. Laparoscopy in adnexal pathology in
the child: a study of 28 cases. Eur J Pediatr Surg
1993 Apr;3(2):75—8.

Hulka JF, Parker WH, Surrey MW, Phillips JM.
Management of ovarian masses. AAGL 1990
survey. J Reprod Med 1992 Jul;37(7):599-602.

Johns A. Laparoscopic oophorectomy/
oophorocystectomy. Clin Obstet Gynecol 1991 Jun;
34(2):460—6.

Khanna AK, Misra MK, Khanna A, Misra VK, Khanna
S. Fine-needle aspiration cytology of abdominal
masses. J Surg Oncol 1990 May;44(1):15-9.

Khaw KT, Walker WJ. Ultrasound guided fine needle
aspiration of ovarian cysts: diagnosis and treatment
in pregnant and non-pregnant women. Clin Radiol
1990 Feb;41(2):105-8.

Kier R, McCarthy SM, Scoutt LM, Viscarello RR,
Schwartz PE. Pelvic masses in pregnancy: MR
imaging. Radiology 1990 Sep;176(3):709-13.

Kullendorff CM. Diagnosis and treatment of ovarian
cysts in children. Ann Chir Gynaecol 1991;80(1):
65-7.

Langebrekke A, Umes A. Laparoscopic adnexectomy.
Acta Obstet Gynecol Scand 199l;70(7-8):605-9.

Larkin KR. Cancer and pregnancy. NAACOGS Clin
Issu Perinat Womens Health Nurs 1990;1(2):
255-61.

Lee CL, Soong YK. Laparoscopic management of
benign ovarian tumors. J Formos Med Assoc 1993
Mar;92(3):245-8.

Lee CL, Soong YK, Lai YM, Chang SY, Chang MY.
Simplified instrumentation for laparoscopic ovarian
cystectomy. Chang Keng I Hsueh 1992 Mar;15(1):
28-32.

Lipitz S, Seidman DS, Menczer J, Bider D, Oclsner G,
Moran O, Shalev J. Recurrence rate after fluid
aspiration from sonographically benign-appearing
ovarian cysts. J Reprod Med 1992 Oct;37(10):
845-8.

Maiman M, Seltzer V, Boyce J. Laparoscopic excision
of ovarian neoplasms subsequently found to be
malignant. Obstet Gynecol 1991 Apr;77(4):563-5.
Comment in: Obstet Gynecol 1991 Aug;78(2):
319-21.

Martin DC. Laparoscopic treatment of ovarian
endometriomas. Clin Obstet Gynecol 1991 Jun;
34(2) :452-9.

Mettler L, Irani S, Semm K. Ovarian surgery via
pelviscopy. J Reprod Med 1993 Feb;38(2):130—2.

Miller RC, Nash JD, Weiser EB, Hoskins WJ. The
postmenopausal palpable ovary syndrome. A

retrospective review with histopathologic correlates.
J Reprod Med 1991 Aug;36(8):568-71.

Moore JL Jr, Martin JN Jr. Cancer and pregnancy.
Obstet Gynecol Clin North Am 1992;l9(4):815-27.

Moran O, Menczer J, Ben-Baruch G, Lipitz S, Goor E.
Cytologic examination of ovarian cyst fluid for the

distinction between benign and malignant tumors.
Obstet Gynecol 1993 Sep;82(3):444-6.

Nezhat F, Nezhat C, Silfen SL. Videolaseroscopy for
oophorectomy. Am J Obstet Gynecol 1991 Nov;
165(5 Pt l):1323-30. Comment in: Am J Obstet
Gynecol 1992 Oct;167(4 Pt 1):]150.

Obwegeser R, Deutinger J, Bemascheck G. The risk of
malignancy with an apparently simple adnexal cyst
on ultrasound. Arch Gynecol Obstet 1993;253(3):
1 17-20.

Ovadia J, Goldman GA. Ovarian masses in
postmenopausal women. Int J Gynaecol Obstet 1992
Scp;39(1):35-9.

Parker WH, Berek J S. Management of the adnexal mass
by operative laparoscopy. Clin Obstet Gynecol 1993
Jun;36(2):413-22.

Phipps JH, Monaghan JM. Laparoscopic hysterectomy
and cancer. Surg Oncol 1993;2 Suppl 1:67-72.

Pinto MM, Bernstein LH, Brogan DA, Parikh F, Lavy
G. Measurement of CA125, carcinoembryonic
antigen, and alpha-fetoprotein in ovarian cyst fluid:
diagnostic adjunct to cytology. Diagn Cytopathol
1990;6(3):160—3.

23

Reich H, McGlynn F, Sekel L, Taylor P. hparoscopic
management of ovarian derrnoid cysts. J Reprod
Med 1992 Jul;37(7):640-4.

Ron-El R, Herman A, Weinraub Z, Golan A, Langer
R, Caspi E, Bukovsky 1. Clear ovarian cyst
aspiration guided by vaginal ultrasonography. Eur J
Obstet Gynecol Reprod Biol 1991 Nov 3;42(l):
43-7.

Rubin SC, Curtin JP. Surgery for gynecologic
malignancies. Curr Opin Oncol 1992 Oct;
4(5):923-9.

Seltzer V. Laparoscopic surgery for ovarian lesions:
potential pitfalls. Clin Obstet Gynecol 1993 Jun;
36(2):402-12.

Semm K, O’Neill-Freys I. Pelviscopy. Curr Opin
Obstet Gynecol 1991 Jun;3(3):413—21.

Sommerville M, Grimes DA, Koonings PP, Campbell
K. Ovarian neoplasms and the risk of adnexal
torsion. Am J Obstet Gynecol 1991 Feb;l64(2):
577-8.

Sutton C. Operative laparoscopy. Curr Opin Obstet
Gynecol 1992 Jun;4(3):430—8.

Thornton KL, DeCherney AH. Laparoscopic
management of ovarian cysts: an endocrinologist
view. Yale J Biol Med 1991 Nov-Dec;64(6):
599-606.

Warner BW, Kuhn JC, Barr LL. Conservative
management of large ovarian cysts in children: the

value of serial pelvic ultrasonography. Surgery
1992 Oct;112(4):749-55.

Westhoff C, Clark CJ. Benign ovarian cysts in England
and Wales and in the United States. Br J Obstet
Gynaecol 1992 Apr;99(4):329-32.

24

Early Stage Epithelial Ovarian Cancer

Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS,
Kjorstad K. Prognostic factors in patients with stage

I epithelial ovarian cancer. Obstet Gynecol 1990
Feb;75(2):263-73.

DiSaia PJ. Fertility-sparing treatment of patients with
ovarian cancer. Compr Ther 1990 Nov;16(11):
35—42.

Dottino PR, Plaxe SC, Cohen CJ. A phase II trial of
adjuvant cisplatin and doxorubicin in stage I
epithelial ovarian cancer. Gynecol Oncol 1991
Dec;43(3):203-5.

Finn CB, Luesley DM, Buxton EJ, Blackledge GR,
Kelly K, Dunn JA, Wilson S. Is stage I epithelial
ovarian cancer overtreated both surgically and
systemically? Results of a five-year cancer registry
review. Br J Obstet Gynaecol 1992 Jan;99(l):54—8.
Comment in: Br J Obstet Gynaecol 1992 Jun;99(6):
530—1.

Finn CB, Luesley DM, Buxton EJ, Blackledge GR,
Kelly K, Dunn JA, Wilson S. Is stage I epithelial
ovarian cancer over-treated both surgically and
systematically? Results of a five-year cancer
registry review. Obstet Gynecol Surv 1992;
47(7):491-3.

Fox H. Pathology of early maligth change in the
ovary. Int J Gynecol Pathol 1993 Apr;12(2)2153-5.

Gadducci A, Del Bravo B, Cardosi Carrara A,
D’Amico M, Fioretti P. Adjuvant treatment of early

stage ovarian carcinoma. Clin Exp Obstet Gynecol
1990;17(3-4):131-9.

Hudson CN, Potsides P, Curling OM. An audit of
surgical treatment of ovarian cancer in a
metropolitan health region. Association of
Obstetricians and Gynaecologists of the North East
Thames Region. I R Soc Med 1991 Apr;84(4):
206-9.

Lentz SS, Cha SS, Wieand HS, Podratz KC. Stage I
ovarian epithelial carcinoma: survival analysis
following defmitive treatment. Gynecol Oncol 1991
Dec;43(3):198-202. Comment in: Gynecol Oncol
1991 Dec;43(3):193-4.

Linasmita V, Sakonratanakul P, Bhamarapravati Y.
Survival of patients with stage I epithelial ovarian
carcinoma, 1981-1985 at Ramathibodi Hospital.

J Med Assoc Thai 1990 Feb;73 Suppl 1:7-10.

Malmstrom H, Larsson D, Simonsen E. Phase I study
of intraperitoneal carboplatin as adjuvant therapy in

early ovarian cancer. Gynecol Oncol 1990 Dec;
39(3):289—94.

Marchetti M, Romagnolo C. Fertility after ovarian
cancer treatment. Clin Exp Obstet Gynecol 1992;
19(3):199-202.

Marchetti M, Romagnolo C. Fertility after ovarian
cancer treatment. Eur J Gynaecol Oncol 1992;
13(6):498-501.

Monga M, Carmichael JA, Shelley WE, Kirk ME,
Krepart GV, Jeffrey J F, Pater J L. Surgery without
adjuvant chemotherapy for early epithelial ovarian
carcinoma after comprehensive surgical staging.
Gynecol Oncol 1991 Dec;43(3):195-7. Comment in:
Gynecol Oncol 1991 Dec;43(3):193-4.

Moore DH. Primary surgical management of early
epithelial ovarian carcinoma. In: Rubin SC, Sutton
GP, eds. Ovarian cancer. New York: McGraw-Hill;
1993. p. 219-39.

O’Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C,
Wiltshaw E. Clear cell epithelial ovarian cancer
(mesonephroid): bad prognosis only in early stages.
Gynecol Oncol 1993 May;49(2):250—4.

Ozols RF. Ovarian cancer, Part H: Treatment. Curr
Probl Cancer 1992 Mar-Apr;16(2):61-126.

Piver MS, Malfetano J, Baker TR, Hempling RE. Five-
year survival for stage IC or stage I grade 3
epithelial ovarian cancer treated with cisplatin-based
chemotherapy. Gynecol Oncol 1992 Sep;46(3):
357-60.

Plaxe SC, Deligdisch L, Dottino PR, Cohen CJ.
Ovarian intraepithelial neoplasia demonstrated in

patients with stage I ovarian carcinoma. Gynecol
Oncol 1990 Sep;38(3):367-72.

Raju KS, Wolfe CD. Is Stage I epithelial ovarian cancer
overtreated both surgically and systemically?
Results of a five~year cancer registry review (5).

Br J Obstet Gynaecol 1992;99(6):530—1.

Rubin SC, Jones WB, Curtin JP, Barakat RR, Hakes
TB, Hoskins WJ. Second-look laparotomy in stage I
ovarian cancer following comprehensive surgical
staging. Obstet Gynecol 1993 Jul;82(1):139-42.

Rubin SC, Wong GY, Curtin JP, Barakat RR, Hakes
TB, Hoskins WJ. Platinum-based chemotherapy of
high-risk stage I epithelial ovarian cancer following

comprehensive surgical staging. Obstet Gynecol
1993 Jul;82(1):143-7.

Schilder R], Young RC. Management of early—stage
ovarian cancer. Hematol Oncol Clin North Am
1992 Aug;6(4):867-77.

Schneider J, Centeno MM, Montoya F, Rodriguez-
Escudero FJ. Negative second-look laparotomy does
not preclude recurrence in stage I ovarian
carcinoma of any histological variety. Eur J
Gynaecol Oncol 1993;14(1):36-9.

Schueler JA, Comelisse CJ, Hermans J, Trimbos JB,
van der Burg ME, Fleuren GJ. Prognostic factors in
well-differentiated early-stage epithelial ovarian
cancer. Cancer 1993 Feb 1;71(3):787—95.

Sevelda P, Vavra N, Schemper M, Salzer H. Prognostic
factors for survival in stage I epithelial ovarian
carcinoma. Cancer 1990 May 15;65(10):2349-52.

Soper JT, Berchuck A, Clarke-Pearson DL. Adjuvant
intraperitoneal chromic phosphate therapy for
women with apparent early ovarian carcinoma who
have not undergone comprehensive surgical staging.
Cancer 1991 Aug 15;68(4):725-9.

Soper JT, Berchuck A, Dodge R, Clarke-Pearson DL.
Adjuvant therapy with intraperitoneal chromic
phosphate (32P) in women with early ovarian
carcinoma after comprehensive surgical staging.
Obstet Gynecol 1992 Jun;79(6):993-7.

Thigpen JT, Lambuth BW, Vance RB. Management of
stage I and II ovarian carcinoma. Semin Oncol 1991
Dec;18(6):596-602.

Trimbos J B, Schueler JA, van der Burg M, Hermans J,
van Lent M, Heintz AP, Fleuren GJ. Watch and
wait afier careful surgical treatment and staging in
well-differentiated early ovarian cancer. Cancer
1991 Feb 1;67(3):597-602.

Trimbos J B, Schueler JA, van Lent M, Her-mans J,
Fleuren GJ . Reasons for incomplete surgical staging
in early ovarian carcinoma. Gynecol Oncol 1990
Jun;37(3):374-7.

van Nagell JR Jr, DePriest PD. Early diagnosis of
epithelial ovarian cancer. In: Markman M, Hoskins
W], eds. Cancer of the ovary. New York: Raven
Press; 1993. p. 127-31.

Vergote IB, Kaem J, Abeler VM, Pettersen E0, De
Vos LN, Trope CG. Analysis of prognostic factors
in stage I epithelial ovarian carcinoma: importance
of degree of differentiation and deoxyribonucleic
acid ploidy in predicting relapse. Am J Obstet
Gynecol 1993 Jul;169(1):40-52.

Walton LA, Yadusky A, Rubinstein L, Roth LM,
Young RC. Stage H carcinoma of the ovary: an
analysis of survival after comprehensive surgical
staging and adjuvant therapy. Gynecol Oncol 1992
Jan;44(l):55-60.

Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L,
Berchuck A, Soper JT, Clarke-Pearson DL, Oram
DH, Bast RC Jr. Elevation of multiple serum
markers in patients with stage I ovarian cancer.

J Natl Cancer Inst 1993 Nov 3;85(21):1748-51.

Young RC. Management of early stage ovarian cancer.
In: Markman M, Hoskins WJ, eds. Cancer of the
ovary. New York: Raven Press; 1993. p. 359-73.

25

Young RC, Brady MF, Walton LA, Homesley HD,
Averette HE, Long HJ. Localized ovarian cancer in
the elderly. The Gynecologic Oncology Group
experience. Cancer 1993 Jan 15;71(2 Suppl):601-5.

Young RC, Walton LA, Ellenberg SS, Homesley HD,
Wilbanks GD, Decker DG, Miller A, Park R,
Major F Jr. Adjuvant therapy in stage I and stage II
epithelial ovarian cancer. Results of two prospective
randomized trials. N Engl J Med 1990 Apr 12;
322(15):1021—7. Comment in: N Engl J Med 1990
Apr 12;322(15):1(T76-8 and N Engl J Med 1991
Mar 14;324(11):775.

26

Ovarian Tumors of Low Malignant
Potential (Borderline Tumors)

Ayhan A, Akar'in R, Develioglu O, Yarali H, Kucukali
T, Bilgin F. Borderline epithelial ovarian tumours.
Aust N Z J Obstet Gynaecol 1991 May;31(2):
174—6.

Ball NJ, Robertson DI, Duggan MA, Snider DD.
Intestinal differentiation in ovarian mucinous
tumours. Virchows Arch A Pathol Anat Histopathol
1990;417(3):197-201.

Barnhill DR, O’Connor DM. Management of ovarian
neoplasms of low malignant potential. Oncology
(Huntingt) 1991 Apr;5(4):21—6; discussion 26, 28,
31-2.

Bell DA, Scully RE. Clinical perspective on borderline
tumors of the ovary. In: Greer BE, Berek JS, eds.
Gynecologic oncology: treatment rationale and
techniques. New York: Elsevier; 1991. p. 119-34.

Bell DA, Scully RE. Ovarian serous borderline tumors
with stromal microinvasion: a report of 21 cases.
Hum Pathol 1990 Apr;21(4):397-403.

Biscotti CV, Hart WR. Peritoneal serous
micropapillomatosis of low malignant potential
(serous borderline tumors of the peritoneum). A
clinicopathologic study of 17 cases. Am J Surg
Pathol 1992 May;16(5):467-75.

Cajigas HE, Fariza E, Scully RE, Thor AD.
Enhancement of tumor-associated glycoprotein-72
antigen expression in hormone-related ovarian
serous borderline tumors. Cancer 1991 Jul 15;
68(2):348-54.

Carter 1, Fowler J, Carlson J, Carson L, Twiggs LB.
Borderline and invasive epithelial ovarian tumors in
young women. Obstet Gynecol 1993 Nov;82(5):
752-6.

Casey AC, Bell DA, Lage JM, Fuller AF, Nikrui N,
Rice LW. Epithelial ovarian tumors of borderline

malignancy: long-tenn follow—up. Gynecol Oncol
1993 Sep;50(3):3l6-22.

Criscuolo M, Martinelli AM, Migaldi M, Zunarelli E,
Bergamaschi M, Falchi AM, De Gaetani C.
Prognostic significance of nucleolar organizer
regions in ovarian epithelial tumors. Int J Gynecol
Pathol 1993 Jul;12(3):259-63.

de Nictolis M, Montironi R, Tommasoni S, Carinelli S,
Ojeda B, Matias-Guiu X, Prat J. Serous borderline
tumors of the ovary. A clinicopathologic,
immunohistochemical, and quantitative study of 44
cases. Cancer 1992 Jul 1;70(1):152-60.

Drescher CW, Flint A, Hopkins MP, Roberts JA.
Prognostic significance of DNA content and nuclear

morphology in borderline ovarian tumors. Gynecol
Oncol 1993 Feb;48(2):242-6.

Eriksen B, Miller DS, Murad TM, Lurain JR, Bauer
KD. Dual-parameter flow cytometric analysis
coupling the measurements of forward-angle light
scatter and DNA content of archival ovarian
carcinomas of low malignant potential. Anal Quant
Cytol Histol 1991 Feb;13(1):45-53.

Gershenson DM, Silva EG. Serous ovarian tumors of
low malignant potential with peritoneal implants.
Cancer 1990 Feb l;65(3):578-85.

Goldman TL, Chalas E, Chumas J, Loesch M, Mann
WJ. Management of borderline tumors of the ovary.
South Med J 1993 Apr;86(4):423-5.

Griffiths AP, Cross D, Kingston RE, Harkin P, Wells
M, Quirke P. Flow cytometry and AgNORs in
benign, borderline, and malignant mucinous and
serous tumours of the ovary. Int J Gynecol Pathol
1993 Oct;12(4):307-14.

Hanselaar AG, Vooijs GP, Mayall B, Ras-Zeijlmans
GJ, Chadha-Ajwani S. Epithelial markers to detect
occult microinvasion in serous ovarian tumors. Int J
Gynecol Pathol 1993 Jan;12(1):20-7.

Harlow BL, Fuhr JE, McDonald TW, Schwartz SM,
Beuerlein FJ, Weiss NS. Flow cytometry as a
prognostic indicator in women with borderline

epithelial ovarian tumors. Gynecol Oncol 1993
Sep;50(3):305-9.

Harlow BL, Weiss NS, Holmes EH. Plasma alpha-L-
fucosidase activity and the risk of borderline

epithelial ovarian tumors. Cancer Res 1990 Aug 1;
50(15):4702-3.

Hata K, Hata T, Manabe A, Kitao M. Ovarian tumors
of low malignant potential: transvaginal Doppler
ultrasound features. Gynecol Oncol 1992 Jun;
45(3):259-64.

Heinonen PK. Androgen production by epithelial
ovarian tumours in post-menopausal women.
Maturitas 1991 Jun;13(2):117-22.

Hytiroglou P, Harpaz N, Heller DS, Liu ZY,
Deligdisch L, Gil J. Differential diagnosis of
borderline and invasive serous cystadenocarcinomas
of the ovary by computerized interactive
morphometric analysis of nuclear features. Cancer
1992 Feb 15;69(4):988-92.

Kaem J, Trope C, Kjorstad KE, Abeler V, Pettersen
E0. Cellular DNA content as a new prognostic tool
in patients with borderline tumors of the ovary.
Gynecol Oncol 1990 Sep;38(3):452—7.

Kaem J, Trope CG, Abeler VM. A retrospective study
of 370 borderline tumors of the ovary treated at the
Norwegian Radium Hospital from 1970 to 1982. A

review of clinicopathologic features and treatment
modalities. Cancer 1993 Mar 1;71(5):1810-20.

Khattech A, Spatz A, Prade M, Duvillard P,
Charpentier P, Bognel C, Michel G, Lhomme C.
Nucleolar organizer regions in ovarian tumors:
discrimination between carcinoma and borderline
tumor. Int J Gynecol Pathol 1992;11(1):11-4.

Kurman RJ, Trimble CL. The behavior of serous
tumors of low malignant potential: are they ever
malignant? Int J Gynecol Pathol 1993 Apr;12(2):
120-7.

Leake J F. Tumors of low maligth potential. Curr
Opin Obstet Gynecol 1992 Feb;4(l):81-5.

Leake J F, Currie JL, Rosenshein NB, Woodruff JD.
Long-term follow-up of serous ovarian tumors of
low malignant potential. Gynecol Oncol 1992 Nov;
47(2):150—8.

Leake JF, Rader JS, Woodruff JD, Rosenshein NB.
Retroperitoneal lymphatic involvement with
epithelial ovarian tumors of low malignant potential.
Gynecol Oncol 1991 Aug;42(2):124-30.

Long L, Jiang P, Liu FZ, Wang XP, Zhao TJ.
Treatment of ovarian malignant germ cell tumors
with preservation of fertility. Chin Med J (Engl)
1993 Apr;106(4):303-6.

Manchul LA, Simm J, Levin W, Fyles AW, Dembo
AJ, Pringle JF, Rawlings GA, Sturgeon JF,
Thomas GM. Borderline epithelial ovarian tumors:
a review of 81 cases with an assessment of the
impact of treatment. Int J Radiat Oncol Biol Phys
1992;22(5):867-74.

Massad LS Jr, Hunter VJ, Szpak CA, Clarke-Pearson
DL, Creasman WT. Epithelial ovarian tumors of
low malignant potential. Obstet Gynecol 1991 Dec;
78(6): 1027-32.

McLellan R, Buscema J, Guerrero E, Shah KV,
Woodruff JD, Currie JL. Investigation of ovarian
neoplasia of low malignant potential for human
papillomavirus. Gynecol Oncol 1990 Sep;38(3):
383-5.

Michael H, Roth LM, Kotylo PK. Recent developments
in the pathology of ovarian epithelial tumors of low
malignant potential and related neoplasms. Pathol
Annu 1993;28(Pt 2):1-22.

Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch
WR, Muto MG, Berkowitz RS, Tsao SW. Mutation
of K-ras protooncogene in human ovarian epithelial
tumors of borderline malignancy. Cancer Res 1993
Apr 1;53(7):1489—92.

Nakashima N, Nagasaka T, Oiwa N, Nara Y, Fukata S,
Fukatsu T, Takeuchi J. Ovarian epithelial tumors of
borderline malignancy in Japan. Gynecol Oncol
1990 Jul;38(1):90-8.

27

Norris HJ. Proliferative endometrioid tumors and
endometrioid tumors of low malignant potential of
the ovary. Int J Gynecol Pathol 1993 Apr;12(2):
134-40.

Ozols RF. Ovarian cancer, Part II: Treatment. Curr
Probl Cancer 1992 Mar-Apr;16(2):61-126.

Padberg BC, Arps H, Franke U, Thiedemann C,
Rehpenning W, Stegner HE, Lietz H, Schroder S,
Dietel M. DNA cytophotometry and prognosis in
ovarian tumors of borderline malignancy. A
clinicomorphologic study of 80 cases. Cancer 1992
May 15;69(10):2510—4.

Padberg BC, Stegner HE, von Sengbusch S, Arps H,
Schroder S. DNA-cytophotometry and
immunocytochemistry in ovarian tumours of
borderline malignancy and related peritoneal
lesions. Virchows Arch A Pathol Anat Histopathol
1992;421(6):497-503.

Paranini F, Restelli C, La Vecchia C, Negri E, Chiari
S, Maggi R, Mangioni C. Risk factors for epithelial

ovarian tumours of borderline malignancy. Int J
Epidemiol 1991 Dec;20(4):871—7.

Rice LW, Berkowitz RS, Mark SD, Yavner DL, Lage
J M. Epithelial ovarian tumors of borderline
malignancy. Gynecol Oncol 1990 Nov;39(2):195-8.

Rice LW, Lage J M, Berkowitz RS, Goodman A, Muto
MG, Knapp RC, Bell DA. Preoperative serum
CA- 125 levels in borderline tumors of the ovary.
Gynecol Oncol 1992 Aug;46(2):226—9.

Rutgers JL, Bell DA. Immunohistochemical
characterization of ovarian borderline tumors of
intestinal and mullerian types. Mod Pathol 1992
Jul;5(4):367-71.

Segal GH, Hart WR. Ovarian serous tumors of low
malignant potential (serous borderline tumors). The
relationship of exophytic surface tumor to peritoneal
implants. Am J Surg Pathol 1992 Jun;16(6):577-83.

Seidman JD, Norris HJ, Griffin JL, Hitchcock CL.
DNA flow cytometric analysis of serous ovarian
tumors of low malignant potential. Cancer 1993
Jun 15;71(12):3947-51.

Shiromizu K, Kawana T, Sugase M, Izumi R, Mizuno
M. Clinicostatistical study of low potential
malignancy ovarian cystadenoma (borderline cases).
Asia Oceania J Obstet Gynaecol 1991 Jun;17(2):
107-12.

Snider DD, Stuart GC, Nation JG, Robertson DI.
Evaluation of surgical staging in stage 1 low
malignant potential ovarian tumors. Gynecol Oncol
1991 Feb;40(2):129-32.

Sutton GP. Ovarian tumors of low malignant potential.
In: Rubin SC, Sutton GP, eds. Ovarian cancer.
New York: McGraw—Hill; 1993. p. 425-49.

28

Sutton GP, Bundy BN, Omura GA, Yordan EL,
Beecham JB, Bonfiglio T. Stage III ovarian tumors
of low malignant potential treated with cisplatin
combination therapy (a Gynecologic Oncology
Group study). Gynecol Oncol 1991 Jun;4l(3):
230-3.

Trimble EL, Trimble CL. Epithelial ovarian tumors of
low malignant potential. In: Markman M, Hoskins
WJ, eds. Cancer of the ovary. New York: Raven
Press; 1993. p. 415-29.

Vaccarello L, Kanbour A, Kanbour-Shakir A,
Whiteside TL. Tumor-infiltrating lymphocytes from
ovarian tumors of low malignant potential. Int J
Gynecol Pathol 1993 Jan;12(l):41-50.

Yazigi R, Munoz AK, Sandstad J, Lifshitz S, Choi DJ .
Cisplatin based combination chemotherapy in the
treatment of stage III ovarian epithelial tumors of

low malignant potential. Eur J Gynaecol Oncol
1991;12(6):451-5.

Germ Cell and Sex-Cord Stromal
Tumors

Barrenetxea G, Schneider J, Ccnteno MM, Martinez
AJ, Fernandez de Larrino A, Gonzales del Tanago
J, Rodriguez-Escudero F]. Pure theca cell tumors.
A clinicopathologic study of 29 cases. Eur J
Gynaecol Oncol 1990;11(6):429-32.

Bazot M, Ghossain MA, Buy IN, Deligne L, Hugol D,
Truc IB, Poitout P, Vadrot D. Fibrothccomas of the
ovary: CT and US findings. J Comput Assist
Tomogr 1993 SepOct;17(5):754-9.

Beamer WG, Shultz KL, Tennent BJ, Shultz LD.
Granulosa cell tumorigcnesis in genetically
hypogonadal-immunodeficient mice grafted with
ovaries from tumor-susceptible donors. Cancer Res
1993 Aug 15;53(16):374l-6.

Berkowitz RS. Recent advances in the biology and
treatment of gestational trophoblastic diseases and
germ cell tumors. Curr Opin Oncol 1990 Oct;2(5):
901-5.

Bjorkholm E, Lundell M, Gyftodimos A, Silfversward
C. Dysgerminoma. The Radiumhemmet series
1927-1984. Cancer 1990 Jan 1;65(1):38-44.

Brammer HM 3d, Buck JL, Hayes WS, Sheth S,
Tavassoli FA. From the archives of the AFIP.
Malignant germ cell tumors of the ovary:
radiologic-pathologic correlation. Radiographics
1990 Jul;10(4):715-24.

Chadha S, Comelisse CJ, Schaberg A. Flow cytometric
DNA ploidy analysis of ovarian granulosa cell
tumors. Gynecol Oncol 1990 Feb;36(2):240-5.

Chang CY, Yeh WR, Chao KC, Ng HT. Granulosa cell
tumor of the ovary. Chung Hua I Hsueh Tsa Chih
(Taipei) 1990 Sep;46(3):172—6.

Chiara S, Merlini L, Campora E, Bruzzone M, Giudici
S, Rosso R, Ragni N. Cisplatin—based chemotherapy
in recurrent or high risk ovarian granulosa-cell
tumor patients. Eur J Gynaecol Oncol 1993;14(4):
314-7.

Contc M, Guariglia L, Benedetti Panici P, Scambia G,
Rabitti C, Capelli A, Mancuso S. Ovarian
fibrothecoma: sonographic and histologic findings.
Gynecol Obstet Invest l99l;32(1):51-4.

Coppes MJ, Ye Y, Racldey R, Zhao XL, Liefers GJ,
Casey G, Williams BR. Analysis of WT1 in
granulosa cell and other sex cord-stromal tumors.
Cancer Res 1993 Jun 15;53(12):2712-4.

Danhier S, Van Houtte P. Ovarian dysgerminoma: a
therapeutic challenge. I Belge Radiol 1993 Mar;
76(2):102-4.

Daugaard G, Hansen HH, Rorth M. Treatment of
malignant germ cell tumors. Ann Oncol 1990;
1(3):195-202.

De Jong FH, Grootenhuis AJ, Steenbergen J, van Sluijs
FJ, Foekens JA, ten Kate FJ, Oosterhuis J W,
Lamberts SW, Klijn JG. Inhibin immunoreactivity
in gonadal and non-gonadal tumors. J Steroid
Biochem Mol Biol 1990 Dec 20;37(6):863-6.

De Palo G, Zambetti M, Pilotti S, Rottoli L, Spatti G,
Fontanelli R, Musumeci R, Kenda R, Bombardieri
E, Stefanon B, et al. Nondysgerminomatous tumors
of the ovary treated with cisplatin, vinblastine, and

bleomycin: long-term results. Gynecol Oncol 1992
Nov ;47(2) :239-46.

Dietl J, Horny HP, Ruck P, Kaiserling E.
Dysgerminoma of the ovary. An
immunohistochemical study of tumor—infiltrating

lymphoreticular cells and tumor cells. Cancer 1993
Apr 15;71(8):2562-8.

dos Santos Silva I, Swerdlow AJ. Ovarian germ cell
malignancies in England: epidemiological parallels
with testicular cancer. Br J Cancer 1991 May;63(5):
814-8.

Fletcher JA, Gibas Z, Donovan K, Perez-Atayde A,
Genest D, Morton CC, Lage JM. Ovarian
granulosa-stromal cell tumors are characterized by
trisomy 12. Am J Pathol 1991 Mar;l38(3):515-20.

Germa JR, Izquierdo MA, Segui MA, Climent MA,
Ojeda B, Alonso C. Malignant ovarian germ cell
tumors: the experience at the Hospital de la Santa
Creu i Sant Pau. Gynecol Oncol 1992 May;45(2):
153-9.

Gershenson DM. Ovarian germ cell and stromal
tumors. In: Greer BE, Berek JS, eds. Gynecologic
oncology: treatment rationale and techniques. New
York: Elsevier; 1991. p. 167-84.

Gershenson DM. Update on malignant ovarian germ
cell tumors, Cancer 1993 Feb 15;71(4 Suppl):
1581-90.

Gershenson DM, Morris M, Cangir A, Kavanagh JJ ,
Stringer CA, Edwards CL, Silva EG, Wharton JT.
Treatment of malignant germ cell tumors of the
ovary with bleomycin, etoposide, and cisplatin.

J Clin Oncol 1990 Apr;8(4):715—20.

Gitsch G, Kohlberger P, Hanzal E, Kolbl H,
Breitenecker G. Immunohistochemical
differentiation between ovarian granulosa cell
tumors and ovarian carcinomas. Arch Gynecol
Obstet 1991;249(4):173-7.

Gitsch G, Kohlberger P, Steiner A, Neumeister B,
Breitenecker G. Expression of cytokeratins in
granulosa cell tumors and ovarian carcinomas. Arch
Gynecol Obstet 1992;251(4):193-7.

29

Gorski GK, McMorrow LE, Blumstein L, Faasse D,
Donaldson MH. Trisomy 14 in two cases of

granulosa cell tumor of the ovary. Cancer Genet
Cytogenet 1992 Jun;60(2):2UZ-S.

Gribbon M, Ein SH, Mancer K. Pediatric malignant
ovarian tumors: a 43-year review. J Pediatr Surg
1992 Apr;27(4):480—4.

Haba R, Mild H, Kobayashi S, Ohmori M. Combined
analysis of flow cytometry and morphometry of
ovarian granulosa cell tumor. Cancer 1993 Dec 1;
72(11):3258-62.

Hawkins EP. Pathology of germ cell tumors in
children. Crit Rev Oncol Hematol l990;10(2):
165-79.

Healy DL, Burger HG, Mamers P, Jobling T, Bangah
M, Quinn M, Grant P, Day A], Rome R, Campbell
JJ. Elevated serum inhibin concentrations in
postmenopausal women with ovarian tumors.
N Engl J Med 1993 Nov 18;329(21):1539-42.

Hicks ML, Piver MS. Conservative surgery plus
adjuvant therapy for vulvovaginal
rhabdomyosarcoma, diethylstilbestrol clear cell
adenocarcinoma of the vagina, and unilateral germ
cell tumors of the ovary. Obstet Gynecol Clin North
Am 1992 Mar;19(1):219-33.

Inoue M, Fujita M, Azuma C, Saji F, Tanizawa O.
Histogenetic analysis of ovarian germ cell tumors
by DNA fingerprinting. Cancer Res 1992 Dec 15;
52(24):6823-6.

Jacoby AF, Young RH, Colvin RB, Flotte TJ, Preffer .
F, Scully RE, Swymer CM, Bell DA. DNA content
in juvenile granulosa cell tumors of the ovary: a
study of early- and advanced-stage disease. Gynecol
Oncol 1992 Jul;46(1):97-103.

Jones WB. Sex cord-stromal tumors of the ovary. In:
Markman M, Hoskins WJ, eds. Cancer of the
ovary. New York: Raven Press; 1993. p. 385-405.

Kawai M, Furuhashi Y, Kano T, Misawa T, Nakashima
N, Hattori S, Okamoto Y, Kobayashi I, Ohta M,
Arii Y, et al. Alpha-fetoprotein in malignant germ
cell tumors of the ovary. Gynecol Oncol 1990 Nov;
39(2):160—6.

Kawai M, Kano T, Furuhashi Y, Iwata M, Nakashima
N, Imai N, Kuzuya K, Hayashi H, Ohta M, Arii Y,
et a1. Immature teratoma of the ovary. Gynecol
Oncol 1991 Feb;40(2):133-7.

Kawai M, Kano T, Furuhashi Y, Mizuno K, Nakashima
N, Hattori SE, Kazeto S, Iida S, Ohta M, Arii Y,
et al. Prognostic factors in yolk sac tumors of the
ovary. A clinicopathologic analysis of 29 cases.
Cancer 1991 Jan l;67(1):184-92.

Kawai M, Kano T, Kikkawa F, Morikawa Y, Oguchi
H, Nakashima N, Ishizuka T, Kuzuya K, Ohta M,

30

Arii Y, et 31. Seven tumor markers in benign and
malignant germ cell tumors of the ovary. Gynecol
Oncol 1992 Jun;45(3):248-53.

Kelley J L 3d, Naus GJ, Christopherson WA.
Endodermal sinus tumor of the ovary: a case series
with flow cytometric DNA content analysis.
Gynecol Oncol 1991 Ju1;42(1):34-8.

Klemi PJ, Joensuu H, Salmi T. Prognostic value of
flow cytometric DNA content analysis in granulosa
cell tumor of the ovary. Cancer 1990 Mar 1;65(5):
1189—93.

Kumar L, Bhargawa VL, Kumar S. Cisplatin,
vinblastine and bleomycin in advanced and relapsed
germ cell tumours of ovary. Asia Oceania J Obstet
Gynaecol 1993 Jun;19(2):133-40.

Lappohn RE, Burger HG, Bouma J, Bangah M, Krans
M. Inhibin as a marker for granulosa cell tumor.
Acta Obstet Gynecol Scand Suppl 1992;155:61-5.

Malik ST, Slevin ML. Medroxyprogesterone acetate
(MFA) in advanced granulosa cell tumours of the
ovary--a new therapeutic approach? Br J Cancer
1991 Mar;63(3):410—1. Comment in: Br J Cancer
1992 Jan;65(1):140.

Motawy MS, Szymendera JJ, al-Jazzaf H, Behbehani
AE, Foudeh MO, Ebraheem AK, Nasralla MY, Ali
MA. Serum AFP, hCG and CEA in the
management of patients with testicular, ovarian and
extragonadal germ cell tumors. Int J Biol Markers
1992 Apr-Jun;7(2):80-6.

Muram D, Gale CL, Thompson E, Marina N. Ovarian
cancer in children and adolescents. Adolesc Pediatr
Gynecol 1992;5(1):21-6.

Murty VV, Dmitrovsky E, Bosl GJ, Chaganti RS.
Nonrandom chromosome abnormalities in testicular
and ovarian germ cell tumor cell lines. Cancer
Genet Cytogenet 1990 Nov 1;50(1):67-73.

Onnis A, Marchetti M, Piazza M. Clinical experience
in gynaecological cancer management. D) Ovarian
tumors-~non-epithelial: report from the
Gynaecological Institute of Padua University. Eur J
Gynaecol Oncol 1993;14(1):5—17.

Otis CN, Powell JL, Barbuto D, Carcangiu ML.
Intermediate filamentous proteins in adult granulosa
cell tumors. An immunohistochemical study of 25
cases. Am J Surg Pathol 1992 Oct;l6(10):962-8.

Ozols RF. Ovarian cancer, Part II: Treatment. Curr
Probl Cancer 1992 Mar-Apr;16(2):6l-126.

Palmquist MB, Webb MJ, Lieber MM, Gaffey TA,
Nativ 0. DNA ploidy of ovarian dysgerminomas:
correlation with clinical outcome. Gynecol Oncol
1992 Jan;44(1):l3-6.

Pectasides D, Alevizakos N, Athanassiou AE.
Cisplatin-containing regimen in advanced or
recurrent granulosa cell tumours of the ovary. Ann
Oncol 1992 Apr;3(4):316-8.

Pfleiderer A. Therapy of ovarian malignant germ cell
tumors and granulosa tumors. Int J Gynecol Pathol
1993 Apr;12(2):162-5.

Pliskow S. Endodermal sinus tumor of the ovary:
review of 10 cases. South Med J 1993 Feb;86(2):
187—9.

Porter S, Gilks CB. Genomic imprinting: a proposed
explanation for the different behaviours of testicular
and ovarian germ cell tumors. Med Hypotheses
1993 Ju1;41(1):37-41.

Price FV, Schwartz PE. Management of ovarian
stromal tumors. In: Rubin SC, Sutton GP, eds.
Ovarian cancer. New York: McGraw-Hill; 1993.
p. 405-23.

Rajkumar T, Sagar TG, Maitreyan V, Vasanthan A,
Devika A, Sastry DV, Shanta V. Germ-cell tumours
of the ovary--treatment and results at Cancer
Institute, Madras. Indian J Cancer 1992 Mar;
29(1):18-23.

Rogo KO, Persson H, Stendahl U. Dysgerminoma of
the ovary: treatment results in northern Sweden.
Eur J Gynaecol Oncol 1990;11(1):43-9.

Schwartz PE, Chambers SK, Chambers JT, Kohom E,
McIntosh S. Ovarian germ cell malignancies: the
Yale University experience. Gynecol Oncol 1992
Apr;45(1):26-31.

Shiromizu K, Kawana T, Sugase M, Izumi R, Mizuno
M. Clinicostatistical study of ovarian tumors of
germ cell origin. Asia Oceania J Obstet Gynaecol
1991 Sep;l7(3):207-15.

Sivanesaratnam V, Dutta R, Jayalakshmi P. Ovarian
fibroma—-clinical and histopathological
characteristics. Int J Gynaecol Obstet 1990 Nov;
33(3):243-7.

Skinner MA, Schlatter MG, Heifetz SA, Grosfeld JL.
Ovarian neoplasms in children. Arch Surg 1993
Aug;128(8):849-53; discussion 853-4.

Stewart CJ, Farquharson MA, Foulis AK.
Characterization of the inflammatory infiltrate in
ovarian dysgerminoma: an immunocytochemical
study. Histopathology 1992 Jun;20(6):491-7.

Suh KS, Silverberg SG, Rhame JG, Wilkinson DS.
Granulosa cell tumor of the ovary. Histopathologic
and flow cytometric analysis with clinical
correlation. Arch Pathol Lab Med 1990 May;
114(5):496-501.

Susnerwala SS, Pande SC, Shrivastava SK, Dinshaw
KA. Dysgerminoma of the ovary: review of 27
casesa. J Surg Oncol 1991 Jan;46(1):43-7.

Swanson SA, Norris HJ, Kelsten ML, Wheeler JE.
DNA content of juvenile granulosa tumors
determined by flow cytometry. Int J Gynecol Pathol
1990;9(2):101-9.

Tandon R, Kumar L, Vaid A, Kochupillai V, Kumar S,
Kriplani A, Bhargava VL. Management of
malignant germ cell tumours of ovary. Indian J
Cancer 1992 Sep;29(3):122-5.

Tennent BJ, Shultz KL, Beamer WG. Genetic
susceptibility for C19 androgen induction of ovarian
granulosa cell tumorigenesis in SWXJ strains of
mice. Cancer Res 1993 Mar 1;53(5):1059-63.

Tennent BJ, Shultz KL, Sundberg JP, Beamer WG.
Ovarian granulosa cell tumorigenesis in SWR-
derived F1 hybrid mice: preneoplastic follicular

abnormality and malignant disease progression.
Am J Obstet Gynecol 1990 Aug;163(2):625-34.

Ulbright TM, Roth LM. A pathologic analysis of
lesions following modern chemotherapy for
metastatic germ-cell tumors. Pathol Annu 1990;25
(Pt 1):313-40.

van den Berg—Bakker CA, Hagemeijer A, Franken—
Postma EM, Smit VT, Kuppen PJ, van Ravenswaay
Claasen HH, Comelisse CJ, Schrier PI.
Establishment and characterization of 7 ovarian
carcinoma cell lines and one granulosa tumor cell
line: growth features and cytogenetics. Int J Cancer
1993 Feb 20;53(4):613-20.

Vergote IB, Abeler VM, Kjorstad KE, Trope C.
Management of malignant ovarian immature
teratoma. Role of adriamycin. Cancer 1990 Sep 1;
66(5):882—6.

Williams SD. Chemotherapy of ovarian germ cell
tumors. Hematol Oncol Clin North Am 1991 Dec;
5(6):]261-9.

Williams SD. Germ cell tumors. Hematol Oncol Clin
North Am 1992 Aug;6(4):967—74.

Williams SD. Ovarian germ cell tumors. In: Rubin SC,
Sutton GP, eds. Ovarian cancer. New York:
McGraw-Hill; 1993. p. 391-404.

Williams SD. Treatment of germ cell tumors of the
ovary. Semin Oncol 1991 Jun;l8(3):292-6.

Williams SD, Blessing JA, Hatch KD, Homesley HD.
Chemotherapy of advanced dysgerminoma: trials of
the Gynecologic Oncology Group. J Clin Oncol
1991 Nov;9(11):1950—5.

Williams SD, Gershenson DM. Management of germ
cell tumors of the ovary. In: Markman M, Hoskins

31

W], eds. Cancer of the ovary. New York: Raven
Press; 1993. p. 375-84.

Williams SD, Gershenson DM, Horowitz CJ, Scully
RE. Ovarian germ cell and stromal tumors. In:
Hoskins WJ, Perez CA, Young RC, eds. Principles
and practice of gynecologic oncology. Philadelphia:
Lippincott; 1992. p. 715-30.

Williams SD, Loehrer PJ, Nichols CR, Einhorn LN.
Chemotherapy of male and female germ cell
tumors. Semin Oncol 1992 Apr;l9(2 Suppl 5):
19-23; discussion 23—4.

Wollner N, Ghavimi F, Wachtel A, Luks E, Exelby P,
Woodruff J. Germ cell tumors in children: gonadal
and extragonadal. Med Pediatr Oncol 1991;19(4):
228-39.

Wong LC, Collins RJ, Ngan HY, Ma I-IK. Etoposide
combination chemotherapy in refractory ovarian
malignant germ cell tumor. Gynecol Oncol 1990
Nov;39(2):123-6.

Wozniak AJ, Samson MK, Shah NT, Crawford ED,
Ford CD, Altman SJ, Stephens RL, Natale RB,
Bouroncle BA, Blumenstein BA, et al. A
randomized trial of cisplatin, vinblastine, and
bleomycin versus vinblastine, cisplatin, and
etoposide in the treatment of advanced germ cell
tumors of the testis: 3 Southwest Oncology Group
study. J Clin Oncol 1991 Jan;9(1):70-6. Comment
in: J Clin Oncol 1991 Jun;9(6):1092-4.

Wu PC, Huang RL, Lang JH, Huang HF, Lian LJ,
Tang MY. Treatment of malignant ovarian germ
cell tumors with preservation of fertility: a report of
28 cases. Gynecol Oncol 1991 Jan;40(1):2-6.

Young RH. New and unusual aspects of ovarian germ
cell tumors. Am J Surg Pathol 1993 Dec;17(12):
1210-24.

Young RH. Ovarian tumors other than those of surface
epithelial-stromal type. Hum Pathol 1991 Aug;
22(8):763—75.

Zaghloul MS, Khattab TY. Dysgerminoma of the
ovary: good prognosis even in advanced stages.
Int J Radiat Oncol Biol Phys 1992;24(1):161—5.

Zambetti M, Escobedo A, Pilotti S, De Palo G. cis-
platinum/vinblastine/bleomycin combination
chemotherapy in advanced or recurrent granulosa
cell tumors of the ovary. Gynecol Oncol 1990 Mar;
36(3):317-20.

32

Radiotherapy

Arian-Schad KS, Kapp DS, Hack] A, Juettner FM,
Leitner H, Porsch G, Lahousen M, Pickel H.
Radiation therapy in stage III ovarian cancer
following surgery and chemotherapy: prognostic
factors, patterns of relapse, and toxicity: a
preliminary report. Gynecol Oncol 1990 Oct;
39(1):47-55.

Belch RZ, Coughlin CT, Cooney LC, Forcier RJ,
Maurer LH. Lack of acute toxicity associated with a
multimodality treatment of stage IH ovarian
epithelial carcinoma. Gynecol Oncol 1990 Apr;
37(1):]7-20.

Bertelsen K, Jakobsen A. Radiotherapy for gynecologic
cancer. Curr Opin Oncol 1993 Sep;5(5):885-90.

Bolis G, Zanaboni F, Vanoli P, Russo A, Franchi M,
Scarfone G, Pecorelli S. The impact of whole-
abdomen radiotherapy on survival in advanced
ovarian cancer patients with minimal residual
disease after chemotherapy. Gynecol Oncol 1990
Nov;39(2):150—4.

Bruzzone M, Repetto L, Chiara S, Campora E, Conte
PF, Orsatti M, Vitale V, Rubagotti A, Rosso R.
Chemotherapy versus radiotherapy in the
management of ovarian cancer patients with
pathological complete response or minimal residual
disease at second look. Gynecol Oncol 1990 Sep;
38(3):392-5.

Buckman R, De Angelis C, Shaw P, Covens A,
Osborne R, Kerr I, Reed R, Michaels H, Woo M,
Reilly R, et al. Intraperitoneal therapy of malignant
ascites associated with carcinoma of ovary and
breast using radioiodinated monoclonal antibody
2G3. Gynecol Oncol 1992 Oct;47(1):102-9.

Calkins AR, Rosenshein NB, Fox MG, Order SE.
Delayed split whole abdominal irradiation in the
combined modality treatment of ovarian cancer.

Int J Radiat Oncol Biol Phys 1991 Apr;20(4):661-5.

Carey MS, Dembo AJ, Simm JE, Fyles AW, Treger T,
Bush RS. Testing the validity of a prognostic
classification in patients with surgically optimal
ovarian carcinoma: a 15-year review. Int J Gynecol
Cancer 1993;3(1):24-35.

Chiara S, Orsatti M, Franzone P, Scarpati D, Bruzzone
M, Repetto L, Vitale V, Conte PF, Rosso R.
Abdominopelvic radiotherapy following surgery and
chemotherapy in advanced ovarian cancer. Clin
Oncol (R Coll Radiol) 1991 Nov;3(6):340—4.

De Pooter CM, Scalliet PG, Elst HJ, Huybrechts JJ ,
Gheuens EE, Van Oosterom AT, Fichtinger-
Schepman AM, De Bruijn EA. Resistance patterns
between cis—diamminedichloroplatinumfll) and
ionizing radiation. Cancer Res 1991 Sep 1; 51(17):
4523-7.

Dembo AJ. Epithelial ovarian cancer: the role of
radiotherapy. Int J Radiat Oncol Biol Phys 1992;
22(5):835—45.

Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF,
Sturgeon J, Reid JG. Ovarian carcinoma: improved
survival following abdominopelvic irradiation in
patients with a completed pelvic operation. Am J
Obstet Gynecol 1979 Aug 1;134(7):793-800.

Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF,
Sturgeon J F. The Princess Margaret Hospital study
of ovarian cancer: stages I, H, and asymptomatic IH
presentations. Cancer Treat Rep 1979 Feb;63(2):
249-54.

Dufour P, Bergerat JP, Liu KL, Bohbot A, Maloisel F,
Duclos B, Herbrecht R, Faradji A, Jung JM,
Oberling F. High dose melphalan and ABMT with
or without abdominal radiotherapy as consolidation
treatment for ovarian carcinoma in complete
remission or with microscopic residual disease.

Eur J Gynaecol Oncol 1991;12(6):457—61.

Eifel PJ, Gershenson DM, Delclos L, Wharton JT,
Peters LI. Twice-daily, split-course abdominopelvic
radiation therapy after chemotherapy and positive
second-look laparotomy for epithelial ovarian
carcinoma. Int J Radiat Oncol Biol Phys 1991 Sep;
21(4):1013—8.

Franchin G, Tumolo S, Scarabelli C, De Paoli A, Boz
G, Crivellari D, Arcicasa M, Bortolus R, Gobitti
C, Minatel E, et a]. Whole abdomen radiation
therapy after a short chemotherapy course and
second-look laparotomy in advanced ovarian cancer.
Gynecol Oncol 1991 Jun;41(3):206-11.

Fuller DB, Sause WT, Plenk HP, Menlove RL.
Analysis of postoperative radiation therapy in stage
I through In epithelial ovarian carcinoma. J Clin
Oncol 1987 Jun;5(6):897-905.

Fyles AW, Dembo AJ, Bush RS, Levin W, Manchul
LA, Pringle JF, Rawlings GA, Sturgeon J F,
Thomas GM, Simm J. Analysis of complications in
patients treated with abdomino-pclvic radiation

therapy for ovarian carcinoma. Int J Radiat Oncol
Biol Phys l992;22(5):847-51.

Garton GR, Gunderson LL, Webb MJ, Wilson TO,
Martenson JA Jr, Cha SS, Podratz KC.
Intraoperative radiation therapy in gynecologic

cancer: the Mayo Clinic experience. Gynecol Oncol
1993 Mar;48(3):328—32.

Goldberg N, Peschel RE. Postoperative abdominopelvic
radiation therapy for ovarian cancer. Int J Radiat
Oncol Biol Phys 1988 Mar;14(3):425-9.

Hammond R, Bull C, Houghton CR. Primary
adjunctive whole abdominal radiotherapy in
epithelial ovarian cancer: results of lO—years’
experience. Aust N Z J Obstet Gynaecol 1992 Aug;
32(3):267-9.

Hird V, Maraveyas A, Snook D, Dhokia B, Soutter
WP, Meares C, Stewart 18, Mason P, Lambert HE,
Epenetos AA. Adjuvant therapy of ovarian cancer
with radioactive monoclonal antibody. Br J Cancer
1993 Aug;68(2):403-6.

Holt JA, Scharl A, Kullander S, Beckmann MW.
Intracellular actions of steroid hormones and their
therapeutic value, including the potential of
radiohalosteroids against ovarian cancer. Acta
Obstet Gynecol Scand Suppl 1992;155:39-54.

Hreshchyshyn MM, Park RC, Blessing JA, Norris HJ,
Levy D, Lagasse LD, Creasman WT. The role of
adjuvant therapy in Stage I ovarian cancer. Am J
Obstet Gynecol 1980 Sep 15;]38(2):139-45.

Jacobs A], Fer M, Su FM, Breitz H, Thompson J,
Goodgold H, Cain J, Heaps J, Weiden P. A phase I
trial of a rhenium 186—labeled monoclonal antibody
administered intraperitoneally in ovarian carcinoma:
toxicity and clinical response. Obstet Gynecol 1993
Oct;82(4 Pt 1):586—93.

Jusko WJ, Kung LP, Schmelter RF.
Immunopharmacokinetics of 111In—CYT-103 in

ovarian cancer patients. Targeted Diagn Ther
1992;6z177-90.

King LA, Downey GO, Potish RA, Adcock LL, Carson
LF, Twiggs LB. Concomitant whole-abdominal
radiation and intraperitoneal chemotherapy in
advanced ovarian carcinoma. A pilot study. Cancer
1991 Jun 1:67(11):2867—71.

Kohler MF, Soper JT, Tucker JA Jr, Clarke—Pearson
DL. Isolated incisional metastases after
intraperitoneal radioactive chromic phosphate

therapy for ovarian carcinoma. Cancer 1991;68(6):
1380-3.

Konski AA, Neisler J, Phibbs G, Bronn DG,
Dobelbower R Jr. A pilot study investigating
intraoperative electron beam irradiation in the
treatment of ovarian malignancies. Gynecol Oncol
1990 Jul;38(l):121-4.

Kosmas C, Man S, Epenetos AA, Courtenay—Luck NS.
The role of humoral and cellular immunity in
patients developing human anti-murine
immunoglobulin antibody responses after
radioimmunotherapy. Br J Cancer Suppl 1990
Jul;10:85-8.

Kosmas C, Snook D, Gooden CS, Courtenay-Luck NS,
McCall MJ, Meares CF, Epenetos AA.
Development of humoral immune responses against
a macrocyclic chelating agent (DOTA) in cancer
patients receiving radioimmunoconjugates for
imaging and therapy. Cancer Res 1992 Feb 15;
52(4):904-11.

Kucera PR, Berman ML, Treadwell P, Sheets EE,
Micha JP, Rettenmaier MA, Colman M, DiSaia PJ.
Whole—abdominal radiotherapy for patients with

33

minimal residual epithelial ovarian cancer. Gynecol
Oncol 1990 Mar;36(3):338-42.

Lanciano RM, Randall M. Update on the role of
radiotherapy in ovarian cancer. Semin Oncol 1991
Jun;18(3):233-47.

Lawton F, Luesley D, Blackledge G, Hilton C, Kelly
K, Latief T, Mould J, Spooner D, Rollason T,
Wade-Evans T, et al. A randomized trial comparing
whole abdominal radiotherapy with chemotherapy
following cisplatinum cytoreduction in epithelial
ovarian cancer. West Midlands Ovarian Cancer
Group Trial II. Clin Oncol (R Coll Radiol) 1990
Jan;2(1):4-9.

Ledermann JA, Dembo AJ, Sturgeon JF, Fine S, Bush
RS, Fyles AW, Pringle JF, Rawlings GA, Thomas
GM, Simm J. Outcome of patients with unfavorable
optimally cytoreduced ovarian cancer treated with
chemotherapy and whole abdominal radiation.
Gynecol Oncol 1991 Apr;41(1):30—5.

Lentz SS, Schray MF, Wilson TO. Chylous ascites
after whole-abdomen irradiation for gynecologic
malignancy. Int J Radiat Oncol Biol Phys 1990
Aug;19(2):435-8.

Lindner H, Willich H, Atzinger A. Primary adjuvant
whole abdominal irradiation in ovarian carcinoma.
Int J Radiat Oncol Biol Phys 1990 Nov;19(5):
1203-6.

Linstadt DE, Stern JL, Quivey JM, Leibel SA, Lacey
CG. Salvage whole-abdominal irradiation following
chemotherapy failure in epithelial ovarian
carcinoma. Gynecol Oncol 1990 Mar;36(3):327-30.

Marietta A, Lucci J, Soopikian J, Granger G, Berman
ML, DiSaia PI . In vitro cytotoxicity of human
recombinant tumor necrosis factor alpha in
association with radiotherapy in a human ovarian
carcinoma cell line. Gynecol Oncol 1990 Aug;
38(2):200-2.

Martinez A, Schray MF, Howes AE, Bagshaw MA.
Postoperative radiation therapy for epithelial
ovarian cancer: the curative role based on a 24-year
experience. J Clin Oncol 1985 Jul;3(7):901-11.

Martinez Monge R, Jurado M, Azinovic I, Aristu JJ,
Tangco E, Viera JC, Berian JM, Calvo FA.
Intraoperative radiotherapy in recurrent
gynecological cancer. Radiother Oncol 1993 Aug;
28(2):127-33.

May LF, Belinson J L, Roland TA. Palliative benefit of
radiation therapy in advanced ovarian cancer.
Gynecol Oncol 1990 Jun;37(3):408-11.

Moore DH. Role of radiation therapy in ovarian cancer.
Curr Opin Obstet Gynecol 1990 Feb;2(1):64-8.

Mothersill C, Seymour CB, Bonnar J. Effect of
radiation and other cytotoxic agents on the growth

34

of cells cultured from normal and tumor tissues
from the female genital tract. Gynecol Oncol 1990
May;37(2):210—8.

Muto MG, Finkler NJ, Kassis AI, Howes AE,
Anderson LL, Lau CC, Zurawski VR Jr, Weadock
K, Tumeh SS, Lavin P, et a1. Intraperitoneal
radioimmunotherapy of refractory ovarian
carcinoma utilizing iodine-l31—labeled monoclonal
antibody OC125. Gynecol Oncol 1992 Jun;45(3):
265-72.

Mychalczak BR, Fuks Z. The current role of
radiotherapy in the management of ovarian cancer.
Hematol Oncol Clin North Am 1992 Aug;6(4):
895-913.

Mychalczak BR, Fuks Z. The role of radiotherapy in
the management of epithelial ovarian cancer. In:
Markman M, Hoskins WJ, eds. Cancer of the
ovary. New York: Raven Press; 1993. p. 229-41.

Peters WA 3d, Smith MR, Cain JM, Lee RB, Yon JL
Jr. Intraperitoneal P-32 is not an effective
consolidation therapy after a negative second-look
laparotomy for epithelial carcinoma of the ovary.
Gynecol Oncol 1992 Nov;47(2):146-9.

Pickel H, Petru E, Lahousen M, Stettner H,
Heydarfadai M, Arian—Schad K, Hack] A.
Consolidation radiotherapy following carboplatin—
based chemotherapy in radically operated advanced
ovarian cancer. A pilot study. Am J Clin Oncol
1991 Jun;14(3):184—7.

Pirkowski M, Holloway R, Delgado G, Barnes W,
Thomas D, Torrisi J, Popescu G, Rodgers J,
Dritschilo A. Radiotherapy of malignant
subdiaphragmatic implants in advanced ovarian
carcinoma: a new technique. Int J Radiat Oncol Biol
Phys l992;22(5):]105-8.

Piver MS, Malfetano J, Hempling RE, Baker TR,
Driscoll DL. Cisplatin—based chemotherapy for
stage H ovarian adenocareinoma: a preliminary
report. Gynecol Oncol 1990 Dec;39(3):249-52.

Potish RA, King LA, Downey GO, Adcock LL, Carson
LF, Twiggs LB. The integration of whole
abdominal radiotherapy and intraperitoneal cisplatin
into the primary management of advanced ovarian
carcinoma. Am J Clin Oncol 1991 Aug;14(4):
312-6.

Randall ME. Curative potential of primary whole—
abdomen irradiation in ovarian carcinoma. South
Med J 1991 Sep;84(9):1119-22.

Randall ME, Evans L. Issues in gynecologic radiation
oncology. Curr Opin Oncol 1991 Oct;3(5):920—9.

Reddy S, Lee MS, Yordan E, Graham J, Sarin P,
Hendrickson FR. Salvage whole abdomen radiation
therapy: its role in ovarian cancer. Int J Radiat
Oncol Biol Phys 1993 Nov 15;27(4):879-84.

Redman CW, Mould J, Warwick J, Rollason T,
Luesley DM, Budden J, Lawton FG, Blackledge
GR, Chan K. The West Midlands epithelial
ovarian cancer adjuvant therapy trial. Clin Oncol
(R Coll Radiol) 1993;5(1):1-5.

Reid GC, Roberts JA, Hopkins MP, Schoeppel SL,
Perez—Tamayo C, Drescher C, Chamberlain D,
Morley GW. Primary treatment of stage III ovarian
carcinoma with sequential chemotherapy and whole
abdominal radiation therapy. Gynecol Oncol 1993
Jun;49(3):333-8.

Reinfuss M, Kojs Z, Skolyszewski J. External beam
radiotherapy in the management of ovarian
carcinoma. Radiother Oncol 1993 Jan;26(1):26-32.

Rodriguez GC, Soper JT, Berchuck A, Oleson J,
Dodge R, Montana G, Clarke-Pearson DL.
Improved palliation of cerebral metastases in
epithelial ovarian cancer using a combined modality
approach including radiation therapy,
chemotherapy, and surgery. J Clin Oncol 1992 Oct;
10(10):1553-60.

Rogers L, Varia M, Halle J, Freddo J, Qaqish B,
O’Keefe T, Fowler W. 32P following negative
second-look laparotomy for epithelial ovarian
cancer. Gynecol Oncol 1993 Aug;50(2):141-6.
Comment in: Gynecol Oncol 1993 Aug;50(2):
139-40.

Rothenberg ML, Ozols RF, Glatstein E, Steinberg SM,
Reed E, Young RC. Dose—intensive induction
therapy with cyclophosphamide, cisplatin, and
eonsolidative abdominal radiation in advanced-stage
epithelial ovarian cancer. J Clin Oncol 1992 May;
10(5):727-34. Comment in: J Clin Oncol 1992
May;10(5):683-5 and J Clin Oncol 1992 Nov;
10(11):1820-1.

Rotmensch J, Roeske J, Chen G, Pelizzan' C, Montag
A, Weichselbaum R, Herbst AL. Estimates of dose
to intraperitoneal micrometastases from alpha and
beta emitters in radioimmunotherapy. Gynecol
Oncol 1990 Sep;38(3):478-85.

Sell A, Bertelsen K, Andersen J E, Stroyer I, Panduro J.
Randomized study of whole—abdomen irradiation
versus pelvic irradiation plus cyclophosphamide in
treatment of early ovarian cancer. Gynecol Oncol
1990 Jun;37(3):367-73.

Slotman BJ, Karim AB, Rao BR. Ovarian cancer:
radiation sensitivity in vitro. Radiother Oncol 1990
Dec; 19(4):323-7.

Sorbe B, Berglind AM, De Bruijn K. Tropisetron, a
new 5-HT3 receptor antagonist, in the prevention of
irradiation-induced nausea, vomiting and diarrhoea.
Eur J Gynaecol Oncol 1992;13(5):382-9.

Spanos W] Jr, Day T, Abner A, Jose B, Paris K,
Pursell S. Complications in the use of intra-

abdominal 32P for ovarian carcinoma. Gynecol
Oncol 1992 Jun;45(3):243-7.

Stewart JS, Hird V, Snook D, Dhokia B, Sivolapenko
G, Hooker G, Papadimitriou JT, Rowlinson G,
Sullivan M, Lambert I-IE, et al. Intraperitoneal
yttrium-90—labeled monoclonal antibody in ovarian
cancer. J Clin Oncol 1990 Dec;8(12):1941—50.
Comment in: J Clin Oncol 1990 Dec;8(12):
1938—40.

Thomas GM. Is there a role for consolidation or
salvage radiotherapy after chemotherapy in
advanced epithelial ovarian cancer? Gynecol Oncol
1993 0ct;51(1):97-103.

Thomas GM, Dembo AJ. Integrating radiation therapy
into the management of ovarian cancer. Cancer
1993 Feb 15;71(4 Suppl):l7lO-8.

Vergote IB. Adjuvant treatment of ovarian carcinoma.
Acta Obstet Gynecol Scand 1993;72(8):682-4.

Vergote IB, Vergote-De Vos LN, Abeler VM, Aas M,
Lindegaard MW, Kjorstad KE, Trope CG.
Randomized trial comparing cisplatin with
radioactive phosphorus or whole-abdomen
irradiation as adjuvant treatment of ovarian cancer.
Cancer 1992 Feb l;69(3):741-9.

Vergote IB, Winderen M, De Vos LN, Trope CG.
Intraperitoneal radioactive phosphorus therapy in
ovarian carcinoma. Analysis of 313 patients treated
primarily or at second-look laparotomy. Cancer
1993 Apr 1;71(7):2250-60.

Wahl RL. Radiolabeled monoclonal antibodies for the
diagnosis and treatment of ovarian carcinoma. Front
Radiat Ther Oncol 1990;24:228—259.

Walton LA, Yadusky A, Rubinstein L. Intraperitoneal
radioactive phosphate in early ovarian carcinoma:

an analysis of complications. Int J Radiat Oncol
Biol Phys 1991 May;20(5):939-44.

Weiser EB, Burke TW, Heller PB, Woodward J,
Hoskins WJ , Park RC. Determinants of survival of
patients with epithelial ovarian carcinoma following
whole abdomen irradiation (WAR). Gynecol Oncol
1988 Jun;30(2):201-8.

Whelan TJ, Dembo AJ, Bush RS, Sturgeon JF, Fine S,
Pringle JF, Rawlings GA, Thomas GM, Simm J.
Complications of whole abdominal and pelvic
radiotherapy following chemotherapy for advanced
ovarian cancer. Int J Radiat Oncol Biol Phys 1992;
22(5):853-8.

35

MANAGEMENT OF ADVANCED
EPITHELIAL OVARIAN CANCER

Preoperative Evaluation and Preparation

Adelson MD. Cytoreduction of diaphragmatic
metastases using the Cavitron Ultrasonic Surgical
Aspirator. Gynecol Oncol 1991 Jun;41(3):220—2.

Adelson MD. Ultrasonic surgical aspirator in
cytoreduction of splenic metastases to avoid
splenectomy. J Reprod Med 1992 Nov;37(11):
917-20.

Barbieri RL, Niloff JM, Bast RC Jr, Scaetzl E, Kistner
RW, Knapp RC. Elevated serum concentrations of
CA-125 in patients with advanced endometriosis.
Fertil Steril 1986 May;45(5):630—4.

Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM,
Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT,
Parker L, Zurawski VR Jr, Knapp RC. A
radioimmunoassay using a monoclonal antibody to

monitor the course of epithelial ovarian cancer.
N Engl J Med 1983 Oct 13;309(15):883-7.

Beck DE, Fazio VW. Current preoperative bowel
cleansing methods. Results of a survey. Dis Colon
Rectum 1990 Jan;33(l):12-5.

Bertelsen K. Tumor reduction surgery and long-term
survival in advanced ovarian cancer: a DACOVA
study. Gynecol Oncol 1990 Aug;38(2):203-9.

Bertelsen K, J akobsen A, Stroyer J, Nielsen K,
Sandberg E, Andersen JE, Ahrons S, Nyland M,
Hjortkjaer Pedersen P, Larsen G, ct al. A
prospective randomized comparison of 6 and 12
cycles of cyclophosphamide, adriamycin, and
cisplatin in advanced epithelial ovarian cancer: a
Danish Ovarian Study Group trial (DACOVA).
Gynecol Oncol 1993 Apr;49(1):30—6.

Bostofte E, Larsen T, Torp-Pedersen S, Ottesen M.
Preoperative investigations for suspected pelvic
masses. Eur J Obstet Gynecol Reprod Biol 1992
Dec 28;47(3):239—43.

Boume TH, Campbell S, Whitehead MI, Royston P,
Steer CV, Collins WP. Detection of endometrial
cancer in postmenopausal women by transvaginal
ultrasonography and colour flow imaging. BMJ
1990 Aug 18-25;301(6748):369. Comment in: BMJ
1990 Oct 13;301(6756)873-4.

Buchsbaum HJ, Lifshitz S. Staging and surgical
evaluation of ovarian cancer. Semin Oncol 1984
Sep;l 1(3):227-37.

Buy JN, Ghossain MA, Sciot C, Bazot M, Guinet C,
Prevot S, Hugol D, Laromiguiere M, Truc JB,
Poitout P, et al. Epithelial tumors of the ovary: CT
findings and correlation with US. Radiology 1991
Mar;178(3):811-8.

36

Corfitsen MT, Pedersen IR, Lebech AM, Kaae HH.
Appendectomy and carcinoma ovarii.
Cytoreduction, palliation, or simple tradition? Acta
Obstet Gynecol Scand 1991;70(7-8):601-4.

Creasman WT. New gynecologic cancer staging. Obstet
Gynecol 1990 Feb;75(2):287-8.

Crippa F, Presti M, Marini A, D’Onofrio B, Bolis G,
Buraggi GL. Clinical value of
radioimmunoscintigraphy in the follow-up of
ovarian carcinoma: a prospective study. Int J Biol
Markers 1990 Jul-Sep;5(3):103-8.

Deppe G, Malviya VK, Malone JM Jr, Christensen
CW. Debulking of pelvic and para-aortic lymph
node metastases in ovarian cancer with the cavitron
ultrasonic surgical aspirator. Obstet Gynecol 1990
Dec;76(6): 1 140-2.

Dershaw DD, Panicek DM. Radiologic evaluation of
ovarian cancer. In: Markman M, Hoskins WJ, eds.
Cancer of the ovary. New York: Raven Press;
1993. p. 133-52.

Einhom N, Bast RC Jr, Knapp RC, Tjemberg B,
Zurawski VR Jr. Preoperative evaluation of serum
CA 125 levels in patients with primary epithelial
ovarian cancer. Obstet Gynecol 1986 Mar;67(3):
414-6.

Eisenkop SM, Nalick RH, Teng NN. Modified
posterior exenteration for ovarian cancer. Obstet
Gynecol 1991 Nov;78(5 Pt 1):879-85.

Eisenkop SM, Spirtos NM, Montag TW, Nalick RH,
Wang H]. The impact of subspecialty training on
the management of advanced ovarian cancer.
Gynecol Oncol 1992 Nov;47(2):203-9.

Eisner RF, Montz FJ, Berek IS. Cytoreductive surgery
for advanced ovarian cancer: cardiovascular
evaluation with pulmonary artery catheters. Gynecol
Oncol 1990 Jun;37(3):311-4.

Gore ME, Cooke JC, Wiltshaw E, Crow J M, Cosgrove
DO, Parsons CA. The impact of computed
tomography and ultrasonography on the
management of patients with carcinoma of the
ovary. Br J Cancer 1989 Nov;60(5):751-4.

Granberg S, Wikland M, Jansson I. Macroscopic
characterization of ovarian tumors and the relation
to the histological diagnosis: criteria to be used for
ultrasound evaluation. Gynecol Oncol 1989 Nov;
35(2):139-44.

Grilli R, Alexanian A, Apolone G, Fossati R, Marsoni
S, Nicolucci A, Torri V, Zola P, Compagnucci M,
Di Mambro E, et al. The impact of cancer
treatment guidelines on actual practice in Italian
general hospitals: the case of ovarian cancer. Ann
Oncol 1990;1(2):112-8. Comment in: Ann Oncol
1991 Mar;2(3):216.

Grilli R, Apolone G, Marsoni S, Nicolucci A, Zola P,
Liberati A. The impact of patient management
guidelines on the care of breast, colorectal, and
ovarian cancer patients in Italy. Med Care 1991
Jan;29(l):50—63.

Guidozzi F, Sonnendecker EW. Evaluation of
preoperative investigations in patients admitted for
ovarian primary cytoreductive surgery. Gynecol
Oncol 1991 Mar;40(3):244—7.

Hallenbeck P, Sanniez CK, Ryan AB, Neiley B,
Sugarbaker PH. Cytoreductive surgery and
intraperitoneal chemotherapy. Treatment for
peritoneal carcinomatosis. AORN J 1992 Jul;
56(1):50-7, 60-72.

Hammond RH, Houghton CR. The role of bowel
surgery in the primary treatment of epithelial
ovarian cancer. Aust N Z J Obstet Gynaecol 1990
May;30(2):166-9.

Hricak H. Role of imaging in the evaluation of pelvic
cancer. Important Adv Oncol 1991:103-33.

Jacobs 1, Oram D, Fairbanks J, Turner J, Frost C,
Grudzinskas JG. A risk of malignancy index
incorporating CA 125, ultrasound and menopausal
status for the accurate preoperative diagnosis of
ovarian cancer. Br J Obstet Gynaecol 1990 Oct;
97(10):922-9.

Johnson RJ, Blackledge G, Eddleston B, Crowther D.
Abdomino—pelvic computed tomography in the

management of ovarian carcinoma. Radiology 1983
Feb;146(2):447-52.

Kurjak A, Zalud I, Alfirevic 2. Evaluation of adnexal
masses with transvaginal color ultrasound.
J Ultrasound Med 1991 Jun;10(6):295-7. Comment
in: J Ultrasound Med 1992 Mar;11(3):80.

La Fianza A, Campani R, Dore R, Babilonti L, Tateo
S. The clinical value of computed tomography and
lymphography in detecting lymph node metastases
from epithelial ovarian cancer. Rofo Fortschr Geb
Rontgenstr Neuen Bildgeb Verfahr 1992 Aug;
157(2): 162—6.

Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR
Jr, Podratz KC, Stanhope CR, Mortel R, Berek JS,
Bast RC Jr, Ritts RE. Preoperative evaluation of
serum CA 125 levels in premenopausal and
postmenopausal patients with pelvic masses:
discrimination of benign from malignant disease.
Am J Obstet Gynecol 1988 Aug;159(2):341-6.

Penalver M, Averette H, Sevin BU, Lichtinger M,
Girtanner R. Gastrointestinal surgery in gynecologic
oncology: evaluation of surgical techniques.
Gynecol Oncol 1987 Sep;28(l):74-82.

Perioperative total parenteral nutrition in surgical
patients. The Veterans Affairs Total Parenteral
Nutrition Cooperative Study Group. N Engl J Med

1991 Aug 22;325(8):525-32. Comment in: N Engl J
Med 1991 Aug 22;325(8):573-5; Comment in:

N Engl J Med 1992 Jan 23;326(4):273; discussion
274; N Engl J Med 1992 Jan 23; 326(4):273—4.

Russell AH, Anderson M, Walter J, Kinney W, Smith
L, Scudder S. The integration of computed
tomography and magnetic resonance imaging in

treatment planning for gynecologic cancer. Clin
Obstet Gynecol 1992 Mar;35(1):55-72.

Schwartz PE. An oncologic View of when to do
endoscopic surgery. Clin Obstet Gynecol 1991
Jun;34(2):467—72.

Solla J A, Rothenberger DA. Preoperative bowel
preparation. A survey of colon and rectal surgeons.
Dis Colon Rectum 1990 Feb;33(2):154-9.

Taylor 171‘, consultant. Advanced ovarian cancer:
principles of management. In: Wanabo HJ, ed.
Common problems in cancer surgery. Chicago:
Year Book; 1990. p.280-4.

Whitley N, Brenner D, Francis A, Kwon T, Villasanta
U, Aisner J, Wiemik P, Whitley I. Use of the
computed tomographic whole body scanner to stage
and follow patients with advanced ovarian
carcinoma. Invest Radiol 1981 Nov-Dec;16(6):
479-86.

37

Principles of Primary Surgery

Aalders JG, Neijt I P. Aspects of surgery in ovarian and
endometrial carcinoma. Eur J Cancer 1993;29A(4):
624-8.

Archer JC, Soeters RP, Bloch B, Dehaeck CM, Levin
W. Repeat laparotomy in ovarian carcinoma after
primary surgery. S Afr Med J 1991 Sep 21;
80(6):276-7.

Averette HE, Hoskins W, Nguyen HN, Boike G, Flessa
HC, Chmiel JS, Zuber K, Karnell LH, Winchester
DP. National survey of ovarian carcinoma. I. A
patient care evaluation study of the American
College of Surgeons. Cancer 1993 Feb 15;71
(4 Suppl):1629-38.

Brand E, Lidor Y. The decline of CA 125 level after
surgery reflects the size of residual ovarian cancer.
Obstet Gynecol 1993 Jan;81(1):29-32.

Brand E, Pearlman N. Electrosurgical debulking of
ovarian cancer: a new technique using the argon
beam coagulator. Gynecol Oncol 1990 Nov;39(2):
1 15-8 .

Bridges JE, Leung Y, Hammond IG, McCartney AJ.
En bloc resection of epithelial ovarian tumors with
concomitant rectosigmoid colectomy: The KEMH
experience. Int J Gynecol Cancer 1993;3(4):
199-202.

Buchsbaum HJ, Lifshitz S. Staging and surgical

evaluation of ovarian cancer. Semin Oncol 1984
Sep;11(3):227-37.

Burghardt E, Girardi F, Lahousen M, Tamussino K,
Stettner H. Patterns of pelvic and paranortic lymph
node involvement in ovarian cancer. Gynecol Oncol
1991 Feb;40(2):103—6.

Fioretti P, Gadducci A, Del Bravo B, Prato B. The
potential of primary cytoreductive surgery in
patients with FIGO stages III and IV ovarian
carcinoma. Eur J Gynaecol Oncol l990;11(3):
175-9.

Fontanelli R, Paladini D, Raspagliesi F, di Re E. The
role of appendectomy in surgical procedures for
ovarian cancer. Gynecol Oncol 1992 Iul;46(1):42-4.

Hacker NF. Surgery for gynaecological cancer: results
since the introduction of radical operations. Aust N
Z J Obstet Gynaecol 1990 Feb;30(1):24—8.

Hakes TB, Chalas E, Hoskins W], Jones WB,
Markman M, Rubin SC, Chapman D, Almadrones
L, Lewis J L Jr. Randomized prospective trial of 5
versus 10 cycles of cyclophosphamide, doxorubicin,
and cisplatin in advanced ovarian carcinoma.
Gynecol Oncol 1992 Jun;45(3):284-9.

38

Hand R, Fremgen A, Chmiel JS, Recant W, Berk R,
Sylvester J, Sener S. Staging procedures, clinical
management, and survival outcome for ovarian
carcinoma. JAMA 1993 Mar 3;269(9):1119-22.
Comment in: JAMA 1993 Mar 3;269(9):1163 and
JAMA 1993 Sep 8;270(10):1196—7.

Heintz AP. Cytoreductive surgery for ovarian cancer.
In: Greer BE, Berek JS, eds. Gynecologic
oncology: treatment rationale and techniques. New
York: Elsevier; 1991. p. 135-48.

Hoskins WJ. Primary cytoreduction. In: Markman M,
Hoskins WJ, eds. Cancer of the ovary. New York:
Raven Press; 1993. p. 163-73.

Hoskins WJ. Primary surgical management of advanced
epithelial ovarian cancer. In: Rubin SC, Sutton GP,
eds. Ovarian cancer. New York: McGraw-Hill;
1993. p. 241-53.

Hoskins WJ. Surgical staging and cytoreductive surgery
of epithelial ovarian cancer. Cancer 1993 Feb 15;
71(4 Suppl):1534-40.

Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The
influence of cytoreductive surgery on recurrence-
free interval and survival in small-volume stage In
epithelial ovarian cancer: a Gynecologic Oncology
Group study. Gynecol Oncol 1992 Nov;47(2):
159—66.

Hoskins WJ, Rubin SC. Surgery in the treatment of
patients with advanced ovarian cancer. Semin Oncol
1991 Jun;18(3):213-21.

Hudson CN, Potsides P, Curling OM. An audit of
surgical treatment of ovarian cancer in a
metropolitan health region. Association of
Obstetricians and Gynaecologists of the North East
Thames Region. J R Soc Med 1991 Apr;84(4):
206-9.

Hunter RW, Alexander ND, Soutter WP. Meta-analysis
of surgery in advanced ovarian carcinoma: is
maximum cytoreductive surgery an independent
determinant of prognosis? Am J Obstet Gynecol
1992 Feb;166(2):504-11. Comment in: Am J Obstet
Gynecol 1993 Jul;169(1):236—7.

Jadhon ME, Morgan MA, Kelsten ML, Carlson JA Jr,
Mikuta JJ. Cytologic smears of peritoneal surfaces
as a sampling technique in epithelial ovarian
carcinoma. Obstet Gynecol 1990 Jan;75(1):102-5.

Kapnick SJ, Griffiths CT, Finkler NJ. Occult pleural
involvement in stage HI ovarian carcinoma: role of
diaphragm resection. Gynecol Oncol 1990 Nov;
39(2): 135-8 .

Kigawa J, Minagawa Y, Ishihara H, Kanamori Y,
Itamochi H, Terakawa N. Evaluation of
cytoreductive surgery with lymphadenectomy
including para-aortic nodes for advanced ovarian
cancer. Eur J Surg Oncol 1993 Jun;19(3):273-8.

Kirschner CV, DeSerto TM, Isaacs JH. Surgical
treatment of the elderly patient with gynecologic
cancer. Surg Gynecol Obstet 1990 May;170(5):
379-84.

Lawton F, Luesley D, Redman C, Chan KK, Varma R,
Blackledge G. Feasibility and outcome of complete
secondary tumor resection for patients with
advanced ovarian cancer. J Surg Oncol 1990 Sep;
45(1):l4-9.

Luesley DM, Williams DR, Ward K, Redman CR,
Lawton FG. Prospective comparative cytologic
study of direct peritoneal smears and lavage fluids
in patients with epithelial ovarian cancer and benign
gynecologic disease. Acta Cytol 1990 Jul-Aug;
34(4):539-44.

Magli G, De Marco I, Biello A, Turtoro L, Esposito A.
Regional surgery in advanced ovarian carcinoma.
Eur J Gynaecol Oncol 1992;13(l Suppl):97—8.

Marchetti DL, Lele SB, Priore RL, McPhee ME,
Hreshchyshyn MM. Treatment of advanced ovarian
carcinoma in the elderly. Gynecol Oncol 1993 Apr;
49(1):86-91.

Markman M. Surgeon's skill key to ovarian cancer
management. Cleve Clin J Med 1993 May-Jun;
60(3): 183-4.

Mayer AR, Chambers SK, Graves E, Holm C, Tseng
PC, Nelson BE, Schwartz PE. Ovarian cancer
staging: does it require a gynecologic oncologist?
Gynecol Oncol 1992 Nov;47(2):223-7.

McGowan L. Patterns of care in carcinoma of the
ovary. Cancer 1993 Jan 15;71(2 Suppl):628-33.

Menczer J. Cytoreductive surgery in the treatment of
advanced ovarian carcinoma. Some controversial
aspects. Eur J Gynaecol Oncol 1992;l3(3):246-55.

Nelson BE, Rosenfield AT, Schwartz PE. Preoperative
abdominopelvic computed tomographic prediction of
optimal cytoreduction in epithelial ovarian
carcinoma. J Clin Oncol 1993 Jan;ll(1):166-72.

Nishimura H, Hamaguchi K, Miyahara K, Tazaki T,
Tateno N, Yakushiji M. The current therapeutic
approaches to advanced ovarian cancer. Nippon
Sanka Fujinka Gakkai Zasshi 1990 Dec;42(12):
1691-6.

Obiakor I, Maiman M, Mittal K, Awobuluyi M,
DiMaio T, Demopoulos R. The accuracy of frozen
section in the diagnosis of ovarian neoplasms.
Gynecol Oncol 1991 Oct;43(l):61-3.

Onnis A, Marchetti M, Maggino T, De Toffoli J,
Blandamura S. Clinical experience in gynecological
cancer management. d). Ovarian tumors--l)
Epithelial: report from the Gynaecological Institutes
of Padua University (1963-1990). Eur J Gynaecol
Oncol 1992;13(1):17-33.

Ozols RF. Ovarian cancer, Part II: Treatment. Curr
Probl Cancer 1992 Mar-Apr;16(2):61-126.

Partridge EE, Gunter BC, Gelder MS, Alvarez RD,
Soong SJ, Austin JM, Kilgore LC. The validity and
significance of substages of advanced ovarian
cancer. Gynecol Oncol 1993 Feb;48(2):236-41.

Penalver M, Averette H, Sevin BU, Lichtinger M,
Girtanner R. Gastrointestinal surgery in gynecologic
oncology: evaluation of surgical techniques.
Gynecol Oncol 1987 Sep;28(1):74-82.

Petru E, Pickel H, Tamussino K, Lahousen M,
Heydarfadai M, Posawetz W, Jakse R.
Pretherapeutic scalene lymph node biopsy in
ovarian cancer. Gynecol Oncol 1991 Dec;
43(3):262—4.

Petru E, Sevin BU, Averette HE, Koechli OR,
Hilsenbeck S. Long—term survival in stage III and
IV ovarian cancer. Arch Gynecol Obstet 1991;
249(2):87-93.

Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin
JM, Shingleton HM. Primary surgical therapy of
ovarian cancer: how much and when. Gynecol
Oncol 1991 Mar;40(3):195-200.

Rader J S. Therapeutic advances in ovarian cancer. Curr
Opin Obstet Gynecol 1992 Feb;4(1):IZO-7.

Rakar S, Kovacic J, Cavic M, Lukanovic A, Mozina A.
Prognostic factors in ovarian cancer. Eur J
Gynaecol Oncol 1990;11(3):171-3.

Rose PG. The cavitational ultrasonic surgical aspirator
for cytoreduction in advanced ovarian cancer. Am J
Obstet Gynecol 1992 Mar;166(3):843-6. Comment
in: Am J Obstet Gynecol 1993 Feb;168(2):736.

Rose PG, Reale FR, Fisher A, Hunter RE.
Appendectomy in primary and secondary staging
operations for ovarian malignancy. Obstet Gynecol
1991 Jan;77(1):116—8.

Rubin SC. Surgery for ovarian cancer. Hematol Oncol
Clin North Am 1992 Aug;6(4):851-65.

Scott NA, Schofield PF. Cytoreductive surgery for
ovarian carcinoma. Br J Surg 1990 May;77(5):
481-2.

Soper JT, Couchman G, Berchuck A, Clarke-Pearson
D. The role of partial sigmoid colectomy for
debulking epithelial ovarian carcinoma. Gynecol
Oncol 1991 Jun;4l(3):239-44. Comment in:
Gynecol Oncol 1992 Jul;46(l):138.

Soper JT, Johnson P, Johnson V, Berchuck A, Clarke-
Pearson DL. Comprehensive restaging laparotomy
in women with apparent early ovarian carcinoma.
Obstet Gynecol 1992 Dec;80(6):949-53.

39

Tsuruchi N, Kamura T, Tsukamoto N, Akazawa K,
Saito T, Kalcu T, To N, Nakano H. Relationship
between paraaortic lymph node involvement and
intraperitoneal spread in patients with ovarian
cancer--a multivariate analysis. Gynecol Oncol 1993
Apr;49(1):51-5.

Tummarello D, Menichetti ET, Miseria S, Torresi U,
Guidi F, Gramazio A, Vissani L, Cellerino R.
Advanced epithelial ovarian cancer: no difference in
survival rate between exploratory laparotomy and
inadequate debulking surgery as treatment approach
before chemotherapy. J Chemother 1990 Aug;2(4):
260-3.

Unzelman RF. Advanced epithelial ovarian carcinoma:
long-term survival experience at the community
hospital. Am J Obstet Gynecol 1992 Jun;166(6 Pt
1)11663-71; discussion 1671-2.

Vardi JR, Tadros GH, Zamurovic D, Rafla SD. Tumor
debulking followed by immediate combination
chemotherapy in advanced ovarian carcinoma.
Phase II. Acta Obstet Gynecol Scand 1992 Jul;
71(5):361-7.

Venesmaa P, Ylikorkala O. Morbidity and mortality
associated with primary and repeat operations for
ovarian cancer. Obstet Gynecol 1992 Feb;79(2):
168-72. Comment in: Obstet Gynecol 1992 Jul;
80(1):155—6.

Vergote IB. Surgery for gynecologic malignancies. Curr
Opin Oncol 1993 Sep;5(5):877-84.

Wils JA. Long-term follow-up of patients with
advanced ovarian carcinoma treated with debulking
surgery and chemotherapy consisting of cisplatin,
doxorubicin, and cyclophosphamide. Gynecologic
Oncology Group of the Comprehensive Cancer
Center. Oncology 1990;47(2):115-20.

Wong RJ, DeCosse JJ. Cytoreductive surgery. Surg
Gynecol Obstet 1990 Mar;170(3):276-81.

Yedema CA, Kenemans P, Thomas CM, Massuger LF,
Wobbes T, Verstraeten R, van Kamp GJ, Hilgers J.
CA 125 serum levels in the early post-operative
period do not reflect tumour reduction obtained by
cytoreductive surgery. Eur J Cancer 1993;29A(7):
966-71.

40

Primary Adjuvant Chemotherapy

Abel U. Chemotherapy of advanced epithelial cancer -
A critical review. Biomed Pharmacother 1992;
46(10):439-52.

Alberts DS, Canetta R, Mason-Liddil N. Carboplatin in
the first-line chemotherapy of ovarian cancer.
Semin Oncol 1990 Feb;17(1 Suppl 2):54-60.

Alberts DS, Dahlberg S, Green SJ, Garcia D, Hannigan
EV, O’Toole R, Stock-Novack D, Surwit EA,
Malviya VK, Jolles CJ. Analysis of patient age as
an independent prognostic factor for survival in a
phase III study of cisplatin-cyclophosphamide versus
carboplatin-cyclophosphamide in stages III
(suboptimal) and IV ovarian cancer. A Southwest
Oncology Group study. Cancer 1993 Jan 15;

71(2 Suppl):618-27.

Alberts DS, Green S, Hannigan EV, O’Toole R, Stock-
Novack D, Anderson P, Surwit EA, Malvlya VK,
Nahhas WA, Jolles CJ. Improved therapeutic index
of carboplatin plus cyclophosphamide versus
cisplatin plus cyclophosphamide: final report by the
Southwest Oncology Group of a phase III
randomized trial in stages HI and IV ovarian
cancer. J Clin Oncol 1992 May;10(5):706-17.
Published erratum appears in J Clin Oncol 1992
Sep;10(9):1505. Comment in: J Clin Oncol 1992
May;10(5):683-5.

Ansell SM, Rapoport BL, Falkson G, Raats JI, Moeken
CM. Survival determinants in patients with
advanced ovarian cancer. Gynecol Oncol 1993
Aug;50(2):215-20.

Araujo CE, Cervellino JC, Pirisi C, Pannunzio O,
Callegari J. Chemotherapy with high dose
ifosfamide/mesna plus cisplatin for the treatment of
ovarian cancer: a study of the Grupo de Estudio y
Tratamiento Latino-Americano del Cancer. J Surg
Oncol 1991 Mar;46(3):198-202.

Barrett RJ, Muss HB. Gynecologic malignancies. In:
Lokich JJ, ed. Cancer chemotherapy by infusion.
2nd ed. Chicago; Precept Press; 1990. p.463-83.

Belinson JL, Lee KR, Jarrell MA, McClure M.
Management of epithelial ovarian neoplasms using a
platinum-based regimen: a 10—year experience.
Gynecol Oncol 1990 Apr;37(l):66-73.

Beller U, Speyer J, Colombo N, Sorich J, Wemz J,
Hochster H, Zeleniuch-Jacquotte A, Porges R,
Beckman EM. Consolidation with intraperitoneal
cisplatin in first-line therapy of advanced ovarian
cancer. J Clin Oncol 1991 May;9(5):809-17.

Bertelsen K, Bastholt L. High-dose platinum
chemotherapy in advanced ovarian cancer: a phase
II study. Gynecol Oncol 1992 Jan;44(l):79-82.

Bicher A, Sarosy G, Kohn E, Adamo DO, Davis P,
Jacob J, Chabner BA, Reed E. Age does not
influence taxol dose intensity in recurrent carcinoma
of the ovary. Cancer 1993 Jan 15;71(2 Suppl):
594-600.

Bruckner HW, Cohen C, Mandeli J, Chesser MR,
Kabakow B, Wallach R, Holland J.
Hexamethylmelamine for the treatment of ovarian
cancer--the Mount Sinai experience. Cancer Treat
Rev 1991 Mar;18 Suppl A257-65.

Chambers JT, Chambers SK, Voynick IM, Schwartz
PE. Neoadjuvant chemotherapy in stage X ovarian
carcinoma. Gynecol Oncol 1990 Jun;37(3):327-31.

Chemotherapy in advanced ovarian cancer: an overview
of randomised clinical trials. Advanced Ovarian
Cancer Trialists Group. BMJ 1991 Oct 12;
303(6807):884-93. Comment in: BMJ 1991 Nov 16;
303(6812):1269 and BMJ 1992 Jan 11; 304(6819):

1 19.

Cherchi PL, Bagella MP, Campiglio A, Rubattu A,
Farina M, Ambrosini A. Fist line chemotherapy in
advanced ovarian cancer: a comparison of three
therapeutic regimes. Eur J Gynaecol Oncol 1990;
11(6):453-6.

Cheson BD. Clinical trials referral resource. Ovarian
cancer. Oncology (Huntingt) 1990 Aug;4(8):69-75.

Chiara S, Mammoliti S, Oliva C, Merlini L, Bruzzone
M, Sertoli MR, Parodi GC, Ragni N, Foglia G,
Odicino F, et al. Adjuvant cisplatin-based
chemotherapy for stage I and II ovarian cancer: a
7-year experience. Eur J Cancer 1991;27(10):
1211-5. Comment in: Eur J Cancer 1991;27(10):

l 196.

Conte PF. Role of anthracyclines in first line
combination chemotherapy of ovarian carcinoma.
Bull Cancer l993;80(2):152-5.

Conte PF, Bruzzone M, Carnino F, Chiara S, Donadio
M, Facchini V, Fioretti P, Foglia G, Gadducci A,
Gallo L, et al. Carboplatin, doxorubicin, and
cyclophosphamide versus cisplatin, doxorubicin,
and cyclophosphamide: a randomized trial in stage
III-IV epithelial ovarian carcinoma. J Clin Oncol
1991 Apr;9(4):658-63.

Comelison TL, Reed E. Dose intensity analysis of high-
dose carboplatin in refractory ovarian carcinoma
relative to age. Cancer 1993 Jan 15;71(2 Suppl):
650-5.

Comelissen G, Halberg F, Halberg E, Bingham C,
Haus E, Bast RCJr, Fujii S, Long HJ 3d, Halberg
F, Tamura K. Toward a chronotherapy of ovarian
cancer. Part IH: Salivary CA125 for
chronochemotherapy by efficacy. Chronobiologia
1992;l9(3-4):131-49.

Creasman WT, Omura GA, Brady MF, Yordan E,
DiSaia PJ , Beecham J. A randomized trial of
cyclophosphamide, doxorubicin, and cisplatin with
or without bacillus Calmette-Guerin in patients with
suboptimal stage In and IV ovarian cancer: a
Gynecologic Oncology Group study. Gynecol Oncol
1990 Dec;39(3):239-43.

Cruickshank DJ, Paul J, Lewis CR, McAllister EJ,
Kaye SB. An independent evaluation of the potential
clinical usefulness of proposed CA-125 indices
previously shown to be of prognostic significance in

epithelial ovarian cancer. Br J Cancer 1992 Apr;
65(4):597-600.

Cruickshank DJ, Terry PB, Fullerton WT. CA125-
response assessment in epithelial ovarian cancer.
Int J Cancer 1992 Apr 22;51(1):58-61.

Cruickshank DJ, Terry PB, Fullerton WT. The
potential value of CA125 as a tumour marker in
small volume, non-evaluable epithelial ovarian
cancer. Int J Biol Markers 1991 Oct-Dec;6(4):
247-52.

Cyclophosphamide plus cisplatin versus
cyclophosphamide, doxorubicin, and cisplatin
chemotherapy of ovarian carcinoma: a meta-
analysis. The Ovarian Cancer Meta—Analysis
Project. J Clin Oncol 1991 Sep;9(9):1668-74.

Davidson NG, Khanna S, Kirwan PH, Bircumshaw D.
Prechemotherapy serum CA125 level as a predictor
of survival outcome in epithelial carcinoma of the
ovary. Clin Oncol (R Coll Radiol) 1991 Jan;3(1):
32-6.

Davidson NG, Khanna S, Kirwan PH, Naftalin NJ, Roy
UK, Chui D, Mitchell S. Long-term survival after
chemotherapy with cisplatinum, adriamycin and
cyclophosphamide for carcinoma of the ovary. Clin
Oncol (R Coll Radiol) 1990 Jul;2(4):206-9.

de Oliveira CF, Lacave AJ, Villani C, Wolff JP, di Re
F, Namer M, Maskens A, George M, Dalesio O,
Rotmensz N, et al. Randomized comparison of
cyclophosphamide, doxorubicin and cisplatin (CAP)
versus cyclophosphamide and doxorubicin (CA) for
the treatment of advanced ovarian cancer
(ADOVCA). A EORTC Gynecological Cancer
Cooperative Group Study. Eur J Gynaecol Oncol
1990;11(5):323-30.

de Vries EG, Biesma B, Willemse PH, Mulder NH,
Stem AC, Aalders JG, Vellenga E. A double-blind
placebo—controlled study with granulocyte-
macrophage colony-stimulating factor during
chemotherapy for ovarian carcinoma. Cancer Res
1991 Jan 1;51(1):116—22.

Edmonson J H, Su J, Krook J E. Treatment of ovarian
cancer in elderly women. Mayo Clinic-North
Central Cancer Treatment Group studies. Cancer
1993 Jan 15;71(2 Suppl):615—7.

41

Eiermann W, Achterrath W, Lenaz L, Hepp H.
Carboplatin/etoposide as first-line chemotherapy in
advanced ovarian carcinoma: a pilot study. Cancer
Chemother Pharmacol 1991;27(5):389-93.

Fanning J, Bennett TZ, Hilgers RD. Meta-analysis of
cisplatin, doxorubicin, and cyclophosphamide
versus cisplatin and cyclophosphamide
chemotherapy of ovarian carcinoma. Obstet Gynecol
1992 Dec;80(6):954-60. Comment in: Obstet
Gynecol 1993 Apr;81(4):641-2.

Fisken J, Leonard RC, Stewart M, Beattie GJ, Sturgeon
C, Aspinall L, Roulston J E. The prognostic value
of early CA125 serum assay in epithelial ovarian
carcinoma. Br J Cancer 1993 Jul;68(l):140—5.

Gadducci A, Brunetti I, Bruzzone M, Camino F,
Chiara S, Conte PF, Fioretti P, Foglia G, Ragni N.
Cisplatin-based combination chemotherapy with or
without doxorubicin in advanced epithelial ovarian
cancer: 8-year update of a randomized multicentric
clinical trial. The Gruppo Oncologico Nord Ovest
(GONO). Eur J Gynaecol Oncol 1992;13(1 Suppl):
36-9.

Gadducci A, Ferdeghini M, Ceccarini T, Prontera C,
Facchini V, Bianchi R, Fioretti P. A comparative
evaluation of the ability of serum CA 125, CA
19-9, CA 15-3, CA 50, CA 72-4 and TATI assays
in reflecting the course of disease in patients with
ovarian carcinoma. Eur J Gynaecol Oncol 1990;
11(2):127-33.

Gadducci A, Ferdeghini M, Cristofani R, Fioretti P.
Comparison of common clinico—pathological
prognostic variables and serum CA 125 assay as
predictors of clinical outcome in patients with

advanced ovarian carcinoma. Ital J Gynaecol Obstet
1993;5(1):16-23.

Gershenson DM, Mitchell MF, Atkinson N, Silva EG,
Burke TW, Morris M, Kavanagh JJ, Warner D,
Wharton JT. Age contrasts in patients with
advanced epithelial ovarian cancer. The M.D.
Anderson Cancer Center experience. Cancer 1993
Jan 15;71(2 Suppl):638-43.

Gershenson DM, Mitchell MF, Atkinson N, Silva EG,
Kavanagh JJ, Morris M, Burke TW, Warner D,
Wharton JT. The effect of prolonged cisplatin-based
chemotherapy on progression-free survival in
patients with optimal epithelial ovarian cancer:
maintenance therapy reconsidered. Gynecol Oncol
1992 Oct;47(1):7-13. Comment in: Gynecol Oncol
1992 Oct;47(1):5-6.

Gershenson DM, Silva EG, Mitchell MF, Atkinson EN,
Wharton JT. Transitional cell carcinoma of the
ovary: a matched control study of advanced—stage
patients treated with cisplatin-based chemotherapy.
Am J Obstet Gynecol 1993 Apr;168(4):1178-85;
discussion 1185-7.

42

Goodman HM, Harlow BL, Sheets EE, Muto MG,
Brooks S, Steller M, Knapp RC, Berkowitz RS.
The role of cytoreductive surgery in the
management of stage IV epithelial ovarian
carcinoma. Gynecol Oncol 1992 Sep;46(3):367—71.

Greco FA, Johnson DH, Hainsworth JD. A comparison
of hexamethylmelamine (altretamine),
cyclophosphamide, doxorubicin, and cisplatin (H-
CAP) vs. cyclophosphamide, doxorubicin, and
cisplatin (CAP) in advanced ovarian cancer. Cancer
Treat Rev 1991 Mar;18 Suppl A:47-55.

Grem J, O’Dwyer P, Elson P, Simon N, Trump D,
Frontiera M, Falkson G, Vogl S. Cisplatin,
carboplatin, and cyclophosphamide combination
chemotherapy in advanced-stage ovarian carcinoma:
an Eastern Cooperative Oncology Group pilot
study. J Clin Oncol 1991 Oct;9(10):1793—800.

Hainsworth JD, Burnett LS, Jones HW 3d, Grosh WW,
Johnson DH, Greco FA. High-dose cisplatin
combination chemotherapy in the treatment of
advanced epithelial ovarian carcinoma. J Clin Oncol
1990 Mar;8(3):502-8. Comment in: J Clin Oncol
1990 Jul;8(7):1287—8.

Hainsworth JD, Jones HW 3d, Burnett LS, Johnson
DH, Greco FA. The role of hexamethylmelamine in
the combination chemotherapy of advanced ovarian
cancer: a comparison of hexamethylmelamine,
cyclophosphamide, doxorubicin, and cisplatin (H-
CAP) versus cyclophosphamide, doxorubicin, and
cisplatin (CAP). Am J Clin Oncol 1990 Oct;13(5):
410-5.

Hallmark RJ, Snyder JM, Jusenius K, Tamimi HK.
Factors influencing ototoxicity in ovarian cancer
patients treated with Cis-platinum based
chemotherapy. Eur J Gynaecol Oncol l992;13(1):
35-44.

Hannigan EV, Green S, Alberts DS, O’Toole R, Surwit
E. Results of a Southwest Oncology Group phase
III trial of carboplatin plus cyclophosphamide
versus cisplatin plus cyclophosphamide in advanced
ovarian cancer. Oncology 1993 Nov;50 Suppl 2:
2-9.

Harding M, Milsted R, Hole D, Cordiner J, Barr W,
Soukop M, Kennedy J, Soutter WP, Kaye S. Long
term results of cyclophosphamide, adriamycin and
platinum chemotherapy in advanced epithelial
ovarian cancer. Ann Oncol 1991 Mar;2(3):231-3.

Hardy JR, Wiltshaw E, Blake PR, Harper P, Slevin M,
Perren TJ , Tan S. Cisplatin and carboplatin in
combination for the treatment of stage IV ovarian
carcinoma. Ann Oncol 1991 Feb;2(2):131-6.

Harvey VJ, Evans BD, Mitchell PL, Mak D, Neave
LM, Langley GB, Dickson DS. Reduction of
carboplatin induced emesis by ondansetron. Br J
Cancer 1991 Jun;63(6):942-4.

Heintz AP. Sequential cisplatin-—doxorubicin, early
debulking in advanced ovarian cancer. Eur J Cancer
1992;28A(6-7):1009—10.

Hempling RE, Piver MS, Natarajan N, Baker TR,
Thompson JM, Hicks ML, Mettlin CJ. Predictive
value of serum CA125 following optimal
cytoreductive surgery during weekly cisplatin
induction therapy for advanced ovarian cancer.

J Surg Oncol 1993 Sep;54(l):38-44.

Hogberg T, Carstensen J, Simonsen E. Treatment
results and prognostic factors in a population-based
study of epithelial ovarian cancer. Gynecol Oncol
1993 Jan;48(1):38-49.

Hogberg T, Kagedal B. Serum half-life of the tumor
marker CA 125 during induction chemotherapy as a
prognostic indicator for survival in ovarian
carcinoma. Acta Obstet Gynecol Scand 1990;
69(5):423-9.

Homesley HD, Harry DS, O’Toole RV, Hoogstraten B,
Franklin EW, Cavanagh D, Nahhas WA, Smith JJ,
Lovelace JV. Randomized comparison of cisplatin
plus epirubicin or doxorubicin for advanced
epithelial ovarian carcinoma. A multicenter trial.
Am J Clin Oncol 1992 Apr;15(2):129—34.

Hoskins PJ, O’Reilly SE, Swenerton KD, Spinelli JJ,
Fairey RN, Benedet JL. Ten-year outcome of
patients with advanced epithelial ovarian carcinoma
treated with cisplatin-based multimodality therapy.
J Clin Oncol 1992 Oct;10(10):1561-8. Comment in:
J Clin Oncol 1993 Mar;11(3):587-8.

Hoskins WJ. Treatment strategies for advanced ovarian
cancer. In: Greer BE, Berek JS, eds. Gynecologic
oncology: treatment rationale and techniques. New
York: Elsevier; 1991. p. 149—66.

Hunter RE, Griffin TW, Stevens S, Roman LD,
Bokhari F, Reale FR, Tak WK, Fitzgerald TJ,
Dillon MB, Rose PG. High—dose, short-duration
cisplatin/doxorubicin combination chemotherapy for
advanced ovarian epithelial cancer. Cancer 1991
Nov l;68(9):1890—4.

Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A,
Clarke-Pearson DL, Bast RC J r. The prognostic
significance of CA 125 half-life in patients with
ovarian cancer who have received primary
chemotherapy after surgical cytoreduction. Am J
Obstet Gynecol 1990 Oct;163(4 Pt 1):1164-7.
Comment in: Am J Obstet Gynecol 1991 Sep;
165(3):779.

Inoue M, Nakanishi K, Ueda G, Tanizawa O.
Intermittent intensive combination chemotherapy
with cisplatin, doxorubicin, and cyclophosphamide
(cyclic PAC chemotherapy) for ovarian cancer.
Am J Clin Oncol 1992 Feb;15(1):l-6.

Inoue M, Tanaka Y, Sugita N, Yamasaki M, Yamanaka
T, Minagawa J, Nakamuro K, Tani T, Okudaira Y,

Karita T, et al. Improvement of long-term prognosis
in patients with ovarian cancers by adjuvant
sizofiran immunotherapy: a prospective randomized
controlled study. Biotherapy 1993;6(1):13-8.

Iversen OE. Modern cytostatic therapy and survival in
ovarian carcinoma (1). Acta Obstet Gynecol Scand
1993;72(1):69.

Jacob J H, Gershenson DM, Morris M, Copeland LJ,
Burke TW, Wharton JT. Neoadjuvant chemotherapy
and interval debulking for advanced epithelial
ovarian cancer. Gynecol Oncol 1991 Aug;42(2):
146-50.

Jodrell DI, Egorin MJ, Canetta RM, Langenberg P,
Goldbloom EP, Burroughs JN, Goodlow J L, Tan S,
Wiltshaw E. Relationships between carboplatin
exposure and tumor response and toxicity in
patients with ovarian cancer. J Clin Oncol 1992
Apr;10(4):520-8. Comment in: J Clin Oncol 1992
Apr;10(4):513—4.

Kaldor J M, Day NE, Pettersson F, Clarke EA,
Pedersen D, Mehnert W, Bell J, Host H, Prior P,
Karjalainen S, et al. Leukemia following
chemotherapy for ovarian cancer. N Engl J Med
1990 Jan 4;322(1):1-6. Comment in: N Engl J Med
1990 Jan 4;322(1):52-3.

Karrer K, Salzer H, Sevelda P, Dittrich C. The role of
chemotherapy including ifosfamide for ovarian
carcmoma. Austrian Collab. Ovarian Cancer Study
Group. Cancer Chemother Pharmacol 1990;

26 Supp12S30-2.

Kaye SB. Chemotherapy for ovarian cancer. Eur J
Cancer 1993;29A(4):632-5.

Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK,
Kitchener HC, Cruickshank DJ, Atkinson RJ,
Soukop M, Rankin EM, et al. Randomised study of
two doses of cisplatin with cyclophosphamide in
epithelial ovarian cancer. Lancet 1992 Aug 8;
340(8815):329-33. Comment in: Lancet 1992
Sep 12;340(8820):678—9.

Kehoe S, Redman C, Varma R, Buxton J, Luesley D,
Blackledge G, Stanley A. Single agent high-dose
cisplatin (200 mg m-Z) treatment in ovarian
carcinoma. Br J Cancer 1992 Oct;66(4):717-9.

Kjorstad K, Harris A, Bertelsen K, Slevin M, Schultz
H, Hellman K, Janssens N, Martin A, Canetta R. A
multicenter phase II study of carboplatin in
advanced ovarian carcinoma: final report. Ann
Oncol 1992 Mar;3(3):217-22.

Kolb BA, Buller RE, Connor JP, DiSaia PJ, Berman
ML. Effects of early postoperative chemotherapy on
wound healing. Obstet Gynecol 1992 Jun;79(6):
988-92. Comment in: Obstet Gynecol 1992 Oct;
80(4):730.

43

Krommer CF, Szalai JP. Cyclophosphamide,
adriamycin and cisplatin (CAP) versus
cyclophosphamide, adriamycin and vincristin (CAV)
in the treatment of advanced ovarian cancer: a
randomized study. Ann Oncol 1992 Jan;3(1):37-9.

Krommer CF, Szalai JP. A review of 28 years of
treating advanced ovarian cancer. Anticancer Res
1993 May-Jun;13(3):817-25.

Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A
randomized trial comparing single-agent carboplatin
with carboplatin followed by radiotherapy for
advanced ovarian cancer: a North Thames Ovary
Group study. J Clin Oncol 1993 Mar;11(3):440-8.

Lawton F, Meanwell C, Mould J, Blacldedge G. A
five—drug alternating chemotherapy regimen for
patients with advanced epithelial ovarian cancer.
Gynecol Oncol 1990 Jan;36(1):19-22.

Lawton FG, Hilton C, Mould JJ, Chan KK, Blackledge
G. Short-duration (three cycles) cisplatin
combination chemotherapy with alkylating agent
consolidation in advanced epithelial ovarian cancer.
Gynecol Oncol 1991 Mar;40(3):225-9.

Levin L, Simon R, Hryniuk W. Importance of
multiagent chemotherapy regimens in ovarian
carcinoma: dose intensity analysis. J Natl Cancer
Inst 1993 Nov 3;85(21):1732-42.

Lim JT, Green JA. Neoadjuvant carboplatin and
ifosfamide chemotherapy for inoperable FIGO stage
III and IV ovarian carcinoma. Clin Oncol (R Coll
Radiol) 1993;5(4):198—2(T.Z.

Locatelli MC, D’Antona A, Carcione R, Cesana B,
Dallavalle G, Vinci M, Clerici M, Labianca R,
Pasquinucci C, Luporini G. A cisplatinum-
cyclophosphamide regimen in advanced ovarian
cancer: reporting 5-year results. Oncology 1993
Mar-Apr;50(2):92-9.

Long-term results of a randomized trial comparing
cisplatin with cisplatin and cyclophosphamide with
cisplatin, cyclophosphamide, and adriamycin in
advanced ovarian cancer. GICOG (Gruppo
Interregionale Cooperative Oncologico
Ginecologia), Italy. Gynecol Oncol 1992 May;
45(2):115-7.

Lund B. Clinical and prognostic features of advanced
ovarian carcinoma. Dan Med Bull 1993;40(5):
537-45.

Lund B, Hansen M, Hansen HH, Thomsen HK,
Sorensen BL, Nielsen NC, Lundvall F. A
randomized study of sequential versus alternating
combination chemotherapy in advanced ovarian
carcinoma. Ann Oncol 1990;1(2):134-40.

Lund B, Hansen M, Hansen OP, Hansen HH.
Combined high-dose carboplatin and cisplatin, and
ifosfamide in previously untreated ovarian cancer

patients with residual disease. J Clin Oncol 1990
Jul;8(7):1226-30.

Lund B, Hansen OP, Hansen HH, Hansen M.
Combination therapy with carboplatin/
cisplatin/ifosfamide/etoposide in ovarian cancer.
Semin Oncol 1992 Feb;19(1 Suppl 1):26-9.

Lund B, Williamson P. Prognostic factors for overall
survival in patients with advanced ovarian
carcinoma. Ann Oncol 1991 Apr;2(4):281-7.
Comment in: Ann Oncol 1991 Apr;2(4):245-7.

Makar AP, Kristensen GB, Bormer OP, Trope CG.
Serum CA 125 level allows early identification of
nonresponders during induction chemotherapy.
Gynecol Oncol 1993 Apr;49(1):73-9.

Makar AP, Kristensen GB, Kaem J, Bormer OP,
Abeler VM, Trope CG. Prognostic value of pre-
and postoperative serum CA 125 levels in ovarian
cancer: new aspects and multivariate analysis.
Obstet Gynecol 1992 Jun;79(6):1002-10.

Malviya VK, Deppe G, Boike G, Young J.
Phannacokinetics of intraperitoneal doxorubicin in
combination with systemic cyclophosphamide and
cis-platinum in the treatment of stage III ovarian
cancer. Gynecol Oncol 1990 Feb;36(2):185—8.

Marchetti DL, Lele SB, Priore RL, McPhee ME,
Hreshchyshyn MM. Treatment of advanced ovarian

carcinoma in the elderly. Gynecol Oncol 1993 Apr;
49(1):86-91.

Markman M, Lewis JL Jr, Saigo P, Hakes T, Jones W,
Rubin S, Reichman B, Barakat R, Curtin J,
Almadrones L, et al. Epithelial ovarian cancer in
the elderly. The Memorial Sloan-Kettering Cancer
Center experience. Cancer 1993 Jan 15;

71(2 Suppl):634-7.

Markmann M, Rothman R, Reichman B, Hakes T,
Lewis JL Jr, Rubin S, Jones W, Almadrones L,
Hoskins W. Persistent hypomagnesemia following
cisplatin chemotherapy in patients with ovarian
cancer. J Cancer Res Clin Oncol 1991;117(2):
89-90.

Markowska J, Kopczynski Z, Manys G, Szewierski Z.
CA 125 in monitoring chemotherapy of patients
with ovarian cancer: early response to the
treatment. Neoplasma 1990;37(6):687-92.

Markowska J, Manys G, Kubaszewska M. Value of CA
125 as a marker of ovarian cancer. Eur J Gynaecol
Oncol 1992;13(4):360—5.

Markowska J, Manys G, Szewierski Z. CA 125 in
monitoring clinical course in ovarian cancer
patients. A prospective clinical study. Eur J
Gynaecol Oncol 1992;13(2):201-4.

Martoni A, Ercolino L, Bellucco A, Canova N, Lelli
G, Pannuti F. Cisplatinum plus epirubicin alternated

with cyclophosphamide plus S-fluorouracil in
ovarian cancer. J Chemother 1990 Feb;2(1):62-6.

Martoni A, Panetta A, Angelelli B, Melotti B, Pannuti
F. A phase H study of carboplatin and
cyclophosphamide in advanced ovarian carcinoma.
J Chemother 1993 Feb;5(1):47-51.

Masding J, Sarkar TK, White WF, Barley VL, Chawla
SL, Boesen E, Rostom AY, Menday AP.
Intravenous treosulfan versus intravenous treosulfan
plus cisplatinum in advanced ovarian carcinoma.
Br J Obstet Gynaecol 1990 Apr;97(4):342-51. ‘

McGuire WP. Primary chemotherapy of epithelial
ovarian cancer. In: Rubin SC, Sutton GP, eds.
Ovarian cancer. New York: McGraw-Hill; 1993.
p. 255-68.

McGuire WP. Primary treatment of epithelial ovarian
malignancies. Cancer 1993 Feb 15;71(4 Suppl):
1541-50.

McGuire WP, Rowinsky EK. Old drugs revisited, new
drugs, and experimental approaches in ovarian
cancer therapy. Semin Oncol 1991 Jun;18(3):
255—69.

Mirshahi SS, Pujade—Lauraine E, Soria C, Mirshahi M,
Fretault J, Bemadou A, Soria J. D-dimer and CA
125 levels in patients with ovarian cancer during
antineoplastic therapy. Prognostic significance for
the success of anti—cancer treatment. Cancer 1992
May 1;69(9):2289-92.

Mogensen O. Prognostic value of CA 125 in advanced
ovarian cancer. Gynecol Oncol 1992 Mar;44(3):
2(fl-12. Comment in: Gynecol Oncol 1992 Mar;
44(3):205 and Gynecol Oncol 1992 Oct;47(1):
131-2.

Mogensen O, Mogensen B, Jakobsen A. Predictive
value of CA 125 during early chemotherapy of
advanced ovarian cancer. Gynecol Oncol 1990 Apr;
37(1):44-6.

Morikawa Y, Kawai M, Kano T, Kikkawa F, Oguchi
H, Nakashima N, Ishizuka T, Fumhashi Y, Hattori
SE, Kuzuya K, et al. Clinical remission criteria for
epithelial carcinoma of the ovary. Gynecol Oncol
1993 Mar;48(3):342-8.

Murphy D, Crowther D, Renninson J, Prendiville J,
Ranson M, Lind M, Patel U, Dougal M, Buckley
CH, Tindall VR. A randomised dose intensity study
in ovarian carcinoma comparing chemotherapy
given at four week intervals for six cycles with half
dose chemotherapy given for twelve cycles. Ann
Oncol 1993 May;4(5):377-83.

Nash JD, Young RC. Gynecologic malignancies.
Cancer Chemother Biol Response Modif 1991;
12:549—69.

Neijt JP. Treatment of advanced ovarian cancer:
10 years of experience. Ann Oncol 1992 Jan;
3(1): 17-27.

Neijt JP, ten Bokkel Huinink W, van der Burg ME,
van Oosterom AT, Willemse PH, Vermorken JB,
van Lindert AC, Heintz AP, Aartsen E, van Lent
M, et al. Long-term survival in ovarian cancer.
Mature data from The Netherlands Joint Study
Group for Ovarian Cancer. Eur J Cancer 1991;
27(11):1367-72.

Ng LW, Rubin SC, Hoskins W], Jones WB, Hakes TB,
Markman M, Reichman B, Almadrones L, Lewis
J L Jr. Aggressive chemosurgical debulking in
patients with advanced ovarian cancer. Gynecol
Oncol 1990 Sep;38(3):358-63.

Nguyen HN, Averette HE, Hoskins W, Penalver M,
Sevin BU, Steren A. National survey of ovarian
carcinoma. Part V. The impact of physician’s
specialty on patients’ survival. Cancer 1993
Dec 15;72(12):3663-70.

Nguyen HN, Averette HE, Hoskins W, Sevin BU,
Penalver M, Steren A. National survey of ovarian
carcinoma. VI. Critical assessment of current
International Federation of Gynecology and
Obstetrics staging system. Cancer 1993 Nov 15;
72(10):30(T7-11.

Nishida T, Nagasue N, Yakushiji M. Treatment of
gynecological malignancies with a combination of
cisplatin, Addamycin and ifosfamide. Cancer
Chemother Pharmacol 1990;26 Suppl:S39-42.

Ojeda-Gonzalez MB, Alvarez-Lopez I, Alonso-Munoz
MC, Badia—Serra J, Delgado-Latre E, de Andres-
Basauri L, Lopez-Lopez JJ. Chemotherapy (CAP)
for the treatment of advanced ovarian cancer and
second-effort surgery in the second look. Oncology
1991;48(1):7-12.

Omura GA, Brady MF, Fanning J, Hilgers RD. Meta-
analysis of cisplatin, doxorubicin, and
cyclophosphamide versus cisplatin and

cyclophosphamide chemotherapy of ovarian
carcinoma (1). Obstet Gynecol 1993; 81(4):641-2.

Omura GA, Brady MF, Homesley HD, Yordan E,
Major FJ, Buchsbaum HJ, Park RC. Long-term
follow-up and prognostic factor analysis in
advanced ovarian carcinoma: the Gynecologic
Oncology Group experience. J Clin Oncol 1991 Jul;
9(7): 1 138-50.

Omura GA, Buyse M, Marsoni S, Bertelsen K, Conte
PF, Jakobsen A, Vermorken J. Cyclophosphamide
plus cisplatin versus cyclophosphamide,
doxorubicin, and cisplatin chemotherapy of ovarian
carcinoma: A meta-analysis. J Clin Oncol 1991;
9(9): 1668-74.

Onnis A, Marchetti M, Maggino T, De Toffoli J,
Blandamura S. Clinical experience in gynecological

45

cancer management. d). Ovarian tumors--1)
Epithelial: report from the Gynaecological Institutes
of Padua University (1963—1990). Eur J Gynaecol
Oncol 1992;13(1):17-33.

Ozols RF. Advances in the chemotherapy of
gynecologic malignancies. Hematol Oncol 1992 Jan-
Feb;10(1):43-51.

Ozols RF. Chemotherapy for advanced epithelial
ovarian cancer. Hematol Oncol Clin North Am
1992 Aug;6(4):879-94.

Ozols RF. New developments with carboplatin in the
treatment of ovarian cancer. Semin Oncol 1992
Feb;19(1 Suppl 2):85—9.

Ozols RF. Ovarian cancer. Semin Surg Oncol 1990;
6(6):328-38.

Ozols RF. Ovarian cancer: new clinical approaches.
Cancer Treat Rev 1991 Mar;l8 Suppl A277-83.

Ozols RF. Ovarian cancer, Part H: Treatment. Curr
Probl Cancer 1992 Mar-Apr;16(2):61-126.

Ozols RF. Role of carboplatin in ovarian cancer.
Current results and thoughts for the future. Acta
Obstet Gynecol Scand Suppl 1992;155:75-7.

Ozols RF. Role of chemotherapy in the future treatment
of ovarian cancer. Acta Obstet Gynecol Scand
Suppl 1992;155:55-60.

Ozols RF, Young RC. Chemotherapy of ovarian
cancer. Semin Oncol 1991 Jun;18(3):222-32.

Panici PB, Greggi S, Scambia G, Baiocchi G,
Lomonaco M, Conti G, Mancuso S. Efficacy and
toxicity of very high-dose cisplatin in advanced
ovarian carcinoma: 4-Year survival analysis and
neurological follow-up. Int J Gynecol Cancer 1993;
3(1):44-53.

Perren TJ, Wiltshaw E, Harper P, Slevin M, Stein R,
Tan S, Gore M, Fryatt IJ, Blake PR. A randomised
study of carboplatin vs sequential ifosfamide/
carboplatin for patients with FIGO stage III
epithelial ovarian carcinoma. Br J Cancer 1993;
68(6): 1 190-4.

Petru E, Pickel H, Heydarfadai M, Lahousen M.
Remission induction with carboplatin-epirubicin-
prednimustine followed by consolidation
radiotherapy in advanced ovarian cancer. Int J Clin
Pharmacol Res 1992;12(4):205—7.

Petru E, Pickel H, Lahousen M, Boike G, Heydarfadai
M. Combination chemotherapy in radically operated
advanced ovarian cancer. Cancer Treat Rev 1990
Sep;17(2—3):329-34.

Petru E, Sevin BU, Averette HE, Koechli OR,
Hilsenbeck S. Long-term survival in stage III and

46

IV ovarian cancer. Arch Gynecol Obstet 1991;
249(2):87-93.

Piccart MJ, Nogaret JM, Marcelis L, Longree H, Ries
F, Kains JP, Gobert P, Domange AM, Sculier JP,
Gompel C. Cisplatin combined with carboplatin: a
new way of intensification of platinum dose in the
treatment of advanced ovarian cancer. Belgian
Study Group for Ovarian Carcinoma. J Natl Cancer
Inst 1990 Apr 18;82(8):703-7.

Pinto V, Marinaccio M, Miniello G, Cagnazzo G.
Simplified ondansetron regimens for antiemetic
prophylaxis in cisplatin-based chemotherapy of
ovarian cancer. Eur J Gynaecol Oncol 1993;
14(4):302-7.

Piura B, Glezerman M, Cohen Y. Experience in the
treatment of epithelial ovarian carcinoma with
cisplatinum-containing combination chemotherapy
and dose intensity calculation. Eur J Gynaecol
Oncol 1990;11(5):389-93.

Fiver MS, Malfetano J, Hempling RE, Baker TR,
Driscoll DL. Cisplatin-based chemotherapy for
stage H ovarian adenocarcinoma: a preliminary
report. Gynecol Oncol 1990 Dec;39(3):249-52.

Plaxe SC, Dottino PR, Cohen CJ . Therapeutic and
metabolic effects of high (greater than 1 g/mZ)
systemic cumulative doses of cis-platinum in
patients with ovarian carcinoma. Gynecol Oncol
1990 May;37(2):250—3.

Poka R, Hemadi Z, Juhasz B, Lampe L. Comparison of
four antiemetic regimens for the treatment of
cisplatin-induced vomiting. Int J Gynaecol Obstet
1993 Jul;42(1):19-24.

Quaranta M, Coviello M, Donadeo A, Rella C, Lorusso
V, Micelli G, Lucarelli C. Measurement of the
ovarian cancer-associated antigen CA 125 in
monitoring tumor burden and response to
chemotherapy. Tumori 1991 Apr 30;77(2):167-9.

Rader J S. Therapeutic advances in ovarian cancer. Curr
Opin Obstet Gynecol 1992 Feb;4(1):120-7.

Rankin EM, Mill L, Kaye SB, Atkinson R, Cassidy L,
Cordiner J, Cruickshank D, Davis J , Duncan ID,
Fullerton W, et al. A randomised study comparing
standard dose carboplatin with chlorambucil and

carboplatin in advanced ovarian cancer. Br J Cancer
1992 Feb;65(2):275-81.

Redman CW, Blackledge GR, Kelly K, Powell J,
Buxton FJ, Luesley DM. Early serum CA125
response and outcome in epithelial ovarian cancer.
Eur J Cancer 1990;26(5):593-6.

Reed E, Jacob J, Brawley 0. Measures of renal
function in patients with cisplatin-related chronic
renal disease. J Natl Med Assoc 1991 Jun;
83(6):522-6.

Reed E, Janik J, Bookman MA, Rothenberg M, Smith
J, Young RC, Ozols RF, VanderMolen L, Kohn E,
Jacob J L, et al. High-dose carboplatin and
recombinant granulocyte-macrophage colony—
stimulating factor in advanced-stage recurrent
ovarian cancer. J Clin Oncol 1993 Nov;11(11):

21 18-26.

Repetto L, Chiara S, Pace M, Guido T, Bruzzone M,
Oliva C, Murolo C, Conte PF, Rosso R. Prognostic
factors in stage IV ovarian carcinoma treated with
platinum-based regimens. Tumori 1990 Jun 30;
76(3):274-7.

Repetto L, Pace M, Mammoliti S, Bruzzone M, Chiara
S, Oliva C, Guido T, Conte PF, Campora E,
Rubagotti A, et al. The impact of received dose
intensity on the outcome of advanced ovarian
cancer. Eur J Cancer 1993;29A(2):181—4.

Reyno LM, Egorin MJ, Canetta RM, Jodrell DI,
Swenerton KD, Pater J L, Burroughs JN, Novak
MJ, Sridhara R. Impact of cyclophosphamide on
relationships between carboplatin exposure and
response or toxicity when used in the treatment of
advanced ovarian cancer. J Clin Oncol 1993 Jun;
11(6):1156-64.

River MS, Fanning J, Sprance HE. Five-year survival
for cisplatin-based chemotherapy versus single-agent
melphalan in patients with advanced ovarian cancer
and optimal debulking surgery. J Surg Oncol 1991
Sep;48(1):39-44.

Rosen A, Sevelda P, Klein M, Spona J, Beck A. A
CA125 score as a prognostic index in patients with
ovarian cancer. Arch Gynecol Obstet l990;247(3):
125-9.

Rubin SC, Curtin JP. Surgery for gynecologic
malignancies. Curr Opin Oncol 1992 Oct;4(5):
923-9.

Russo A, Gebbia V, Palmeri S, Geraci P, Maneschi F,
Guarnieri G, Carollo F, Leonardi V, Meli M,
Gebbia N, et al. Results of the combination of
cisplatin, adriamycin and cyclophosphamide in the
treatment of ovarian carcinoma. Eur J Gynaecol
Oncol l993;14(3):228-33.

Rustin GJ. Impact of tumour marker measurements
upon management of patients with carcinoma of the
ovary. Dis Markers 1991 May-Aug;9(3-4):153-8.

Rustin GJ, Nelstrop A, Stilwell J, Lambert HE. Savings
obtained by CA-125 measurements during therapy

for ovarian carcinoma. The North Thames Ovary
Group. Eur J Cancer 1992;28(1):79-82.

Saksela E. Prognostic markers in epithelial ovarian
cancer. Int J Gynecol Pathol 1993 Apr;12(2):
156-61.

Sawada M, Yamasaki M, Urabe T, Ozaki M, Yanagita
T, Takayama K, Taki 1. Comparative study of

combination chemotherapy of ovarian cancer:
cyclophosphamide, adriamycin and cisplatin versus
5-fluorouracil, cyclophosphamide and mitomycin C.
Asia Oceania J Obstet Gynaecol 1990 Dec;16(4):
315-21.

Schneider J, Martin M, Erasun F, Matia JC,
Rodriguez-Escudero FJ. Cisplatin-containing versus
cisplatin-free adjuvant chemotherapy in ovarian
carcinoma. Results after second-look laparotomy.
Oncology 1990;47(2):109-11.

Sessa C, Colombo N, Bolis G, Marsoni S, Mangioni C.
Randomized comparison of hexamethylmelamine,
adriamycin, cyclophosphamide (HAC) vs. cisplatin,
adriamycin, cyclophosphamide (PAC) in advanced
ovarian cancer: long—term results. Cancer Treat Rev
1991 Mar;18 Suppl A:37-46.

Sevclda P, Dittrich C, Kurz C, Schemper M, Haider F,
Denison U, Breitenecker G, Czerwenka K, Salzer
H. Prospective randomized trial of sequential
alternating chemotherapy in advanced ovarian
carcinoma. Onkologie 1992;15(4):288-92.

Shapira J, Gotfried M, Lishner M, Ravid M. Reduced
cardiotoxicity of doxorubicin by a 6-hour infusion
regimen. A prospective randomized evaluation.
Cancer 1990 Feb 15;65(4):870—3.

Shimizu Y, Hasumi K. Treatment of ovarian cancer at
FIGO stage III and IV - Prognostic factors for
patients receiving neoadjuvant chemotherapy. Acta
Obstet Gynaecol Jpn 1993;45(7):665-72.

Smith DB, Rustin GJ, Howells N, Lambert HE,
McQuade B. A phase II study of ondansetron as
antiemetic prophylaxis in patients receiving
carboplatin for advanced ovarian cancer. The North
Thames Ovary Group. Ann Oncol 1991 Sep;2(8):
607-8.

Smyth J F, Beattie GJ, Stewart ME, Cowie VJ, Smart
GE, Livingstone JR, Leonard RC. Cisplatinum and
prednimustine, an active regimen for advanced
epithelial ovarian cancer. Ann Oncol 1991 Nov-
Dec;2(10):755—8.

Sorbe B, Hallen C. Betamethasone—dixyrazine versus
betamethasone-metoclopramide as antiemetic
treatment of cisplatin-doxorubicin—induced nausea in
ovarian carcinoma patients. Eur J Gynaecol Oncol
1991;12(1):31-7.

Sorensen BT, Stromgren A, Jakobsen P, Jakobsen A.
Dose-toxicity relationship of carboplatin in
combination with cyclophosphamide in ovarian
cancer patients. Cancer Chemother Pharmacol
1991;28(5):397—401.

Stoot J, Wils J, von Geuns H, Smeets J, Schouten L.
Chemotherapy consisting of cisplatin, epirubicin,
and cyclophosphamide in advanced ovarian
carcinoma. The Gynecologic Oncology Group of

47

the Comprehensive Cancer Center, Limburg, The
Netherlands. Cancer Invest 1993;11(1):l-5.

Sweetenham J W, McKendrick JJ, Jones DH,
Whitehouse J M, Williams CJ. High dose intensity
combination chemotherapy for advanced epithelial

ovarian carcinoma: results of a pilot study. Br J
Cancer 1990 Feb;61(2):319-22.

Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G,
Carmichael J, Drouin P, Stanimir R, O’Connell G,
MacLean G, et al. Cisplatin—cyclophosphamide
versus carboplatin—cyclophosphamide in advanced
ovarian cancer: a randomized phase III study of the
National Cancer Institute of Canada Clinical Trials
Group. J Clin Oncol 1992 May;10(5):718-26.
Comment in: J Clin Oncol 1992 May;10(5):683-5.

Swenerton KD, Pater J L. Carboplatin in the treatment
of carcinoma of the ovary: the National Cancer
Institute of Canada experience. Ovarian Cancer
Subcommittee. Semin Oncol 1992 Feb;

19(1 Suppl 2):114-9.

Takada M, Usui N, Yoshida K, Hirayama H, Suzuki
M, Takeuchi H, Wada H, Iwasa T, Yamamoto T,
Nagasawa I. Cumulative survival rate of
chemotherapy with CDDP for maligth ovarian
tumors. Acta Obstet Gynaecol Jpn 1990;42(4):
333-8.

Tattersall MH, Swanson CE, Solomon HJ. Long-term
survival with advanced ovarian cancer: an analysis
of 5-year survivors in the Australian trial comparing
combination versus sequential chlorambucil and
cisplatin therapy. Gynecol Oncol 1992 Dec;47(3):
292-7.

Tedeschi M, De Cesare A, Oriana S, Perego P, Silva
A, Venturino P, Zunino F. The role of glutathione
in combination with cisplatin in the treatment of
ovarian cancer. Cancer Treat Rev 1991 Dec;18(4):
253—9.

Teeling M, Carney DN. Phase H study of carboplatin
and cyclophosphamide combination chemotherapy
for the treatment of advanced ovarian cancer. Eur J
Gynaecol Oncol 1990;ll(3):219-24.

Teeling M, Hayes Y, Fitzmaurice B, McGing P,
Carney DN. Carboplatin/cyclophosphamide
combination chemotherapy for advanced ovarian
cancer. Semin Oncol 1992 Feb;19(1 Suppl 2):
102-6.

ten Bokkel Huinink WW, Dalesio O, Rodenhuis S,
Dubbelman R, Hilton A, Franklin H, Koier I, van
Tinteren H, van der Burg ME, van Oosterom AT,
et al. Replacement of cisplatin with carboplatin in
combination chemotherapy against ovarian cancer:
long—term treatment results of a study of the
Gynaecological Cancer Cooperative Group of the
EORTC and experience at The Netherlands Cancer
Institute. Semin Oncol 1992 Feb;19(1 Suppl 2):
99-101.

48

Thigpen JT. Chemotherapy in the management of
celomic epithelial carcinoma of the ovary. In:
Markman M, Hoskins WJ, eds. Cancer of the
ovary. New York: Raven Press; 1993. p. 277-86.

Tibben JG, Schijf CP, Beex LV. Results of
cyclophosphamide and cisplatin combination
chemotherapy in patients with ovarian carcinoma.
Eur J Gynaecol Oncol 1992;13(4):331-9.

Torri V, Korn EL, Simon R. Dose intensity analysis in
advanced ovarian cancer patients. Br J Cancer 1993
Jan;67(1):190—7.

Torri V, Simon R, Russek—Cohen E, Midthune D,
Friedman M. Statistical model to determine the
relationship of response and survival in patients
with advanced ovarian cancer treated with
chemotherapy. J Natl Cancer Inst 1992 Mar 18;
84(6):407-14. Comment in: J Natl Cancer Inst 1992
Mar 18;84(6):376-8.

Tothill P, Klys HS, Matheson LM, McKay K, Smyth
J F. The long-term retention of platinum in human
tissues following the administration of cisplatin or
carboplatin for cancer chemotherapy. Eur J Cancer
1992;28A(8-9):1358-61.

Trask C, Silverstone A, Ash CM, Earl H, Irwin C,
Bakker A, Tobias J S, Souhami RL. A randomized
trial of carboplatin versus iproplatin in untreated
advanced ovarian cancer. J Clin Oncol 1991 Jul;
9(7):1131—7.

Unzelman RF. Advanced epithelial ovarian carcinoma:
long—term survival experience at the community
hospital. Am J Obstet Gynecol 1992 Jun;166(6 Pt
1):]663-71; discussion 1671-2.

van der Hoop RG, van der Burg ME, ten Bokkel
Huinink WW, van Houwelingen C, Neijt JP.
Incidence of neuropathy in 395 patients with

ovarian cancer treated with or without cisplatin.
Cancer 1990 Oct 15;66(8):1697-702.

van der Hoop RG, Vecht CJ, van der Burg ME,
Elderson A, Boogerd W, Heimans JJ, Vries EP,
van Houwelingen JC, Jennekens FG, Gispen WH,
et al. Prevention of cisplatin neurotoxicity with an
ACTH(4—9) analogue in patients with ovarian
cancer. N Engl J Med 1990 Jan 11;322(2):89-94.
Comment in: N Engl J Med 1990 Jan 11;322(2):
126—7.

Vardi JR, Tadros GH, Zamurovic D, Rafla SD. Tumor
debulking followed by immediate combination
chemotherapy in advanced ovarian carcinoma.
Phase II. Acta Obstet Gynecol Scand 1992 Jul;
71(5):361-7.

Vergote IB. Adjuvant treatment of ovarian carcinoma.
Acta Obstet Gynecol Scand 1993;72(8):682-4.

Vergote IB, Abeler VM, Bormer OP, Stigbrand T,
Trope C, Nustad K. CA125 and placental alkaline

phosphatase as serum tumor markers in epithelial
ovarian carcinoma. Tumour Biol 1992;13(3):
168—74.

Vermorken J B. High-dose intensity regimens with
epirubicin in ovarian cancer. Pathol Biol (Paris)
1992 N0v;39(9):833.

Vinokurov VL, Dudarev AL, Jurkova LE, Lapchenkov
VI, Barbanel El. Tumor marker CA 125 in
diagnosis, monitoring management and follow-up of
patients with ovarian tumors. Eur J Gynaecol Oncol
1992;13(2):205—8.

Ward BG, McGuckin MA, Ramm LE, Coglan M,
Sanderson B, Tripcony L, Free KB. The
management of ovarian carcinoma is improved by
the use of cancer-associated serum antigen and CA
125 assays. Cancer 1993 Jan 15;71(2):430-8.

Waters GS, Ahmad M, Katsarkas A, Stanimir G,
McKay J. Ototoxicity due to cis-
diamminedichloroplatinum in the treatment of
ovarian cancer: influence of dosage and schedule of
administration. Ear Hear 1991 Apr;12(2):91-102.

Welander CE. What do CA 125 and other antigens tell
us about ovarian cancer biology? Acta Obstet
Gynecol Scand Suppl 1992;155:85-93.

Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL,
Falkson G, Davis TE, Fazzini E, Cheuvart B,
Horton J. Hexamethylmelamine and low or
moderate dose cisplatin with or without pyridoxine
for treatment of advanced ovarian carcinoma: a
study of the Eastern Cooperative Oncology Group.
Cancer Invest 1992;10(1):1—9.

Willemse PH, Aalders JG, de Bruyn HW, Mulder NH,
Sleijfer DT, de Vries EG. CA-125 in ovarian
cancer: relation between half-life, doubling time and
survival. Eur J Cancer 1991;27(8):993—5.

Willemse PH, van Lith J, Mulder NH, Aalders JG,
Bouma J, de Vries EG, Sleijfer DT. Risks and
benefits of cisplatin in ovarian cancer. A quality-
adjusted survival analysis. Eur J Cancer 1990 Mar;
26(3):345-52.

Williams CJ. Implications of an overview of

chemotherapy in advanced ovarian carcinoma. Br J
Cancer 1992;66(2):225—6.

Williams CJ, Stewart L, Parmar M, Guthrie D. Meta—
analysis of the role of platinum compounds in
advanced ovarian carcinoma. The Advanced
Ovarian Cancer Trialists Group. Semin Oncol 1992
Feb;l9(l Suppl 2):120—8.

Wils J A. Long-term follow-up of patients with
advanced ovarian carcinoma treated with debulking
surgery and chemotherapy consisting of cisplatin,
doxorubicin, and cyclophosphamide. Gynecologic
Oncology Group of the Comprehensive Cancer
Center. Oncology 1990;47(2):115-20.

Wiltshaw E, Perren TJ, Fryatt ID, Blake PR, Harper P,
Slevin M. Carboplatin and ifosfamide in ovarian
cancer phase II and III trials. London
Gynaecological Oncology Group. Cancer
Chemother Pharmacol 1990;26 Suppl:S48-50.

Yedema CA, Kenemans P, Voorhorst F, Bon G, Schijf
C, Beex L, Verstraeten A, Hilgers J, Vermorken J .
CA 125 half-life in ovarian cancer: a multivariate
survival analysxs. Br J Cancer 1993 Jun;67(6):
1361-7.

Zambetti M, Gianni L, Di Re F, Spatti G, Fontanelli R,
Escobedo A, De Palo G, Bonadonna G. Cisplatin
and cyclophosphamide in advanced ovarian
carcinoma: activity and toxicity of an ambulatory
regimen. Am J Clin Oncol 1990 Jun;13(3):l99-203.

Zylberberg B, Ravina J H, Salat-Baroux J, Madelenat P,
Zarca D, Dormont D. Chemotherapy by the
intravenous and intraperitoneal routes combined in
ovarian cancer. Gynecol Oncol 1990 Feb;36(2):
271-6.

49

Taxanes

Arbuck SG, Canetta R, Onetto N, Christian MC.
Current dosage and schedule issues in the

development of paclitaxel (T axol). Semin Oncol
1993 Aug;20(4 Suppl 3):31-9.

Bissett D, Kaye SB. Taxol and taxotere--current status
and future prospects. Eur J Cancer 1993;29A(9):
1228-31.

Boven E, Venema-Gaberscek E, Erkelens CA, Bissery
MC, Pinedo HM. Antitumor activity of taxotere
(RP 56976, NSC 628503), a new taxol analog, in
experimental ovarian cancer. Ann Oncol 1993 Apr;
4(4):321-4.

Brown J, McDermott B, Runzer N. Taxol: women with
ovarian cancer participate in a new clinical trial.
Can Oncol Nurs J 1992 May;2(2):47-50.

Brown T, Havlin K, Weiss G, Cagnola J, Koeller J,
Kuhn J, Rizzo J, Craig J, Phillips J, Von Hoff D.
A phase I trial of taxol given by a 6—hour
intravenous infusion. J Clin Oncol 1991 Jul;
9(7):1261-7.

Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer
D, Fields S, Weiss G, Eckardt J, Rodriguez G, et
31. Phase I clinical trial of taxotere administered as

either a 2—hour or 6—hour intravenous infusion.
J Clin Oncol 1993 May;11(5):950-8.

Caldas C, McGuire WP 3d. Paclitaxel (Taxol) therapy
in ovarian carcinoma. Semin Oncol 1993 Aug;
20(4 Suppl 3):50-5.

Cheson BD. Clinical trials referral resource. Clinical
trials with taxol. Oncology (Huntingt) 1992 Mar;
6(3):67-70.

Cheson BD. Clinical trials referral resource. Update on
taxol trials. Oncology (Huntingt) 1993 Jan;7(1):
63, 66-7.

Cheson BD, Arbuck SG, Phillips PH. Clinical trials
referral resource. Clinical trials with Docetaxel
(Taxotere). Oncology (Huntingt) 1993 Sep;7(9):
51-2.

Chuang LT, Lotzova E, Cook KR, Cristoforoni P,
Morris M, Wharton JT. Effect of new
investigational drug taxol on oncolytic activity and
stimulation of human lymphocytes. Gynecol Oncol
1993 Jun;49(3):291-8.

Comelissen G, Halberg E, Long HJ 3d, Prem K,
Bakken E, Touitou Y, Elg S, Haus E, Halberg F.
Toward a chronotherapy of ovarian cancer with
taxol. Part I: Basic background. Chronobiologia
1991 Oct-Dec;18(4):153—66.

Diergarten K, Dreps A. Taxol: A new antineoplastic
agent. Onkologie 1993;16(5):329-37.

50

Einzig Al, Wiemik PH, Sasloff J, Runowicz CD,
Goldberg GL. Phase II study and long-term follow—
up of patients treated with taxol for advanced
ovarian adenocarcinoma. J Clin Oncol 1992 Nov;
10(11):1748-53.

Einzig AI, Wiemik PH, Schwartz EL. Taxol: a new
agent active in melanoma and ovarian cancer.
Cancer Treat Res 1991;58:89-100.

Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N,
Marty M. Phase I and pharmacokinetic study of
Taxotere (RP 56976; NSC 628503) given as a short
intravenous infusion. Cancer Res 1993 Mar 1;
53(5): 1037-42.

Granai CO. Ovarian cancer--unrealistic expectations. N
Engl J Med 1992 Jul 16;327(3):197—200. Comment
in: N Engl J Med 1993 Mar 4;328(9):663-4 and N
Engl J Med 1993 Mar 4;328(9): 664; discussion
664-5.

Gregory RE, DeLisa AF. Paclitaxel: a new
antineoplastic agent for refractory ovarian cancer.
Clin Pharm 1993 Jun;12(6):401-15.

Hahn SM, Liebmann JE, Cook J, Fisher J, Goldspiel
B, Venzon D, Mitchell JB, Kaufman D. Taxol in
combination with doxorubicin or etoposide. Possible
antagonism in vitro. Cancer 1993 Nov 1;72(9):
2705-1 1.

Hamers FP, Pette C, Neijt JP, Gispen WH. The
ACTH—(4—9) analog, ORG 2766, prevents taxol-

induced neuropathy in rats. Eur J Pharmacol 1993
Mar 16;233(l):177-8.

Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC,
Von Hoff DD. Effects of Taxotere and taxol on in
vitro colony formation of freshly explanted human
tumor cells. Anticancer Drugs 1992 Apr;3(2):
121-4.

Huizing MT, Keung AC, Rosing H, van der Kuij V,
ten Bokkel Huinink WW, Mandjes IM, Dubbelman
AC, Pinedo HM, Beijnen J H. Pharmacokinetics of
paclitaxel and metabolites in a randomized
comparative study in platinum-pretreated ovarian
cancer patients. J Clin Oncol 1993 Nov;ll(11):
2127-35.

Jachez B, Nordmann R, Loor F. Restoration of taxol
sensitivity of multidrug—resistant cells by the
cyclosporine SDZ PSC 833 and the cyclopeptolide
SDZ 280-446. J Natl Cancer Inst 1993 Mar 17;
85(6):478-83.

Kelland LR, Abel G. Comparative in vitro cytotoxicity
of taxol and Taxotere against cisplatin-sensitive
and -resistant human ovarian carcinoma cell lines.
Cancer Chemother Pharmacol 1992;30(6):444-50.

Knox J D, Mitchel RE, Brown DL. Effects of taxol and
taxol/hyperthermia treatments on the functional

polarization of cytotoxic T lymphocytes. Cell Motil
Cytoskeleton 1993 ;24(2): 129-38.

Leu JG, Chen BX, Schiff PB, Erlanger BF.
Characterization of polyclonal and monoclonal anti-
taxol antibodies and measurement of taxol in serum.
Cancer Res 1993 Mar 15;53(6):1388—91.

Lubejko BG, Sartorius SE. Nursing considerations in
paclitaxel (Taxol) administration. Semin Oncol 1993
Aug;20(4 Suppl 3):26-30.

Markman M. Taxol: an important new drug in the
management of epithelial ovarian cancer. Yale J
Biol Med 1991 Nov-Dec;64(6):583-90.

Markman M, Rowinsky E, Hakes T, Reichman B,
Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat
R, Phillips M, et 81. Phase I trial of intraperitoneal
taxol: a Gynecoloic Oncology Group study. J Clin
Oncol 1992 Sep;10(9):1485-91.

McGuire WP. Taxol: a new drug with significant
activity as a salvage therapy in advanced epithelial
ovarian carcinoma. Gynecol Oncol 1993 Oct;51(1):
78-85.

McGuire WP, Rowinsky EK. Old drugs revisited, new
drugs, and experimental approaches in ovarian
cancer therapy. Semin Oncol 1991 Jun;18(3):
255-69.

Nicolaou KC, Riemer C, Kerr MA, Rideout D,
Wrasidlo W. Design, synthesis and biological
activity of protaxols. Nature 1993 Jul 29;
364(6436):464-6.

Ozols RF. Advances in the chemotherapy of
gynecologic malignancies. Hematol Oncol 1992 Jan-
Feb;lO(1):43-51.

Ozols RF. Chemotherapy for advanced epithelial
ovarian cancer. Hematol Oncol Clin North Am
1992 Aug;6(4):879-94.

Ozols RF. Ovarian cancer. Semin Surg Oncol 1990;
6(6):328-38.

Ozols RF. Ovarian cancer, Part II: Treatment. Curr
Probl Cancer 1992 Mar-Apr;16(2):61-126.

Ozols RF. Role of chemotherapy in the future treatment
of ovarian cancer. Acta Obstet Gynecol Scand
Suppl 1992;155:55—60.

Pazdur R, Kudelka AP, Kavanagh J], Cohen PR, Raber
MN. The taxoids: paclitaxel (Taxol) and docetaxel
(Taxotere). Cancer Treat Rev 1993 Oct;19(4):
351-86.

Pazdur R, Newman RA, Newman BM, Fuentes A,
Benvenuto J, Brcady B, Moore D J r, Jaiyesimi l,
Vreeland F, Bayssas MM, et a]. Phase I trial of
Taxotere: five-day schedule. J Natl Cancer Inst
1992 Dec 2;84(23):1781-8.

Peereboom DM, Donehower RC, Eisenhauer EA,
McGuire WP, Onetto N, Hubbard JL, Piccart M,
Gianni L, Rowinsky EK. Successful re—treatment
with taxol after major hypersensitivity reactions.
J Clin Oncol 1993 May;11(5):885-90.

Pokalo CL. The promise of taxol. Todays OR Nurse
1992 Dec;14(12):31-2.

Rowinsky EK, Citardi MJ, Noe DA, Donehower RC.
Sequence-dependent cytotoxic effects due to
combinations of cisplatin and the antimicrotubule
agents taxol and vincristine. J Cancer Res Clin
Oncol l993;119(12):727-33.

Rowinsky EK, Donehower RC. The clinical
pharmacology of paclitaxel (Taxol). Semin Oncol
1993 Aug;20(4 Suppl 3):16—25.

Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck
SG, Donehower RC. Clinical toxicities encountered
with paclitaxel (Taxol). Semin Oncol 1993 Aug;
20(4 Suppl 3):1-15.

Rowinsky EK, Gilbert MR, McGuire WP, Noe DA,
Grochow LB, Forastiere AA, Ettinger DS, Lubejko
BG, Clark B, Sartorius SE, et al. Sequences of
taxol and cisplatin: a phase I and pharmacologic
study. J Clin Oncol 1991 Sep;9(9):1692-703.

Rowinsky EK, Grochow LB, Hendricks CB, Ettinger
DS, Forastiere AA, Hurowitz LA, McGuire WP,
Sartorius SE, Lubejko BG, Kaufmann SH, et al.
Phase I and pharmacologic study of topotecan: a
novel topoisomerase I inhibitor. J Clin Oncol 1992
Apr; 10(4):647-56.

Rowinsky EK, Onetto N, Canetta RM, Arbuck SG.
Taxol: the first of the taxanes, an important new
class of antitumor agents. Semin Oncol 1992
Dec;19(6):646-62.

Runowicz CD, Wiemik PH, Einzig AI, Goldberg GL,
Horwitz SB. Taxol in ovarian cancer. Cancer 1993
Feb 15;71(4 Suppl)2159l-6.

Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J ,
Adamo DO, Ognibene FP, Cunnion RE, Reed E.
Phase I study of taxol and granulocyte colony-
stimulating factor in patients with refractory ovarian
cancer. J Clin Oncol 1992 Jul;10(7):1165—70.

Sarosy G, Reed E. Taxol dose intensification and its
clinical implications. J Natl Med Assoc 1993 Jun;
85(6):427-31.

Slichenmyer WJ, Von Hoff DD. New natural products
in cancer chemotherapy. J Clin Pharmacol 1990
Sep;30(9):770-88.

Steren A, Sevin BU, Perras J, Angioli R, Nguyen H,
Guerra L, Koechli 0, Averette HE. Taxol sensitizes
human ovarian cancer cells to radiation. Gynecol
Oncol 1993 Feb;48(2):252-8.

51

Steren A, Sevin BU, Perras J, Ramos R, Angioli R,
Nguyen H, Koechli O, Averette HE. Taxol as a
radiation sensitizer: a flow cytometric study.
Gynecol Oncol 1993 Jul;50(1):89-93.

ten Bokkel Huinink WW, Eisenhauer E, Swenerton K.
Preliminary evaluation of a multicenter, randomized
comparative study of TAXOL (paclitaxel) dose and
infusion length in platinum-treated ovarian cancer.
Canadian-European Taxol Cooperative Trial Group.
Cancer Treat Rev 1993;19 Suppl C:79-86.

Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a
novel radiation sensitizer. Int J Radiat Oncol Biol
Phys 1992;22(3):613-7.

Trimble EL, Adams JD, Vena D, Hawkins MJ,
Friedman MA, Fisherman J S, Christian MC,
Canetta R, Onetto N, Hayn R, et al. Paclitaxel for
platinum-refractory ovarian cancer: results from the
first 1,000 patients registered to National Cancer
Institute Treatment Referral Center 9103. J Clin
Oncol 1993 Dec;11(12):2405-10.

Webster L, Linsenmeyer M, Millward M, Morton C,
Bishop J, Woodcock D. Measurement of cremophor
EL following taxol: plasma levels sufficient to
reverse drug exclusion mediated by the multidrug-
resistant phenotype. J Natl Cancer Inst 1993
Oct 20;85(20):1685-90.

Weiss RB, Donehower RC, Wiemik PH, Ohnuma T,
Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA,
Von Hoff DD, Leyland-Jones B. Hypersensitivity
reactions from taxol. J Clin Oncol 1990 Jul;
8(7):1263-8.

Williams S, Mutch DG, Xu L, Collins JL. Divergent
effects of taxol on tumor necrosis factor-alpha-
mediated cytolysis of ovarian carcinoma cells. Am J
Obstet Gynecol 1992 Dec;167(6):1870—6.

Workman P, Kaye SB, Schwartsmann G. Laboratory
and phase I studies of new cancer drugs. Curr Opin
Oncol 1992 Dec;4(6):1065-72. Published erratum
appears in Curr Opin Oncol 1993 Mar;5(2):434.

52

Second-Look Surgery

Aravantinos D, Michalas S, Papazefltos V,
Christoforaki M, Stypsaneli A, Vlachos G,
Athanasiadis P. Predictive values of CA 125 antigen
levels and CT scan in second-look procedures for
ovarian cancer. Eur J Obstet Gynecol Reprod Biol
1990 Dee;37(3):265-70.

Ayhan A, Urman B, Yarali H, Yuce K, Ayhan A.
Predictors of recurrent disease after negative
second—look laparotomy for epithelial ovarian
cancer. J Surg Oncol 1990 Jun;44(2):119-21.

Ayhan A, Yarali H, Develioglu O, Uren A, Ozyilmaz
F. Prognosticators of second-look laparotomy
findings in patients with epithelial ovarian cancer.
J Surg Oncol 1991 Apr;46(4):222-5.

Bar-Am A, Kovner F, Lessing JB, Inbar M, Chaitchik
S, Azem F, Brenner SH, Peyser MR. A second
thought on second look laparotomy. Acta Obstet
Gynecol Scand 1993 Jul;72(5):386-90.

Barakat RR, Rubin SC, Saigo PE, Lewis JL Jr, Jones
WB, Curtin JP. Second-look laparotomy in

carcinoma of the fallopian tube. Obstet Gynecol
1993 Nov;82(5):748-51.

Barrenetxea G, Martin-Mateos M, Banazan MJ,
Montoya F, Matia JC, Rodriguez—Escudero FJ.
Serum CA 125, CA 15.3 and CA 19.9 levels and
surgical findings in patients undergoing second look
operations for ovarian carcinomas. Eur J Gynaecol
Oncol 1990;11(5):369-74.

Barter JF, Barnes WA. Second-look laparotomy. In:
Rubin SC, Sutton GP, eds. Ovarian cancer. New
York: McGraw-Hill; 1993. p. 269-300.

Bell J, Mojzisik C, Hinkle G Jr, Derman H, Schlom J,
Martin E. Intraoperative radioimmunodetection of
ovarian cancer using monoclonal antibody B723
and a portable gamma-detecting probe. Obstet
Gynecol 1990 Oct;76(4):607—11.

Bokhman YaV, Vinokurov VL, Gulo El. The
controversial ’second-look’ laparotomy. Acta Obstet
Gynecol Scand Suppl 1992;155:79-83.

Camera L, Del Vecchio S, Petrillo A, Esposito G,
Frasci G, Iaffaioli RV, Bianco AR, Salvatore M.
Evaluation of therapeutic response using iodine-131-
B72.3 monoclonal antibody in patients with ovarian
carcinoma. Eur J Nucl Med 1991;18(4):269-73.

Carson LF, Rubin SC. Secondary cytoreduction--
thoughts on the pro side. Gynecol Oncol 1993 Oct;
51(1):127-30.

Cromer DW. Second-look laparotomy in ovarian
carcinoma patients after 8 and after 12 courses of
cisplatin-based chemotherapy. Surg Gynecol Obstet
1990;170(4):69.

Davidson NG, Khanna S, Kirwan P, Bircumshaw D.
Advanced ovarian cancer: long-ten-n results
following chemotherapy and second-look
laparotomy. Gynecol Oncol 1990 Dec;39(3):295-9.

Deligdisch L, Kemer H, Cohen CJ, Dargent D, Gil J.
Morphometric differentiation between responsive
tumor cells and mesothelial hyperplasia in second-
look operations for ovarian cancer. Hum Pathol
1993 Feb;24(2):l43-7.

Edmonson JH, McCormack GM, Wiand HS, Kugler
JW, Krook JE, Stanhope CR, Everson LK, Laurie
JA, Ebbert LP, Malkasian GD, et a1.
Cyclophosphamide—cisplatin versus
cyclophosphamide—carboplatin in stage III-IV
ovarian carcinoma: a comparison of equally
myelosuppressive regimens. J Natl Cancer Inst 1989
Oct 4;81(19):1500—4.

Elg SA, Yu Y, Carson LF, Adcock LL, Twiggs LB,
Prem KA, Ramakrishnan S. Serum levels of
macrophage colony-stimulating factor in patients
with ovarian cancer undergoing second-look
laparotomy. Am J Obstet Gynecol 1992 Jan;
166(1 Pt 1):134-7.

Friedman J B, Weiss NS. Second thoughts about second-
look laparotomy in advanced ovarian cancer.
N Engl J Med 1990 Apr 12;322(15):1079-82.

Gallion HH, Hunter JE, van Nagell JR, Averette HE,
Cain JM, Copeland Ll, Higgins RV, Husseinzadeh
N, Nahhas WA, Partridge EE, et al. The prognostic
implications of low serum CA 125 levels prior to
the second-look operation for stage III and IV
epithelial ovarian cancer. Gynecol Oncol 1992 Jul;
46(1):29-32.

Gershenson DM, Copeland LJ, Wharton JT, Atkinson
EN, Sneige N, Edwards CL, Rutledge FN.
Prognosis of surgically determined complete

responders in advanced ovarian cancer. Cancer
1985 Mar 1;55(5):1129-35.

Ghatage P, Krepart GV, Lotocki R. Factor analysis of
false-negative second-look laparotomy. Gynecol
Oncol 1990 Feb;36(2):172-5.

Goldberg GL, Scheiner J, Friedman A, O’Hanlan KA,
Davidson SA, Runowicz CD. Lymph node
sampling in patients with epithelial ovarian
carcinoma. Gynecol Oncol 1992 Nov;47(2):143-5.

Granowska M, Mather SJ, Britton KE. Diagnostic
evaluation of lllIn and 99mTc radiolabelled
monoclonal antibodies in ovarian and colorectal
cancer: correlations with surgery. Int J Rad Appl
Instrum [B] 1991;18(4):413-24.

Granowska M, Mather SJ, Jobling T, Naeem M,
Burchell J, Taylor-Papadimitriou J, Shepherd J,
Britton KE. Radiolabelled stripped mucin, SM3,
monoclonal antibody for immunoscintigraphy of

ovarian tumours. Int J Biol Markers 1990 Apr-Jun;
5(2):89-96.

Hartmann LC, Sebo TJ, Kamel NA, Podratz KC, Cha
SS, Wieand HS, Keeney GL, Roche PC.
Proliferating cell nuclear antigen in epithelial
ovarian cancer: relation to results at second-look
laparotomy and survival. Gynecol Oncol 1992 Nov;
47(2):191—5.

Hoskins JH, Rubin SC, Dulaney E, Chapman D,
Almadrones L, Saigo P, Markman M, Hakes T,
Reichman B, Jones WB, et al. Influence of
secondary cytoreduction at the time of second-look
laparotomy on the survival of patients with
epithelial ovarian carcinoma. Gynecol Oncol 1989
Sep;34(3) : 365-71.

Hoskins WJ. Surgical staging and cytoreductive surgery
of epithelial ovarian cancer. Cancer 1993 Feb 15;
71(4 Suppl):1534-40.

Hoskins WJ, Rubin SC. Surgery in the treatment of
patients with advanced ovarian cancer. Semin Oncol
1991 Jun;18(3):213d21.

Jager W, Feistel H, Paterok EM, Ronay G, Tulusan
AH, Wolf F, Lang N. Resection guided by
antibodies (REGAJ): a diagnostic procedure during
second-look operation in ovarian cancer patients.
Br J Cancer Suppl 1990 Jul;10:18-20.

Kamura T, Tsukamoto N, Saito T, Kaku T, Matsuyama
T, Nakano H. Efficacy of second-look laparotomy
for patients with epithelial ovarian carcinoma. Int J
Gynaecol Obstet 1990 Oct;33(2):141-7.

Krag DN, Ford P, Smith L, Taylor M, Schneider PD,
Bushberg JT, Goodnight JE. Clinical
immunoscintigraphy of recurrent ovarian cancer
with indium Ill-labeled B723 monoclonal
antibody. Arch Surg 1993 Jul;128(7):819-23.

Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker
LM, Welch WR, Klatt M, Andersen J. Predictive
factors for long-term survival in patients with

advanced ovarian cancer. Gynecol Oncol 1989 Jul;
34(1):88-93.

Kudo R, Takashina T, Ito E, Mizuuchi H, Sagae S,
Moriwaka O, Tamagawa A. Peritoneal washing
cytology at second-look laparotomy in cisplatin-
treated ovarian cancer patients. Acta Cytol 1990
Jul-Aug;34(4):545-8.

Lastoria S, Panza N, Esposito G, Vergara E, Castelli
L, Caraco C, Battista C, Pacilio G, Salvatore M.
Management of patients with ovarian cancer using
monoclonal antibodies. Biomed Pharmacother 1992;
46(10):453-63.

Liu L, Hong W, Hou Y, Yao Z, Wu A, Wang X.
Evaluation of second—look laparotomy for ovarian
cancer: second-look vs. serum CA125. Chin Med
Sci J 1991 Jun;6(2):96-9.

53

Lund B, Williamson P. Prognostic factors for outcome
of and survival after second-look laparotomy in
patients with advanced ovarian carcinoma. Obstet
Gynecol 1990 Oct;76(4):617-22.

Makar AP, Kristensen GB, Bormer OP, Trope CG. CA
125 measured before second-look laparotomy is an
independent prognostic factor for survival in

patients with epithelial ovarian cancer. Gynecol
Oncol 1992 Jun;45(3):323-8.

Miller DS, Spirtos NM, Ballon SC, Cox RS, Soriero
OM, Teng NN. Critical reassessment of second-
look exploratory laparotomy for epithelial ovarian
carcinoma. Minimal diagnostic and therapeutic
value in patients with persistent cancer. Cancer
1992 Jan 15;69(2):502-10.

Morgan MA, Noumoff Is, King S, Mikuta J]. A
formula for predicting the risk of a positive second-
look laparotomy in epithelial ovarian cancer:
implications for a randomized trial. Obstet Gynecol
1992 Dec;80(6):944-8.

Mottolese M, Salzano M, Vincenzoni C, Benevolo M,
Bigotti A, Iacovelli A, Lombardi A, Atlante G,
Natali PG. The use of a panel of monoclonal
antibodies can lower false-negative diagnoses of
peritoneal washings in ovarian tumors. Cancer 1991
Oct 15;68(8):1803-7.

Nishimura H, Hamaguchi K, Miyahara K, Tazaki T,
Tateno N, Yakushiji M. The current therapeutic
approaches to advanced ovarian cancer. Nippon
Sanka Fujinka Gakkai Zasshi 1990 Dec;42(12):
1691-6.

Ojeda—Gonzalez MB, Alvarez-Lopez l, Alonso-Munoz
MC, Badia—Serra J, Delgado-Latre E, de Andres—
Basauri L, Lopez-Lopez JJ. Chemotherapy (CAP)
for the treatment of advanced ovarian cancer and
second-effort surgery in the second look. Oncology
1991;48(1):7-12.

Omura GA, Brady MF, Homesley HD, Yordan E,
Major FJ, Buchsbaum HJ, Park RC. Long-term
follow-up and prognostic factor analysis in
advanced ovarian carcinoma: the Gynecologic
Oncology Group experience. J Clin Oncol 1991
Jul;9(7):1138-50.

Papazeflms V, Michalas S, Papantoniou V, Datseris J,
Athanasiadis P, Akrivos T, Leonti A, Xygakis A,
Aravantinos D. Comparative study of R18 with the
l3ll-OC 125 F(ab’)2 Mab and CT scan prior to
second look operation for ovarian cancer. Eur J
Obstet Gynecol Reprod Biol 1990 Dec;37(3):271-7.

Patsner B, Orr JW Jr, Mann W] Jr, Taylor PT,
Partridge E, Allmen T. Does scrum CA-125 level
prior to second-look laparotomy for invasive
ovarian adenocarcinoma predict size of residual
disease? Gynecol Oncol 1990 Jun;37(3):319-22.

54

Patsner B, Orr JW Jr, Mann W] Jr, Taylor PT,
Partridge E, Allmen T. Does serum CA-125 level
prior to second-look laparotomy for invasive
ovarian adenocarcinoma predict size of residual
disease? Gynecol Oncol 1990 Sep;38(3):373—6.

Pcctasides D, Kayianni H, Facou A, Bobotas N,
Barbounis V, Zis J, Athanassiou A. Correlation of
abdominal computed tomography scanning and
second—look operation findings in ovarian cancer
patients. Am J Clin Oncol 1991 Dec;14(6):457-62.

Podczaski E, Manetta A, Kaminski P, Ricelli A, Larson
J, DeGeest K, Mortel R. Survival of patients with
ovarian epithelial carcinomas after second-look
laparotomy. Gynecol Oncol 1990 Jan;36(1):43-7.

Podratz KC, Kinney WK. Second-look operation in
ovarian cancer. Cancer 1993 Feb 15;7l(4 Suppl):
1551-8.

Podratz KC, Malkasian GD Jr, Hilton JF, Harris EA,
Gaffey TA. Second-look laparotomy in ovarian
cancer: evaluation of pathologic variables. Am J
Obstet Gynecol 1985 May 15;52(2):230-8.

Podratz KC, Malkasian GD Jr, Wieand HS, Cha SS,
Lee RA, Stanhope CR, Williams TJ. Recurrent
disease after negative second—look laparotomy in
stages III and IV ovarian carcinoma. Gynecol Oncol
1988 Mar;29(3):274-82.

Podratz KC, Schray MF, Wieand HS, Edmonson JH,
Jefferies JA, Long HJ, Malkasian GD, Stanhope
CR, Wilson TO. Evaluation of treatment and
survival after positive second-look laparotomy.
Gynecol Oncol 1988 Sep;31(l):9-24.

Potter ME. Secondary cytoreduction in ovarian cancer:
pro or con? Gynecol Oncol 1993 Oct;51(l):13l-5.

Potter ME, Hatch KD, Soong SJ, Partridge EE, Austin
JM Jr, Shingleton HM. Second-look laparotomy and
salvage therapy: a research modality only? Gynecol
Oncol 1992 Jan;44(1):3—9. Comment in: Gynecol
Oncol 1992 Nov;47(2):275.

Quaranta M, Coviello M, Donadeo A, Rella C, Lorusso
V, Micelli G, Lucarelli C. Measurement of the
ovarian cancer-associated antigen CA 125 in
monitoring tumor burden and response to
chemotherapy. Tumori 1991 Apr 30;77(2):167-9.

Rader J S. Therapeutic advances in ovarian cancer. Curr
Opin Obstet Gynecol 1992 Feb;4(l):120-7.

Redman CW, Blackledge G, Lawton FG, Varma R,
Luesley DM, Chan KK. Early second surgery in
ovarian cancer--improving the potential for cure or

another unnecessary operation? Eur J Surg Oncol
1990 Oct;16(5):426—9.

Redman CW, Chapman SE, Chan SY, Buxton EJ,
Blackledge G, Luesley DM. Out-patient peritoneal
lavage cytology in the detection of residual

epithelial ovarian cancer. Cytopathology 1991;
2(6):291-8.

Rose PG, Reale FR, Fisher A, Hunter RE.
Appendectomy in primary and secondary staging
operations for ovarian malignancy. Obstet Gynecol
1991 Jan;77(1):116-8.

Rubin SC. Second-look laparotomy in ovarian cancer.
In: Markinan M, Hoskins WJ, eds. Cancer of the
ovary. New York: Raven Press; 1993. p. 175-85.

Rubin SC. Surgery for ovarian cancer. Hematol Oncol
Clin North Am 1992 Aug;6(4):851-65.

Rubin SC, Hoskins WJ, Saigo PE, Chapman D, Hakes
TB, Markman M, Reichman B, Almadrones L,
Lewis J L Jr. Prognostic factors for recurrence
following negative second-look laparotomy in
ovarian cancer patients treated with platinum-based
chemotherapy. Gynecol Oncol 1991 Aug;42(2):
137-41.

Scambia G, Panici PB, Baiocchi G, Gallo A, Laurelli
G, Iacobelli S, Mancuso S. Recombinant alpha-2b-
interferon dynamic test as a potential tool in
predicting disease status during second look in
ovarian cancer. A preliminary report. Cancer 1991
Dec 15;68(12):2582-5.

Second-look surgery for ovarian carcinoma. ACOG
Committee Opinion: Committee on Gynecologic
Practice. Number IOU—November 1991. Int J
Gynaecol Obstet 1992 Sep;39(1):61—2.

Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen
CJ. Secondary cytoreduction for ovarian cancer
following cisplatin therapy. J Clin Oncol 1993
Mar;11(3):434-9.

Soeters RP, Bloch B, Dehaeck K, Levin W. The
influence of initial residual disease on the outcome
of second-look laparotomy in patients with
carcinoma of the ovary. Eur J Gynaecol Oncol
l992;13(3):223-7.

Soper JT, Couchman G, Berchuck A, Clarke—Pearson
D. The role of partial sigmoid colectomy for
debulking epithelial ovarian carcinoma. Gynecol
Oncol 1991 Jun;41(3):239-44. Comment in:
Gynecol Oncol 1992 Jul;46(l):138.

Tomas C, Kauppila A. Tumor markers of epithelial and
stromal cell origin at second-look laparotomy in
ovarian carcinoma. Gynecol Oncol 1992 Jun;45(3):
279-83.

Torretta L, Balestreri D, Fasola M, Schinko E, Scorbati
E, Tateo S. Diagnostic alternatives to second look
in ovarian cancer. Eur J Gynaecol Oncol 1990;
11(2):145-8.

Torri V, Simon R, Russek-Cohen E, Midthune D,
Friedman M. Statistical model to determine the
relationship of response and survival in patients

with advanced ovarian cancer treated with
chemotherapy. J Natl Cancer Inst 1992 Mar 18;
84(6):407-14. Comment in: J Natl Cancer Inst 1992
Mar 18;84(6):376-8.

Tuxen MK, Lund B, Hansen OP, Hansen M. Second-
look laparotomy in the management of patients after
radical surgery for ovarian cancer. Ann Oncol 1993
Feb ;4(2): 169-71 .

van der Burg ME, Lammes FB, Verweij J. CA 125 in
ovarian cancer. Neth J Med 1992 Feb;40(1—2):
36-51.

van Kranenburg DL, van Kroonenburgh MJ, Trimbos
J B, Fleuren GJ, Pauwels EK. Imaging of ovarian
cancer with radiolabelled monoclonal antibodies.
Arch Gynecol Obstet 1990;247(3):107-16.

Venesmaa P, Ylikorkala O. Morbidity and mortality
associated with primary and repeat operations for
ovarian cancer. Obstet Gynecol 1992 Feb;79(2):
168-72. Comment in: Obstet Gynecol 1992 Jul;
80(1):155-6.

Vergote IB. Surgery for gynecologic malignancies. Curr
Opin Oncol 1993 Sep;5(5):877-84.

Vergote IB, Onsrud M, Bormer OP, Sert BM, Moen
M. CA 125 in peritoneal fluid of ovarian cancer
patients. Gynecol Oncol 1992 Feb;44(2):161-5.

Wangensteen OH, Lewis P], Tongen LA. The "second-
look" in cancer surgery: a patient with colic cancer
and involved lymph nodes negative on the "sixth -
look." I Lancet 1951 Aug;51(8):303-7.

Ward BG, McGuckin MA, Ramm LE, Coglan M,
Sanderson B, Tripcony L, Free KB. The
management of ovarian carcinoma is improved by
the use of cancer-associated serum antigen and
CA 125 assays. Cancer 1993 Jan 15;71(2):430—8.

Williams L. The role of secondary cytoreductive
surgery in epithelial ovarian malignancies.
Oncology (Huntingt) 1992 Aug;6(8):25-32;
discussion 37—9. Comment in: Oncology (Huntingt)
1993 Feb;7(2):21.

Wong RJ, DeCosse JJ. Cytoreductive surgery. Surg
Gynecol Obstet 1990 Mar;170(3):276-81.

Xu FJ, Yu YH, Daly L, DeSombre K, Anselmino L,
Hass GM, Berchuck A, Soper JT, Clarke-Pearson
DL, Boyer C, et al. OVXl radioimmunoassay
complements CA-125 for predicting the presence of
residual ovarian carcinoma at second-look surgical
surveillance procedures. J Clin Oncol 1993 Aug;
11(8): 1506-10.

55

FOLLOW-UP AFI‘ER PRIMARY
SURGERY

Follow-Up of the Asymptomatic Patient

Beattie GJ, Sturgeon C, Fisken J, Roulston J E. The
effect of surgery on the serum concentration of

CA 125 in epithelial ovarian cancer. Ann Clin
Biochem 1993 Jul;30(Pt 4):402-3.

Bruzzone M, Onetto M, Campora E, Chiara S, Oliva
C, Guido T, Merlini L, Parodi S, Bentivoglio G,
Ventrella W, et al. CA-125 monitoring in the
management of ovarian cancer. Anticancer Res
1990 Sep—Oct;10(5A):1353-9.

Buller RE, Berman ML, Bloss JD, Marietta A, DiSaia
PJ. CA 125 regression: a model for epithelial
ovarian cancer response. Am J Obstet Gynecol
1991 Aug;165(2):360-7.

Buller RE, Berman ML, Bloss JD, Marietta A, DiSaia
PJ. Serum CA125 regression in epithelial ovarian
cancer: correlation with reassessment findings and
survival. Gynecol Oncol 1992 Oct;47(l):87-92.

Buller RE, Marietta A, Bloss JD, DiSaia PJ, Berman
ML. Does intraperitoneal CA-125 reflect disease
status? Gynecol Oncol 1991 Jan;40(1):66-9.

Eeles RA, Tan S, Wiltshaw E, Fryatt I, A’I-Iem RP,
Shepherd JH, Harmer CL, Blake PR, Chilvers CE.
Hormone replacement therapy and survival after
surgery for ovarian cancer. BMJ 1991 Feb 2;
302(6771):259-62. Comment in: BMJ 1991 Mar 30;
302(6779):790.

Fioretti P, Gadducci A, Ferdeghini M, Prontera C,
Malagnino G, Facchini V, Mariani G, Bianchi R.
The concomitant determination of different serum
tumor markers in epithelial ovarian cancer:
relevance for monitoring the response to
chemotherapy and follow-up of patients. Gynecol
Oncol 1992 Feb;44(2):155-60.

Fisken J, Leonard RC, Badley A, Jonrup I, Aspinall L,
Sturgeon C, Roulston J E. Serological monitoring of
epithelial ovarian cancer. Dis Markers 1991 May-
Aug;9(3—4):175-90.

Gerli M, Palumbo R, Angelini A, Gerli S, Brunelli E,
Pupita P, Bonaca S, Spagnolo W.
Immunoscintigraphy in the follow up of patients

with ovarian cancer. Eur J Gynaecol Oncol 1990;
11(3):203-4.

Guidozzi F. Living with ovarian cancer. Gynecol Oncol
1993 Aug;50(2):2(TZ-7.

Hising C, Anjegard IM, Einhom N. Clinical relevance
of the CA 125 assay in monitoring of ovarian
cancer patients. Am J Clin Oncol 1991 Apr;14(2):
1 1 1—4.

56

Hogberg T, Kagedal B. Long-term follow-up of ovarian
cancer with monthly determinations of serum
CA 125. Gynecol Oncol 1992 Aug;46(2):191-8.

Jimenez-Vicioso A, Torres M, Jimenez-Heffeman A,
Grana MD, Latre JM, Llamas JM, Carreras JL,
Mateo A. Immunoscintigraphy with 1311 or lllln
labelled 0C 125 F(ab’)2 fragments in patients with
ovarian carcinoma. Int J Biol Markers 1990 Oct—
Dec;5(4):159—65.

Kamiya N, Mizuno K, Kawai M, Kano T, Furuhashi
Y, Tomoda Y. Simultaneous measurement of CA
125, CA 19-9, tissue polypeptide antigen, and
immunosuppressive acidic protein to predict
recurrence of ovarian cancer. Obstet Gynecol 1990
Sep;76(3 Pt 1):417-21.

Kenemans P, Yedema CA, Bon GG, von Mensdorff—
Pouilly S. CA 125 in gynecological pathology--a
review. Eur J Obstet Gynecol Reprod Biol 1993
Apr;49(1-2):115-24.

Lund B, Jacobsen K, Rasch L, Jensen F, Olesen K,
Feldt-Rasmussen K. Correlation of abdominal
ultrasound and computed tomography scans with
second- or third-look laparotomy in patients with
ovarian carcinoma. Gynecol Oncol 1990 May;37(2):
279-83.

Makar AP, Kristensen GB, Bormer OP, Trope CG. Is
serum CA 125 at the time of relapse a prognostic
indicator for further survival prognosis in patients
with ovarian cancer? Gynecol Oncol 1993 Apr;
49(1):3-7. Comment in: Gynecol Oncol 1993 Apr;
49(1):1-2.

Markowska J, Kojczynski Z, Szewierski Z, Manys G.
CA 125 in monitoring chemotherapy of the patients
with ovarian cancer. Eur J Gynaecol Oncol 1990;
11(3):209-14.

Markowska J, Manys G, Kubaszewska M. Value of CA
125 as a marker of ovarian cancer. Eur J Gynaecol
Oncol 1992;13(4):360—5.

Maughan TS, Haylock B, Hayward M, Facey P, Evans
WD, Shelley MD, Fish RG, Adams M. OC125
immunoscintigraphy in ovarian carcinoma: a
comparison with alternative methods of assessment.
Clin Oncol (R Coll Radiol) 1990 Jul;2(4):199-205.

Menczer J, Ben-Baruch G, Rizel S, Brenner H.
Intraperitoneal chemotherapy versus no treatment in
patients with ovarian carcinoma who are in
complete clinical remission. Cancer 1992 Oct 1;
70(7): 1956-9.

Menczer J, Ben-Baruch G, Rizel S, Brenner H.
Intraperitoneal cisplatin chemotherapy in ovarian
carcinoma patients who are clinically in complete
remission. Gynecol Oncol 1992 Aug;46(2):222-5.

Ngan HY, Wong LC, Chan SY, Ma HK. Role of
CA 125 and abdominal pelvic computerized axial

tomogram in the monitoring of chemotherapy
treatment of ovarian cancer. Cancer Invest 1990;
8(5):467-70.

Nishimura H, Tashiro M, Harnaguchi K, Kiyorzuka Y,
Ide H, Tateno N, Miyoshi T, Yakushiji M.
Significance of the serum CA125 level in recurrent
ovarian cancer. Asia Oceania J Obstet Gynaecol
1992 Mar;18(l)z37-43.

Oncoscint for detection of disseminated colorectal and
ovarian cancer. Med Lett Drugs Ther 1993 Jun 11;
35(898):52-3.

Patsner B. Is there a role for CT scanning to monitor
therapy of optimally debulked patients with
advanced ovarian epithelial cancer? Int J Gynecol
Cancer 1994;4(1):19-21.

Peltier P, Dutin JP, Chatal JF, Fumoleau P, Bourguet
P, Liehn JC, Vuillez JP, Herry JY, Loboguerrero
A. Usefulness of imaging ovarian cancer recurrence
with In—lll-labeled monoclonal antibody (0C 125)
specific for CA 125 antigen. The INSERM
Research Network (Nantes, Rennes, Reims,
Vuillejuif, Saclay). Ann Oncol 1993 Apr;4(4):
307-1 1.

Peltier P, Wiharto K, Dutin JP, Chatal JF, Bourguet P,
Liehn JC, Vuillez JP, Herry JY, Loboguerrero A.
Correlative imaging study in the diagnosis of
ovarian cancer recurrences. The INSERM Research
Network (Nantes, Rennes, Reims, Villejuif, Saclay,
France). Eur J Nucl Med 1992;19(12):1006-10.

Perkins AC, Powell MC, Wastie ML, Scott IV,
Hitchcock A, Worthington BS, Symonds EM. A
prospective evaluation of OC125 and magnetic
resonance imaging in patients with ovarian
carcinoma. Eur J Nucl Med 1990;16(4-6):311-6.

Pirtoli L, Risso G, Inaudi P, Landoni F, Pepi F, Bindi
M, Tucci E, D’Antona N, Mangioni C. A role for
tumor markers in therapeutic decisions afler
chemotherapy induction of objective remission in
stage 1]] epithelial ovarian neoplasms. Int J Biol
Markers 1991 Apr—Jun;6(2):lU7-14.

Prayer L, Kainz C, Kramer J, Stiglbauer R,
Schurawitzki H, Baldt M, Schima W, Poelzleitner
D, Reinthaller A, Koelbl H, et a]. CT and MR
accuracy in the detection of tumor recurrence in
patients treated for ovarian cancer. J Comput Assist
Tomogr 1993 Jul—Aug;17(4):626-32.

Prayer L, Stiglbauer R, Kramer J, Wimberger D,
Poelzleitner D, Schima W, Kainz C, Koelbl H,
Haugen I, Imhof H. Superparamagnetic particles as
oral contrast medium in magnetic resonance
imaging of patients with treated ovarian cancer--
comparison with plain MRI. Br J Radiol 1993 May;
66(785):415—9.

Prosser ES, Pomeroy M, Barker F, Carroll K, Davis
M, Duffy J, Duffy G, Fennelly JJ, O’Kennedy R.

The relationship between lllIn-labelled gynecologic malignancies. Gynecol Oncol 1992
immunoscintigraphy and serum CA-125 levels in Sep;46(3):281-6.

ovarian carcinoma patients postchemotherapy.
Biochem Soc Trans 1992 Feb;20(l):54S.

Quaranta M, Coviello M, Donadeo A, Rella C, Lorusso
V, Micelli G, Lucarelli C. Measurement of the
ovarian cancer-associated antigen CA 125 in
monitoring tumor burden and response to
chemotherapy. Tumori 1991 Apr 30;77(2):167-9.

Rustin GJ . Impact of tumour marker measurements
upon management of patients with carcinoma of the
ovary. Dis Markers 1991 May-Aug;9(3-4):153-8.

Sevelda P, Rosen A, Denison U, Barrada M, Spona J,
Salzer H. Is CA-125 monitoring useful in patients
with epithelial ovarian carcinoma and preoperative
negative CA-125 serum levels? Gynecol Oncol 1991
Nov;43(2):154-8.

van der Burg ME, Lammes FB, Verweij J. CA 125 in
ovarian cancer. Neth J Med 1992 Feb;40(1-2):
36—5 1.

van der Burg ME, Lammes FB, Verweij J. The role of
CA 125 and conventional examinations in
diagnosing progressive carcinoma of the ovary.
Surg Gynecol Obstet 1993 Apr;176(4):3IO-4.

van der Burg ME, Lammes FB, Verweij J. The role of
CA 125 in the early diagnosis of progressive
disease in ovarian cancer. Ann Oncol 1990 Jul;
1(4):301—2.

van Kranenburg DL, van Kroonenburgh MJ, Trimbos
JB, Fleuren GJ, Pauwels EK. Imaging of ovarian
cancer with radiolabelled monoclonal antibodies.
Arch Gynecol Obstet 1990;247(3):107—16.

Vergote IB, Abeler VM, Bormer OP, Stigbrand T,
Trope C, Nustad K. CA125 and placental alkaline
phosphatase as serum tumor markers in epithelial
ovarian carcinoma. Tumour Biol 1992;13(3):
168-74.

Vinokurov VL, Dudarev AL, Jurkova LE, Lapchenkov
VI, Barbanel EJ. Tumor marker CA 125 in
diagnosis, monitoring management and follow—up of
patients with ovarian tumors. Eur J Gynaecol Oncol
1992;13(2):205-8.

Ward BG, McGuckin MA, Ramm LE, Coglan M,
Sanderson B, Tripcony L, Free KB. The
management of ovarian carcinoma is improved by
the use of cancer-associated serum antigen and CA
125 assays. Cancer 1993 Jan 15;71(2):430-8.

Welander CE. What do CA 125 and other antigens tell
us about ovarian cancer biology? Acta Obstet
Gynecol Scand Suppl 1992;155:85-93.

Wojcik EM, Selvaggi SM, Johnson SC, Martier SS,
Ager J W. Factors influencing fine-needle aspiration
cytology in the management of recurrent

57

58

Surgery for the Symptomatic Patient

Adelson MD, Kasowitz MH. Percutaneous endoscopic
drainage gastrostomy in the treatment of
gastrointestinal obstruction from intraperitoneal
malignancy. Obstet Gynecol 1993 Mar;81(3):
467-71.

Allum WH, Ambrose NS, Fielding JW, Chan KK.
Selective salvage surgery in gastrointestinal and
gynaecological cancer. Ann R Coll Surg Engl 1990
Jan;72(1):2-5.

Ball HG 3d. Secondary surgery for epithelial ovarian
cancer. Curr Opin Obstet Gynecol 1990 Feb;2( 1):
57-63.

Barnhill D, Doering D, Remmenga S, Bosscher J, Nash
J, Park R. Intestinal surgery performed on
gynecologic cancer patients. Gynecol Oncol 1991
Jan;40(1):38-41.

Belfort MA, Stevens PJ, DeHaek K, Soeters R, Krige -
J E. A new approach to the management of
malignant ascites; a permanently implanted
abdominal drain. Eur J Surg Oncol 1990 Feb;
16(1):47-53.

Brown CL, Lewis J L Jr. Palliative surgery in ovarian
cancer. In: Markman M, Hoskins WJ, eds. Cancer
of the ovary. New York: Raven Press; 1993.
p. 217-28.

Burke TW, Morris M. Secondary cytoreductive
operations. In: Rubin SC, Sutton GP, eds. Ovarian
cancer. New York: McGraw-Hill; 1993. p. 301-12.

Chevinsky AH, Minton JP. Ablation of recurrent and

metastatic intraabdominal tumor with the C02 laser.

Lasers Surg Med l990;10(1):5-11.

Clarke-Pearson DL, Rodriguez GC, Boente M.
Palliative surgery for epithelial ovarian cancer. In:
Rubin SC, Sutton GP, eds. Ovarian cancer. New
York: McGraw-Hill; 1993. p. 351-73.

Donato D, Angelides A, Irani H, Penalver M, Averette
H. Infectious complications after gastrointestinal
surgery in patients with ovarian carcinoma and
malignant ascites. Gynecol Oncol 1992 Jan;44(1):
40-7.

Gilly FN, Carry PY, Brachet A, Sayag AC, Panteix G,
Salle B, Bienvenu J, Banssillon V, Burgard G,
Manchon M, Rochette A, Braillon G. Treatment of
malignant peritoneal effusion in digestive and
ovarian cancer. Med Oncol Tumor Pharmacother
1992;9(4):177-81.

Herman LL, Hoskins WJ, Shike M. Percutaneous
endoscopic gastrostomy for decompression of the
stomach and small bowel. Gastrointest Endosc 1992
May-Jun;38(3):314-8.

Hogan WM, Boente MP. The role of surgery in the
management of recurrent gynecologic cancer. Semin
Oncol 1993 Oct;20(5):462-72.

Hoskins WJ. Surgical staging and cytoreductive surgery
of epithelial ovarian cancer. Cancer 1993 Feb 15;
71(4 Suppl):1534-40.

Hoskins WJ, Rubin SC. Surgery in the treatment of
patients with advanced ovarian cancer. Semin Oncol
1991 Jun;18(3):213-21.

Isaacs J H. Cytoreductive surgery for nonresectable
ovarian cancer. In: Economou SG, Witt TR, Deziel
DJ, et al., eds. Adjuncts to cancer surgery.
Philadelphia: Lea and Febiger; 1991. p. 334-8.

Janicke F, Holscher M, Kuhn W, von Hugo R, Pache
L, Siewert JR, Graeff H. Radical surgical
procedure improves survival time in patients with

recurrent ovarian cancer. Cancer 1992 Oct 15;
70(8):2129-36.

Lee M], Saini S, Brink JA, Morrison MC, Hahn PF,
Mueller PR. Malignant small bowel obstruction and
ascites: not a contraindication to percutaneous
gastrostomy. Clin Radiol 1991 Nov;44(5):332-4.

LeRoux PD, Berger MS, Elliott JP, Tamimi HK.
Cerebral metastases from ovarian carcinoma.
Cancer 1991 Apr 15;67(8):2194—9.

Morris M, Gershenson DM, Wharton JT, Copeland LJ,
Edwards CL, Stringer CA. Secondary cytoreductive
surgery for recurrent epithelial ovarian cancer.
Gynecol Oncol 1989 Sep;34(3):334-8.

Paganelli AM, Leone V, Malagutti V, Vescovo M,
Sallusto A. Intestinal surgery in patients with
ovarian carcinoma. Eur J Gynaecol Oncol 1990;
11(2): 157—60.

Potter ME. Secondary cytoreduction in ovarian cancer:
pro or con? Gynecol Oncol 1993 Oct;51(1):131—5.

Rader J S. Therapeutic advances in ovarian cancer. Curr
Opin Obstet Gynecol 1992 Feb;4(1):120-7.

Rubin SC. Surgery for ovarian cancer. Hematol Oncol
Clin North Am 1992 Aug;6(4):851-65.

Rubin SC, Benjamin I, Hoskins WJ, Pierce VK, Lewis
JL Jr. Intestinal surgery in gynecologic oncology.
Gynecol Oncol 1989 Jul;34(1):30-3.

Rubin SC, Hoskins WJ, Benjamin I, Lewis JL Jr.
Palliative surgery for intestinal obstruction in
advanced ovarian cancer. Gynecol Oncol 1989 Jul;
34(1):16-9.

Rubin SC, Hoskins WJ, Hakes TB, Markman M: Cain
J M, Lewis J L Jr. Recurrence after negative second-
look laparotomy for ovarian cancer: analysis of risk
factors. Am J Obstet Gynecol 1988 Nov;159(5):
1094-8.

Rubin SC, Lewis J L Jr. Tumor antigens in ovarian
malignancy. Clin Obstet Gynecol 1986 Sep;
29(3):693-704.

Sun A, Lian L, Tang M. Surgical treatment for
recurrent ovarian malignancies. Proc Chin Acad
Med Sci Peking Union Med Coll l990;5(4):219—22.

Taal BG, Steinmetz R, Den Hartog Jager FC.
Rectosigmoid obstruction caused by ovarian cancer.
Clin Radiol 1990 Mar;41(3):170—4.

van der Burg ME, van Lent M, Kobierska A, Colombo
N, Favalli G, Lacave AJ, Nardi M, Renard J,
Buyse M, Pecorelli S. Intervention debulking
surgery (IDS) does improve survival in advanced
epithelial ovarian cancer (EOC): an EORTC
Gynecological Cancer Cooperative Group (GCCG)
Study [abstract]. Program Proc Am Soc Clin Oncol
1993 Mar;12:258.

van Ooijen B, van der Burg ME, Planting AS, Siersema
PD, Wiggers T. Surgical treatment or gastric
drainage only for intestinal obstruction in patients
with carcinoma of the ovary or peritoneal
carcinomatosis of other origin. Surg Gynecol Obstet
1993 May;176(5):469-74.

Williams L. The role of secondary cytoreductive
surgery in epithelial ovarian malignancies.
Oncology (Huntingt) 1992 Aug;6(8):25-32;
discussion 37-9. Comment in: Oncology (Huntingt)
1993 Feb;7(2):21.

Williams LL. Secondary cytoreduction of ovarian
malignancies. In: Markman M, Hoskins WJ, eds.
Cancer of the ovary. New York: Raven Press;
1993. p. 187-203.

59

Salvage Chemotherapy

Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F,
Lokich JJ, Sinclair PR, Ueno W, Wampler GL,
Yeung KY, Alt D, et al. Hormonal palliation of
chemoresistant ovarian cancer: three consecutive
phase II trials of the Mid-Atlantic Oncology
Program. J Clin Oncol 1993 Oct;11(10):1957—68.

Alberts DS, Mason-Liddil N, Stock-Novack D, O’Toole
RV, Abbott TM, Salmon SE. A phase II evaluation
of esorubicin in ovarian cancer. A Southwest
Oncology Group study. Am J Clin Oncol 1992 Apr;
15(2):146-9.

Altretamine for ovarian cancer. Med Lett Drugs Ther
1991 Aug 9;33(850):76-7.

Asbury RF, Blessing JA, Look KY, Clarke-Pearson D,
Homesley HD. A Gynecologic Oncology Group
phase H study of amonafide (NSC 308847) in
epithelial ovarian cancer. Am J Clin Oncol 1993
Dec;16(6):529—31.

Baker TR, Piver MS, Hempling RE. The addition of
etoposide and ifosfamide to cisplatin as second line
therapy in ovarian carcinoma. Eur J Gynaecol
Oncol 1993;14(1):l8-22.

Beddoe AM, Dottino PR, Cohen CJ. Phase II trial of
etoposide, carboplatin, and ifosfamide as salvage
therapy in advanced ovarian carcinoma. Mt Sinai J
Med 1993 Sep;60(4):311-6.

Benedetti Panici P, Greggi S, Scambia G, Salerno MG,
Baiocchi G, Cento R, Mancuso S. Mitomycin C
and 5—fluorouracil salvage chemotherapy in

platinum-resistant ovarian carcinoma. Oncology
1992;49(3):183-7.

Benedetti Panici P, Scambia G, Greggi S, Salerno G,
Cento R, Mancuso S. Doxorubicin and
cyclophosphamide, alternated with bleomycin and
mitomycin C as a second-line regimen in advanced
ovarian carcinoma resistant to cisplatin-based
chemotherapy. Oncology 1990;47(4):296—8.

Bezwoda WR, Golombick T, Dansey R, Keeping J.
Treatment of malignant ascites due to
recurrent/refractory ovarian cancer: the use of
interferon-alpha or interferon—alpha plus
chemotherapy in vivo and in vitro. Eur J Cancer
1991;27(11):1423-9.

Bruzzone M, Campora E, Merlini L, Giudici S, Bottero
G, Iskra L, Donadio M, Ferrari I, Ragni N.
Ifosfamide and etoposide salvage treatment in
advanced ovarian cancer. J Chemother 1991 Oct;
3(5):332-4.

Chauvergne J, Fumoleau P, Cappelaere P, Metz R,
Armand JP, Chevallier B, Kerbrat P, de Fomi M,
Lhomme C, Roche H, et al. Phase II study of
pirarubicin (T HP) in patients with cervical,

60

endometrial and ovarian cancer: study of the
Clinical Screening Group of the European
Organization for Research and Treatment of Cancer
(EORTC). Eur J Cancer 1993;29A(3):350—4.

Chiara S, Campora E, Merlini L, Simoni C, Iskra L,
Odicino F, Ragni N, Conto PF, Rosso R. Recurrent
ovarian carcinoma: Salvage treatment with platinum
in patients responding to first-line platinum—based
regimens (3). Eur J Cancer 1993;29A(4):652.

Covens A, O’Connell G, Rusthoven J, Mazurka J.
Phase II study of mitomycin C and 5 fluorouracil in
platinum resistant ovarian cancer. Eur J Gynaecol
Oncol 1992;13(2):125-30.

Curtin JP, Koonings PP, Gutierrez M, Schlaerth JB,
Morrow CP. Ifosfamide—induced neurotoxicity.
Gynecol Oncol 1991;42(3):l93-6.

de Graeff A, van Hoef ME, Tjia P, Heintz AP, Neijt
JP. Continuous infusion of 5-fluorouracil in ovarian

cancer patients refractory to cisplatin and
carboplatin. Ann Oncol 1991 Oct;2(9):691-2.

De Vriese G, Bonte J. Possible role of goserelin, an
LH-RH agonist in the treatment of gynaecological
cancers. Eur J Gynaecol Oncol 1993;l4(3):187-91.

De Vriese G, Bonte J. Possible role of goserelin, an
LH—RH agonist in the treatment of gynaecological
cancers. J Gynaecol Endocrinol 1991-92; 7-8(1-4):
5-9.

Delaloye JF, Tran L, Leyvraz S, Bauer J, De Grandi P.
Intraperitoneal carboplatin in advanced ovarian
carcinoma. Gynakol Geburtshilfliche Rundsch 1993;
33(1):25-30.

Dittrich C, Baur M, Vavra N, Hudec M, Fazeny B,
Barrada M, Salzer H, Sevelda P. Etoposide and
carboplatin as salvage and first-line therapy in
ovarian cancer patients. Ann Oncol 1993 Sep;4(8):
697-9.

Du Bois A, Meerpohl HG, Madjar H, Spinner D, Dall
P, Pfisterer J, Baukneckt T. Phase II study of
pirarubicin combined with cisplatin in recurrent

ovarian cancer. J Cancer Res Clin Oncol 1994;
120(3):]73~8.

Dufour P, Maloisel F, Bergerat JP, Barats JC,
Dellenbach P, Renaud R, Ritter P, Herbrecht R,
Wendling C, Audhuy B, et al. Intraperitoneal
mitoxantrone as consolidation treatment for stage III

ovarian carcinoma: a pilot study. Bull Cancer
(Paris) l99l;78(3):273-80.

Eckhardt S, Hemadi Z, Thuno L, Telekes A, Sopkova
B, Mechl Z, Pawlicki M, Kerpel-Fronius S. Phase
H clinical evaluation of etoposide (VP-16-213,
Vepesid) as a second-line treatment in ovarian
cancer. Results of the South-East European
Oncology Group (SEEOG) Study. Oncology 1990;
47(4):289-95.

Faulds D, Balfour JA, Chrisp P, Langtry HD.
Mitoxantrone. A review of its pharmacodynamic
and pharmacokinetic properties, and therapeutic
potential in the chemotherapy of cancer. Drugs
1991;41(3):40l—49.

Frasci G, Pacelli R, Scala S, Facchini G, Rinaldi L,
Tinessa V, Bianco AR, Iaffaioli RV. Intraperitoneal
mitoxantrone via temporary catheter in patients with
ovarian cancer: Toxicity and feasibility evaluation.
Adv Ther 1990;7(3):124-35.

Frasci G, Tortoriello A, Facchini G, Conforti S,
Cardone A, Persico G, Mastrantonio P, Iaffaioli
RV. Intraperitoneal (ip) cisplatin-mitoxantrone-
interferon-alpha 2b in ovarian cancer patients with
minimal residual disease. Gynecol Oncol 1993 Jul;
50(1):60-7.

Fromm GL, Freedman RS, Fritsche HA, Atkinson EN,
Scott W. Sequentially administered ethinyl estradiol
and medroxyprogesterone acetate in the treatment of
refractory epithelial ovarian carcinoma in patients
with positive estrogen receptors. Cancer 1991
Nov 1;68(9):1885-9.

Gallion HH, Liu PY, Alberts DE, O’Toole RV,
O’Sullivan J, Mills G, Smith HO, Hynes HE. Phase
H trial of amonafide in previously treated patients
with advanced ovarian cancer: a Southwest
Oncology Group study. Gynecol Oncol 1992 Aug;
46(2):230—2.

Gore ME, Fryatt I, Wiltshaw I, Dawson T. Treatment
of relapsed carcinoma of the ovary with cisplatin or
carboplatin following initial treatment with these
compounds. Obstet Gynecol Surv 1990;45(8):553-4.

Greco FA. Chronic etoposide administration: overview
of clinical experience. Cancer Treat Rev 1993;
19 Suppl C:35—45.

Green MD, Speyer J L, Wemz JC, Colombo N, Beller
U, Muggia FM, Beckman EM. Phase II study of
esorubicin (4’deoxydoxorubicin) in anthracycline
naive patients with ovarian cancer. Invest New
Drugs 1990 Aug;8(3):333-6.

Hamilton TC, Ozols RF, Dabrow MB. Multidrug
resistance to alkylating agents and platinum
compounds: state of our knowledge. Oncology
(Huntingt) 1990 Mar;4(3):101-6; discussion 106,
109.

Hamilton TC, Schilder RJ, Onishi Y, Ozols RF.
Mechanisms of resistance to the cytotoxicity of
classic alkylating agents and platinum-containing
drugs. In: Nagoumey RA and Sheikh KM, eds.
Clinical management of the drug-resistant cancer
patient: new options in clinical oncology. Long
Beach (CA): Memorial Medical Center Foundation
Press; 1991. p. 49-59.

Hansen F, Malthe I, Krog H. Phase II clinical trial of
VP-16-213 (etoposide) administered orally in

advanced ovarian cancer. Gynecol Oncol 1990 Mar;
36(3):369-70.

Hansen LA, Hughes TE. Altretamine. DICP 1991 Feb;
25(2): 146-52.

Hatch KD, Beecham JB, Blessing JA, Creasman WT.
Responsiveness of patients with advanced ovarian
carcinoma to tamoxifen. A Gynecologic Oncology
Group study of second-line therapy in 105 patients.
Cancer 1991 Jul 15;68(2):269-71.

Hauge MD, Long HJ, Hartmann LC, Edmonson JH,
Webb MJ , Su J. Phase II trial of intravenous
hexamethylmelamine in patients with advanced
ovarian cancer. Invest New Drugs 1992 Nov;
10(4):299-301.

Hendrick AM, Harris AL, Cantwell BM. Verapamil
with mitoxantrone for advanced ovarian cancer: a
negative phase II trial. Ann Oncol 1991 Jan; 2(1):
71-2.

Hirono M, Yoshihara T, Hayashi Y, Suzuki M, Majima
H. Multi-drug chemotherapy for patients with
peritonitis carcinomatosa associated with ascites.

J Jpn Soc Cancer Ther 1990;25(3):672-8.

Hoskins PJ, McMurtrie E, Swenerton KD. A phase II
trial of mitomycin in patients with epithelial ovarian
carcinoma resistant to cisplatin or carboplatin. Am J
Clin Oncol 1990 Oct;13(5):416-9.

Judson IR, Calvert AH, Gore ME, Balmanno K,
Gumbrell LA, Perren T, Wiltshaw E. Phase II trial

of trimelamol in refractory ovarian cancer. Br J
Cancer 1991 Feb;63(2):311-3.

Kaye SB. Chemotherapy for ovarian cancer. Eur J
Cancer 1993;29A(4):632-5.

Kaye SB, Wanders J, Clavel M, Verweij J, Piccart MJ,
Smyth J F, Ten Bokkel Huinink WW, Wagener DJ,
Judson IR, Cavalli F. Phase H trials of fosquidone
(GR63178A) in carcinoma of the breast, head and
neck, ovary and melanoma. Ann Oncol 1992 May;
3(5):406-8.

Kirmani S, Lucas WE, Kim S, Goel R, McVey L,
Morris J, Howell SB. A phase II trial of
intraperitoneal cisplatin and etoposide as salvage

treatment for minimal residual ovarian carcinoma.
J Clin Oncol 1991 Apr;9(4):649-57.

Kirmani S, McVey L, Loo D, Howell SB. A phase I
clinical trial of intraperitoneal thiotepa for
refractory ovarian cancer. Gynecol Oncol 1990
Mar;36(3):331—4.

Langer CJ, Nash S, Catalano R, Rosenblum NG,
Hogan WM, Comis RL, O’Dwyer PJ. Phase II trial
of thio-TEPA in relapsed and refractory ovarian
carcinoma. Gynecol Oncol 1991 Dec;43(3):242-6.

61

Leopold KA, Oleson JR, Clarke-Pearson D, Soper J,
Berchuck A, Samulski TV, Page RL, Blivin J,
Tomberlin JK, Dewhirst MW. Intraperitoneal
cisplatin and regional hyperthermia for ovarian
carcinoma. Int J Radiat Oncol Biol Phys 1993;
27(5):1245—51.

Lind MJ, Cantwell BM, Millward MJ, Robinson A,
Proctor M, Simmons D, Carmichael J, Harris AL.
A phase II trial of goserelin (Zoladex) in relapsed
epithelial ovarian cancer. Br J Cancer 1992 Apr;
65(4):621-3.

Long HJ 3d, Laurie JA, Wieand HS, Edmonson JH,
Levitt R, Krook JE, Abu-Ghazaleh S. A phase H
evaluation of menogaril in cisplatin-refractory
advanced ovarian carcinoma. A collaborative trial
of the North Central Cancer Treatment Group and
the Mayo Clinic. Cancer 1991 Aug 15;68(4):730—2.

Look KY, Blessing JA, Muss HB, DeGeest K. 5-
fluorouracil and low-dose leucovorin in the
treatment of recurrent epithelial ovarian carcinoma.
A phase II trial of the Gynecologic Oncology
Group. Am J Clin Oncol 1992 Dec;15(6):494-6.

Lorusso V, Catino A, Leone B, Rabinovich M,
Gargano G, Paradiso A, De Lena M. Carboplatin
plus ifosfamide as salvage treatment of epithelial
ovarian cancer: a pilot study. J Clin Oncol 1993
Oct; 1 1(10): 1952-6.

Louvet C, de Gramont A, Demuynck B, Varette C,
Beerblock K, Bennamoun M, Krulik M. Bi-weekly
2-day schedule of high-dose folinic acid, 5-
fluorouracil bolus and infusion in pretreated
advanced epithelial ovarian cancer: a phase H study.
Ann Oncol 1992 Sep;3(8):657—8.

Malfetano J, Beecham JB, Bundy BN, Hatch KD. A
phase II trial of medroxyprogesterone acetate in
epithelial ovarian cancers. A Gynecologic Oncology
Group study. Am J Clin Oncol 1993 Apr;16(2):
149-51.

Malfetano JH, Blessing JA, Adelson MD. A phase II
trial of gallium nitrate (NSC #15200) in previously
treated ovarian carcinoma. A Gynecologic
Oncology Group Study. Am J Clin Oncol 1991
Aug;14(4):349-51.

Malfetano JH, Blessing JA, Jacobs AJ. A phase H trial
of Didemnin B (NSC #335319) in patients with
previously treated epithelial ovarian cancer. A
Gynecologic Oncology Group Study. Am J Clin
Oncol 1993 Feb;16(1):47-9.

Manetta A, MacNeill C, Lyter JA, Scheffler B,
Podczaski ES, Larson JE, Schein P. Analysis of
prognostic factors and survival in patients with
ovarian cancer treated with second-line
hexamethylmelamine (altretamine). Cancer Treat
Rev 1991 Mar;18 Suppl A123-9.

62

Manetta A, MacNeill C, Lyter JA, Scheffler B,
Podczaski ES, Larson JE, Schein P.
Hexamethylmelamine as a single second-line agent
in ovarian cancer. Gynecol Oncol 1990 Jan;
36(1):93-6.

Markman M. Salvage intraperitoneal chemotherapy for
ovarian cancer: a possible role for mitoxantrone?
Eur J Cancer 1993;29A(9):1225-6. Comment on:
Eur J Cancer 1993;29A(9):1242-8.

Markman M. Salvage therapy in ovarian cancer: is
there a role for intraperitoneal drug delivery?
Gynecol Oncol 1993 Oct;51(l):86—9.

Markman M, Alberts D, Rubin S, Hakes T, Lewis JL
Jr, Reichman B, Jones W, Curtin J, Barakat R,
Brodar F, et al. Evidence for persistence of
mitoxantrone within the peritoneal cavity following
intraperitoneal delivery. Gynecol Oncol 1993 Feb;
48(2):185-8.

Markman M, Berek JS, Blessing JA, McGuire WP,
Bell J, Homesley HD. Characteristics of patients
with small—volume residual ovarian cancer
unresponsive to cisplatin—based ip chemotherapy:
lessons learned from a Gynecologic Oncology
Group phase H trial of ip cisplatin and recombinant
alpha-interferon. Gynecol Oncol 1992 Apr;45(1):
3-8. Comment in: Gynecol Oncol 1992 Apr;45(1):
1-2.

Markman M, Blessing JA, Major F, Manetta A.
Salvage intraperitoneal therapy of ovarian cancer
employing cisplatin and etoposide: a Gynecologic
Oncology Group study. Gynecol Oncol 1993 Aug;
50(2):191-5.

Markman M, DeMarco LC, Birkhofer M, Budman D,
Hakes T, Reichman B, Rubin S, Jones W, Barakat
R, Curtin J, et al. Phase II trial of zeniplatin (CL
286,558), a new patinum compound, in patients
with advanced ovarian cancer previously treated
with organoplatinum-based therapy. J Cancer Res
Clin Oncol 1993;119(4):234-6.

Markman M, George M, Hakes T, Reichman B,
Hoskins W, Rubin S, Jones W, Almadrones L,
Lewis J L Jr. Phase II trial of intraperitoneal
mitoxantrone in the management of refractory
ovarian cancer. J Clin Oncol 1990 Jan;8(1):146-50.

Markman M, Hakes T, Reichman B, Barakat R, Curtin
J, Jones W, Lewis JL Jr, Rubin S, Almadrones L,
Hoskins W. Exploring the use of chronic low-dose
oral etoposide in ovarian cancer: is there a role for
this new drug in the management of platinum-
refractory disease? Semin Oncol 1992 Dec;

19(6 Suppl 14):25-7.

Markman M, Hakes T, Reichman B, Curtin J, Barakat
R, Rubin S, Jones W, Lewis JL Jr, Almadrones L,
Hoskins W. Phase 2 trial of chronic low-dose oral
etoposide as salvage therapy of platinum-refractory

ovarian cancer. J Cancer Res Clin Oncol 1992;
ll9(l):55—7.

Markman M, Hakes T, Reichman B, Hoskins W, Rubin
S, Jones W, Almadrones L, Yordan EL Jr,
Eriksson J, Lewis J L Jr. Intraperitoneal cisplatin
and cytarabine in the treatment of refractory or
recurrent ovarian carcinoma. J Clin Oncol 1991
Feb;9(2):204—10. Comment in: J Clin Oncol 1991
Feb;9(2):197-9.

Markman M, Hakes T, Reichman B, Lewis JL Jr,
Rubin S, Jones W, Almadrones L, Hoskins W.
Phase H trial of weekly or biweekly intraperitoneal
mitoxantrone in epithelial ovarian cancer. J Clin
Oncol 1991 Jun;9(6):978-82.

Markman M, Hakes T, Reichman B, Lewis JL Jr,
Rubin S, Jones W, Almadrones L, Pizzuto F,
Hoskins W. Ifosfamide and mesna in previously
treated advanced epithelial ovarian cancer: activity
in platinum-resistant disease. J Clin Oncol 1992
Feb; 10(2):243-8.

Markman M, Hakes T, Reichman B, Rubin S, Curtin J,
Barakat R, Jones W, Lewis JL Jr, Almadrones L,
Hoskins W. Salvage intraperitoneal mitoxantrone
therapy of ovarian cancer: influence of increasing
the volume of treatment. Gynecol Oncol 1993 May;
49(2):l85-9.

Markman M, Iannotti N, Hakes T, Reichman B, Rubin
S, Jones W, Hoskins W, Lewis JL Jr. A pilot trial
of the daily intraperitoneal administration of
recombinant interleukin-2. Reg Cancer Treat 1990;
3(1):44—6.

Markman M, Reichman B, Hakes T, Curtin J, Barakat
R, Rubin S, Jones W, Lewis JL Jr, Almadrones L,
Hoskins W. Association between pretreatment
CA-125 levels and surgically documented complete
responses in patients with ovarian cancer treated
with second-line intraperitoneal therapy. J Cancer
Res Clin Oncol 1992;118(5):391-4.

Markman M, Reichman B, Hakes T, Lewis JL Jr,
Jones W, Rubin S, Barakat R, Curtin J,
Almadrones L, Hoskins W. Impact on survival of
surgically defined favorable responses to salvage
intraperitoneal chemotherapy in small-volume
residual ovarian cancer. J Clin Oncol 1992 Sep;
10(9): 1479-84.

Markman M, Reichman B, Hakes T, Rubin S, Jones
W, Lewis JL Jr, Barakat R, Curtin J, Almadrones
L, Hoskins W. Phase 2 trial of intraperitoneal
carboplatin and etoposide as salvage treatment of
advanced epithelial ovarian cancer. Gynecol Oncol
1992 Dec;47(3):353-7.

Markman M, Reichman B, Hakes T, Rubin S, Jones
W, Lewis JL Jr, Barakat R, Curtin J, Almadrones
L, Hoskins W. The use of recombinant human
erythropoietin to prevent carboplatin—induced
anemia. Gynecol Oncol 1993 May;49(2):172—6.

Markman M, Reichman B, Hakes T, Rubin S, Lewis
JL Jr, Jones W, Barakat R, Curtin J, Almadrones
L, Hoskins W. Evidence supporting the superiority
of intraperitoneal cisplatin compared to
intraperitoneal carboplatin for salvage therapy of
small—volume residual ovarian cancer. Gynecol
Oncol 1993 Jul;50(1):100—4.

Markman M, Rothman R, Hakes T, Reichman B,
Hoskins W, Rubin S, Jones W, Almadrones L,
Lewis J L Jr. Second-line platinum therapy in
patients with ovarian cancer previously treated with
cisplatin. J Clin Oncol 1991 Mar;9(3):389—93.

Markman M, Rothman R, Hakes T, Reichman B,
Lewis JL Jr, Rubin S, Jones W, Almadrones L,
Hoskins W. Late effects of cisplatin-based
chemotherapy on renal function in patients with
ovarian carcinoma. Gynecol Oncol 1991 Jun;4l(3):
217—9.

Marzola M, Zucchetti M, Colombo N, Sessa C, Pagani
O, D’Incalci M, Cavalli F, Mangioni C. Low-dose
oral etoposide in epithelial cancer of the ovary. Ann
Oncol 1993 Jun;4(6):517-9.

McGuire WP, Rowinsky EK. Old drugs revisited, new
drugs, and experimental approaches in ovarian
cancer therapy. Semin Oncol 1991 Jun;18(3):
255—69.

McGuire WP 3d, Blessing JA, Berek JS, Munoz A.
Phase II study of N-methylformamide (N-MF)
(NSC 3051) in patients with advanced epithelial
ovarian cancer. A Gynecologic Oncology Group
study. Invest New Drugs 1990 May;8(2):191—4.

Menczcr J, Ben—Baruch G, Rizel S, Brenner H.
Cisplatin in combination with continuous VP16
infusion as second line chemotherapy in ovarian

carcinoma. A pilot study. Eur J Gynaecol Oncol
l992;13(4):316-8.

Menczer J, Ben-Baruch G, Rizel S, Brenner H.
Extraperitoneal metastases after intraperitoneal
chemotherapy of ovarian cancer patients with a

negative second—look laparotomy. Int J Gynecol
Cancer 1993;3(6):359-62.

Miller DS, Brady MF, Barrett R]. A phase II trial of
leuprolide acetate in patients with advanced
epithelial ovarian carcinoma. A Gynecologic
Oncology Group study. Am J Clin Oncol 1992 Apr;
15(2):125-8.

Moore DH, Fowler WC Jr, Jones CP, Crumpler LS.
Hexamethylmelamine chemotherapy for persistent
or recurrent epithelial ovarian cancer. Am J Obstet
Gynecol 1991 Sep;l65(3):573-6.

Moore DH, Valea F, Crumpler LS, Fowler WC Jr.
Hexamethylmelamine/altretamine as second-line
therapy for epithelial ovarian carcinoma. Gynecol
Oncol 1993 Oct;51(1):109—12.

63

Muggia FM, Groshen S, Russell C, Jeffers S, Chen
SC, Schlaerth J, Curtin J, Morrow CP.
Intraperitoneal carboplatin and etoposide for
persistent epithelial ovarian cancer: analysis of
results by prior sensitivity to platinum-based
regimens. Gynecol Oncol 1993 Aug;50(2):232-8.

Murphy D, Lind MJ, Prendiville J, Renninson J, Smith
DR, Thompson G, Ranson M, Crowther D. Phase
I/II study of intraperitoneal iproplatin in patients
with minimal residual disease following platinum-
based systemic therapy for epithelial ovarian
carcinoma. Eur J Cancer 1992;28A(4-5):870—2.

Muss HB, Blessing JA, Baker VV, Barnhill DR,
Adelson MD. Echinomycin (NSC 526417) in
advanced ovarian cancer. A phase H trial of the
Gynecologic Oncology Group. Am J Clin Oncol
1990 Aug;13(4):299-301.

Nardi M, Cognetti F, Pollera CF, Giulia MD,
Lombardi A, Atlante G, Calabresi F.
Intraperitoneal recombinant alpha-Z-interferon
alternating with cisplatin as salvage therapy for
minimal residual-disease ovarian cancer: a phase II
study. J Clin Oncol 1990 Jun;8(6):1036-41.

Nash JD, Young RC. Gynecologic malignancies.
Cancer Chemother Biol Response Modif 1991;12:
549-69.

Neijt JP. Treatment of advanced ovarian cancer: 10
years of experience. Ann Oncol 1992 Jan;3(1):
17-27.

Nicoletto MO, Fiorentino MV, Vinante O, Prosperi A,
Tredese F, Tumolo S, Cima GP, Monfardini S.
Experience with intraperitoneal alpha-2a interferon.
Oncology 1992;49(6):467-73.

Nicoletto MO, Padrini R, Ferrazzi E, Nascimben O,
Visona E, Tumolo S, Palumbo M, Costa L, Vinante
O, Monfardini S, et a]. Phase I-H intraperitoneal
mitoxantrone in advanced pretreated ovarian cancer.
Eur J Cancer 1993;29A(9):1242—8. Comment in:
Eur J Cancer 1993;29A(9):1225-6.

Nieminen U, Kauppila A, Gronroos M, Kuoppala T,
Vayrynen M. Placebo-controlled study on the
efficacy of the pyrimido—pyrimidine derivative RA
233 in ovarian cancer. Gynecol Oncol 1990 Feb;
36(2) :226-3 1 .

O’Brien ME, Hardy J, Tan S, Walling J, Peters B,
Hatty S, Wiltshaw E. A phase II study of sulofenur,
a novel sulfonylurea, in recurrent epithelial ovarian
cancer. Cancer Chemother Pharmacol 1992;30(3):
245-8.

O’Dwyer PJ, LaCreta F, Hogan M, Rosenblum N,
O’Dwyer JL, Comis RL. Pharmacologic study of
etoposide and cisplatin by the intraperitoneal route.
J Clin Pharmacol 1991 Mar;31(3):253-8.

64

Onnis A, Marchetti M, Maggino T, De Toffoli J,
Blandamura S. Clinical experience in gynecological
cancer management. d). Ovarian tumors--1)
Epithelial: report from the Gynaecological Institutes
of Padua University (1963-1990). Eur J Gynaecol
Oncol 1992;13(1):17-33.

Ozols RF. Advances in the chemotherapy of
gynecologic malignancies. Hematol Oncol 1992 Jan-
Feb;10(1):43-51.

Ozols RF. Chemotherapy for advanced epithelial
ovarian cancer. Hematol Oncol Clin North Am
1992 Aug;6(4):879-94.

Ozols RF. New developments with carboplatin in the
treatment of ovarian cancer. Semin Oncol 1992
Feb;19(l Suppl 2):85-9.

Ozols RF. Ovarian cancer. Semin Surg Oncol 1990;
6(6):328-38.

Ozols RF. Ovarian cancer, Part 11: Treatment. Curr
Probl Cancer 1992 Mar-Apr;16(2):61-126.

Ozols RF. Role of carboplatin in ovarian cancer.
Current results and thoughts for the future. Acta
Obstet Gynecol Scand Suppl 1992;155:75-7.

Ozols RF. Role of chemotherapy in the future treatment
of ovarian cancer. Acta Obstet Gynecol Scand
Suppl 1992;155:55-60.

Ozols RF, Young RC. Chemotherapy of ovarian
cancer. Semin Oncol 1991 Jun;18(3):222-32.

Panici PB, Scambia G, Greggi S, Salerno G, Cento R,
Mancuso S. Doxorubicin and cyclophosphamide,
alternated with bleomycin and mitomycin C as a
second-line regimen in advanced ovarian carcinoma
resistant to cisplatin-based chemotherapy. Oncology
1990;47(4):296-8.

Pfeiffer P, Bennedbaek O, Bertelsen K. Intraperitoneal
carboplatin in the treatment of minimal residual
ovarian cancer. Gynecol Oncol 1990 Mar;36(3):
306-1 1 .

Ploin DY, Tranchand B, Guastalla JP, Rebattu P,
Chauvin F, Clavel M, Ardiet C.
Pharmacokinetically guided dosing for intravenous
melphalan: a pilot study in patients with advanced
ovarian adenocarcinoma. Eur J Cancer 1992;
28A(8-9):1311-5. Comment in: Eur J Cancer 1992;
28A(8-9):1302-4.

Potter ME, Hatch KD, Soong SJ, Partridge EE, Austin
J M Jr, Shingleton HM. Second-look laparotomy and
salvage therapy: a research modality only? Gynecol
Oncol 1992 Jan;44(1):3-9. Comment in: Gynecol
Oncol 1992 Nov;47(2):275.

Rader J S. Therapeutic advances in ovarian cancer. Curr
Opin Obstet Gynecol 1992 Feb;4(1):120—7.

Reed E, Cooper MR, LaRocca RV, Bostick-Bruton F,
Myers CE. Suramin in advanced platinum-resistant
ovarian cancer. Eur J Cancer 1992;28A(4-5):864-6.

Reed E, Jacob J, Ozols RF, Young RC, Allegra C. 5-
Fluorouracil (5-FU) and leucovorin in platinum-
refractory advanced stage ovarian carcinoma.
Gynecol Oncol 1992 Sep;46(3):326-9.

Reichman B. Second-line intravenous chemotherapy for
refractory ovarian cancer. In: Rubin RC, Sutton
GP, eds. Ovarian cancer. New York: McGraw—Hill;
1993. p. 313-24.

Reichman B, Markman M, Hakes T, Rubin S, Jones
W, Curtin J, Barakat R, Almadrones L, Lewis J L
Jr, Hoskins W. Mitomycin—C plus a 3-day
continuous intravenous infusion of 5—fluorouracil:
an inactive salvage regimen for platinum-resistant
ovarian carcinoma. Gynecol Oncol 1993 Jul;50(1):
30-3.

Repetto L, Chiara S, Guido T, Bruzzone M, Oliva C,
Ragni N, Conte PF, Rosso R. Intraperitoneal
chemotherapy with carboplatin and interferon alpha
in the treatment of relapsed ovarian cancer: a pilot
study. Anticancer Res 1991 Jul-Aug;ll(4):1641-3.

Repetto L, Chiara S, Mammoliti S, Guido T, Bruzzone
M, Secondo V, Donadio G, Odicino F, Ragni N,
Conte PF, et al. Crossover study with cisplatin or
carboplatin in advanced ovarian cancer. Gynecol
Oncol 1990 Nov;39(2):l46-9.

Rosso R, Alama A, Repetto L, Conte PF. Timed
sequential chemotherapy following ifosfamide—
induced kinetic recruitment in refractory ovarian
cancer. Cancer Chemother Pharmacol 1990;

26 Suppl:S43—4.

Schein PS, Scheffler B, McCulloch W. The role of
hexamethylmelamine in the management of ovarian
cancer. Cancer Treat Rev 1991 Mar;18 Suppl A:
67—75.

Scotto V, Sbiroli C. Weekly cis-platinum as third line
chemotherapy in advanced ovarian carcinoma.
Phase II study. Eur J Gynaecol Oncol 1991;12(1):
51—3.

Sessa C, ten Bokkel Huinink W, Stoter G, Renard J,
Cavalli F. Phase II study of 5-aza-2’-deoxycytidine
in advanced ovarian carcinoma. The EORTC Early
Clinical Trials Group. Eur J Cancer 1990 Feb;
26(2): 137-8.

Sherman AI, Rosenberg R, Fink D. Use of
intraperitoneal chemotherapy for treatment of

ovarian cancer. Eur J Gynaecol Oncol 1992;13(4):
295-305.

Smalley RV, Goldstein D, Bulkowski D, Hannon C,
Buchler D, Knudsen C, Tuttle RL. A phase II study
of crisnatol mesylate in patients with ovarian

carcinoma. Invest New Drugs 1992 Jul;10(2):
107-12.

Speyer J L, Beller U, Colombo N, Sorich J, Wemz JC,
Hochster H, Green M, Porges R, Muggia FM,
Canetta R, et al. Intraperitoneal carboplatin:
favorable results in women with minimal residual
ovarian cancer after cisplatin therapy. J Clin Oncol
1990 Aug;8(8):1335—41.

Speyer JL, Sorich J. Intraperitoneal carboplatin:
rationale and experience. Semin Oncol 1992 Feb;
19(1 Suppl 2):1(Y7-l3.

Sutton G. Ifosfamide and mesna in epithelial ovarian
carcinoma. Gynecol Oncol 1993 Oct;51(1):104-8.

Sutton GP, Blessing JA, Adelson MD, Hanjani P.
Phase II trial of vinblastine in advanced ovarian
carcinoma. A Gynecologic Oncology Group study.
Invest New Drugs 1990 Nov;8(4):377-9.

Sutton GP, Blessing JA, Manetta A, Homesley H,
McGuire W. Gynecologic Oncology Group studies
with ifosfamide. Semin Oncol 1992 Dec;

19(6 Suppl 12):31-4.

Sutton GP, Blessing JA, Photopulos G, Berman ML,
Homesley HD. Early phase II Gynecologic
Oncology Group experience with ifosfamide/mesna

in gynecologic malignancies. Cancer Chemother
Pharmacol 1990;26 Suppl:SSS-8.

Sutton GP, Blessing JA, Photopulos G, Berman ML,
Homesley HD. Gynecologic Oncology Group
experience with ifosfamide. Semin Oncol 1990
Apr;17(2 Suppl 4):6-10.

Tarraza HM Jr, Boyce CR, Smith WG, Jones MA.
Consolidation intraperitoneal chemotherapy in
epithelial ovarian cancer patients following negative
second-look laparotomy. Gynecol Oncol 1993 Sep;
50(3):287-90.

Taylor CW, Alberta DS, Peng YM, McCloskey TM,
Matzner M, Roe DJ, Plezia PM, Grindey GB,
Hamilton M, Seitz D. Antitumor activity and
clinical pharmacology of sulofenur in ovarian
cancer. J Natl Cancer Inst 1992 Dec 2;84(23):
1798-802.

ten Tije BJ, Wils J. Intraperitonea] cisplatin in the
treatment of refractory or recurrent advanced
ovarian carcinoma. Oncology 1992;49(6):442-4.

Thigpen JT, Vance RB, Khansur T. Second—line
chemotherapy for recurrent carcinoma of the ovary.
Cancer 1993 Feb 15;71(4 Suppl):1559-64.

Thigpen T, Lambuth BW, Vance RB. Ifosfamide in the
management of gynecologic cancers. Semin Oncol
1990 Apr;17(2 Suppl 4):11-8.

Thompson P, Wilson P, Osborne R, Slevin M,
Wiltshaw F, Blake P, Harper P, Coleman R,

65

Williams C, Sweetenham J, et al. The clinical
activity of cyproterone acetate in advanced ovarian
carcinoma. A London Gynaecology Oncology
Group Study. Br J Cancer 1991 Nov;64(5):973-4.

Triptorelin pamoate. Phase III Drug Profiles 1993;
3(3):1-8.

Trope C, Kaem J, Vergote I, Vossli S. A phase II
study of etoposide combined with ifosfamide as
second-line therapy in cisplatin-resistant ovarian
carcinomas. Cancer Chemother Pharmacol 1990;
26 Suppl:S45—7.

van der Burg ME, Hoff AM, van Lent M, Rodenburg
CJ, van Putten WL, Stoter G. Carboplatin and
cyclophosphamide salvage therapy for ovarian
cancer patients relapsing after cisplatin combination
chemotherapy. Eur J Cancer 1991;27(3):248-50.

van der Gaast A, Splinter TA. Teniposide (VM-26) in
ovarian cancer: a review. Semin Oncol 1992 Apr;
19(2 Suppl 6):95-7.

van Oosterom AT, ten Bokkel Huinink WW, van der
Burg ME, Vermorken JB, Willemse PH, Neijt JP.
Phase II clinical trial of doxifluridine in patients
with advanced ovarian cancer. Eur J Cancer 1991;
27(6):747—9.

Venesmaa P, Ylikorkala O. Subrenal capsule assay in
selection of chemotherapy after operation for
recurrent ovarian cancer. Br J Cancer 1991 Jan;
63(1):84-6.

Vergote I, Himmelmann A, Frankendal B, Scheistroen
M, Vlachos K, Trope C. Hexamethylmelamine as
second-line therapy in platin-resistant ovarian
cancer. Gynecol Oncol 1992 Dec;47(3):282-6.
Comment in: Gynecol Oncol 1992 Dec;47(3):
279-81.

Vergote IB. Adjuvant treatment of ovarian carcinoma.
Acta Obstet Gynecol Scand l993;72(8):682-4.

Weiss G, Green S, Alberts DS, Thigpen JT, Hires HE,
Hanson K, Pierce H], Baker LH, Goodwin JW.
Second—line treatment of advanced measurable
ovarian cancer with iproplatin: a Southwest
Oncology Group study. Eur J Cancer 1991;27(2):
135—8.

Wharton JT. Hexamethylmelamine (altretamine) activity
as a single agent in previously untreated advanced
ovarian cancer. Cancer Treat Rev 1991 Mar;

18 Suppl A:15-21.

Whelan JS, van Dam PA, Shepherd JH, Slevin ML.
The treatment of microscopic residual ovarian
cancer with intraperitoneal interferon: a clinical and
flow cytometric study. Br J Obstet Gynaecol 1992
Jul;99(7):615-7.

Willemse PH, de Vries EG, Mulder NH, Aalders JG,
Bouma J, Sleijfer DT. Intraperitoneal human

66

recombinant interferon alpha-2b in minimal residual
ovarian cancer. Eur J Cancer 1990 Mar;26(3):
353-8.

Willemse PH, Gietema JA, Mulder NH, de Vries EG,
Meijer S, Bouma J, Birkhofer M, Rastogi RB,
Sleijfer DT. Zeniplatin in patients with advanced
ovarian cancer, a phase H study with a third
generation platinum complex. Eur J Cancer 1993;
29A(3):359-62.

Willemse PH, Sleijfer DT, de Vries EG, Boonstra H,
Bouma J, Mulder NH. A phase I-II study with
intraperitoneal cisplatin plus systemic etoposide in
patients with minimal residual ovarian cancer. Eur J
Cancer 1992;28(2-3):479-81.

Willemse PH, v.d. Burg ME, v.d. Gaast A, Neijt JP,
ten Bokkel Huinink WW, Aalders JG, de Vries EG.
Ifosfamide given as a 24-h infusion with mesna in
patients with recurrent ovarian cancer: preliminary
results. Cancer Chemother Pharmacol 1990;

26 Suppl:SSl-4.

Williams CJ . Implications of an overview of
chemotherapy in advanced ovarian carcinoma. Br J
Cancer 1992;66(2):225-6.

Williams CJ. A phase H study of oral idarubicin in
advanced recurrent or refractory ovarian carcinoma.
Cancer Chemother Pharmacol 1990;25(4):304-5.

Williams LL, Fudge M, Burnett LS, Jones HW 3d.
Salvage carboplatin therapy for advanced ovarian
cancer after first-line treatment with cisplatin. Am J
Clin Oncol 1992 Aug;15(4):331-6.

Zanaboni F, Scarfone G, Presti M, Maggi R, Borello
C, Bolis G. Salvage chemotherapy for ovarian
cancer recurrence: weekly cisplatin in combination
with epirubicin or etoposide. Gynecol Oncol 1991
Oct;43(1):24-8.

Zylberberg B, Ravina JH, Salat-Baroux J, Madelenat P,
Zarca D, Dormont D. Chemotherapy by the
intravenous and intraperitoneal routes combined in
ovarian cancer. Gynecol Oncol 1990 Feb;36(2):
271-6.

Quality of Life Considerations

August DA, Thorn D, Fisher RL, Welchek CM. Home
parenteral nutrition for patients with inoperable
malignant bowel obstruction. JPEN J Parenter
Enteral Nutr 1991 May-Jun;15(3):323-7. Comment
in: J PEN J Parenter Enteral Nutr 1992 Mar-Apr;
16(2):190-1.

Cain J M. Quality of life considerations in the therapy of
epithelial ovarian cancer. In: Rubin SC, Sutton GP,
eds. Ovarian cancer. New York: McGraw—Hill;
1993. p. 451-64.

Cassem EH. Appropriate treatment limits in advanced
cancer. In: Billings JA. Outpatient management of
advanced cancer: symptom control, support, and
hospice-in—the-home. Philadelphia: Lippincott;
1985. p. 139-51.

Cella DF, Jacobsen PB, Lesko LM. Research methods
in psychooncology. In: Holland J C; Rowland J H,
eds. Handbook of psychooncology: psychological
care of the patient with cancer. New York: Oxford;
1989. p. 737-49.

Donovan K, Sanson-Fisher RW, Redman S. Measuring
quality of life in cancer patients. J Clin Oncol 1989
Jul;7(7):959-68.

Fries J F. Aging, natural death, and the compression of
morbidity. N Engl J Med 1980 Jul 17;303(3):130—5.

Lamb MA. Psychosexual issues: the woman with
gynecologic cancer. Semin Oncol Nurs 1990 Aug;
6(3):237—43.

Lew S. A tribute to Gayle. Can Oncol Nurs J 1993
Aug;3(3):156.

MacDonald N. Oncology and palliative care: the case
for co—ordination. Cancer Treat Rev 1993;
19 Suppl A229-41.

Makar AP, Trope CG. Gynecologic malignancy and
surgery: from quantity to quality of life. Curr Opin
Obstet Gynecol 1992 Jun;4(3):4l9-29.

Mann SC, Andrews PA, Howell SB. Modulation of cis-
diamminedichloroplatinumfll) accumulation and
sensitivity by forskolin and 3—isobutyl-1-
methylxanthine in sensitive and resistant human
ovarian carcinoma cells. Int J Cancer 1991 Jul 30;

48(6):866-72.

Ovesen L, Allingstrup L, Hannibal J, Mortensen EL,
Hansen OP. Effect of dietary counseling on food
intake, body weight, response rate, survival, and
quality of life in cancer patients undergoing
chemotherapy: A prospective, randomized study.
J Clin Oncol 1993;11(10):2043-9.

Ovesen L, Hannibal J, Mortensen EL. The
interrelationship of weight loss, dietary intake, and

quality of life in ambulatory patients with cancer of
the lung, breast, and ovary. Nutr Cancer 1993;
19(2): 159—67.

Payne SA. Coping with palliative chemotherapy. J Adv
Nurs 1990 Jun;15(6):652-8.

Payne SA. A study of quality of life in cancer patients
receiving palliative chemotherapy. Soc Sci Med
1992 Dec;35(12):1505-9.

Pickard-Holley S. Fatigue in cancer patients. A
descriptive study. Cancer Nurs 1991 Feb;14(1):
13-9.

Reuben DB, Mor V, Hiris J. Clinical symptoms and
length of survival in patients with terminal cancer.
Arch Intern Med 1988 Jul;148(7):1586—91.

Roberts CS, Rossetti K, Cone D, Cavanagh D.
Psychosocial impact of gynecologic cancer: a
descriptive study. J Psychosoc Oncol 1992;
10(1):99-1o9.

Schonwetter RS, Teasdale TA, Storey P, Luchi RJ.
Estimation of survival time in terminal cancer
patients: an impedance to hospice admissions?
Hosp J 1990;6(4):65-79.

Smith EM, Redman R, Burns TL, Sagert KM.
Perceptions of social support among patients with
recently diagnosed breast, endometrial, and ovarian

cancer: An exploratory study. J Psychosoc Oncol
1985 Fall;3(3):65-81.

Sneed NV, Edlund B, Dias JK. Adjustment of
gynecological and breast cancer patients to the
cancer diagnosis: comparisons with males and

females having other cancer sites. Health Care
Women Int 1992 Jan-Mar;l3(l):ll—22.

Stjemsward J. WHO cancer pain relief programme.
Cancer Surv 1988;7(1):195-208.

67

NEW DIRECTIONS FOR RESEARCH

Abbate I, Correale M, Gargano G, Tedone T, Izzi G,
Catino A, Musci MD, Dragone D, Cramarossa A.
Tumor necrosis factor and soluble interleukin-2
receptor: two immunological biomarkers in female
neoplasms. Eur J Gynaecol Oncol 1992;

13(1 Suppl):92-6.

Adelson MD. Future directions in the surgical
management of ovarian carcinoma. In: Rubin SC,
Sutton GP, eds. Ovarian cancer. New York:
McGraw-Hill; 1993. p. 465-83.

Alama A, Merlo F, Chiara S, Muttini MP, Guido T,
Nicolo G, Conte PF, Ragni N. Prediction of
survival by thymidine labelling index in patients
with resistant ovarian carcinoma. Eur J Cancer
1992;28A(6-7):1079-80.

Antman KH, Souhami RL. High-dose chemotherapy in
solid tumours. A review of published data in
selected tumours with a commentary. Ann Oncol
1993;4 Suppl 1:29-44.

Ariad S, Bezwoda WR. High-dose chemotherapy:
Therapeutic potential in the age of growth factor
support. Isr J Med Sci 1992;28(6):377-85.

Autio—Harmainen H, Karttunen T, Hurskainen T,
Hoyhtya M, Kauppila A, Tryggvason K.
Expression of 72 kilodalton type IV collagcnase
(gelatinase A) in benign and malignant ovarian
tumors. Lab Invest 1993 Sep;69(3):312-21.

Baker V. Oncogenes in gynecologic malignancy. Curr
Opin Obstet Gynecol 1992 Feb;4(1):75-80.

Balkwill FR. Tumour necrosis factor and cancer. Prog
Growth Factor Res 1992;4(2):121-37.

Barletta C, Lazzaro D, Prosperi Porta R, Testa U,
Grignani F, Ragusa RM, Leone R, Patella A,
Carenza L, Peschle C. C-MYB activation and the
pathogenesis of ovarian cancer. Eur J Gynaecol
Oncol 1992;13(1):53-9.

Bast RC Jr, Boyer CM, Jacobs 1, Xu F], Wu S, Wiener
J, Kohler M, Berchuck A. Cell growth regulation in
epithelial ovarian cancer. Cancer 1993 Feb 15;

71(4 Suppl):1597-60l.

Beattie GJ, Roulston JE, Eccles DM, Richardson J M,
Fisken J, Leonard RC. Alpha-fucosidase as a

marker of genetic deletion in ovarian carcinoma.
Ann Clin Biochem 1993 Mar;30(Pt 2):207—8.

Becker JL, Prewett TL, Spaulding GF, Goodwin TJ.
Three-dimensional growth and differentiation of
ovarian tumor cell line in high aspect rotating-wall
vessel: morphologic and cmbryologic
considerations. J Cell Biochem 1993 Mar;51(3):
283-9.

68

Bell DA. Flow cytometry of ovarian neoplasms. Curr
Top Pathol 1992;85:337—56.

Benchekroun MN, Parker R, Reed E, Sinha BK.
Inhibition of DNA repair and sensitization of
cisplatin in human ovarian carcinoma cells by
interleukin-1 alpha. Biochem Biophys Res Commun
1993 Aug 31;195(1):294-300.

Berchuck A, Boente MP, Kems BJ, Kinney RB, Soper
JT, Clarke-Pearson DL, Bast RC Jr, Bacus SS.
Ploidy analysis of epithelial ovarian cancers using
image cytometry. Gynecol Oncol 1992 Jan;44(1):
61—5.

Berchuck A, Kohler MF, Bast RC Jr. Oncogenes in
ovarian cancer. Hematol Oncol Clin North Am
1992 Aug;6(4):813-27.

Berchuck A, Kohler MF, Boente MP, Rodriguez GC,
Whitaker RS, Bast RC Jr. Growth regulation and
transformation of ovarian epithelium. Cancer 1993
Jan 15;71(2 Suppl):545-51.

Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente
MP, Arrick BA, Clarke—Pearson DL, Bast RC Jr.
Regulation of growth of normal ovarian epithelial
cells and ovarian cancer cell lines by transforming
growth factor-beta. Am J Obstet Gynecol 1992 Feb;
166(2):676-84.

Berek J S. Intraperitoneal immunotherapy for ovarian
cancer with alpha interferon. Eur J Cancer 1992;
28A(4-5):719-21.

Bems EM, Klijn JG, Henzen-Logmans SC, Rodenburg
CJ , van der Burg ME, Foekens JA. Receptors for
hormones and growth factors and (onco)—gene

amplification in human ovarian cancer. Int J Cancer
1992 Sep 9;52(2):218-24.

Bhalla K, Holladay C, Lutzky J, Ibrado AM, Bullock
G, J asiok M, Singh S. Deoxycytidine protects
normal bone marrow progenitors against Ara-C and
gemcitabine cytotoxicity without compromising their
activity against cisplatin-resistant human ovarian
cancer cells. Gynecol Oncol 1992 Apr;45(1):32—9.

Bicher A, Kohn E, Sarosy G, Davis P, Adamo DO,
Jacob J, Christian M, Reed E. The absence of
cumulative bone marrow toxicity in patients with
recurrent adenocarcinoma of the ovary receiving
dose-intense taxol and granulocyte colony
stimulating factor. Anticancer Drugs 1993 Apr;
4(2):141-8.

Biesma B, Willemse PH, Mulder NH, Sleijfer DT,
Gietema JA, Mull R, Limburg PC, Bouma J,
Vellenga E, de Vries EG. Effects of interleukin-3
after chemotherapy for advanced ovarian cancer.
Blood 1992 Sep 1;80(5):1141-8.

Bissett D, McLaughlin K, Kelland LR, Brown R.
Cisplatin—DNA damage recognition proteins in

human tumour extracts. Br J Cancer 1993 Apr;
67(4):742-8.

Blaakaer J, Hogdall CK, Hording U, Bennett P,
Toftager-Larsen K, Daugaard S, Bock J. Hormonal
factors and prognosis in epithelial ovarian cancer: A
multivariate analysis. Eur J Obstet Gynecol Reprod
Biol 1993;51(1):21-7.

Boente MP, Berchuck A, Rodriguez GC, Davidoff A,
Whitaker R, Xu FJ, Marks J, Clarke-Pearson DL,
Bast RC Jr. The effect of interferon gamma on
epidermal growth factor receptor expression in
normal and malignant ovarian epithelial cells. Am J
Obstet Gynecol 1992 Dec;167(6):1877-82.

Boente MP, Hurteau J, Rodriguez GC, Bast RC Jr,
Berchuck A. The biology of ovarian cancer. Curr
Opin Oncol 1993 Sep;5(5):900-7.

Bolhuis RL, Lamers CH, Goey SH, Eggermont AM,
Trimbos J B, Stoter G, Lanzavecchia A, di Re E,
Miotti S, Raspagliesi F, et al. Adoptive
immunotherapy of ovarian carcinoma with bs—MAb-
targeted lymphocytes: a multicenter study. Int J
Cancer Suppl 1992;7278-81.

Bonetti A, Howell SB, McClay E, Kirmani S, Goel R,
Plaxe S, Braly P, Kim S. High-dose biweekly
intraperitoneal cisplatin: An effective way to
increase cisplatin dose intensity. Gynecol Oncol
1993;49(3):318-24.

Bookman MA. Biologic therapy in the management of
refractory ovarian cancer. Gynecol Oncol 1993
Oct;51(1):113-26.

Bookman MA, Berek JS. Biologic and immunologic
therapy of ovarian cancer. Hematol Oncol Clin
North Am 1992 Aug;6(4):941-65.

Borresen AL. Oncogenesis in ovarian cancer. Acta
Obstet Gynecol Scand Suppl 1992;155:25-30.

Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E,
Coggi G. p53 accumulation in ovarian carcinomas
and its prognostic implications. Hum Pathol 1993
Nov;24(11):1175—9.

Bose CK, Mukherjea M. Alpha—fetoprotein in advanced
epithelial ovarian cancer. Br J Obstet Gynaecol
1993;100(12):1149-50.

Braly PS, Klevecz RR. Flow cytometric evaluation of
ovarian cancer. Cancer 1993 Feb 15;71(4 Suppl):
1621-8.

Brown R, Clugston C, Burns P, Edlin A, Vasey P,
Vojtesek B, Kaye SB. Increased accumulation of
p53 protein in cisplatin-resistant ovarian cell lines.
Int J Cancer 1993 Oct 21;55(4):678-84.

Buijs WC, Massuger LF, Claessens RA, Kenemans P,
Corstens FH. Dosimetric evaluation of
immunoscintigraphy using indium-1 1 1—labeled

monoclonal antibody fragments in patients with
ovarian cancer. J Nucl Med 1992 Jun;33(6):
11 13-20.

Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD.
Clinical trials with the topoisomerase I inhibitors.
Semin Oncol 1992;19(6):663-9.

Campo E, Merino MJ, Tavassoli FA, Charonis AS,
Stetler-Stevenson WG, Liotta LA. Evaluation of
basement membrane components and the 72 kDa
type IV collagenase in serous tumors of the ovary.
Am J Surg Pathol 1992 May;16(5):500-7.

Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim
Y, Ottensmeier C. Binding of ovarian cancer cells
to peritoneal mesothelium in vitro is partly mediated
by CD44H. Cancer Res 1993 Aug 15;53(16):
3830-8.

Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC,
van der Kwast TH. An immunohistochemical
evaluation of androgen and progesterone receptors
in ovarian tumors. Hum Pathol 1993 Jan;24(1):
90-5.

Chang K, Pai LH, Batra JK, Pastan I, Willingham MC.
Characterization of the antigen (CAKl) recognized
by monoclonal antibody Kl present on ovarian
cancers and normal mesothelium. Cancer Res 1992
Jan 1;52(1):181-6.

Chang K, Pastan I, Willingham MC. Isolation and
characterization of a monoclonal antibody, K1,
reactive with ovarian cancers and normal
mesothelium. Int J Cancer 1992 Feb 1;50(3):
373-81.

Chen G, Zeller WJ. Multiple effects of 3-
aminobenzamide on DNA damage induced by
cisplatin (DDP) in DDP-sensitive and —resistant rat
ovarian tumor cell lines. Cancer Lett 1992 Oct 30;
67(1):27-33.

Chen JT, Hasumi K, Masubuchi K. Interferon-alpha,
interferon-gamma and sizofiran in the adjuvant
therapy in ovarian cancer--a preliminary trial.
Biotherapy 1992;5(4):275-80.

Cheng JQ, Godwin AK, Bellacosa A, Taguchi T,
Franke TF, Hamilton TC, Tsichlis PN, Testa JR.
AKT2, a putative oncogene encoding a member of a
subfamily of protein-serine/threonine kinases, is
amplified in human ovarian carcinomas. Proc Natl
Acad Sci U S A 1992 Oct 1;89(19):9267-71.

Chien CH, Chow SN. Point mutation of the ras
oncogene in human ovarian cancer. DNA Cell Biol
1993 Sep;12(7):623-7.

Christen RD, Jekunen AP, Jones JA, Thiebaut F,
Shalinsky DR, Howell SB. In vitro modulation of
cisplatin accumulation in human ovarian carcinoma
cells by pharmacologic alteration of microtubules.
J Clin Invest 1993 Jul;92(1):431—40.

69

Cimoli G, Valenti M, Venturini M, Conte P, Russo P.
Augmentation of antineoplastic effects by the
combination of recombinant human tumor necrosis
factor and mitoxantrone on primary culture of

human ovarian cancer cells. Anticancer Res 1992
Sep-Oct; 12(5): 141 1-4.

Colombo N, Peccatori F, Paganin C, Bini S, Brandely
M, Mangioni C, Mantovani A, Allavena P. Anti—
tumor and immunomodulatory activity of
intraperitoneal IFN-gamma in ovarian carcinoma
patients with minimal residual tumor after
chemotherapy. Int J Cancer 1992 Apr 22;51(1):
42-6.

Crown J, Wassherheit C, Hakes T, Fennelly D, Reich
L, Moore M, Schneider J, Curtin J, Rubin SC,
Reichman B, Moore M, Yao TJ, Gilewski T, Gulati
S, Markman M, Norton L. Rapid delivery of
multiple high-dose chemotherapy courses with
granulocyte colony-stimulating factor and peripheral
blood-derived hematopoietic progenitor cells.

J Natl Cancer Inst 1992;84(24):1935—6.

Cuijpers VM, Boennan 0C, Salet van de Pol MR,
Vooijs GP, Poels LG, Ramaekers FC.
Immunocytochemical detection of ovarian

carcinoma cells in serous effusions. Acta Cytol
1993 May—Jun;37(3):272-9.

Daoud SS, Sakata MK. In vitro interaction of liposomal
valinomycin and platinum analogs: cytotoxic and
cytokinetic effects. Anticancer Drugs 1993 Aug;
4(4):479-86.

de Gramont A, Demuynck B, Louvet C, Gonzalez-
Canali G, Varette C, Pigne A, Marpeau L,
Herbulot P, Lagadec B, Cady J, et al. Survival with
intraperitoneal cisplatin in advanced ovarian cancer
after second-look laparotomy. Am J Clin Oncol
1992 Feb;15(1):7—11.

de Gramont A, Demuynck B, Varette C, Louvet C,
Pigne A, Marpeau L, Lagadec B, Cady J, Couturier
JY, Delfau S, et al. Sequential cisplatin-
doxorubicin, early debulking surgery and
intraperitoneal chemotherapy in advanced ovarian
cancer. Groupe d’Etude et de Recherche sur les
Cancers de l’Ovaire et Digestifs (GERCOD). Eur J
Cancer 1992;28(1):53-8.

Deisseroth AB, Kavanagh JJ, Hanania EG, Fu S,
Komblau SM, Estey E, Talpaz M, Kantarjian HM,
Claxton DF, Reading CL, Dixon DA, Anderson
RW, Lopez-Berestein G, Holmes FA, Logothetis
CJ, Andreeff M, Benedict W. Gene therapy:
Chemoprotection, immunoenhancement, and
modification of tumor cells. Cancer Bull 1993;
45(2): 139-45 .

DeLaney TF, Sindelar WF, Tochner Z, Smith PD,
Friauf WS, Thomas G, Dachowski L, Cole JW,
Steinberg SM, Glatstein E. Phase I study of
debulking surgery and photodynamic therapy for

70

disseminated intraperitoneal tumors. Int J Radiat
Oncol Biol Phys 1993 Feb 15;25(3):445-57.

Dempke WC, Shellard SA, Hosking LK, Fichtinger-
Schepman AM, Hill BT. Mechanisms associated
with the expression of cisplatin resistance in a
human ovarian tumor cell line following exposure
to fractionated X-irradiation in vitro.
Carcinogenesis 1992 Jul;13(7): 1209-15.

Dempke WC, Whelan RD, Hill BT. Expression of
resistance to etoposide and vincristine in vitro and
in vivo after X-irradiation of ovarian tumor cells.
Anticancer Drugs 1992 Aug;3(4):395—9.

Devine PL, McGuckin MA, Ramm LE, Ward BG, Pee
D, Long S. Serum mucin antigens CASA and MSA
in tumors of the breast, ovary, lung, pancreas,
bladder, colon, and prostate. A blind trial with 420
patients. Cancer 1993 Sep 15;72(6):2007-15.

Devine PL, McGuckin MA, Ward BG. Circulating
mucins as tumor markers in ovarian cancer
(review). Anticancer Res 1992 May-Jun;12(3):
709-17.

Di Re F, Bohm S, Oriana S, Spatti GB, Pirovano C,
Tedeschi M, Zunino F. High-dose cisplatin and
cyclophosphamide with glutathione in the treatment
of advanced ovarian cancer. Ann Oncol 1993 Jan;
4(1):55-61.

Dittrich C, Sevelda P, Baur M, Marth C, Hudec M,
Vavra N, Grunt T, Fazeny B, Salzer H. In vitro
and in vivo evaluation of the combination of
cisplatin and its analogue carboplatin for platinum
dose intensification in ovarian carcinoma. Cancer
1993 May 15;71(10):3082-90.

Eccles DM, Brett L, Lessells A, Gruber L, Lane D,
Steel CM, Leonard RC. Overexpression of the p53
protein and allele loss at 17p13 in ovarian
carcinoma. Br J Cancer 1992 Jan;65(1):40-4.

Elg SA, Carson LF, Fowler JM, Twiggs LB, Moradi
MM, Ramakrishnan S. Ascites levels of haptoglobin

in patients with ovarian cancer. Cancer 1993
Jun 15;71(12):3938-41.

Elsasser-Beile U, von Kleist S, Sauther W, Gallati H,
Monting J S. Impaired cytokine production in whole
blood cell cultures of patients with gynaecological
carcinomas in different clinical stages. Br J Cancer
1993 Jul;68(l):32-6.

Emons G, Ortmann O, Pahwa GS, Hackenberg R,
Oberheuser F, Schulz KD. Intracellular actions of
gonadotropic and peptide hormones and the
therapeutic value of GnRH—agonists in ovarian
cancer. Acta Obstet Gynecol Scand Suppl 1992;
155:31-8.

Erba E, Sen S, Lorico A, D’Incalci M. Potentiation of
etoposide cytotoxicity against a human ovarian
cancer cell line by pretreatment with non-toxic

concentrations of methotrexate or aphidicolin. Eur J
Cancer 1992;28(1):66-7l.

Fady C, Gardner AM, Gera J F, Lichtenstein A.
Interferon-induced increase in sensitivity of ovarian
cancer targets to lysis by lymphokine—activated
killer cells: selective effects on HER2/neu—
overexpressing cells. Cancer Res 1992 Feb 15;
52(4):764-9.

Ferrandina G, Scambia G, Benedetti Panici P, Bonanno
G, De Vincenzo R, Rumi C, Bussa S, Genuardi M,
Spica Romano V, Mancuso S. Effects of
dexamethasone on the growth and epidermal growth
factor receptor expression of the OVCA 433
ovarian cancer cells. Mol Cell Endocrinol 1992
Feb;83(2-3):183—93.

Ferrandina G, Scambia G, Benedetti Panici P, Ranelletti
F0, De Vincenzo R, Piantelli M, Distefano M,
Capelli A, Mancuso S. Type II estrogen-binding
sites in human ovarian cancer: correlation with
estrogen, progesterone, and epidermal growth factor
receptor. Gynecol Oncol 1993 Apr;49(1):67-72.

Fisken J, Roulston JE, Sturgeon C, Badley RA, Jonrup
I, Aspinall L, Leonard RC. The value of the human
milk fat globule membrane antigen HMFGZ in
epithelial ovarian cancer monitoring: comparison
with CA125. Br J Cancer 1993 May;67(5):1065-70.

Flynn MK, Johnston W, Bigner S. Carcinoma of
ovarian and other origins in effusions.
Immunocytochemical study with a panel of
monoclonal antibodies. Acta Cytol 1993 Jul-Aug;
37(4):439-47.

Francis P, Markman M, Hakes T, Reichman B, Rubin
S, Jones W, Lewis JL Jr, Curtin J, Barakat R,
Phillips M, et al. Diethyldithiocarbamate
chemoprotection of carboplatin--induced
hematological toxicity. J Cancer Res Clin Oncol
1993;119(6):360—2.

Freedman RS, Ioannides CG, Mathioudakis G,
Platsoucas CD. Novel immunologic strategies in
ovarian carcinoma. Am J Obstet Gynecol 1992
Nov; 167(5): 1470-8 .

Funato T, Yoshida E, Jiao L, Tone T, Kashani-Sabet
M, Scanlon KJ. The utility of an anti-fos ribozyme
in reversing cisplatin resistance in human
carcinomas. Adv Enzyme Regul 1992;32:195—209.

Galtier-Dereure F, Capony F, Maudelonde T,
Rochefort H. Estradiol stimulates cell growth and
secretion of procathepsin D and a 120—kilodalton
protein in the human ovarian cancer cell line BG-l.
J Clin Endocrinol Metab 1992 Dec;75(6):1497-502.

Garin-Chesa P, Campbell I, Saigo PE, Lewis JL Jr,
Old LJ, Rettig WJ. Trophoblast and ovarian cancer
antigen LK26. Sensitivity and specificity in
immunopathology and molecular identification as a

folate-binding protein. Am J Pathol 1993 Feb;
142(2):557-67.

Garzetti GG, Cignitti M, Ciavattini A, Fabris N,
Romanini C. Natural killer cell activity and
progression-free survival in ovarian cancer.
Gynecol Obstet Invest 1993;35(2):118-20.

Garzetti GG, Possati L, Ciavattini A, Recanatini E,
Cignitti M, Valensise H, Romanini C. Immuno-
biologic integration for therapeutic approach in
ovarian carcinoma. Eur J Gynaecol Oncol 1992;
13(6):514-21.

Gastl G, Plante M, Finstad CL, Wong GY, Federici
MG, Bander NH, Rubin SC. High IL—6 levels in
ascitic fluid correlate with reactive thrombocytosis
in patients with epithelial ovarian cancer. Br J
Haematol 1993 Mar;83(3):433-41.

Gatanaga M, Grosen EA, Burger RA, Granger GA,
Gatanaga T. Release of soluble TNF/LT receptors
from a human ovarian tumor cell line (PA-1) by
stimulation with cytokines in vitro. Lymphokine
Cytokine Res 1993 Aug;12(4):249-53.

Godwin AK, Meister A, O’Dwyer PJ, Huang CS,
Hamilton TC, Anderson ME. High resistance to
cisplatin in human ovarian cancer cell lines is
associated with marked increase of glutathione
synthesis. Proc Natl Acad Sci U S A 1992 Apr 1;
89(7):3(T/0—4.

Godwin AK, Perez RP, Johnson SW, Hamaguchi K,
Hamilton TC. Growth regulation of ovarian cancer.
Hematol Oncol Clin North Am 1992 Aug;6(4):
829—41.

Godwin AK, Testa JR, Hamilton TC. The biology of
ovarian cancer development. Cancer 1993 Jan 15;

71(2 Suppl):530—6.

Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer
LA, Tracey PA, Hamilton TC. Spontaneous

transformation of rat ovarian surface epithelial cells:

association with cytogenetic changes and
implications of repeated ovulation in the etiology of
ovarian cancer. J Natl Cancer Inst 1992 Apr 15;
84(8):592-601. Comment in: J Natl Cancer Inst
1992 Apr 15;84(8):556-8.

Goldberg BB, Liu JB, Merton DA, Feld RI, Miller LS,
Cohn HE, Barbot D, Gillum DR, Vemick JJ,
Winkel CA. Sonographically guided laparoscopy
and mediastinoscopy using miniature catheter—based
transducers. J Ultrasound Med 1993 Jan;12(1):
49-54.

Gordon J D, Polan ML. The use of GnRH agonists in
breast and gynecologic cancers. Semin Reprod
Endocrinol 1993;11(2):187-94.

Gorn AH, Lin HY, Yamin M, Auron PE, Flannery
MR, Tapp DR, Manning CA, Lodish HF, Krane
SM, Golddng SR. Cloning, characterization, and

71

expression of a human calcitonin receptor from an
ovarian carcinoma cell line. J Clin Invest 1992
Nov;90(5):1726-35.

Gotlieb WH, Abrams JS, Watson JM, Velu TJ, Berek
J S, Martinez-Man 0. Presence of interleukin 10
(IL- 10) in the ascites of patients with ovarian and
other intra-abdominal cancers. Cytokine 1992 Sep;
4(5):385—90.

Green JA, Robertson LJ, Clark AH. Glutathione S-
transferase expression in benign and malignant
ovarian tumours. Br J Cancer 1993 Aug;68(2):
235-9.

Grosen EA, Granger GA, Gatanaga M, Ininns EK,
Hwang C, DiSaia P, Berman M, Marietta A, Emma
D, Gatanaga T. Measurement of the soluble
membrane receptors for tumor necrosis factor and
lymphotoxin in the sera of patients with gynecologic
malignancy. Gynecol Oncol 1993 Jul;50(1):68-77.

Grunt TW, Oeller H, Somay C, Dittrich E, Fazeny B,
Mannhalter C, Dittrich C. Modulation of the
immunophenotype of ovarian cancer cells by N,N-
dimethylformamide and transforming growth factor-
beta 1. J Cell Physiol 1993 Aug;156(2):358-66.

Grunt TW, Somay C, Ellinger A, Pavelka M, Dittrich
E, Dittrich C. The differential effects of N,N—
dimethylfonnamide and transforming growth factor-
beta 1 on a human ovarian cancer cell line
(HOC-7). J Cell Physiol 1992 Apr;151(l):l3-22.

Grunt TW, Somay C, Oeller H, Dittrich E, Dittrich C.
Comparative analysis of the effects of dimethyl
sulfoxide and retinoic acid on the antigenic pattern
of human ovarian adenocarcinoma cells. J Cell Sci
1992 Oct;lO3(Pt 2):501-9.

Gupta-Burt S, Shamkhani H, Reed E, Tarone RE,
Allegra CJ, Pai LH, Poitier MC. Relationship
between patient response in ovarian and breast
cancer and platinum drug-DNA adduct formation.
Cancer Epidemiol Biomarkers Prev 1993 May-Jun;
2(3):229-34.

Hamaguchi K, Godwin AK, Yakushiji M, O’Dwyer PJ,
Ozols RF, Hamilton TC. Cross-resistance to diverse
drugs is associated with primary cisplatin resistance
in ovarian cancer cell lines. Cancer Res 1993
Nov 1; 53(21):5225-32.

Harant H, Korschineck I, Krupitza G, Fazeny B,
Dittrich C, Grunt TW. Retinoic acid receptors in
retinoid responsive ovarian cancer cell lines
detected by polymerase chain reaction following
reverse transcription. Br J Cancer 1993;68(3):
530-6.

Harlozinska A, Bar JK, Cislo M, Richter R,
Rabczynski J. Density distribution and
immunological reactivity of tumor cells from
peritoneal effusions of patients with ovarian
neoplasms. Anal Cell Pathol 1992 Jan;4(1):1-12.

72

Harlozinska A, Bar JK, Jothy S, Sedlaczek P, Slesak B,
Richter R. Carcinoembryonic antigen isotypes in
tissue sections and loose cyst fluid cells of ovarian
neoplasms. Tumour Biol 1993;14(1):1-8.

Harlozinska A, Bar JK, Richter R, Cislo M.
Comparison of cellular phenotypes in tumor cyst
and ascitic fluid from ovarian serous carcinoma.
Acta Cytol 1992 Nov-Dec;36(6):869-74.

Harstrick A, Schmoll HJ, Sass G, Poliwoda H, Rustum
Y. Titanocendichloride activity in cisplatin and
doxorubicin—resistant human ovarian carcinoma cell
lines. Eur J Cancer 1993;29A(7):1000—2.

Hawkins MJ. New anticancer agents: taxol,
camptothecin analogs, and anthrapyrazoles
Oncology (Huntingt) 1992 Dec;6(12):17-23;
discussion 27-30. Published erratum appears in
Oncology (Huntingt) 1993 Mar;7(3):105.

Hayward IP, Hurst T, Parsons PG, Khoo SK.
Combination chemotherapy tested in a short-term
thymidine incorporation assay in primary cultures of
ovarian adenocarcinomas. Int J Cell Cloning 1992
May;10(3):182—9.

Healy DL, Burger HG, Mamers P, Jobling T, Bangah
M, Quinn M, Grant P, Day A], Rome R, Campbell
JJ. Elevated serum inhibin concentrations in

postmenopausal women with ovarian tumors.
N Engl J Med 1993 Nov 18;329(21):1539—42.

Helle M, Helin H, Ashom P, Putkinen EL, Krohn K,
Wahlstrom T. The expression of CEA, CA 19-9
and HMFG antigens in ovarian clear-cell and

endometrioid carcinomas. Pathol Res Pract 1992
Feb;188(l—2):74-7.

Helm CW, Shrestha K, Thomas S, Shingleton HM,
Miller DM. A unique c-myc-targeted triplex-
forming oligonucleotide inhibits the growth of
ovarian and cervical carcinomas in vitro. Gynecol
Oncol 1993 Jun;49(3):339-43.

Hengstler JG, Fuchs J, Oesch F. DNA strand breaks
and DNA cross-links in peripheral mononuclear
blood cells of ovarian cancer patients during

chemotherapy with cyclophosphamide/carboplatin.
Cancer Res 1992 Oct 15;52(20):5622-6.

Henriksen R, Funa K, Wilander E, Backstrom T,
Ridderheim M, Oberg K. Expression and
prognostic significance of plateletoderived growth
factor and its receptors in epithelial ovarian
neoplasms. Cancer Res 1993 Oct 1;53(19):4550—4.

Henzen-Logmans SC, van der Burg ME, Foekens JA,
Bems PM, Brussee R, Fieret JH, Klijn JG, Chadha
S, Rodenburg CJ. Occurrence of epidermal growth
factor receptors in benign and malignant ovarian
tumors and normal ovarian tissues: an
immunohistochemical study. J Cancer Res Clin
Oncol 1992;118(4):303-7.

Hereiz HA, Bayoumi FA. Evaluation of diagnosis of
ovarian malignancy using immunohistochemical
technique. J Egypt Public Health Assoc 1992;
67(5-6):697-707 .

Hightower RD, Sevin BU, Perras J, Nguyen H, Angioli
R, Untch M, Averette H. In vitro evaluation of the
novel chemotherapeutic agents U-73,975, U-77,779,
and U—80,244 in gynecologic cancer cell lines.
Cancer Invest 1993;11(3):276—82.

Hightower RD, Sevin BU, Perras JP, Untch M, Angioli
R, Ramos R, Averette H. Comparison of U-73,975 '
and cisplatin cytotoxicity in fresh cervical and
ovarian carcinoma specimens with the ATP-
chemosensitivity assay. Gynecol Oncol 1992 Nov;
47(2): 186-90. '

Hill BT, Shellard SA, Hosking LK, Dempke WC,
Fichtinger-Schepman AM, Tone T, Scanlon KJ,
Whelan RD. Characterization of a cisplatin—resistant
human ovarian carcinoma cell line expressing cross-
resistance to 5-fluorouracil but collateral sensitivity
to methotrexate. Cancer Res 1992 Jun 1;52(11):
3110-8.

Hirata J, Kikuchi Y, Kita T, Imaizumi E, Tode T, Ishii
K, Kudoh K, Nagata 1. Modulation of sensitivity of
human ovarian cancer cells to cis-
diamminedichloroplatinumal) by 12-0-
tetradecanoylphorbol-13—acetate and D,L- .
buthionine—S,R-sulphoximine. Int J Cancer 1993
Sep 30;55(3):521-7.

Hirte HW, Clark DA, Mazurka J, O’Connell G,
Rusthoven J. A rapid and simple method for the
purification of tumor cells from ascitic fluid of
ovarian carcinoma. Gynecol Oncol 1992 Mar;44(3):
223-6.

Hirte HW, Clark DA, O’Connell G, Rusthoven J,
Mazurka J. Reversal of suppression of lymphokine—
activated killer cells by transforming grth factor-
beta in ovarian carcinoma ascitic fluid requires
interleukin-2 combined with anti-CD3 antibody.
Cell Immunol 1992 Jun;142(1):207-16.

Hoffman AG, Burghardt RC, Tilley R, Auersperg N.
An in vitro model of ovarian epithelial
carcinogenesis: changes in cell-cell communication

and adhesnon occurring during neoplastic
progression. Int J Cancer 1993 Jul 9;54(5):828-38.

Hogdall CK, Christensen L, Clemmensen I. The
prognostic value of tetranectin immunoreactivity
and plasma tetranectin in patients with ovarian
cancer. Cancer 1993 Oct 15;72(8):2415—22.

Homby AE, Pan J, Auersperg N. Intermediate
filaments in rat ovarian surface epithelial cells:
changes with neoplastic progression in culture.
Biochem Cell Biol 1992 Jan;70(1):16-25.

Hovestadt A, van der Burg ME, Verbiest HB, van
Putten WL, Vecht CJ . The course of neuropathy

after cessation of cisplatin treatment, combined wrth
Org 2766 or placebo. J Neurol 1992 Mar;239(3):
143-6.

Hruza C, Dobianer K, Beck A, Czerwenka K, Hanak
H, Klein M, Leodolter S, Medl M, Mullauer-Ertl
S, Preiser J , et al. HER-2 and INT-2 amplification
estimated by quantitative PCR in paraffin-embedded
ovanan cancer tissue samples. Eur J Cancer 1993;
29A(11):1593-7.

Hsieh-Ma ST, Eaton AM, Shi T, Ring DB. In vitro
cytotoxic targeting by human mononuclear cells and
bispecific antibody 2B1, recognizing c—erbB-2
protooncogene product and Fc gamma receptor III.
Cancer Res 1992 Dec 15;52(24):6832-9.

Huettner PC, Carney WP, Naber SP, DeLellis RA,
Membrino W, Wolfe HJ. Neu oncogene expression
in ovarian tumors: a quantitative study. Mod Pathol
1992 May;5(3):250—6.

Huettner PC, Weinberg DS, Lage JM. Assessment of
proliferative activity in ovarian neoplasms by flow
and static cytometry. Correlation with prognostic
features. Am J Pathol 1992 Sep;141(3):699-706.

Hughes PM, Zammit—Maempel I, Murphy D. Computed
tomographic assessment of intraperitoneal fluid
distribution prior to intraperitoneal chemotherapy
for ovarian cancer. Br J Radiol 1992;65(772):
295-7.

Hung MC, Zhang X, Yan DH, Zhang HZ, He GP,
Zhang TQ, Shi DR. Aberrant expression of the c-
erbB—Z/neu protooncogene in ovarian cancer.
Cancer Lett 1992 Jan 10;61(2):95—103.

ku P, Shafer GE, Treisman J, Schindler DG, Gross
G, Cowherd R, Rosenberg SA, Eshhar Z. Lysis of
ovarian cancer cells by human lymphocytes
redirected with a chimeric gene composed of an

antibody variable region and the Fc receptor gamma
chain. J Exp Med 1993 Jul 1;178(1):361-6.

Hyafrl F, Vergely C, Du Vignaud P, Grand-Ferret T.
In vitro and in vivo reversal of multidrug resistance
by GF120918, an acr‘idonecarboxamide derivative.
Cancer Res 1993 Oct 1;53(19):4595-609..

Ikarashi H, Aoki Y, Fujita K, Kodama S, Tanaka K.
Solid-phase anti-CD3 antibody activation and
cryopreservation of human tumor-infiltrating
lymphocytes derived from epithelial ovarian cancer.
Jpn J Cancer Res 1992 Dec;83(12):1359-65.

Imaishi K. Intraperitoneal transplantation of ascitic
cancer cells from a 7,12-dimethylbenz[a]anthracene
(DMBA)-induced ovarian cancer. Kurume Med J
l992;39(3):195-201.

Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton
JT, O’Brian CA. Cytotoxic T cells isolated from
ovarian malignant ascites recognize a peptide

73

derived from the HER-2/neu protooncogene. Cell
Immunol 1993 Oct 1;151(l):225-34.

Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton
JT, Finn OJ. Cytotoxic T cells from ovarian
malignant tumors can recognize polymorphic

epithelial mucin core peptides. J Immunol 1993
Oct 1;151(7):3693-703.

Ioannides CG, Fisk B, Pollack MS, Frazier ML, Taylor
Wharton J, Freedman RS. Cytotoxic T—cell clones
isolated from ovarian tumour infiltrating
lymphocytes recognize common determinants on
non—ovarian tumour clones. Scand J Immunol 1993
Apr;37(4):413-24.

Ioannides CG, Fisk B, Tomasovic B, Pandita R,
Aggarwal BB, Freedman RS. Induction of
interleukin-2 receptor by tumor necrosis factor
alpha on cultured ovarian tumor-associated

lymphocytes. Cancer Immunol Immunother 1992;
35(2):83-91.

Ishii K, Kikuchi Y, Hirata J, Tode T, Kita T, Nagata I,
Tsuru S, Rokutanda M. Antitumor effect of PSK in
nude mice with human ovarian carcinoma cells and

its combined effect with cis—diammine—
dichloroplatinum (II). Cancer J 1993;6(2):87-90.

Ishii S, Naito M, Tsuruo T. Expression behavior of 85-
kDa membrane protein in adriamycin-resistant
tumor cells and the inhibition of human tumor
growth in athymic mice by MRK-ZO monoclonal
antibody against the protein. Jpn J Cancer Res 1993
Jul;84(7):776-82.

Islam MQ, Kopf l, Levan A, Granberg S, Friberg LG,
Levan G. Cytogenetic findings in 111 ovarian
cancer patients: therapy-related chromosome
aberrations and heterochromatic variants. Cancer
Genet Cytogenet 1993 Jan;65(1):35-46.

Isonishi S, Jekunen AP, Hom DK, Eastman A,
Edelstein PS, Thiebaut FB, Christen RD, Howell
SB. Modulation of cisplatin sensitivity and growth
rate of an ovarian carcinoma cell line by bombesin
and tumor necrosis factor-alpha. J Clin Invest 1992
Oct;90(4):1436—42.

Ito K, Sasano H, Ozawa N, Sato S, Silverberg SG,
Yajima A. Immunolocalization of epidermal growth
factor receptor and c-erbB-2 oncogene product in

human ovarian carcinoma. Int J Gynecol Pathol
1992 Oct;11(4):253-7.

James RD, Wilkinson PM, Belli F, Welch R, Cowan
R. Recombinant human erythropoietin in patients
with ovarian carcinoma and anaemia secondary to
cisplatin and carboplatin chemotherapy: preliminary
results. Acta Haematol 1992;87 Suppl 1:12-5.

Jekunen A, Vick J, Sanga R, Chan TC, Howell SB.
Synergism between dipyridamole and cisplatin in
human ovarian carcinoma cells in vitro. Cancer Res
1992 Jul 1;52(13):3566—71.

74

Johnson SW, Ozols RF, Hamilton TC. Mechanisms of
drug resistance in ovarian cancer. Cancer 1993
Jan 15;71(2 Suppl):644-9.

Jones M, Siracky J, Kelland LR, Harrap KR.
Acquisition of platinum drug resistance and
platinum cross resistance patterns in a panel of
human ovarian carcinoma xenografts. Br J Cancer
1993 Jan;67(1):24-9.

Jordan PA, Kems BJ, Pence JC, Kohler MF, Bast RC
Jr, Kinney RB, Berchuck A. Determination of
proliferation index in advanced ovarian cancer using
quantitative image analysis. Am J Clin Pathol 1993
Jun;99(6):736—40.

Jozan S, Guerrin M, Mazars P, Dutaur M, Monsarrat
B, Cheutin F, Bugat R, Martel P, Valette A.
Transforming growth factor beta 1 (T GF-beta 1)
inhibits grth of a human ovarian carcinoma cell
line (OVCCRl) and is expressed in human ovarian
tumors. Int J Cancer 1992 Nov 11;52(5):766-70.

Kacinski BM, Mayer AG, King BL, Carter D,
Chambers SK. NEU protein overexpression in
benign, borderline, and malignant ovarian
neoplasms. Gynecol Oncol 1992 Mar;44(3):245-53.

Kamada M, Mori T, Sakamoto Y, Daitoh T, Furumoto
H, Irahara M, Aono T, Mori T. Heterophile
antigens in serous cystadenocarcinoma of the human
ovary. Asia Oceania J Obstet Gynaecol 1992 Dec;
18(4):387—95.

Karlan BY, Chamorro T, Fowler JM, Muderspach LI,
Greenberg S, Lagasse LD. Concurrent interstitial
radiotherapy and infusional chemotherapy for
recurrent gynecologic malignancies. Int J Gynecol
Cancer 1993;3(5):304-10.

Kavanagh JJ, Kudelka AP. Systemic therapy for
gynecologic cancer. Curr Opin Oncol 1993 Sep;
5(5):891-9.

Kelland LR, Abel G, McKeage M], Jones M, Goddard
PM, Valenti M, Murrer BA, Harrap KR.
Preclinical antitumor evaluation of bis-acetato—
ammine—dichloro—cyclohexylamine platinum(IV): an
orally active platinum drug. Cancer Res 1993
Jun l;53(ll):2581—6.

Kelland LR, Jones M, Abel G, Valenti M, Gwynne J,
Harrap KR. Human ovarian-carcinoma cell lines
and companion xenografts: a disease—oriented
approach to new platinum anticancer drug
discovery. Cancer Chemother Pharmacol 1992;
30(1):43-50.

Kelland LR, Mistry P, Abel G, Loh SY, O’Neill CF,
Murrer BA, Harrap KR. Mechanism-related
circumvention of acquired cis-
diamminedichloroplatinumfll) resistance using two
pairs of human ovarian carcinoma cell lines by
ammine/amine platinum(IV) dicarboxylates. Cancer
Res 1992 Jul 15;52(14):3857-64.

Kelland LR, Murrer BA, Abel G, Giandomenico CM,
Mistry P, Harrap KR. Ammine/amine platinum(IV)
dicarboxylates: a novel class of platinum complex
exhibiting selective cytotoxicity to intrinsically
cisplatin-resistant human ovarian carcinoma cell
lines. Cancer Res 1992 Feb 15;52(4):822-8.

Kems B], Jordan PA, Moore MB, Humphrey PA,
Berchuck A, Kohler MF, Bast RC Jr, lglehart JD,
Marks JR. p53 overexpression in formalin-fixed,
paraffin-embedded tissue detected by
immunohistochemistry. J Histochem Cytochem
1992 Jul;40(7):1047-51.

Kido Y, Khokhar AR, Siddik ZH. Differential
cytotoxicity, uptake and DNA binding of tetraplatin
and analogous isomers in sensitive and resistant
cancer cell lines. Anticancer Drugs 1993 Apr;
4(2):251-8.

Kieback DG, McCamant SK, Press MF, Atkinson EN,
Gallager HS, Edwards CL, Hajek RA, Jones LA.
Improved prediction of survival in advanced
adenocarcinoma of the ovary by
immunocytochemical analysis and the composition
adjusted receptor level of the estrogen receptor.
Cancer Res 1993 Nov 1;53(21):5188-92.

Kigawa J, Minagawa Y, Ishihara H, Kanamori Y,
Terakawa N. Tumor DNA ploidy and prognosis of
patients with serous cystadenocarcinoma of the
ovary. Cancer 1993 Aug 1;72(3):804-8.

Kihana T, Tsuda H, Teshima S, Okada S, Matsuura S,
Hirohashi S. High incidence of p53 gene mutation
in human ovarian cancer and its association with
nuclear accumulation of p53 protein and tumor
DNA aneuploidy. Jpn J Cancer Res 1992 Sep;
83(9):978-84.

Kikkawa F, Kojima M, Oguchi H, Maeda O, Ishikawa
H, Tamakoshi K, Mizuno K, Kawai M, Suganuma
N, Tomoda Y. Potentiating effect of amphotericin B
on five platinum anticancer drugs in human cis-
diamminedichloroplatinum (II) sensitive and
resistant ovarian carcinoma cells. Anticancer Res
1993 Jul-Aug;l3(4):891-6.

Kikuchi Y, Hirata J, Kita T, Imaizumi E, Tode T,
Nagata I. Enhancement of antiproliferative effect of
cis-diamminedichloroplatinumfll) by clomiphene
and tamoxifen in human ovarian cancer cells.
Gynecol Oncol 1993 Jun;49(3):365-72.

Kikuchi Y, Kita T, Miyauchi M, Hirata J, Sasa H,
Nagata I, Fukushima M. Adjuvant effects of
antineoplastic prostaglandins to cisplatin in nude
mice bearing human ovarian cancer cells. J Cancer
Res Clin Oncol 1992;] 18(6):453-7.

Kimura E, Enns RE, Alcaraz JE, Arboleda J, Slamon
DJ, Howell SB. Correlation of the survival of
ovarian cancer patients with mRNA expression of
the 60-kD heat—shock protein HSP-60. J Clin Oncol
1993 May;11(5):891-8.

 

 

Kimura E, Enns RE, Thiebaut F, Howell SB.
Regulation of HSP60 mRNA expression in a human
ovarian carcinoma cell line. Cancer Chemother
Pharmacol 1993;32(4):279-85.

Kimura E, Howell SB. Analysis of the cytotoxic
interaction between cisplatin and hyperthermia in a
human ovarian carcinoma cell line. Cancer
Chemother Pharmacol 1993;32(6):419-24.

King BL, Carter D, Foellmer HG, Kacinski BM. Neu
proto-oncogene amplification and expression in
ovarian adenocarcinoma cell lines. Am J Pathol
1992 Jan;140(1):23-31.

Kobayashi H, Moniwa N, Sugimura M, Shinohara H,
Ohi H, Terao T. Increased cell-surface urokinase in
advanced ovarian cancer. Jpn J Cancer Res 1993
Jun;84(6):633—40.

Kobayashi H, Ohi H, Fujii T, Terao T.
Characterisation and clinical usefulness of CA130
antigen recognised by monoclonal antibodies,
130-22 and 145-9, in ovarian cancers. Br J Cancer
1993 Feb;67(2):237-43.

Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii
T, Terao T. Inhibition of in vitro ovarian cancer
cell invasion by modulation of urokinase-type
plasminogen activator and cathepsin B. Cancer Res
1992 Jul 1;52(13):3610-4.

Kobayashi H, Ohi H, Sugimura M, Shinohara H, Terao
T. Characterization and clinical evaluation of
tumor-associated antigen CA54/61 identified by
monoclonal antibodies MA54 and MA61 in
epithelial ovarian cancer. Gynecol Oncol 1992
Dec;47(3):328-36.

Kobayashi H, Ohi H, Sugimura M, Shinohara H, Terao
T. Monoclonal antibodies MA54 and MA61 as
potential reagents in the prognosis of patients with
ovarian cancer. Gynecol Oncol 1993 Apr;49(1):
80-5.

Kobayashi H, Sakahara H, Saga T, Hosono M, Shirato
M, Kanda H, Ishibashi K, Watanabe T, Endo K,
Ishiwata I, et al. A human/mouse chimeric
monoclonal antibody against CA125 for
radioimmunoimaging of ovarian cancer. Cancer
Immunol Immunother 1993 Aug;37(3):143-9.

Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn
as an independent predictor of poor prognosis in
patients with epithelial ovarian cancer. J Clin Oncol
1992 Jan;10(1):95-101.

Kobayashi H, Terao T, Kawashima Y. Sialyl Tn as a
prognostic marker in epithelial ovarian cancer. Br J
Cancer 1992;66(5):984-5.

Kobayashi H, Tsuruchi N, Sugihara K, Kaku T, Saito
T, Kamura T, Tsukamoto N, Nakano H, Taniguchi
S. Expression of alpha-smooth muscle actin in

75

benign or malignant ovarian tumors. Gynecol Oncol
71993 Mar;48(3):308-13.

Kohler M, Bauknecht T, Grimm M, Birmelin G,
Kommoss F, Wagner E. Epidermal growth factor
receptor and transforming growth factor alpha
expression in human ovarian carcinomas. Eur J
Cancer 1992;28A(8-9):1432-7.

Kohler MF, Kems BJ, Humphrey PA, Marks JR, Bast
RC Jr, Berchuck A. Mutation and overexpression of
p53 in early—stage epithelial ovarian cancer. Obstet
Gynecol 1993 May;81(5 Pt 1):643-50.

Kohler MF, Marks JR, Wiseman RW, Jacobs 1],
Davidoff AM, Clarke-Pearson DL, Soper JT, Bast
RC Jr, Berchuck A. Spectrum of mutation and
frequency of allelic deletion of the p53 gene in
ovarian cancer. J Natl Cancer Inst 1993 Sep 15;
85(18):1513—9.

Kohn E. Aging issues in invasion and metastasis.
Fertile ground for investigation. Cancer 1993
Jan 15;71(2 Suppl):552-7.

Kohn EC, Sandeen MA, Liotta LA. In vivo efficacy of
a novel inhibitor of selected signal transduction
pathways including calcium, arachidonate, and
inositol phosphates. Cancer Res 1992 Jun 1;52(11):
3208-12.

Kommoss F, Bauknecht T, Birmelin G, Kohler M,
Tesch H, Pfleiderer A. Oncogene and growth factor
expression in ovarian cancer. Acta Obstet Gynecol
Scand Suppl 1992;155:19-24.

Kommoss F, Pfisterer J, Thome M, Schafer W,
Sauerbrei W, Pfleiderer A. Steroid receptors in
ovarian carcinoma: immunohistochemical

determination may lead to new aspects. Gynecol
Oncol 1992 Dec;47(3):3l7-22.

Kotylo PK, Michael H, Fineberg N, Sutton G, Roth
LM. Flow cytometric analysis of DNA content and
RAS P21 oncoprotein expression in ovarian
neoplasms. Int J Gynecol Pathol 1992;11(1):30-7.

Krag DN, Haseman MK, Ford P, Smith L, Taylor MH,
Schneider P, Goodnight J E. Gamma probe location
of lllindium-labeled 872.3: an extension of
immunoscintigraphy. J Surg Oncol 1992 Dec;
51(4):226—30.

Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V,
Edgerton SM, Bell DA, Yandell DW. p53 gene
mutations and protein accumulation in human
ovarian cancer. Proc Natl Acad Sci U S A 1993
Jun 1;90(11):4961-5.

Labrecque S, Naor N, Thomson D, Matlashewski G.
Analysis of the anti—p53 antibody response in cancer
patients. Cancer Res 1993 Aug 1;53(15):3468-71.

Lage J M, Weinberg DS, Huettner PC, Mark SD. Flow
cytometric analysis of nuclear DNA content in

76

ovarian tumors. Association of ploidy with tumor
type, histologic grade, and clinical stage. Cancer
1992 Jun 1;69(11):2668-75.

Lai CH, Hsueh S, Lin CY, Huang MY, You GB,
Chang HC, Pao CC. Human papillomavirus in
benign and malignant ovarian and endometrial
tissues. Int J Gynecol Pathol 1992 Jul;11(3):210—5.

Langdon SP, Ritchie A, Young K, Crew AJ, Sweeting
V, Bramley T, Hillier S, Hawkins RA, Tesdale AL,
Smyth J F, et al. Contrasting effects of 17 beta-
estradiol on the growth of human ovarian carcinoma
cells in vitro and in vivo. Int J Cancer 1993 Sep 30;
55(3):459-64.

Lee CY, Chen KW, Sheu FS, Tsang A, Chao KC, Ng
HT. Studies of a tumor-associated antigen, COX-1,
recognized by a monoclonal antibody. Cancer
Immunol Immunother 1992;35(l):19-26.

Lee KS, Kim HK, Moon HS, Hong YS, Kang JH, Kim
DJ , Park JG. Effects of buthionine sulfoximine
treatment on cellular glutathione levels and
cytotoxicities of cisplatin, carboplatin and radiation
in human stomach and ovarian cancer cell lines.
Korean J Intern Med 1992 Jul;7(2):111—7.

Lee SM, Ham's M, Rennison J, McGown A, Bromley
M, Elder RH, Rafferty JA, Crowther D, Margison
GP. Expression of O6-alkylguanine—DNA—
alkyltransferase in situ in ovarian and Hodgkin’s
tumours. Eur J Cancer l993;29A(9):1306-12.

Leu JG, Jech KS, Wheeler NC, Chen BX, ERlanger
BF. Immunoassay of taxol and taxol-like

compounds in plant extracts. Life Sci 1993;
53(12):PL183—7.

Leung BS, Stout LE, Shaskan EG, Thompson RM.
Differential induction of indoleamine-2,3-
dioxygenase (IDO) by interferon-gamma in human
gynecologic cancer cells. Cancer Lett 1992 Sep 14;
66(1):77-81.

Levin L. Dose intensity in the treatment of ovarian
carcinoma. In: Markman M, Hoskins WJ, eds.
Cancer of the ovary. New York: Raven Press;
1993. p. 251-60.

Lewis AD, Duran GE, Lau DH, Sikic BI. Sensitization
of drug resistant human ovarian cancer cells to
cyanomorpholino doxorubicin (MRA-CN) by
modulation of glutathione metabolism. Int J Radiat
Oncol Biol Phys 1992;22(4):821-4.

Li BY, Mohanraj D, Olson MC, Moradi M, Twiggs L,
Carson LF, Ramakrishnan S. Human ovarian
epithelial cancer cells cultures in vitro express both
interleukin 1 alpha and beta genes. Cancer Res
1992 Apr 15;52(8):2248—52.

Li S, Han H, Resnik E, Carcangiu ML, Schwartz PE,
Yang-Feng TL. Advanced ovarian carcinoma:

molecular evidence of unifocal origin. Gynecol
Oncol 1993 Oct;51(1):21-5.

Lidor YJ, O’Briant KC, Xu FJ, Hamilton TC, Ozols
RF, Bast RC Jr. Alkylating agents and
immunotoxins exert synergistic cytotoxic activity

against ovarian cancer cells. Mechanism of action.
J Clin Invest 1993 Nov;92(5):2440-7.

Lidor Y], Xu FJ, Martinez-Maza O, Olt GJ, Marks JR,
Berchuck A, Ramakrishnan S, Berek J S, Bast RC
Jr. Constitutive production of macrophage colony—
stimulating factor and interleukin-6 by human
ovarian surface epithelial cells. Exp Cell Res 1993
Aug;207(2):332-9.

Locatelli MC, D’Antona A, Labianca R, Vinci M,
Tedeschi M, Carcione R, Corbo A, Venturino P,
Luporini G. A phase H study of combination
chemotherapy in advanced ovarian carcinoma with
cisplatin and cyclophosphamide plus reduced
glutathione as potential protective agent against
cisplatin toxicity. Tumori 1993 Feb 28;79(1):37-9.

Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR.
Reduced drug accumulation as a major mechanism
of acquired resistance to cisplatin in a human
ovarian carcinoma cell line: circumvention studies
using novel platinum (II) and (IV) ammine/amine
complexes. Br J Cancer 1992 Dec;66(6):1109—15.

Look KY, Sutton GP, Natsumeda Y, Eble JN, Stehman
FB, Ehrlich CE, Olah E, Prajda N, Bosze P,
Eckhardt S, et a1. Inhibition by tiazofurin of inosine
5’-phosphate dehydrogenase (IMP DH) activity in
extracts of ovarian carcinomas. Gynecol Oncol
1992 Oct;47(1):66-70.

Louie KG, Hamilton TC, Shoemaker RH, Young RC,
Ozols RF. Evaluation of in vitro drug screening
leads using experimental models of human ovarian
cancer. Invest New Drugs 1992 Jul;10(2):73-8.

Lucci JA 3d, Marietta A, Cappuccini F, Ininns EK,
Dett CA, DiSaia P, Yamamoto RS, Berman ML,
Soopikian J, Granger GA. Immunotherapy of
ovarian cancer. II. In vitro generation and
characterization of lymphokine-activated killer T
cells from the peripheral blood of recurrent ovarian
cancer patients. Gynecol Oncol 1992 May;45(2):
129-35.

Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler
KM, Kaubisch S, Halsey J, Sikic BI. Clinical trials
of modulation of multidrug resistance:
Pharmacokinetic and pharmacodynamic
considerations. Cancer 1993;72(11 Suppl):3502-14.

Luqmani YA, Ryall G, Shousha S, Coombes RC. An
immunohistochemical survey of p82 expression in
human epithelial cancers. Int J Cancer 1992 Jan 21;
50(2):3(YZ-4.

MacLean GD, Bowen-Yacyshyn MB, Samuel J, Meikle
A, Stuart G, Nation J, Poppema S, Jerry M,

 

Koganty R, Wong T, et al. Active immunization of
human ovarian cancer patients against a common
carcinoma (Thomsen-Friedenreich) determinant
using a synthetic carbohydrate antigen.

J Immunother 1992 May;11(4):292-305.

Maeda O, Terasawa M, Ishikawa T, Oguchi H, Mizuno
K, Kawai M, Kikkawa F, Tumoda Y, Hidaka H. A
newly synthesized bifunctional inhibitor, W-77,
enhances adriamycin activity against human ovarian
carcinoma cells. Cancer Res 1993 May 1;53(9):
2051-6.

Maenpaa J, Sipila P, Kangas L, Kamani P, Gronroos
M. Chemosensitizing effect of an antiestrogen,
toremifene, on ovarian cancer. Gynecol Oncol 1992
Sep;46(3):292-7.

Maguire RT, Pascucci VL, Maroli AN, Gulfo JV.
Immunoscintigraphy in patients with colorectal,
ovarian, and prostate cancer. Results with site-
specific immunoconjugates. Cancer 1993 Dec 1;
72(11 Suppl):3453-62.

Maher VE, Drukman SJ, Kinders RJ, Hunter RE,
Jennings J, Brigham C, Stevens S, Griffin TW.
Human antibody response to the intravenous and
intraperitoneal administration of the F(ab’)2
fragment of the 0C125 murine monoclonal
antibody. J Immunother 1992 Jan;11(1):56-66.

Maines-Bandiera SL, Kruk PA, Auersperg N. Simian
virus 40—transformed human ovarian surface
epithelial cells escape normal growth controls but
retain morphogenetic responses to extracellular
matrix. Am J Obstet Gynecol 1992 Sep;167(3):
729-35.

Malik ST, East N, Boraschi D, Balkwill FR. Effects of
intraperitoneal recombinant interleukin-1 beta in
intraperitoneal human ovarian cancer xenograft
models: comparison with the effects of tumour
necrosis factor. Br J Cancer 1992 May;65(5):661-6.

Malmstrom H. Prevention of complications of
subcutaneous peritoneal access devices in
intraperitoneal chemotherapy of ovarian carcinoma.
Eur J Gynaecol Oncol 1993;14(4):323-30.

Malmstrom H, Rasmussen S, Simonsen E.
Intrapcritoneal high-dose cisplatin and etoposide
with systemic thiosulfate protection in second-line
treatment of advanced ovarian cancer. Gynecol
Oncol 1993 May ;49(2): 166-71.

Maneschi F, Geraci P, Barreca PV, Palisi F, Adragna
F, Napoli M. Estradiol, progesterone, 17-
hydroxyprogesterone, androstenedione and CA 125

in patients with ovarian carcinoma. Gynecol
Endocrinol 1992 Mar;6(1):25—30.

Manetta A, Emma D, Fuchtner C, Gamboa—Vujicic G,
Paredes P, Lucci J, Gatanaga T, Granger G. Effect
of recombinant human tumor necrosis factor alpha

77

and dequalinium chloride on human ovarian cancer
cell lines in vitro. Int J Oncol 1993;3(1):127-33.

Manetta A, Emma D, Gamboa G, Liao S, Berman M,
DiSaia P. Failure to enhance the in vivo killing of
human ovarian carcinoma by sequential treatment

with dequalinium chloride and tumor necrosis
factor. Gynecol Oncol 1993 Jul;50(1):38-44.

Mans DR, Schuurhuis GJ, Treskes M, Lafleur MV,
Retel J, Pinedo HM, Lankelma J. Modulation by
D,L-buthionine—S,R-sulphoximine of etoposide
cytotoxicity on human non-small cell lung, ovarian

and breast carcinoma cell lines. Eur J Cancer 1992;
28A(8-9):1447-52.

Markman M. Current status of intraperitoneal therapy
for ovarian cancer. Curr Opin Obstet Gynecol 1993
Feb;5(1):99-104.

Markman M. Intrapcritoneal chemotherapy. In:
Markman M, Hoskins WJ, eds. Cancer of the
ovary. New York: Raven Press; 1993. p. 317-25.

Markman M. Intrapcritoneal therapy for treatment of
malignant disease principally confined to the
peritoneal cavity. Crit Rev Oncol Hematol 1993
Feb;14(1):15—28.

Markman M, Jones W, Lewis JL Jr, Rubin S, Hakes T,
Reichman B, Barakat R, Curtin J, Almadrones L,
Hoskins W. Impact of laparotomy finding of
significant intraabdominal adhesions on the
surgically defined complete response rate to
subsequent salvage intraperitoneal chemotherapy.

J Cancer Res Clin Oncol 1992;118(2):163-5.

Markman M, Reichman B, Hakes T, Barakat R, Curtin
J, Rubin S, Jones W, Lewis JL Jr, Almadrones L,
Hoskins W. Salvage intraperitoneal therapy of
small-volume residual ovarian cancer: impact of
pretreatment finding of peritoneal carcinomatosis on

the surgical complete response rate. J Cancer Res
Clin Oncol 1992;118(3):235-7.

Markman M, Reichman B, Hakes T, Curtin J, Jones
W, Lewis JL Jr, Barakat R, Rubin S, Mychalczak
B, Saigo P, et a1. Intrapcritoneal chemotherapy in
the management of ovarian cancer. Cancer 1993

Feb 15;71(4 Suppl): 1565-70.

Marth C, Cronauer MV, Doppler W, Ofner D, Ullrich
A, Daxenbichler G. Effects of interferons on the
expression of the proto-oncogene HER-2 in human
ovarian carcinoma cells. Int J Cancer 1992 Jan 2;
50(1):64-8.

Marth C, Lang T, Cronauer MV, Doppler W, Zeimet
AG, Bachmair F, Ullrich A, Daxenbichler G.
Epidermal growth factor reduces HER—2 protein
level in human ovarian carcinoma cells. Int J

Cancer 1992 Sep 9;52(2):311-6.

78

Marth C, Muller-Holzner E, Gaugg I, Daxenbichler G,
Dapunt 0. Modulation of ovarian carcinoma OV632
antigen by interferons. Oncology 1992;49(1):53-7.

Marth C, Zeirnet AG, Bock G, Daxenbichler G.
Modulation of tumour marker CA- 125 expression in

cultured ovarian carcinoma cells. Eur J Cancer
1992;28A(12):2002-6.

Martignone S, Pellegrini R, Villa E, Tandon NN,
Mastroianni A, Tagliabue E, Menard S, Colnaghi
MI. Characterization of two monoclonal antibodies
directed against the 67 kDa high affinity laminin
receptor and application for the study of breast
carcinoma progression. Clin Exp Metastasis 1992
Nov;10(6):379-86.

Martin AR, Kotylo PK, Kennedy JC, Fineberg NS,
Roth LM. Flow cytometric DNA analysis of
ovarian Brenner tumors and transitional cell
carcinomas. Int J Gynecol Pathol 1992 Jul;
11(3): 188-96.

Martinez-Mam O, Berek J S. Immunotherapy of ovarian
cancer. In: Markman M, Hoskins WJ, eds. Cancer
of the ovary. New York: Raven Press; 1993.
p. 301-16.

Massuger LF, Thomas CM, Segers MF, Corstcns FH,
Verheijen RH, Kenemans P, Poels LG. Specific and
nonspecific immunoassays to detect HAMA after
administration of indium-lll—labeled OV-TL 3
F(ab’)2 monoclonal antibody to patients with
ovarian cancer. J Nucl Med 1992 Nov;33(11):
1958-63.

Mazzoni A, Trave F. Cytoplasmic membrane
cholesterol and doxorubicin cytotoxicity in drug—
sensitive and multidrug—resistant human ovarian
cancer cells. Oncol Res 1993;5(2):75-82.

McClay EF, Albright KD, Jones JA, Christen RD,
Howell SB. Tamoxifen modulation of cisplatin
cytotoxicity in human malignancies. Int J Cancer
1993 Dec 2;55(6):1018-22.

McClay EF, Goel R, Andrews P, Gorelick S, Kirmani
S, Kim S, Braly P, Plaxe S, Hoff S, Alcaraz J, et
al. A phase I and pharmacokinetic study of
intraperitoneal carboplatin and etoposide. Br J
Cancer 1993 Oct;68(4):783-8.

McClay EF, Howell SB. Intraperitoneal therapy in the
management of patients with ovarian cancer.
Hematol Oncol Clin North Am 1992 Aug;6(4):
915-26.

McGuire WP. Experimental agents (nonbiologicsl) in
ovarian cancer. In: Markman M, Hoskins WJ, eds.
Cancer of the ovary. New York: Raven Press;
1993. p. 287-300.

McGuire WP. Ovarian cancer. Experimental
chemotherapy. Hematol Oncol Clin North Am 1992
Aug;6(4):927-40.

McKenzie SJ, DeSombre KA, Bast BS, Hollis DR,
Whitaker RS, Berchuck A, Boyer CM, Bast RC Jr.
Serum levels of HER-2 neu (C-erbB-Z) correlate
with overexpression of p185neu in human ovarian
cancer. Cancer 1993 Jun 15;71(12):3942—6.

Melioli G, Ferrari I, Casartelli G, Ragni N.
Lymphocytes isolated from the peritoneal fluid of
women with advanced ovarian carcinoma differ
significantly from autologous peripheral blood
lymphocytes. Gynecol Oncol 1993 Mar;48(3):
301—7.

Micelli G, Lozupone A, Quaranta M, Donadeo A,
Coviello M, Lorusso V. Determination of
intraperitoneal mitoxantrone in the serum of cancer
patients using a high performance liquid
chromatograph coupled to an Advanced Automated
Sample Processor (AASP). Biomed Chromatogr
1992 Jul-Aug;6(4):168-7l.

Mileo AM, Fanuele M, Battaglia F, Scambia G,
Benedetti-Panici C, Mattei E, Mancuso S, Delpino
A. Preliminary evaluation of HER-Z/neu oncogene
and epidermal growth factor receptor expression in
normal and neoplastic human ovaries. Int J Biol
Markers 1992 Apr-Jun;7(2):114—8.

Mileo AM, Fanuele M, Battaglia F, Scambia G,
Benedetti-Panici C, Mattei E, Mancuso S, Delpino
A. Preliminary evaluation of HER-Z/neu oncogene
and epidermal growth factor receptor expression in
normal and neoplastic human ovaries. Int J Biol
Markers 1992 Jan-Mar;7(1):47-51.

Milner BJ, Allan LA, Eccles DM, Kitchener HC,
Leonard RC, Kelly KF, Parkin DE, Haites NE. p53
mutation is a common genetic event in ovarian
carcinoma. Cancer Res 1993 May 1;53(9):2128—32.

Miotti S, Alberti S, Facheris P, Mantovani L, Fomaro
M, Stella M, Menard S, Canevari S, Colnaghi MI.
Membrane association and shedding of the GH-
anchored Ca-M0v18 antigen in human ovary
carcinoma cells. Int J Cancer 1992 May 28;
51(3):499-505.

Mirshahi SS, Vasse M, Soria C, Moreau JF, Taupin
JL, Mirshahi M, Pujade—Lauraine E, Bemadou A,
Soria J. Incubation of monocytes with adriamycin
increases secretion of hepatocyte stimulating factor
for fibrinogen biosynthesis. Blood Coagul
Fibrinolysis 1993 Feb;4(1):149—52.

Misawa T, Kikkawa F, Oguchi H, Morikawa Y, Kawai
M, Maeda O, Iwata M, Kano T, Furuhashi Y,
Tomada Y. Accumulation of cis—
diamminedichloroplatinum (II) and its analogues in
sensitive and resistant human ovarian carcinoma
cells. Oncology 1992;49(3):173-9.

Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA,
Harrap KR. Comparison of cellular accumulation
and cytotoxicity of cisplatin with that of tetraplatin
and amminedibutyratodichloro(cyclohexylamine)

platinum(IV) (J M221) in human ovarian carcinoma
cell lines. Cancer Res 1992 Nov 15;52(22):
6188-93.

Mistry P, Loh SY, Kelland LR, Harrap KR. Effect of
buthionine sulfoximine on PtII and PtIV drug
accumulation and the formation of glutathione
conjugates in human ovarian-carcinoma cell lines.
Int J Cancer 1993 Nov 11;55(5):848—56.

Mittal KR, Zeleniuch-Jacquotte A, Cooper JL,
Demopoulos RI. Contralateral ovary in unilateral
ovarian carcinoma: a search for preneoplastic
lesions. Int J Gynecol Pathol 1993 Jan;12(1):59-63.

Mizutani Y, Bonavida B. Overcoming cis-
diamminedichloroplatinum (II) resistance of human
ovarian tumor cells by combination treatment with
cis-diamminedichloroplatinum (II) and tumor
necrosis factor-alpha. Cancer 1993 Aug l;72(3):
809-18.

Mobus V, Gerharz CD, Press U, Moll R, Beck T,
Mellin W, Pollow K, Knapstein PG, Kreienberg R.
Morphological, immunohistochemical and
biochemical characterization of 6 newly established
human ovarian carcinoma cell lines. Int J Cancer
1992 Aug 19;52(1):76-84.

Mochizuki H, Sato 1, Nagoya K, Furusako S,
Yamauchi T, Masuko H, Sato H, Morishita H,
Yajima M, Sasaki H, et al. An
immunoenzymometric assay for a CA125—like
antigen, CA602. J Clin Lab Anal 1992;6(2):84—90.

Mogcnsen O, Mogensen B. Measurement of CA 125 by
an automated microparticle enzyme immunoassay;
comparison with a manual enzyme immunoassay.
Scand J Clin Lab Invest 1992 0ct;52(6):507-12.

Mok CH, Tsao SW, Knapp RC, Fishbaugh PM, Lau
CC. Unifocal origin of advanced human epithelial

ovarian cancers. Cancer Res 1992 Sep 15;52(18):
5119-22.

Molthoff CF, Pinedo HM, Schluper HM, Boven E.
Influence of dose and schedule on the therapeutic
efficacy of 13ll-labelled monoclonal antibody
139H2 in a human ovarian cancer xenograft model.
Int J Cancer 1992 Feb 1;50(3):474—80.

Molthoff CF, Pinedo HM, Schluper HM, Nijman HW,
Boven E. Comparison of the pharmacokinetics,
biodistn'bution and dosimetry of monoclonal
antibodies 0C125, OV-TL 3, and 139H2 as IgG
and F(ab’)2 fragments in experimental ovarian
cancer. Br J Cancer 1992 May;65(5):677—83.

Molthoff CF, Pinedo HM, Schluper HM, Rutgers DH,
Boven E. Comparison of 131I-labelled anti-episialin
139H2 with cisplatin, cyclophosphamide or
extemal-beam radiation for anti-tumor efficacy in
human ovarian cancer xenografts. Int J Cancer 1992
Apr 22;51(1):108—15.

79

Monti E, Mimnaugh EG, Sinha BK. Synergistic
antiproliferative effects of interleukin-1 alpha and
doxorubicin against the human ovarian carcinoma
cell line (NIH:OVCAR-3). Biochem Pharmacol
1993 May 25;45(10):2099-107.

Moradi MM, Carson LF, Weinberg B, Haney AF,
Twiggs LB, Ramakrishnan S. Serum and ascitic
fluid levels of interleukin-1, interleukin-6, and
tumor necrosis factor-alpha in patients with ovarian
epithelial cancer. Cancer 1993 Oct 15;72(8):
2433-40.

Morimitsu Y, Yano H, Kojiro M. Morphologic
characteristics, proliferation, and tumor marker
expression of two human ovarian carcinoma cell
lines in three-dimensional culture. Gynecol Oncol
1993 Feb;48(2):155-64.

Muggia FM, LePoidevin E, Jeffers S, Russell C,
Boswell W, Morrow CP, Curtin J, Schlaerth J.
Intraperitoneal therapy for ovarian cancer: analysis
of fluid distribution by computerized tomography.
Ann Oncol 1992 Feb;3(2):149-54.

Murphy D, McGown AT, Bromley M, Tsuruo T,
Crowther D, Fox BW. P—glycoprotein expression in
ovarian tumour biopsies taken before or afier
cytotoxic chemotherapy. J Obstet Gynecol 1992;
12(4):269-73.

Murphy D, McGown AT, Hall A, Cattan A, Crowther
D, Fox BW. Glutathione S-transferase activity and
isoenzyme distribution in ovarian tumour biopsies
taken before or afier cytotoxic chemotherapy. Br J
Cancer 1992 Nov;66(5):937-42.

Mutch DG, Herzog T], Chen CA, Collins IL. The
effects of cyclosporin A on the lysis of ovarian
cancer cells by cisplatin or adriamycin. Gynecol
Oncol 1992 Oct;47(1):28-33.

Mutch DG, Powell CB, Kao MS, Collins IL.
Resistance to cytolysis by tumor necrosis factor
alpha in malignant gynecological cell lines is
associated with the expression of protein(s) that
prevent the activation of phospholipase AZ by tumor
necrosis factor alpha. Cancer Res 1992 Feb 15;
52(4):866—72.

Naito M, Oh-hara T, Yamazaki A, Danki T, Tsuruo T.
Reversal of multidrug resistance by an
immunosuppressive agent FK-506. Cancer
Chemother Phannacol 1992;29(3):195-200.

Naito M, Satake M, Sakai E, Hirano Y, Tsuchida N,
Kanzaki H, Ito Y, Mori T. Detection of p53 gene
mutations in human ovarian and endometrial
cancers by polymerase chain reaction-single strand
conformation polymorphism analysis. Jpn J Cancer
Res 1992 0ct;83(10):1030—6.

Nakopoulou L, Janinis J, Panagos G, Comin G,
Davan's P. The immunohistochemical expression of
proliferating cell nuclear antigen (PCNA/cyclin) in

80

malignant and benign epithelial ovarian neoplasms
and correlation with prognosis. Eur J Cancer 1993;
29A(11):1599-601.

Nassander UK, Steerenberg PA, Poppe H, Storm G,
Poels LG, De Jong WH, Crommelin DJ. In vivo
targeting of OV-TL 3 immunoliposomes to ascitic
ovarian carcinoma cells (OVCAR-3) in athymic
nude mice. Cancer Res 1992 Feb 1;52(3):646—53.

Naumann RW, Alvarez RD, Partridge EE, Kilgore LC,
Austin J M. The Groshong catheter as an
intraperitoneal access device in the treatment of
ovarian cancer patients. Gynecol Oncol 1993 Sep;
50(3):291-3.

Naylor MS, Stamp GW, Foulkes WD, Eccles D,
Balkwill FR. Tumor necrosis factor and its
receptors in human ovarian cancer. Potential role in
disease progression. J Clin Invest 1993 May;91(5):
2194-206.

Neungton N, Moongkamdi P, Laohathai K, Neungton
S, Juntrachotiwit P. Immuno-histological
characterization of OVSl and OVS2 monoclonal
antibodies recognizing human ovarian mucinous
cystadenocarcinoma. Asian Pac J Allergy Immunol
1992 Dec;10(2):129-34.

Neven P, Iles RK, Lee CL, Hudson CN, Shepherd JH,
Chard T. Urinary chorionic gonadotropin subunits
and beta-core in nonpregnant women. A study of

benign and malignant gynecologic disorders. Cancer
1993 Jun 15;7l(12):4124-30.

Nguyen HN, Averette HE, Wyble L, Sevin BU, Donato
D, Penalver M. Preliminary experience with a
modified Tenckhoff catheter for intraperitoneal
chemotherapy. J Surg Oncol 1993 Apr;52(4):
237-40.

Nguyen HN, Sevin BU, Averette HE, Perras J, Ramos
R, Donato D, Ochiai K, Penalver M. Cell cycle
perturbations of platinum derivatives on two ovarian
cancer cell lines. Cancer Invest 1993;11(3):264-75.

Nicoletti MI, Lucchini V, Massazza G, Abbott BJ,
D’Incalci M, Giavazzi R. Antitumor activity of
taxol (NSC-125973) in human ovarian carcinomas
growing in the peritoneal cavity of nude mice. Ann
Oncol 1993 Feb;4(2):151-5.

Niimi S, Nakagawa K, Sugimoto Y, Nishio K,
Fujiwara Y, Yokoyama S, Terashima Y, Saijo N.
Mechanism of cross-resistance to a camptothecin
analogue (CRT-11) in a human ovarian cancer cell
line selected by cisplatin. Cancer Res 1992 Jan 15;
52(2):328-33.

O’Briant K, Chrysson N, Hunter V, Tyson F, Tanner
M, Daly L, George SL, Berchuck A, Soper J,
Fowler W, et al. Ha—ras polymorphisms in
epithelial ovarian cancer. Gynecol Oncol 1992 Jun;
45(3):299-302.

Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC
Jr. Fibronectin is an immunosuppressive substance
associated with epithelial ovarian cancer. Cancer
1992 Oct 15;70(8):2137-42.

Orengo G, Noviello E, Cimoli G, Pagnan G, Parodi S,
Venturini M, Conte P, Schenone F, Conzi G,
Russo P. Potentiation of topoisomerase I and H
inhibitors cell killing by tumor necrosis factor:
relationship to DNA strand breakage formation. Jpn
J Cancer Res 1992 Nov;83(11):1132-6.

Owens OJ, Mutch F. Immunocytochemical staining of
ovarian tumours with Ov632. Cytopathology
1992;3(3):161-6.

Owens OJ, Stewart C, Leake RE, McNicol AM. A
comparison of biochemical and
immunohistochemical assessment of EGFR
expression in ovarian cancer. Anticancer Res 1992
Sep—Oct; 12(5): 1455-8 .

Owens OJ, Taggart C, Wilson R, Walker JJ, McKillop
JH, Kennedy J H. Interleukin-2 receptor and ovarian
cancer. Br J Cancer 1993 Aug;68(2):364—7.

Ozols RF. Advances in the chemotherapy of
gynecologic malignancies. Hematol Oncol 1992 Jan-
Feb;10(1):43-51.

Ozols RF. Chemotherapy for advanced epithelial
ovarian cancer. Hematol Oncol Clin North Am
1992 Aug;6(4):879-94.

Ozols RF. New developments with carboplatin in the
treatment of ovarian cancer. Semin Oncol 1992
Feb;19(1 Suppl 2):85-9.

Ozols RF. Ovarian cancer, Part 11: Treatment. Curr
Probl Cancer 1992 Mar-Apr;16(2):61-126.

Ozols RF. Role of carboplatin in ovarian cancer.
Current results and thoughts for the future. Acta
Obstet Gynecol Scand Suppl 1992;155:75-7.

Ozols RF. Role of chemotherapy in the future treatment

of ovarian cancer. Acta Obstet Gynecol Scand
Suppl 1992;155:55-60.

Ozols RF, O’Dwyer PJ, Hamilton TC. Clinical reversal
of drug resistance in ovarian cancer. Gynecol Oncol
1993 Oct;51(1):90-6.

Ozols RF, O’Dwyer PJ, Hamilton TC. Drug resistance
in ovarian cancer. In: Markman M, Hoskins WJ,
eds. Cancer of the ovary. New York: Raven Press;
1993. p. 261-76.

Paganelli G, Belloni C, Magnani P, Zito F, Pasini A,
Sassi I, Meroni M, Mariani M, Vignali M, Siccardi
AG, et al. Two-step tumour targetting in ovarian
cancer patients using biotinylated monoclonal
antibodies and radioactive streptavidin. Eur J Nucl
Med 1992;19(5):322-9.

Pantazis P, Korzielski A], Mendoza JT, Early JA, Hinz
HR, Giovanella BC. Camptothecin derivatives
induce regression of human ovarian carcinomas
grown in nude mice and distinguish between non—

tumorigenic and tumorigenic cells in vitro. Int J
Cancer 1993 Mar 12;53(5):863—7l.

Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E.
Ormaplatin sensitivity/resistance in human ovarian
cancer cells made resistant to cisplatin. Cancer Res
1993 Jan 15;53(2):242-7.

Pearson JW, Fogler WE, Volker K, Riggs CW, Gruys
E, Groves ES, Wiltrout RH, Longo DL.
Restoration of interferon alpha potentiation of a
recombinant ricin A chain immunotoxin following
cytoreduction of xenografts of advanced ovarian
tumors. J Natl Cancer Inst 1993 Jun 2;85(11):
907-12.

Pedersen N, Schmitt M, Ronne E, Nicoletti MI, Hoyer-
Hansen G, Conese M, Giavazzi R, Dano K, Kuhn
W, Janicke F, et al. A ligand-free, soluble
urokinase receptor is present in the ascitic fluid
from patients with ovarian cancer. J Clin Invest
1993 Nov;92(5):2160—7.

Pejovic T, Himmelmann A, Heim S, Mandahl N,
Floderus UM, Furgyik S, Elmfors B, Helm G,
Willen H, Mitelman F. Prognostic impact of
chromosome aberrations in ovarian cancer. Br J
Cancer 1992 Feb;65(2):282—6.

Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D,
Yarden Y. Cell-type specific interaction of Neu
differentiation factor (NDF/heregulin) with
Neu/HER-2 suggests complex ligand-receptor
relationships. EMBO J 1993 Mar;12(3):961-71.

Peoples GE, Davey MP, Goedegebuure PS, Schoof
DD, Eberlein TJ. T cell receptor V beta 2 and V
beta 6 mediate tumor-specific cytotoxicity by tumor-
infiltrating lymphocytes in ovarian cancer.

J Immunol 1993 Nov 15;151(10):5472-80.

Peoples GE, Goedegebuure PS, Andrews JV, Schoof
DD, Eberlein TJ. HLA-AZ presents shared tumor-
associated antigens derived from endogenous

proteins in ovarian cancer. J Immunol 1993
Nov 15;]51(10):5481—91.

Peoples GE, Schoof DD, Andrews JV, Goedegebuure
PS, Eberlein TJ. T-cell recognition of ovarian
cancer. Surgery 1993 Aug;114(2):227-34.

Perez RP, Godwin AK, Handel LM, Hamilton TC. A
comparison of clonogenic, microtetrazolium and
sulforhodamine B assays for determination of
cisplatin cytotoxicity in human ovarian carcinoma
cell lines. Eur J Cancer l993;29A(3):395-9.

Perez RP, Hamaguchi K, Tracey PA, Handel LM,
Hamilton TC, Godwin AK. Transformation of rat
ovarian epithelial and Rat-l fibroblast cell lines by

81

RAST24 does not influence cisplatin sensitivity.
Cancer Res 1993 Aug 15;53(16):3771-5.

Perez RP, Hamilton TC, Ozols RF, Young RC.
Mechanisms and modulation of resistance to
chemotherapy in ovarian cancer. Cancer 1993
Feb 15;71(4 Suppl):1571-80.

Perez RP, Handel LM, Hamilton TC. Potentiation of
cisplatin cytotoxicity in human ovarian carcinoma
cell lines by trifluoperazine, a calmodulin inhibitor.
Gynecol Oncol 1992 Jul;46(l):82-7.

Perez RP, Perez KM, Handel LM, Hamilton TC. In
vitro interactions between platinum analogues in
human ovarian-carcinoma cell lines. Cancer
Chemother Pharmacol 1992;29(6):430—4.

Perkins AC, Symonds IM, Pimm MV, Price MR,
Wastie ML, Symonds EM. Immunoscintigraphy of
ovarian carcinoma using a monoclonal antibody
(1111n—NCRC48) defining a polymorphic epithelial
mucin (PEM) epitope. Nucl Med Commun 1993
Jul;14(7):578-86.

Perras JP, Ramos R, Sevin BU. Demonstration of an S
phase population of cells without DNA synthesis
generated by cisplatin and pentoxifylline. Cytometry
1993;14(4):441-8.

Peterson CM, Reed R, Jolles CJ, Jones KP, Straight
RC, Poulson AM. Photodynamic therapy of human
ovarian epithelial carcinoma, OVCAR-3,
heterotransplanted in the nude mouse. Am J Obstet
Gynecol 1992 Dec;167(6):1852—5.

Pettersen E0, Larsen R0, Domish JM, Borretzen B,
Juul ME, Aastveit TE, Nesland JM, Rofstad EK,
Oftebro R. Tumour necrotisation in nude mice
xenografts by the reversible protein synthesis
inhibitor zilascorb(2H). Br J Cancer 1993 Apr;
67(4):650—6.

Pico JL, Ibrahim A, Castagna L, Bourhis JH, Chazard
M, Maraninchi D, Droz JP. Escalating high-dose
carboplatin and autologous bone marrow
transplantation in solid tumors. Oncology 1993
Nov;50 Suppl 2:47-52.

Pirovano C, Balzarini A, Bohm S, Oriana S, Spatti GB,
Zunino F. Peripheral neurotoxicity following high-
dose cisplatin with glutathione: clinical and
neurophysiological assessment. Tumori 1992
Aug 31;78(4):253-7.

Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht
A, Gerdin B, Kiessling R. Selective expression of
interleukin 10, interferon gamma, and granulocyte-
macrophage colony-stimulating factor in ovarian
cancer biopsies. Proc Natl Acad Sci U S A 1992
Aug 15;89(16):7708-12.

Plante M, Wong GY, Nisselbaum JS, Almadrones L,
Hoskins WJ, Rubin SC. Relationship between saliva
and serum CA 125 in women with and without

82

epithelial ovarian cancer. Obstet Gynecol 1993 Jun;
81(6):989-92.

Platsoucas CD, Freedman RS. Tumor-infiltrating

lymphocytes in gene therapy. Cancer Bull
1993;45(2):118-24.

Plumb JA, Luo W, Kerr DJ. Effect of polyunsaturated
fatty acids on the drug sensitivity of human tumour

cell lines resistant to either cisplatin or doxorubicin.

Br J Cancer 1993 Apr;67(4):728-33.

Poirier MC, Shamkhani H, Reed E, Tarone RE, Gupta-
Burt S. DNA adducts induced by platinum drug

chemotherapeutic agents in human tissues. Prog
Clin Biol Res 1992;374:197-212.

Poplin E, Smith H, Behrens B, Redman B, Flaherty L,
Neidhart J, Alberts D. SWOG 8825: melphalan
GM-CSF: a phase I study. Gynecol Oncol 1992
Jan;44(1):66-70.

Porter PL, Gown AM, Krarnp SG, Coltrera MD.
Widespread p53 overexpression in human maligth
tumors. An immunohistochemical study using
methacarn-fixed, embedded tissue. Am J Pathol
1992 Jan;l40(1):145-53.

Powell CB, Horuchi T, Kao MS, Collins JL. Interferon
alfa activates a lytic mechanism in ovarian and

cervical carcinoma cells. Am J Obstet Gynecol
1993 Sep;169(3):661-7.

Powell CB, Manning K, Collins JL. Interferon-alpha
(IFN alpha) induces a cytolytic mechanism in
ovarian carcinoma cells through a protein kinase C-
dependent pathway. Gynecol Oncol 1993 Aug;
50(2):208- 14.

Powell DE, Puls L, van Nagell J Jr. Current concepts
in epithelial ovarian tumors: does benign to
malignant transformation occur? Hum Pathol 1992
Aug;23(8):846-7. Comment in: Hum Pathol 1992
Aug;23(8):845 and Hum Pathol 1993
May;24(5):562-3.

Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox
BW, McGown A, Testa N, Stern P, McDermott R,
Potter M, et al. A phase I study of intravenous
bryostatin 1 in patients with advanced cancer. Br J
Cancer 1993 Aug;68(2):418-24.

Price FV, Chambers SK, Chambers JT, Carcangiu ML,
Schwartz PE, Kohom EI, Stanley ER, Kacinski
BM. Colony-stimulating factor-1 in primary ascites
of ovarian cancer is a significant predictor of
survival. Am J Obstet Gynecol 1993 Feb;168(2):
520-7.

Prosperi E, Sala E, Negri C, Oliani C, Supino R,
Astraldi Ricotti GB, Bottiroli G. Topoisomerase II
alpha and beta in human tumor cells grown in vitro
and in vivo. Anticancer Res 1992 Nov-Dec;12(6B):
2093—9.

Provencher DM, Finstad CL, Saigo PE, Rubin SC,
Hoskins WJ , Federici MG, Stockert E, Lloyd KO,
Lewis J L Jr. Comparison of antigen expression on
fresh and cultured ascites cells and on solid tumors

of patients with epithelial ovarian cancer. Gynecol
Oncol 1993 Jul;50(1):78-83.

Pujade—Lauraine E, Lu H, Mirshahi S, Soria J, Soria C,
Bemadou A, Kruithof EK, Lijnen HR, Burtin P.
The plasminogen—activation system in ovarian
tumors. Int J Cancer 1993 Aug 19;55(1):27-31.

Pupa SM, Bazzini P, Menard S, Colnaghi MI. Network
of idiotypic and anti-idiotypic antibodies related to
the ovarian carcinoma-associated folate binding
protein. Anticancer Res 1992 Sep—Oct;12(5):
1565-70.

Qian H, Feng J, Cui H, Gao B, Qi G, Fu T, Wei P, Fu
Z. Clinical evaluation of radioimmunoimaging with
l311—COC183BZ monoclonal antibody against
ovarian carcinoma by intraperitoneal injection.

Gynecol Oncol 1992 Nov;47(2):216-22.

Qian HN, Li WJ . Target therapy of ovarian carcinoma
by monoclonal antibodies bearing chemical drugs
entrapped in liposomes. Chin Med J (Engl) 1993
May;106(5):343-7.

Rader J S. Therapeutic advances in ovarian cancer. Curr
Opin Obstet Gynecol 1992 Feb;4(1):120—7.

Redmond A, Moran E, Clynes M. Multiple drug
resistance in the human ovarian carcinoma cell line
OAW42-A. Eur J Cancer 1993;29A(8):1078-81.

Ridderheim M, Mahlck CG, Selstam G, Stendahl U,
Backstrom T. Steroid production in different parts
of malignant and benign ovarian tumors in vitro.
Cancer Res 1993 May 15;53(10 Suppl):2309-12.

Risteli L, Risteli J, Puistola U, Tomas C, Zhu GG,
Kauppila A. Aminoterminal propeptide of type [II
procollagen in ovarian cancer. A review. Acta
Obstet Gynecol Scand Suppl 1992;155:99-103.

Rodriguez GC, Boente MP, Berchuck A, Whitaker RS,
O’Briant KC, Xu F, Bast RC Jr. The effect of
antibodies and immunotoxins reactive with
HER-Z/neu on growth of ovarian and breast cancer
cell lines. Am J Obstet Gynecol 1993 Jan;

168(1 Pt 1):228-32.

Rosen A, Sevelda P, Klein M, Dobianer K, Hruza C,
Czerwenka K, Hanak H, Vavra N, Salzer H,
Leodolter S, et al. First experience with FGF-3
(INT -2) amplification in women with epithelial
ovarian cancer. Br J Cancer 1993 May;67(5):
1122-5.

Rotmensch J, Atcher RW, Schwartz J L, Grdina DJ.
Analysis of ascites from patients with ovarian

carcinoma by cell flow cytometry. Gynecol Oncol
1992 Jan;44(l):10-2.

Rowlands C, Krishnan V, Wang X, Santostefano M,
Safe S, Miller WR, Langdon S. Characterization of
the aryl hydrocarbon receptor and aryl hydrocarbon
responsiveness in human ovarian carcinoma cell
lines. Cancer Res 1993 Apr 15;53(8):1802-7.

Rubin SC. Monoclonal antibodies in the management of
ovarian cancer. A clinical perspective. Cancer 1993
Feb 15;71(4 Suppl):16(T2-12.

Rubin SC, Finstad CL, Wong GY, Almadrones L,
Plante M, Lloyd K0. Prognostic significance of
HER-Z/neu expression in advanced epithelial
ovarian cancer: a multivariate analysis. Am J Obstet
Gynecol 1993 Jan;168(1 Pt 1):162-9.

Rubin SC, Kairemo KJ, Brownell AL, Daghighian F,
Federici MG, Pentlow KS, Finn RD, Lambrecht
RM, Hoskins WJ, Lewis JL Jr, et a]. High-
resolution positron emission tomography of human
ovarian cancer in nude rats using 124I-labeled
monoclonal antibodies. Gynecol Oncol 1993 Jan;
48(1):61-7.

Rubin SC, Kostakoglu L, Divgi C, Federici MG,
Finstad CL, Lloyd KO, Larson SM, Hoskins WJ .
Biodistribution and intraoperative evaluation of
radiolabeled monoclonal antibody MX35 in patients
with epithelial ovarian cancer. Gynecol Oncol 1993
Oct;51(1):61-6.

Rughetti A, Turchi V, Ghetti CA, Scambia G, Panici
PB, Roncucci G, Mancuso S, Frati L, Nuti M.
Human B-cell immune response to the polymorphic
epithelial mucin. Cancer Res 1993 Jun 1;53(11):
2457-9.

Russo P, Parodi S, Billi G, Oliva C, Venturini M,
Noviello E, Conte P. Potentiation by tumor necrosis
factor of mitoxantrone cytotoxicity to human

ovarian cancer cell lines. Jpn J Cancer Res 1992
Jul;83(7):684-7.

Rusthoven JJ, Eisenhauer E, Mazurka J, Hirte H,
O’Connell G, Muldal A, Lu I-IX, Onetto N,
Swenerton K, Jeffrey J. Phase I clinical trial of
recombinant human interleukin-3 combined with
carboplatin in the treatment of patients with
recurrent ovarian carcinoma. J Natl Cancer Inst
1993 May 19;85(10):823-5.

Ryuko K, Iwanari O, Kitao M, Moriwaki S.
Immunohistochemical evaluation of sialosyl-Tn
antigens in various ovarian carcinomas. Gynecol
Oncol 1993 May;49(2):215-24.

Ryuko K, Iwanari O, Nakayama S, Iida K, Kitao M.
Clinical evaluation of serum sialosyl-Tn antigen
levels in comparison with CA 125 levels in
gynecologic cancers. Cancer 1992 May l;69(9):
2368-78.

Safrit JT, Berek J S, Bonavida B. Sensitivity of drug-
resistant human ovarian tumor cell lines to
combined effects of tumor necrosis factor (TNF-

83

alpha) and doxorubicin: failure of the combination
to modulate the MDR phenotype. Gynecol Oncol
1993 Feb;48(2):214—20.

Sasano H, Garrett CT. Oncogenes in gynecological
tumors. Curr Top Pathol 1992;85:357-72.

Sasano H, Nagura H, Silverberg SG.
Immunolocalization of c-myc oncoprotein in
mucinous and serous adenocarcinomas of the ovary.
Hum Pathol 1992 May;23(5):491-5.

Sass GL, Mohler JD, Walsh RC, Kalfayan LJ, Searles
LL. Structure and expression of hybrid dysgenesis-
induced alleles of the ovarian tumor (otu) gene in
Drosophila melanogaster. Genetics 1993 Feb;
133(2):253-63.

Saunders DE, Christensen C, Lawrence WD, Malviya
VK, Malone JM, Williams JR, Deppe G. Receptors
for 1,25-dihydroxyvitamin D3 in gynecologic
neoplasms. Gynecol Oncol 1992 Feb;44(2):131-6.

Saunders DE, Christensen C, Wappler NL, Schultz J F ,
Lawrence WD, Malviya VK, Malone JM, Deppe
G. Inhibition of c-myc in breast and ovarian
carcinoma cells by 1,25-dihydroxyvitamin D3,
retinoic acid and dexamethasone. Anticancer Drugs
1993 Apr;4(2):201-8.

Savino L, Baldini B, Susini T, Pulli F, Antignani L,
Massi GB. GnRH analogs in gynecological
oncology: a review. J Chemother 1992 Oct;4(5):
312-20.

Scambia G, Benedetti Panici P, Battaglia F, Ferrandina
G, Baiocchi G, Greggi S, De Vincenzo R, Mancuso
S. Significance of epidermal grth factor receptor
in advanced ovarian cancer. J Clin Oncol 1992 Apr;
10(4):529-35.

Scambia G, Catozzi L, Panici PB, Ferrandina G,
Coronetta F, Barozzi R, Baiocchi G, Uccelli L,
Piffanelli A, Mancuso S. Expression of ras
oncogene p21 protein in normal and neoplastic
ovarian tissues: correlation with histopathologic
features and receptors for estrogen, progesterone,
and epidermal growth factor. Am J Obstet Gynecol
1993 Jan;168(1 Pt 1):71-8.

Scambia G, Panici PB, Pierelli L, Baiocchi G, Rumi C,
Menichella G, Foddai ML, Serafini R, Arno E,
Bonanno G, et a1. Immunological reconstitution
after high—dose chemotherapy and autologous blood
stem cell transplantation for advanced ovarian
cancer. Eur J Cancer 1993;29A(11):1518-22.

Scambia G, Ranelletti F0, Benedetti Panici P, Piantelli
M, De Vincenzo R, Bonanno G, Ferrandina G,
Isola G, Mancuso S. Synergistic antiproliferative
activity of tamoxifen and cisplatin on primary
ovarian tumours. Eur J Cancer 1992;28A(11):
1885-9.

84

Scheim DE, Lin JY. Glucose effects in an ovarian
cancer protocol of exceptional activity. Med
Hypotheses 1993 Apr;40(4):235-44.

Schilder RJ, Ozols RF. New therapies for ovarian
cancer. Cancer Invest 1992;10(4):3U7-15.

Schisselbauer JC, Hogan WM, Buetow KH, Tew KD.
Heterogeneity of glutathione S-transferase enzyme
and gene expression in ovarian carcinoma.
Pharmacogenetics 1992 Apr;2(2):63—72.

Schmidt W, Chaney SG. Role of carrier ligand in
platinum resistance of human carcinoma cell lines.
Cancer Res 1993 Feb 15;53(4):799—805.

Schneider-Gadicke E, Humm J L, Lau CC, Macklis
RM, Bastert G, Knapp RC. Analysis of cytotoxicity
of 131I-labelled OC125 F(ab’)2 on human epithelial
ovarian cancer cell lines. Radiother Oncol 1992
Mar;23(3):150—9.

Schwartz PE, Chambers JT. Hormone therapy in
ovarian cancer. In: Markman M, Hoskins WJ, eds.

Cancer of the ovary. New York: Raven Press;
1993. p. 339-48.

See WA, Xia Q. Regional chemotherapy for bladder
neoplasms using continuous intravesical infusion of
doxorubicin: impact of concomitant administration
of dimethyl sulfoxide on drug absorption and
antitumor activity. J Natl Cancer Inst 1992 Apr 1;
84(7):510—5.

Segna RA, Dottino PR, Jennings TS, Cohen CJ.
Feasibility of intraoperative administration of
chemotherapy for gynecologic malignancies:
assessment of acute postoperative morbidity.
Gynecol Oncol 1993 Feb;48(2):227-31.

Sehy DW, Shao LE, Rideout D, Yu J. Sensitivity of
committed hematopoietic progenitor cells in vitro
(BFU—E, CFU—E, CFU-GM) and two human
carcinoma cell lines toward rhodamine—123 and
phosphonium salt 11-41. Leuk Res 1993 Mar;
17(3):247-53.

Seidman JD, Frisman DM, Norris HJ. Expression of
the I-[ER-Z/neu proto—oncogene in serous ovarian
neoplasms. Cancer 1992 Dec 15;70(12):2857-60.

Sekiya S, Nunoyama T, Shirasawa I-I, Kimura H,
Kawata M, Iijima N, Sugimoto Y, Tsuruo T,
Takamizawa H. Expression of a human multidrug
resistance gene in human ovarian carcinoma cell
lines. Arch Gynecol Obstet 1992;251(2):79-86.

Sevin BU, Perras JP, Averette HE, Donato DM,
Penalver M. Chemosensitivity testing in ovarian
cancer. Cancer 1993 Feb 15;7l(4 Suppl):1613-20.

Sheid B. Angiogenic effects of macrophages isolated
from ascitic fluid aspirated from women with
advanced ovarian cancer. Cancer Lett 1992 Feb 29;
62(2):153-8.

Sheldon K, Baumal R, Marks A. Targeting of
[1111n]biocytin to cultured ovarian adenocarcinoma
cells using covalent monoclonal antibody-
streptavidin conjugates. Int J Rad App] Instrum [A]
1992 Nov;43(11):1399-402.

Sheridan E, Hancock BW, Goyns MH. High incidence
of mutations of the p53 gene detected in ovarian

tumours by the use of chemical mismatch cleavage.
Cancer Lett 1993 Jan 15;68(1):83-9.

Shiozawa T, Tsukahara Y, lshii K, Ota H, Nakayama
J, Katsuyama T. Histochemical demonstration of
gastrointestinal mucins in ovarian mucinous
cystadenoma. Acta Pathol Jpn 1992 Feb;42(2):
104-10.

Shiraishi Y, Yamamoto K, Soma H. Characteristic
mucinous ovarian cancer antigen is expressed in
malignantly transformed Bloom’s syndrome cells.
Cancer Res 1993 Jul 15;53(14):3427-32.

Shpall EJ, Stemmer SM, Bearman SI, Bast RC Jr,
Peters WP, Ross M, Jones RB. High-dose
chemotherapy with autologous bone marrow support
for the treatment of epithelial ovarian cancer. In:
Markman M, Hoskins WJ, eds. Cancer of the
ovary. New York: Raven Press; 1993. p. 327-38.

Shpall EJ, Stemmer SM, Bear-man SI, Jones RB. Role
of autotransplantation in treatment of other solid
tumors. Hematol Oncol Clin North Am 1993;7(3):
663-86.

Sikut R, Veromann S, Piirsoo A, Mikelsaar AV, Saar
H, Reintam MA. Ovarian carcinomas express a

sperm acrosomal antigen, defined by monoclonal
antibody 9H8. Tumour Biol 1992;13(4):217-25.

Silvestrini R, Daidone MG, Valentinis B, Ferraris C,
Di Re E, Raspagliesi F, Landoni F, Scarfone G,
Bolis G. Potentials of cell kinetics in the
management of patients with ovarian cancers. Eur J
Cancer 1992;28(2-3):386-90. Comment in: Eur J
Cancer 1992;29A(1):169-70.

Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa
A. Enhancement of cisplatin activity by lonidamine

in human ovarian cancer cells. Int J Cancer 1992
Nov 11;52(5):813-7.

Skrincosky DM, Allen HJ, Bemacki RJ. Galaptin-
mediated adhesion of human ovarian carcinoma
A121 cells and detection of cellular galaptin-binding
glycoproteins. Cancer Res 1993 Jun 1;53(11):
2667-75. Published erratum appears in Cancer Res
1993 Aug 1;53(15):3652.

Slavin S, Ackerstein A, Weiss L, Nagler A, Or R,
Naparstek E. Immunotherapy of minimal residual
disease by immunocompetent lymphocytes and their
activation by cytokines. Cancer Invest 1992;
10(3):221-7.

Smith LH, Yin A, Glasky MS, Tyler N, Robles M,
Foster CA, Bieber M, Teng NN. Human
monoclonal antibody recognizing an antigen
associated with ovarian and other adenocarcinomas.
Am J Obstet Gynecol 1992 Feb;166(2):634-45.

Spitzer G, Velasquez W, Dunphy FR, Spencer V.
Autologous bone marrow transplantation in solid
tumors. Curr Opin Oncol 1992 Apr;4(2):272-8.

Strang P, Stendahl U, Tribukait B. Prognostic
significance of S-phase fraction as measured by
DNA flow cytometry in gynecologic malignancies.
Ann N Y Acad Sci 1993 Mar 20;677:354—63.

Stromberg K, Collins TJ 4th, Gordon AW, Jackson CL,
Johnson GR. Transforming growth factor-alpha acts
as an autocrine growth factor in ovarian carcinoma
cell lines. Cancer Res 1992 Jan 15;52(2):341—7.
Published erratum appears in Cancer Res 1992
Mar 1;52(5):1382.

Stuart GC, Nation JG, Snider DD, Thunberg P.
Intraperitoneal interferon in the management of
malignant ascites. Cancer 1993 Mar 15;71(6):
2027-30.

Surwit EA, Childers J M, Krag DN, Katterhagen JG,
Gallion HH, Waggoner S, Mann W] Jr. Clinical
assessment of lllIn-CYT-103 immunoscintigraphy
in ovarian cancer. Gynecol Oncol 1993 Mar;48(3):
285-92. Comment in: Gynecol Oncol 1993 Mar;
48(3):283-4.

Tagliabue G, Citti L, Massazza G, Damia G, Giavazzi
R, D’Incalci M. Tumour levels of Oé-alkylguanine-
DNA-alkyltransferase and sensitivity to BCNU of
human xenografls. Anticancer Res 1992 Nov-Dec;
12(6B):2123-S.

Taniguchi N, Ishikawa M, Kawaguchi T, Fujii J,
Suzuki K, Nakata T. Expression of Mn-superoxide
dismutase in carcinogenesis. Tohoku J Exp Med
1992 Oct;168(2):105-11.

Tashiro H, Miyazaki K, Okamura H, Iwai A,
Fukumoto M. c-myc over-expression in human
primary ovarian tumours: its relevance to tumour
progression. Int J Cancer 1992 Mar 12;50(5):
828-33.

Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash
JD, Park RC, Birrer MJ. p53 and Ki-ras gene
mutations in epithelial ovarian neoplasms. Cancer
Res 1993 Jul 1;53(13):3103-8.

Tenti P, Aguzzi A, Riva C, Usellini L, Zappatore R,
Bara J, Samloff IM, Solcia E. Ovarian mucinous
tumors frequently express markers of gastric,
intestinal, and pancreatobiliary epithelial cells.
Cancer 1992 Apr 15;69(8):213l-42.

Tepler I, Cannistra SA, Frei E 3d, Gonin R, Anderson
KC, Demetri G, Niloff J, Goodman H, Muntz H,
Muto M, et al. Use of peripheral-blood progenitor

85

cells abrogates the myelotoxicity of repetitive
outpatient high-dose carboplatin and
cyclophosphamide chemotherapy. J Clin Oncol
1993 Aug;11(8):1583-91.

Teyssier JR, Couillin P, Benard J, Ravisse N, Ulrich E,
Comillet P. A multidrug-resistant ovarian
carcinoma cell line with a malignant suppressed
phenotype is a CD44 gene expression defective
mutant. Cancer Genet Cytogenet 1992 May;60(1):
14-9.

Thierry AR, Dritschilo A, Rahman A. Effect of
liposomes on P—glycoprotein function in multidrug
resistant cells. Biochem Biophys Res Commun 1992
Sep 16;187(2):1098-105.

Thompson MA, Adelson MD. Aging and development
of ovarian epithelial carcinoma: the relevance of
changes in ovarian stromal androgen production.
Adv Exp Med Biol 1993;330:155-65.

Thompson S, Dargan E, Turner GA. Increased
fucosylation and other carbohydrate changes in
haptoglobin in ovarian cancer. Cancer Lett 1992
Sep 14;66(1):43-8.

Tibben JG, Massuger LF, Claessens RA, Schijf CP,
Pak KY, Strijk SP, Kenemans P, Corstens FH.
Tumour detection and localization using 99Tcm-
labelled OV-TL 3 Fab’ in patients suspected of
ovarian cancer. Nucl Med Commun 1992 Dec;
13(12):885-93.

Treskes M, Boven E, Holwerda U, Pinedo HM, van
der Vijgh WJ. Time dependence of the selective
modulation of cisplatin-induced nephrotoxicity by
WR2721 in the mouse. Cancer Res 1992 Apr 15;
52(8):2257-60.

Trope C, Makar A, Kaem J. DNA flow cytometry as a
new prognostic factor in ovarian malignancies. A
review. Acta Obstet Gynecol Scand Suppl 1992;
155 :95-7.

Untch M, Sevin BU, Perras JP, Angioli R, Baibl A,
Nguyen HN, Hightower RD, Averette HE.
Chemosensitivity to the new anthracycline
pirarubicin and other chemotherapeutic agents in
primary and recurrent ovarian tumors in vitro.
Gynecol Oncol 1992 Nov;47(2):172-8.

Vaage J, Donovan D, Mayhew E, Abra R, Huang A.
Therapy of human ovarian carcinoma xenografts
using doxorubicin encapsulated in sterically
stabilized liposomes. Cancer 1993 Dec 15;
72(12):3671-5.

Valenti M, Cimoli G, Parodi S, Mariani GL, Venturini
M, Conte P, Russo P. Potentiation of tumour
necrosis factor-mediated cell killing by VP16 on
human ovarian cancer cell lines. In vitro results and
clinical implications. Eur J Cancer 1993;29A(8):

1 157-61 .

86

van den Berg-Bakker CA, Hagemeijer A, Franken-
Postma EM, Smit VT, Kuppen PJ, van Ravenswaay
Claasen HH, Comelisse CJ, Schrier PI.
Establishment and characterization of 7 ovarian
carcinoma cell lines and one granulosa tumor cell
line: growth features and cytogenetics. Int J Cancer
1993 Feb 20;53(4):613-20.

van der Burg MEL, Henzen-Logmans SC, Foekens JA,
Berns EMJJ, Rodenburg CJ, Van Putten WLJ,
Klijn JGM. The prognostic value of epidermal
grth factor receptor, determined by both
immunohistochemistry and ligand binding assays, in
primary epithelial ovarian cancer: A pilot study.
Eur J Cancer 1993;29A(14):1951-7.

van der Zee AG, van Ommen B, Meijer C, Hollema H,
van Bladeren PJ, de Vries EG. Glutathione S-
transferase activity and isoenzyme composition in
benign ovarian tumours, untreated malignant
ovarian tumours, and malignant ovarian tumours
after platinum/cyclophosphamide chemotherapy.

Br J Cancer 1992 Nov;66(5):930—6.

Van Niekerk CC, Ramaekers FC, Hanselaar AG,
Aldeweireldt J, Poels LG. Changes in expression of
differentiation markers between normal ovarian
cells and derived tumors. Am J Pathol 1993 Jan;
142(1):157-77.

van’t Veer LJ, van der Feltz MJ, van den Berg-Bakker
CA, Cheng NC, Hermens RP, van Oorschot DA,
Kievits T, Schrier PI. Activation of the mas
oncogene involves coupling to human alphoid
sequences. Oncogene 1993 Oct;8(10):2673-81.

Vergote IB. Adjuvant treatment of ovarian carcinoma.
Acta Obstet Gynecol Scand 1993;72(8):682—4.

Wagner UA, Oehr PF, Reinsberg J, Schmidt SC,
Schlebusch HW, Schultes B, Werner A, Prietl G,
Krebs D. Immunotherapy of advanced ovarian
carcinomas by activation of the idiotypic network.
Biotechnol Ther 1992;3(1-2):81-9.

Wang DP, Konishi I, Koshiyama M, Nanbu Y, Iwai T,
Nonogaki H, Mori T, Fujii S.
Immunohistochemical localization of c-erbB-2
protein and epidermal growth factor receptor in
normal surface epithelium, surface inclusion cysts,
and common epithelial tumours of the ovary.
Virchows Arch A Pathol Anat Histopathol 1992;
421(5):393-400.

Wasserman L, Aviram R, Levavi H, Ovadia J,
Shneyuor Y, Frisch A, Blau 0, Beery E,
Novogrodsky A, Nordenberg J. A cell line with
unusual characteristics from an ovarian carcinoma
patient: modulation of sensitivity to antitumour
drugs. Eur J Cancer 1992;28(1):22-7.

Watson JM, Berek JS, Martinez-Mm O. Grth
inhibition of ovarian cancer cells induced by
antisense IL-6 oligonucleotides. Gynecol Oncol
1993 Apr;49(l):8-15.

Whittington R, Faulds D. Interleukin-2: A review of its
pharmacological properties and therapeutic use in
patients with cancer. Drugs 1993;46(3):446-514.

Williams CJ. Implications of an overview of
chemotherapy in advanced ovarian carcinoma. Br J
Cancer l992;66(2):225—6.

Wimalasena J, Dostal R, Meehan D. Gonadotropins,
estradiol, and growth factors regulate epithelial
ovarian cancer cell growth. Gynecol Oncol 1992
Sep;46(3):345-50.

Woynarowska B, Wikiel H, Sharma M, Carpenter N,
Fleet GW, Bernacki RJ. Inhibition of human
ovarian carcinoma cell- and hexosaminidase—
mediated degradation of extracellular matrix by
sugar analogs. Anticancer Res 1992 Jan-Feb;12(l):
161-6.

Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener
JR, Weinberg J B, Bast RC Jr. Tumor necrosis
factor alpha as an autocrine and paracrine growth
factor for ovarian cancer: monokine induction of
tumor cell proliferation and tumor necrosis factor
alpha expression. Cancer Res 1993 Apr 15;53(8):
1939-44.

Wu S, Rodabaugh K, Martinez-Mala 0, Watson JM,
Silberstein DS, Boyer CM, Peters WP, Weinberg
J B, Berek J S, Bast RC Jr. Stimulation of ovarian
tumor cell proliferation with monocyte products
including interleukin-1, interleukin-6, and tumor
necrosis factor—alpha. Am J Obstet Gynecol 1992
Mar;166(3):997-1007.

Wunderlich JR, Mezzanzanica D, Garrido MA,
Neblock DS, Daddona PE, Andrew SM, Zurawski
VR Jr, Canevari S, Colnaghi MI, Segal DM.
Bispecific antibodies and retargeted cellular
cytotoxicity: novel approaches to cancer therapy.
Int J Clin Lab Res 1992;22(1):17—20.

Xing PX, Prenzoska J , McKenzie IF. Epitope mapping
of anti-breast and anti-ovarian mucin monoclonal
antibodies. Mol Immunol 1992 May;29(5):641-50.

Yaginuma Y, Westphal H. Abnormal structure and
expression of the p53 gene in human ovarian
carcinoma cell lines. Cancer Res 1992 Aug 1;
52(15):4196-9.

Yaginuma Y, Yamashita K, Kuzumaki N, Fujita M,
Shimizu T. ras oncogene product p21 expression

and prognosis of human ovarian tumors. Gynecol
Oncol 1992 Jul;46(l):45-50.

Yang FE, Brown RS, Koral KF, Clavo AC, Jackson
GA, Wahl RL. Quantitative autoradiographic
evaluation of the influence of protein dose on
monoclonal antibody distribution in human ovarian
adenocarcinoma xenografls. Cancer Immunol
Immunother 1992;35(6):365-72.

Yu D, Wolf JK, Scanlon M, Price JE, Hung MC.
Enhanced c-erbB—Z/neu expression in human
ovarian cancer cells correlates with more severe
malignancy that can be suppressed by ElA. Cancer
Res 1993 Feb 15;53(4):891-8.

Zacharski LR, Memoli VA, Omstein DL, Rousseau
SM, Kisiel W, Kudryk BJ. Tumor cell procoagulant
and urokinase expression in carcinoma of the ovary.
J Natl Cancer Inst 1993 Aug 4;85(15):1225-30.

Zhen W, Link CJ Jr, O’Connor PM, Reed E, Parker R,
Howell SB, Bohr VA. Increased gene-specific
repair of cisplatin interstrand cross-links in

cisplatin-resistant human ovarian cancer cell lines.
Mol Cell Biol 1992 Sep;12(9):3689-98.

Zheng J, Wan M, Zweizig S, Velicescu M, Yu MC,
Dubeau L. Histologically benign or low-grade
malignant tumors adjacent to high-grade ovarian
carcinomas contain molecular characteristics of
high-grade carcinomas. Cancer Res 1993 Sep 15;
53(18):4138-42.

Zhou L, Leung BS. Growth regulation of ovarian
cancer cells by epidermal growth factor and
transforming growth factors alpha and beta 1.
Biochim Biophys Acta 1992 Dec 10;1180(2):130—6.

Zhu GG, Risteli J, Puistola U, Kauppila A, Risteli L.
Progressive ovarian carcinoma induces synthesis of
type I and type III procollagens in the tumor tissue
and peritoneal cavity. Cancer Res 1993 Oct 15;
53(20):5028-32.

Zhu GG, Stenback F, Risteli L, Risteli J, Kauppila A.
Organization of type HI collagen in benign and
malignant ovarian tumors. An irnmunohistochemical
study. Cancer 1993 Sep 1;72(5):1679-84.

Zinkewich-Peotti K, Andrews PA. Loss of cis-
diamminedichloroplatinumfll) resistance in human
ovarian carcinoma cells selected for rhodamine 123
resistance. Cancer Res 1992 Apr 1;52(7):1902-6.

Zoumpourlis V, Kerr DJ, Spandidos DA. Differential
interaction of cisplatin with the HIV-1 long terminal
repeat in a resistant ovarian carcinoma cell line.
Anticancer Drugs 1993 Feb;4(1):77-83.

87

MONOGRAPHS

Al-Azzawi, F. A. Specific human antibodies against
cancer raised by lymphocyte transformation with
Epstein-Barr virus [dissertation]. Glasgow (UK):
University of Strathclyde; 1988. 239 p. Available
from: University Microfilms International, Ann
Arbor, MI; AADD-97065.

Alvarez, V. Psychosexual adjustment of ovarian cancer
patients and their spouses [dissertation]. Los
Angeles: Univ. of California; 1987. 243 p.
Available from: University Microfilms
International, Ann Arbor, MI: AAD87-19920.

Barber, Hugh R. K. Ovarian carcinoma: etiology,
diagnosis, and treatment. 3rd ed. New York:
Springer-Verlag; 1993. 362 p.

Blackledge, George; Jordan, Joseph A.; Shingleton,
Hugh M., eds. Textbook of gynecologic oncology.
London: Saunders; 1991. 504 p.

Burghardt, E., ed. Surgical gynecologic oncology.
Stuttgart: G. Thieme Verlag; 1993. 729 p.

Campbell, V. C. The biologic effects of HER-Z/neu
proto-oncogene overexpression [dissertation]. Los
Angeles: University of California; 1992. 126 p.
Available from: University Microfilms
International, Ann Arbor, MI; AAD92-06689.

Coppleson, Malcolm, ed. Gynecologic oncology:
fundamental principles and clinical practice. 2nd ed.
Edinburgh: Churchill Livingstone; 1992. 2 vol.

Deligdisch, Liane; Altchek, Albert; Cohen, Carmel J.
Atlas of ovarian tumors. New York: Igaku-Shoin;
1994.

DiSaia, Philip J .; Creasman, William T. Clinical
gynecologic oncology. 4th ed. St. Louis: Mosby
Year Book; 1993. 743 p.

Fleischer, Arthur C., ed. Early detection of ovarian
carcinoma with transvaginal sonography: }otentials
and limitations. New York: Raven Press; 1993.
206 p.

Gallup, Donald G.; Talledo, O. Eduardo, eds. Surgical
atlas of gynecologic oncology. Philadelphia : W.B.
Saunders; c1994.

Giancotti, F. R. Isolation of an antigen from ascites-
derived immune complexes and the production and
characterization of an ovarian cancer-associated
monoclonal antibody [dissertation]. New York:
Columbia Univ.; 1989. 190 p. Available from:
University Microfilms International, Ann Arbor,
MI; AAD89-19149.

Greer, Benjamin E.; Berek, Jonathan S., eds.
Gynecologic oncology: treatment rationale and
techniques. New York: Elsevier; c1991. 320 p.

88

Haapasalo, H. K. Prognostic factors in ovarian
carcinoma: a clinicopathologic study with special
reference to mitotic counts, nuclear morphometry
and DNA cytometry [dissertation]. Kuopio
(Finland): Kuopion Yliopisto; 1990. 158 p.

Hagen, B. Thio-TEPA: pharmacokinetics and
pharmacodynamics in ovarian cancer patients, and
experimental studies of serum protein binding and
metabolism [dissertation]. Trondheim (Norway):
Univ. of Trondheim; 1991. 92 p.

Herbst, Arthur L., et al. Comprehensive gynecology.
2nd ed. St. Louis: Mosby Year Book; 1992.
1333 p.

Hernandez, Enrique; Rosenshein, Neil B. Manual of
gynecologic oncology. New York: Churchill
Livingstone; 1989. 184 p.

Hoffman, A. G. An in vitro model of ovarian epithelial
carcinogenesis [dissertation]. College Station (TX):
Texas A & M University; 1992. 165 p. Available
from: University Microfilms International, Ann
Arbor, MI: AAD93-15073.

Holcombe, J. K. Social support, perception of illness,
and self-esteem of women with gynecologic cancer
[dissertation]. Birmingham (AL): Univ. of
Alabama; 1985. 152 p. Available from: University
Microfilms International, Ann Arbor, MI:
AAD86-09028.

Hoskins, William J .; Perez, Carlos A.; Young, Robert
C., eds. Principles and practice of gynecologic
oncology. Philadelphia: Lippincott; 1992. 924 p.

Howell, S. B, ed. Platinum and other metal
coordination compounds in cancer chemotherapy.
6th International Symposium on Platinum and Other
Metal Coordination Compounds in Cancer
Chemotherapy; 1991 Jan 23-26; San Diego. New
York: Plenum Press; 1991. 545 p.

Knapp, Robert C.; Berkowitz, Ross Stuart, eds.
Gynecologic oncology. 2nd ed. New York:
McGraw-Hill, Health Professions Division; c1993.
500 p.

Kullander, Stig; Bertelsen, Kamma; Kauppila, Antti, et
al., eds. Ovarian cancer: a prevailing challenge.
Proceedings of a Nordic symposium. 1991
May 10-11; Stenungsund, Sweden. Goteborg:
Scandinavian Association of Obstetricians and
Gynecologists; Oslo: [distributor] Scandinavian
University Press; 1992. 111 p. (Acta obstetricia et
gynecologica Scandinavica. Supplementum; 155).

Kurjak, Asirn, ed. Ultrasound and the ovary. Camforth
(Lancs. UK): Parthenon Pub. Group; 1994.
(Progress in obstetric and gynecological
sonography; 1).

Lambert, Hannah E.; Blake, Peter R. Gynaecological
oncology. Oxford: Oxford University Press; 1992.
230 p.

Lawton, F. An assessment of the clinical role of urinary
polyamine measurement in epithelial ovarian cancer
[dissertation]. Manchester (UK): Victoria Univ. of
Manchester; 1987. 224 p. Available from:
University Microfilms International, Ann Arbor,
MI: AADD-92362.

Lowe, D. G.; Fox, H., eds. Advances in
gynaecological pathology. Edinburgh: Churchill
Livingstone; 1992. 383 p.

Maguire, Robert T.; Van Nostrand, Douglas, eds.
Diagnosis of colorectal and ovarian carcinoma:
application of immunoscintigraphic technology.
New York: Marcel Dekker; 1992. 237 p. (Targeted
diagnosis and therapy; 6).

Mancuso, Salvatore, ed. Achievements in gynecology,
1989-90. Basel: Karger; 1991. 185 p.
(Contributions to gynecology and obstetrics; 18).

Markman, Maurie; Hoskins, William J., eds. Cancer of
the ovary. New York: Raven Press; 1993. 442 p.

Milatovich, A. Cytogenic studies of ovarian and
endometrial malignancies [dissertation].
Bloomington (IN): Indiana Univ.; 1990. 237 p.
Available from: University Microfilms
International, Ann Arbor, MI: AAD91-(T7317.

Monaghan, John M. Complications in the surgical
management of gynaecological and obstetrical
malignancy. London: Bailliere Tindall; 1989.
170 p.

Morrow, C. Paul; Curtin, John P.; Townsend, Duane
E. Synopsis of gynecologic oncology. 4th ed. New
York: Churchill Livingstone; 1993. 558 p.

Pejovic, T. Cytogenetic analysis of ovarian tumors
[dissertation]. Lund (Sweden): Lunds Univ.; 1991.
141 p.

Phipps, Jeffrey H. Laparoscopic hysterectomy and
oophorectomy: a practical manual and colour atlas.
Edinburgh: Churchill Livingstone; 1993. 78 p.

Piver, M. Steven, ed. Manual of gynecologic oncology
and gynecology. Boston: Little, Brown; 1989.
401 p.

Pocinki, Karen McCrory. Cancer of the ovary: research
report. [Bethesda (MD)]: U.S. Dept. of Health and
Human Services, Public Health Service, National
Institutes of Health; [1989]. 18 p. (NIH publication;
no. 89-3014).

Powell, Martin C.; Worthington, B. S.; Symonds, E.
M. Magnetic resonance imaging in obstetrics and
gynaecology. Oxford: Butterworth-Heinemann;
1993.

Rothenberg, Mace, ed. Gynecologic oncology:
controversies and new developments. Boston:
Kluwer Academic; 1994. (Cancer treatment and
research; CTAR 70).

Rubin, Stephen C.; Sutton, Gregory P., eds. Ovarian
cancer. New York: McGraw-Hill, Health
Professions Division; 1993. 498 p.

Sasano, Nobuaki, ed. Gynecological tumors: recent
progress in diagnostic pathology. Berlin: Springer-
Verlag; 01992. 378 p. (Current topics in pathology;
85).

Scully, Robert E., et a1. Histological typing of female
genital tract tumours. 2nd ed. Berlin: Springer-
Verlag; 1994.

Sharp, F.; Mason, W. Peter; Creasman, William T.,
eds. Ovarian cancer 2: biology, diagnosis and
management. The result of the 3rd Helene Harris
Memorial Trust Biennial International Forum on
Ovarian Cancer; 1991 Apr 16—20; Charleston, SC.
New York: Chapman & Hall Medical; 1992. 453 p.

Sharp, F.; Mason, W. Peter; Leake, R. E., eds.
Ovarian cancer: biological and therapeutic
challenges. Based on the proceedings of the 2nd
Helene Harris Memorial Trust Biennial
International Forum on Ovarian Cancer; [1989];
Graz (Austria). London: Chapman and Hall
Medical; c1990. 480 p.

Sheldon, K. M. Immunoscintigraphy of ovarian
carcinoma using indium-lll-labelled monoclonal
antibodies [dissertation]. Toronto: Univ. of
Toronto; 1991. 139 p. Available from: University
Microfilms International, Ann Arbor, MI:
AADNN—69169.

Shepherd, John H.; Monaghan, John M., eds. Clinical
gynaecological oncology. 2nd ed. Oxford:
Blackwell Scientific Publications; 1990. 479 p.

Teoh, Eng-Soon; Ratnam, S. S.; Macnaughton,
Malcolm C., eds. Gynaecological cancer.
Proceedings of the 13th World Congress of
Gynaecology and Obstetrics; 1991 Sep; Singapore.
Camforth (Lanc., UK): Parthenon Pub. Group;
1993. 235 p. (Current status of gynaecology and
obstetrics series; 3).

Tholander, B. Tumor markers for ovarian carcinoma:
diagnostic and prognostic studies with emphasis on
the CA—125 antigen [dissertation]. Uppsalla
(Sweden): Uppsalla Universitet; 1992. 55 p.

Thorvinger, B. Diagnostic and interventional radiology
in gynecologic neoplasms [dissertation]. Lund
(Sweden): Lunds University; 1990. 46 p.

Tourigny, S. C. Remission or death: the social—
psychology of stress and coping in epithelial ovarian
carcinoma patients [dissertation]. Storrs (CT): Univ.
of Connecticut; 1988. 738 p. Available from

89

University Microfilms International, Ann Arbor,
MI: AAD89-16139.

Uyttenbroeck, Frans. Function and sense of radical
surgery in gynaecological and mammary
cancerology in a period of biological evolution:
controversies and pitfalls. Leuven (Belgium):
Peeters; 1990. 660 p.

Zeller, Kathleen R. Screening for gynecologic
malignancy: what every internist should know.
[Dallas]: University of Texas Southwestern Medical
Center at Dallas; [1992]. 35 p.

90

AUDIOVISUALS

Advances in surgery for gynecologic cancer
[videorecording]. University of Texas Medical
School at Houston. [Houston (TX): UT/T V];
c1991. 1 videocassette: 60 min., sound, color, 1/2
in. (OB/GYN grand rounds). Credits: Mitchell
Morris, presenter.

Cancers that threaten women [videorecording].
Princeton (NJ): Films for the Humanities; 01992.
1 videocassette: 19 min., sound, color, 1/2 in.
Credits: Herbert Hyman.

Current concepts in ovarian cancer [videorecording].
[Houston (TX): UT/TV]; 01990. 1 videocassette:
53 min., sound, color, 1/2 in. Credits: Charles
Levenback, presenter.

Gynecologic tumors [slide]. New York: Gower Medical
Pub.; c1991. 80 slides : color. with black & white.
Accompanied by: 1 guide, 38 p. (Slide atlas of
diagnostic oncology; 5). Credits: Karen J. Krag.

Is there life afler menopause [videorecording].
University of California, San Diego School of
Medicine Office of Learning Resources-Television.
[Berkeley (CA)]: UC Regents; 01990.

1 videocassette: 32 min., sound, color with black &
white, 1/2 in. (Ob/gyn ultrasound; tape 17).
Credits: Barbara B. Gosink.

Ovarian cancer 1991 [videorecording]. Marshfield
Clinic; St. Joseph’s Hospital; Marshfield Medical
Research Foundation. Marshfield (M): Marshfield
Regional Video Network; [1991]. 1 videocassette:
35 min.: sound, color, 1/2 in. Credits: Dale M.
Larson.

Radiation therapy in carcinoma of the ovary:
indications, technical considerations, and results
[sound recording]. American Society for
Therapeutic Radiology and Oncology. Chicago:
Teach’em; [1989]. 2 sound cassettes: analog.
Recorded at ASTRO’s 31st annual meeting.

Screening for epithelial ovarian cancer [videorecording].
Bast, Robert C., Jr. Secaucus (NJ): Network for
Continuing Medical Education; 1992. 1
videocassette: 12 min., sound, color, 1/2 in.
(NCME telecourse; no. 624). Issued with:
Neurological emergencies in head trauma;
Anesthetic infusion assisted by the programmable
calculator.

Screening for ovarian cancer [videorecording].
[Houston (TX)]: UT-TV; c1991. 1 videocassette:
60 min., sound, color with black & white, 1/2 in.
(OB/GYN grand rounds). Credits: Rajat Goswamy,
presenter.

Surgery for staging and treatment of early ovarian
carcinoma [videorecording]. Buschbaum, Herbert
J .; Davis 8L Geek, Inc ., Medical Device Division.
[Wayne (NJ)]: American Cyanamid; c1990.
1 videocassette: 22 min., sound, color, 1/2 in.
Credits: James H. Nelson, co-author and narrator.

Transvaginal color Doppler scanning techniques
[videorecording]. Nashville (TN): Vanderbilt
University Medical Center; c1990. 1 videocassette:
sound, color with black & white, 1/2 in. (Advances
in color Doppler sonography). Credits: Patricia C.
Freeman. From a course given by the Dept. of
Radiological Sciences, Vanderbilt University,
School of Medicine, Nashville, TN, Nov. 1-3,
1990.

Transvaginal color Doppler sonography: current and
potential clinical applications [videorecording].
Health Video Dynamics, Inc. Nashville (TN):
Vanderbilt University Medical Center; c1990.

1 videocassette: sound, color with black & white,
1/2 in. (Advances in color Doppler sonography).
Credits: Arthur C. Fleischer. From a course given
by the Dept. of Radiology and Radiological
Sciences, Vanderbilt University, School of
Medicine, Nashville, Tenn., Nov. 1-3, 1990.

Transvaginalultrasonography for ovarian and
e[n]dometrial cancer [videorecording]. [Houston
(TX)]: UT/TV-Houston; c1992. 1 videocassette:
61 min., sound, color, 1/2 in. (OB/GYN grand
rounds / University of Texas Medical School at
Houston). Credits: Arthur Fleisher, presenter.

Qrder Form

GRATEFUL [WEDo Software

For

Macintosh & IBM

Please send me
copies of GRATEFUL

Please send me
copies of GRATEFUL

 

 

 

 

 

 

   

 

 

MED for the MED for IBM and
Macintosh. compatibles.
‘ 3,, Order No. PB93- Order No. P392-
‘M 502433/GBB at $29.95 105444/GBB at $29.95
each. each.
Total Mag versions + Total IBM versions +
Billing Fee" = Total $

"‘ Add $7.50 Billing Fee if using a Purchase Order.
Please attach this form to any purchase order you use.

 

 

 

 

 

P.O. #:
Enclosed is check / money order payable to NTIS for Islegdgdiiartment of Commerce
g_—— National Technical Information Service
barge t" “he“ me) 5285 Port Royal Rd
American Express D VISA 1:] MasterCard D Springfield VA 22161
C rd N ber E .
Siagnatuli'gnmequmd to validate order): xp Telephme: 1‘800'553'6847
For ordering by FAX: (703) 321-8547

(Only for orders using credit card or purchase order)

 

 

Note: The information you provide below will be used to mail you
yearly upgrades of the software. . _‘ _ , ,

 

 

 

Last Name: First Initial:

 

Title:

 

Company/ Organization:

 

Address:

 

City / State / Zip:

 

Phone Number: ( )

 

In addition to your order you will receive information on obtaining

a user code required to access the National Library of Medicine '8 datafiles.
May 1994

     

 

 

 

‘-

 

x‘

 

 

National Library of Medicine
Reference Bibliography Series

 

    

, .. L“
" 9;} I] Hi] I' -_][(CN _. Rem? ‘l {‘JJJ DE: .3
NW 1M DE] [ll] [(CNN] {11

 

Health Care
for Women:
Access,
Utilization,
Outcomes

mu

 

 

 

 

 

   

or Mudlelne ; in
July In

Nutomt LII-r-ry f 4...", m.
.M...
.- 0... t...

 

 

 

 

 

 

, ll:
$76 ($95 foreign) per year.
A monthly publication. $60 ($75 foreign) per year.
GPO List ID: AID94 GPO List ID: CBM94
Bibliographic listing of references Approximately ten bibliographies per
toeurrent journal articles,books, year are produced on a variety
and audiovisuals on Acquired ofbiomedical topics, excluding AIDS.
Immunodeficiency Syndrome Topics are chosen for their current
(AIDS). Each issue consists of popular interest in distinctsubject
about 800-1000 recent references. areas of biomedicine.

* Subscribers receive all issues for a given calendar year wllhout regard to the date of order.

Superintendent of Documents Subscriptions Order Form

Order Processing Code: ' H

Charge your order. ‘ ,
““5470 Wyn-rm
Please Type or Print (Form is aligned for typewriter use.) To fax your orders (202) 512-2233
Prices include regular domestic postage and handling and are subject to change.

Qtv. L'st |D ‘ Price
' ( I ) Title Each Price

 

Total for Subscriptions

 

(Company or Personal Name) (Please type or print) For privacy protection check the box below
V o

[:1 Do not make my name available to other mailers
Please choose method of payment:
[:1 Check Payable to the Superintendent of Documents

E] GPO Deposit Account m3 — D

(Fit): 5'3“" lecwc’ D VISA or MasterCard Account
(Daytime phone including area code) Li I I L i 1 i L I til i i i i i i iv]
cm (Credit card expiration date) Thank youfor

 

(Additional address/attention line)

 

(Street address)

 

 

 

 

 

(Purchase Order No.) your order!
Mail To: Superintendent of Documents
PO. BOX 371954. Pittsburgh. PA 15250—7954 (Authorizing Signature) 3,94

 
 

w

 

 

 

'1

1
,p.
‘X

 

 

PUBUC F“

=T311994

U. . BERKELEY LIBRARIES

\Iliil IIIIIIIIIIIIIIII

CUH7ESEEUL